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Background: EFA6R functions as a guanine nucleotide exchange factor for 
Arf6 – a Ras-like GTPase protein that potently regulates tumour progression. 
EFA6R is consistently expressed in healthy ovarian epithelium, but is 
drastically downregulated in the vast majority of Epithelial Ovarian Cancers 
(EOC). Therefore, EFA6R could be a novel biomarker for EOC. 
 
Aim: 1. Study EFA6R expression in Epithelial Ovarian Cancer (EOC) cell 
lines and tissues. 2. Identify the mechanisms of EFA6R downregulation and 
its role in mediating cellular phenotype. 3. Delineate the expression, 
localisation and cellular functions of EFA6R isoforms.  
 
Results: In EOC Tissue cDNA array, 73% of 192 samples exhibited little or 
significantly less EFA6R expression than healthy samples. In tissue 
microarrays containing 80 individual cases of different grades, EFA6R 
expression was lost with tumour progression. Similar downregulation was 
observed in tissue lysates (6/7 samples) and 10/10 OC cell lines. In SKOV-3 
cells treated with demethylation agent 5-aza-2’deoxycytidine (5-Aza-Cdr) 
EFA6R expression was restored at mRNA and protein level; ~10-fold increase 
in EFA6R expression corresponded with significant attenuation of cell 
migration (~60% decrease in migration observed in Ibidi wound healing assay 
and ~ 5-fold decrease in migration and invasion in transwell assay). 
Exogenous expression of EFA6R plasmid DNA constructs showed that 
EFA6R localisation to the plasma membrane requires the PH and to a lesser 
extent, the CC domain. There, it functions as an Arf6-specific GEF, 
modulating actin stress fibres. Endogenous expression of EFA6R was 
observed in HEK293 and ReN cells. In the former, it potentially regulates b-
integrin expression and in the latter, it plays a part in neuronal 
differentiation.  
 
Conclusion: EFA6R loss of function can be attributed to epigenetic 
mechanisms. Its downregulation, increases migration and metastasis 
through Arf6-independent pathways. One of the EFA6R isoforms has limited 
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Chapter 1: General Introduction 
 
1.1 Tumorigenesis  
 
Tumour initiation and progression is a multi-step process that can take place 
at a myriad of sites throughout the body. The initial steps likely begin by 
mutational changes of deoxyribonucleic acid (DNA) and epigenetic alterations 
of the nucleosome (a complex consisting of a length of DNA coiled around 
histone proteins) that can perturb genes – and their corresponding protein 
products – associated with key anti-malignancy cellular processes. These 
include cell proliferation, survival and many other traits and characteristics 
that a tumour acquires during its progression (Hanahan and Weinberg 2011). 
Although there is ambiguity about the definite causes of tumour initiation, 
what is certain is that once a cell or a cohort of cells take on the characteristics 
of neoplasticity, they must, actively and successfully remove barriers to 
tumour progression. These barriers - that are the control systems that have 
been built as a result of evolution over millions of years - are therefore 
circumvented prior and during tumour progression.  
 
There are very few factors that have a greater impact on the development of 
human cancer, than age. Epidemiological studies generally show that the risk 
of incident and mortality increases with age, indicating that the 
transformation of healthy cells to neoplastic cells takes place over many years 
and decades (White et al. 2014) . For example, in men, the chances of a person 
having prostate cancer, colon cancer and lung cancer is much higher in a 70-
year-old than a 15-year-old (Vellekoop and Loeb 2013). Similarly, in women, 
the risk of getting ovarian, breast and lung cancer is much higher in a 70-
year-old individual than a 15-year-old. However, there are cancers which do 
not follow this pattern. For example, testicular cancer is more prevalent in 
20-50-year-old men (Verhoeven et al. 2013) and the majority of 
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retinoblastoma cases are diagnosed by the age of 2 (Abramson 2005). 
Therefore, age is not the only factor that predetermines tumorigenesis.  
 
It is evident that the formation of malignant tumours requires exposure to an 
exogenous carcinogen - for an extended period of time. For example, when the 
annual global cigarette consumption is compared with global lung cancer 
deaths, we can see that over the past 50 years there has been an increase in 
cancers caused by smoking versus non-tobacco related cancers (Proctor 2001). 
In addition, the duration of exposure to carcinogens (until which time that 
they cause genomic instability) also has great influence on tumorigenesis. 
Similarly, long-term exposure to ultraviolet radiation can lead to skin cancer 
(Narayanan, Saladi, and Fox 2010). 
 
In the UK, more than 300,000 new cases of cancer are diagnosed each year 
while the overall risk factors, mortality, survival and prevention rates can 
vary depending on the type of cancer (CancerResearchUK 2018). Despite 
advances in early detection diagnosis and surgery, new and effective 
therapeutic treatments, cancer incidents have risen in the UK since the 1970s 
due to a possible combination of various factors: accidental exposure to 
carcinogens, unhealthy lifestyle choices (smoking, poor diet, obesity, excess 
alcohol consumption, etc.) (Vijayvergia and Denlinger 2015), aging, 
inflammation (Grivennikov, Greten, and Karin 2010) and a genetic 
predisposition from acquired or inherited polymorphisms (Evans 2016).  
 
1.2 Epithelial cancer 
 
For some types of cancer such as those that arise from the epithelium, disease 
incidents rates increase more rapidly and exponentially with elapsed lifetime. 
This is probably because the epithelial cells that line the various duct walls, 
cavities are exposed to toxic chemicals. For example, our epidermal 
keratinocytes are exposed to the elements and therefore liable to damage by 
ultraviolet light. Similarly, the epithelial cells lining the alveoli in the lungs 
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take the brunt of the everyday pollutants and particles in the air as well as 
(in some cases) first hand and second-hand smoking.  
 
Considering the multi-step process of tumorigenesis, the initial stages may 
take longer to progress than latter stages which require less time to complete. 
The logical reason behind this is that during the latter stages of malignancy, 
the cells and tissues have acquired multiple hallmarks of cancer; they have 
learnt to work coherently together to evade apoptosis, to proliferate, to 
metastases to distant regions of the body and the genomes of the cells become 
generally more mutable (Hanahan and Weinberg 2011).  
 
The histopathological (study of changes in tissues caused by disease) 
alterations of a healthy tissue into a highly invasive carcinoma illustrates the 
transformation and progression of early cancerous cells into cells that are 
poorly differentiated – cells that no longer retain their relatively ordered 
morphology. Eventually these cells are able to break through the basement 
membrane, invading the surrounding stromal tissues. This penetration into 
the stroma layers is the precursor to metastasis – the consequences of which 
































Figure 1.1. Tumour invasion and metastasis (A) Primary tumor formation: by 
activating metastatic oncogenes genes and inactivating metastatic 
suppressor genes, adenocarcinoma cells proliferate and acquire invasive 
potential. (B) Localised invasion: adenocarcinoma cells acquire enhanced 
protease activity (through upregulation of matrix metalloproteinases, MMPs) 
and breach the basement membrane. Their enhanced motility and weak cell-
cell contact (as a result of reduced adherent and tight junction protein 
activity) allows them to move and interact with the surrounding extracellular 
matrix (ECM) and stromal cells while intravasating into lymphatic or blood 
vessels. (C) Transport of adenocarcinoma cells via the general circulation to 
distant anatomical sites: during this phase, they interact with blood 
components and evade immune cells. (D) Arrest in microvessels of various 
organs: cells are trapped and extravasate into secondary sites. (E) 










The ovaries are the primary female reproductive glands that produce eggs 
(gametes) and they consist of three type of cells: epithelial, germ and stromal. 
In the UK, Ovarian Cancer (OC) is the 6th most common cancer in females 
and also the leading cause of all gynaecological cancer deaths due to late 
diagnosis –resulting from ineffective screening methods; 75% of cases in the 
UK are among females aged 55 years or older. Other risk factors such as 
genetic predispositions, genetic mutations, and obesity have also been 
identified as influencing factors towards OC development (See section 1.3.4). 
Risk of OC cancer tends to be reduced by factors that interrupt ovulation such 
as pregnancy, breastfeeding, and oral contraceptive use (Havrilesky, 
Gierisch, et al. 2013).  
 
When the cells in the ovaries grow abnormally they develop into tumours that 
can be non-cancerous or cancerous. The most common type of OC is epithelial 
adenocarcinomas, which account for ~ 90% of ovarian tumours and hence it 
is the most prevalent studied form and the main focus of this thesis. Around 
1-2% originate from germ cell and other rare tumours and ~ 9-10% are low 
malignant potential or borderline tumours which rarely become cancerous 
(CancerResearchUK 2018).  
 
1.3.2 Classification of EOC 
 
EOC is no longer considered as a single cancer type, rather, it is now generally 
divided along histology subtypes that differ from one another in tumor and 
cells of origin, genetic makeup and risk factors (Matulonis et al. 2016). There 
are essentially four EOC subtypes: serous, endometroid, clear-cell and 
mucinous adenocarcinomas (Figure 1.2). The origins of these EOC subtypes 
has been a recurring issue over the past three decades. Initially, it was 
believed that EOC originated from the ovaries. However, research over the 
past two decades have shown that most of what is defined as EOC, primarily 
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arises outside of the ovaries and involves it secondly (Karnezis et al. 2017). 
The serous histology subtype can exist as high-grade serous adenocarcinoma 
(HGSC) and low-grade serous adenocarcinoma (LGSC), where the former 
originates from the fallopian tube fimbria or ovarian cortical inclusions cysts 
and the latter from fallopian tube secretory epithelial or progenitor cells 
(Karnezis et al. 2017). HGSC and LGSC make up the majority of all epithelial 
EOC diagnosis. The endometroid and the clear-cell subtype likely arise from 
the endometroid tissues located outside of the uterus. Mucinous subtypes 
arise from the tubal-mesothelial junction (Kurman et al. 2011). These 
subtypes are associated with varied genetic characteristics, and therefore 





























Figure 1.2. Histological subtypes of EOC. (A) Low-grade serous 
adenocarcinoma (LGSC) is characterized by mild nuclear atypia, infrequent 
mitotic and well-differentiated cells. (B) High-grade serous adenocarcinomas 
(HGSC) show frequent mitotic and poorly differentiated cells with high 
nuclear atypia and lack of polarity. (C) Endometroid adenocarcinoma have 
glandular architecture with endocrine hyperplasia. (D) Clear-cell 
adenocarcinomas have vacuolated cytoplasm and show stromal hyalinization. 
(E) Mucinous adenocarcinomas show frequent mucins filled goblet cells 
(yellow arrow). Images taken from the database of Ovarian Tissue 




Recent developments in delineating the origins of these EOC subtypes have 
also improved preventions strategies. For example, as the origins of HGSC 
are becoming more established, patients who carry markers of HGSC can 
undergo salpingectomy (removal of the fallopian tube) as a preventative 
measure (Matulonis et al. 2016). Therefore, part of solving the problem of 
EOC is understanding the cells of origin associated with each histotype which 
can greatly enhance diagnosis strategies. Out of all these subtypes, the 
majority of risk is attributed to tumours that arise from the serous histology. 
Germ-cell and other ovarian tumours such as sex cord stromal tumours 
account for only 10% of all OC (Bast, Hennessy, and Mills 2009) and therefore 
not the subject of this thesis.  
 
1.4 Epidemiology  
 
EOC is a disease with a global impact. According to the global cancer 
observatory (2018) Brunei, Serbia and Belarus have the highest incident 
rates of OC while Gambia, Mozambique and Madagascar have the lowest. 
Next year in the UK (2019), it is predicted that 7000 new cases of EOC will 
occur with only 35% of patients having a survival rate of 10 years or more 
(Cancer Research UK, 2018). It is believed that 11% of EOC cases are 
preventable and the chance of survival increases from 46% to 90%, if 
diagnosed early. Part of the reason why early diagnosis has been a challenge 
is due to a lack of effective screening methods that enable early diagnosis. 
However, a lack of awareness of the EOC symptoms has been shown to 
contribute to late diagnosis. Results from the Target EOC Pathfinder study 
in 2016 (Targetovariancancer.org.uk, 2018), have discovered that prior to 
diagnosis, only 4% of women could confidently recognize a symptom of EOC; 
41% of women visit their general practice (GP) three times or more before 
being referred for diagnosis tests by GPs who 44% (504 GP participants) of 
them wrongly believe that EOC symptoms only present in the latter stages of 
the disease. In addition, only 46% of nurses feel that their cancer centre or 
unit has enough nurses to care for all the women treated there while 80% of 
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women diagnosed with EOC experience mental health problems. Overall, the 
accumulation of a lack of effective early screening methods, lack of awareness 
of the biology and inadequate care for patients with EOC have made this 
disease the 5th most common cancer in females and also the leading cause of 
all gynaecological cancer deaths (Cancer Research UK, 2018). Despite a ~ 
17% decrease in mortality rates in the UK over the past two decades, EOC 
prognosis remains the poorest across the European continent  (Lowe et al. 
2013).  
 
1.5 Risk Factors  
 
There are numerous risk factors associated with EOC. They differ both in 
their severity and their effects on the development of different EOC histotype 
(Kim et al. 2012). Some of these risk factors such as genetic predisposition, 
hormonal replacement therapy (HRT) and obesity are discussed in the 
following sections. 
 
1.5.1 Genetic (Inherited) predisposition 
 
There are several established genetic mutations that have been shown to 
predispose patients to EOC. Germline mutations in the Breast Cancer 1 
(BRCA1) and Breast cancer 2 (BRCA2) genes are found in up to 20% of 
patients with metastatic EOC (Zhang et al. 2011, Bolton et al. 2012). Both 
BRCA1/2, play a complementary function in promoting genome instability 
and cell survival as part of the DNA double-stranded break repair 
mechanism, during DNA replication (O'Donovan and Livingston 2010). 
(Zhang et al. 2011) have observed that BRCA1 and BRCA2 mutations to be 
most common in HGSC (18% of 751 cases), followed by endometroid (9.1% of 
287 cases) and clear-cell (2.2% of 91 cases) histologist, with no observable 
cases in mucinous (0% of 112 cases) EOC subtype. Although (Alsop et al. 
2012) showed that patients who carry BRCA1/2 mutations are ~ 10% more 
likely to develop early tumour metastasis to distal organs such as liver and 
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spleen, these difference diminished over time, suggesting that mutations in 
these genes are early indicators of metastatic tumours. Interestingly, 
prognosis for patients with BRCA2 was shown to be better than those with 
BRCA1 mutations, possibly due to a better chemotherapy response in BRCA2 
patients and the more frequent hypermethylation of BRCA1 promoter 
compared with BRCA2 (Yang et al. 2011) (Liu et al. 2012). Therefore, it is 
generally recommended to genetically test all non-mucinous EOC patients in 
order to potentially identify BRCA1/2 mutations.  
 
There are also genes associated with the BRCA DNA repair pathway that 
have been found to be mutated in patients with familial history of EOC. Some 
recently discovered genes implicated in hereditary ovarian carcinoma  include 
RAD51C, RAD51D, BRIP1, PALB2, TP53, CHECK2, MRE11A, NBN, 
RAD50. These genes are found as part of the BRCA-mediated pathway 
involved in the recombinational repair of DNA double stranded breaks during 
the G2/M cell cycle  (Loveday et al. 2011, Meindl et al. 2010, Rafnar et al. 
2011, Pennington and Swisher 2012, Walsh et al. 2011, Norquist et al. 2016). 
The specific phenotypic consequences of the mutations of the stated genes, 
are yet to be fully discovered. 
 
There are also inherited disorders that can increase the risk of EOC. One 
such example is Lynch syndrome – a hereditary nonpolyposis colorectal 
cancer syndrome, characterised by mutations in MLH1,MSH2, MSH6, PMS2 
genes, which increases the risk of EOC by 8-15% (Bonadona et al. 2011).  
 
1.5.2 The use of Oral contraceptives and HRT 
 
A considerable amount of literature has been published on whether the use 
of oral contraceptives (OrC) reduces the risk of developing EOC. A literature 
review and meta-analysis on the use of OrCs as contraception or primary 
prevention of EOC found that in women who carry the BRCA1 and BRCA2  
mutations, the use of OrCs reduced the risk of EOC, however, a modest 
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increase (but not significant) in developing breast cancer was also noted 
(Havrilesky, Moorman, et al. 2013). Similar findings were observed for 
patients without BRCA1 and BCRA2 mutations (Bassuk and Manson 2015). 
Considering the relationship between increases in other forms of cancer as a 
result of using OCs, their use may not be suitable as primary prevention of 
EOC. This view is supported by other studies that show that the benefits of 
using OrC in preventing EOC is overall, inconclusive (Havrilesky, Gierisch, 
et al. 2013).  
 
EOC has also been associated with 40% risk of postmenopausal HRT (Beral 
et al. 2015). One meta-analysis of relative risks of oestrogen only (ET) and 
oestrogen plus progestin (EPT) and duration of their use showed that the use 
of these hormones for 5 years increased the risk of developing EOC by 22% 
for ET and 10% for EPT (Pearce et al. 2009). Since the use of progestin seems 
to reduce some of the detrimental side effects of estrogenic effect on EOC 
(Hildebrand et al. 2010), an optimisation of the of daily usage of progestin and 
number of times per 28-day treatment cycle in which oestrogen is taken. In 
addition to this, a histology-based analysis has yet to be done to better 
understand the association between HRT and the development of EOC 
histotype. Interestingly, women who have  severe menopausal symptoms 
after EOC can safely take HRT without a risk in overall survival (Eeles et al. 
2016).  
 
1.5.3 Surgery and tubal ligation 
 
(Rice, Hankinson, and Tworoger 2014) have conducted an analysis on the 
factors associated with common operations undertaken by carriers of 
BRCA1/2. In their study, they found that patients who undergo Salpingo-
oophorectomy (surgical removal of fallopian tube and ovaries) have a 30% 
lower risk of developing EOC. In addition, hysterectomy (the surgical removal 
of the uterus) was shown to reduce the risk of EOC by 20% - although this is 
more significant for non-serous tumours compared with serous tumours.  
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Furthermore, treatment for tubal ligation (a surgical procedure for 
sterilization of fallopian tube) have been shown to significantly reduce the 
chance of developing EOC, particularity in younger women with non-serous 
ovarian carcinoma (Gaitskell et al. 2016). In the same study, between 
tumours of HGSC and LGSC, it was discovered that tubal ligation was able 
to reduce the risk of EOC by 20% in HGSC compared to 0% in LHSC. This is 
not surprising considering that HGSC is believed to arise from the fallopian 
epithelium and subsequently metastasize to the ovaries, while the origins of 
LGSC remains unresolved (Kurman and Shih Ie 2008). Tubal ligation also 
had a positive impact on endometroid and clear-cell carcinomas; whereby it 
was able to reduce cancer risk by 50%.  
 
1.5.4 Other risk factors  
 
Weight gain and obesity have also been associated with EOC (Nagle et al. 
2015). Among post-menopause women who do not take HRT, every 5-kg 
gained in weight increased the risk of EOC by ~ 13% (Keum et al. 2015). 
Between different EOC histotype, it was shown that obesity increases the risk 
of non-HGSC, suggesting that weight loss is unlikely to reduce the risk of 
EOC due in HGSC patients  (Olsen et al. 2013). Several studies into the 
intake of dietary vitamins, flavonoids and dairy foods have shown that not 
only there is no risk associated with the consumption of these food types, but 
they can also have risk-reducing effects (Merritt et al. 2014, Koushik et al. 
2015). Overall however, there has been relatively little literature published 







1.6 Molecular characteristics of EOC subtypes  
 
Although some molecular features of EOC subtypes converge, they all also 
possess unique genetic abnormalities that demonstrates the heterogeneity of 
EOC. 
 
1.6.1 High Grade Serous adenocarcinoma (HGSC) 
 
A detailed examination of the molecular composition of HGSC showed DNA 
repair defects and varied copy number alterations (The Cancer Genome Atlas 
Research 2011). It was shown that 96% of HGSC samples carried TP53 
mutation. In-fact, mutation in TP53 is a major driver of HGSC (Ahmed et al. 
2010). Furthermore, the data from the (The Cancer Genome Atlas Research 
2011) showed that 22% of HGSC were carriers of BRCA1/2 mutations. They 
also identified several other significantly mutated genes that were involved 
in 2-6% of HGSC, including: CSMD3, NF1, CDK12, FAT3, GABRA6, and 
RB1. In addition to these individually mutated genes, defective signaling 
pathways were also discovered. Retinoblastoma signaling defects were 
observed in 67% of cases, PI3K/RAS signaling was found to be altered in 45% 
of cases, 22% of HGSC cases were defective in the NOTCH signaling pathway 
and 84% of cases carried alterations in FOXM1 signaling. Furthermore, 
within these signaling pathways, somatic mutations in the individual genes 
involved in the pathways showed varied copy number alterations. For 
example, in the PI3K/RAS signaling pathway, 7% of cases carried PTEN 
inactivation while 18% showed an amplified expression of PIK3CA. These 
alterations therefore were identified as result of somatic mutations within 
the signaling pathways found to be altered in HGSC.  
 
Data from several studies have interestingly proposed that there are five 
different subtypes – based on molecular and clinical disparities - within 
HGSC (Tothill et al. 2008). One novel subtype showed characteristics of both 
healthy epithelial and mesenchymal properties, with significantly low serum 
CA-125 levels and expression of the transmembrane glycoprotein Mucin 1 
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[MUC1 is associated with tumorigenicity (Nath and Mukherjee 2014)], 
reduced expression of E-cadherin and overexpression of N-cadherin and P-
cadherin  (Tothill et al. 2008). In the search for finding sub-types that are also 
clinically relevant, another study utilized micro-RNA expression profiles to 
identify HGSC subtype that primarily carry angiogenic markers - making 
them vulnerable to anti-angiogenic therapies (Bentink et al. 2012). Overall, 
drug-based treatments of HGSC has been a tasking challenge. Partly due to 
the molecular complexity associated with aberrations in multiple signalling 
pathways involved. In addition, the plasticity of this EOC subtype means that 
at the time of diagnosis, different subtypes can arise that can potential carry 
molecular features that makes them resistance to various therapies.  
 
1.6.2 Low Grade Serous Carcinoma (LGSC) 
 
LGSC and also tumours categorized as ‘serous borderline tumours’ (SBT) 
account for a small portion of all Serous carcinomas. These subtypes are 
commonly associated with mutations in KRAS and BRAF  (Singer et al. 2003, 
Wong et al. 2010, Romero et al. 2013). Neither the LGSC or SBT carry TP53 
mutation, whereas HGSC does (Wong et al. 2010). Similarly, (Wong et al. 
2010) found that HGSC were wildtype for KRAS and BRAF mutations – 
supporting the general consensus that the pathogenesis of serous tumours 
follow two distinct molecular pathways (Kurman and Shih Ie 2008, Kurman 
et al. 2011). It has been suggested that LGSC actually develop from SBT due 
to similarity in genetic markers associated with both of these serous tumours. 
Furthermore, this model also proposes that HGSC does not have a definite 
intermediate stage, and likely arises from the ovarian surface or the fallopian 
tubal epithelial due to its unique feature of carrying TP53 mutation (Kurman 





1.6.3 Endometroid, Clear-Cell and Mucinous ovarian carcinomas 
 
Both endometroid and clear cell carcinoma are endometriosis-associated 
ovarian carcinomas. As such somatic mutations in ARID1A and PIK3CA are 
associated with both of these ovarian subtypes (Wiegand et al. 2010). 
Although high-grade endometroid EOC carries the same genetic 
characteristics as HGSC, clear-cell and low-grade endometroid ovarian 
adenocarcinoma are not characterized by TP53 mutation (Matulonis et al. 
2016) (Ho et al. 2001). ARID1A is found to be a tumor suppressor gene, that 
is silenced during the early stages of cancer development (Wiegand et al. 
2010). The loss of ARID1A gene product, BFA250, was also observed in 46% 
of Clear-cell adenocarcinomas and 30% of endometroid carcinoma (Wiegand 
et al. 2010). PIK3CA is also found to be mutated in 33% of clear-cell carcinoma 
cases studied (Kuo et al. 2009). Both subtypes can also carry PTEN mutations 
are also prevalent in both clear cell and endometroid adenocarcinomas 
(Djordjevic et al. 2012) 
 
The origins of mucinous EOC is controversial, as is its progression from 
benign to borderline and malignant adenocarcinoma. Nevertheless recent 
profile of mucinous genetic markers have shown that KRAS, TP53, BRAF and 
CDKN2A are the most frequently mutated genes, with less frequent 
mutations in RN43, ELF3, ARID1A, DCLK1, ERBB2, FBXW7, GNAS, KLF5, 
LPHN3, LRRK2 and TTF1 (Ryland, Hunter, Doyle, Caramia, Li, Rowley, 




The development and clinical use of effective therapies depend on accurate 
diagnosis of disease. Combination of early detection and effective treatment 
strategies are key to improving patient survival. Traditional methods of 
classifying and screening for EOC have had limited utility in the development 
and clinical use of effective screening methods and therapies. Over the past 
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two decades, EOC has been separated into several distinct disease 
subcategories, as discussed previously. This explains why so many anti-
cancer therapeutic strategies used over the past three decades have had such 
a low overall success rate in that they have treated heterogonous tumours 
only a subset of which are likely respond to targeted therapeutic attach. 
Ideally a diagnostic tool is one that is refined: one that can accurately predict 
responsiveness to various anti-tumour therapies and avoid the use of 
therapies when they are not needed. Overall there is an urgent need to 
develop molecular markers that enable oncologists to distinguish between 
those tumours that are truly require aggressive treatment and those that can 
be monitored repeatedly for signs of progression.  
 
The international federation of gynaecology and obstetrics (FIGO) staging 
system classifies EOC stages in order to explain the epidemiological changes, 
estate of the disease and understand the impact of new therapies. In short, it 
assigns EOC patients to specific treatments based on the severity and state 
of the disease (Mutch and Prat 2014). Given the heterogeneity of EOC and 
our improved understanding of their molecular and clinical features, these 
guidelines and principles are constantly under review (Figure 1.3). If 
cancerous tumours are not detected at early stages of cancer development, 
where the cancer is confined to ovaries or fallopian tubes and is mostly 
indolent (FIGO Stage I), it can become aggressive and ascertain extensions 
below the pelvic brim (FIGO Stage II) and subsequent spreads to the 
peritoneum (abdominal epithelium) outside of the pelvis and/or metastasise 
to retroperitoneal lymph node  (FIGO Stage III) areas and from there it will 
metastasise to distant regions, beyond the peritoneal (FIGO Sage IV). 
Therefore, the detection of EOC at early stages improves survival by more 
than 90% for more than 5 years after diagnosis; while only 5% survive when 




Figure 1.3. FIGO, International Federation of Gynaecology and Obstetrics. 
(Matulonis et al. 2016). 
 
1.8 Screening and prevention 
 
Currently there are no effective screening methods for early stage EOC that 
can improve the survival of patients. This is partly due to the heterogeneity 
of EOC where each subtype carries diverse molecular signatures – as has 
been described in previous sections. 
 
The commonly used cancer antigen 125 (CA-125) also known as mucin 16 is 
primarily used to detect EOC. The general idea being that the higher the CA-
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125 serum levels, the higher chance of carrying a risk for EOC or that the 
disease is progressing aggressively. However, analysing CA-125 levels in 
blood in order to diagnose early stage cancer, has turned out to be insufficient 
and inconclusive. In a randomized screening study for EOC, only 51 % of stage 
I tumours were detected based on CA-125 levels (Kobayashi et al. 2008). 
Furthermore, there are non-cancerous factors that perturb serum CA-125 
levels such as infectious disease, liver disease and endometriosis (Fortún et 
al. 2009, Devarbhavi et al. 2002, Oliveira et al. 2017). To a lesser extent, 
pregnancy during the first trimester also raises CA-125 levels – however this 
change was only observed in 9% of cases with CA-125 levels normalizing 
during the second trimester and beyond (Amampai and Suprasert 2018). To 
add to the inconsistency of using CA-125 as early indicator of EOC some who 
may have EOC may not show high-levels of CA-125 Patients with Clear-cell 
and Mucinous EOC show lower levels of CA-125 in contrast to high levels 
observed in HGSC (Tian et al. 2009).  
 
Since the sole use of CA-125 as an early indicator screening rest for EOC has 
not proven to be conclusive and is insufficient, patients who may have 
abnormal CA-125 levels undergo transvaginal ultrasound – a test that uses 
high frequency sound waves to look at the uterus and fallopian tubes and 
ovaries is used to detect masses of cancer or benign tissues. A recent 
prevention program study for women who are at different risk of developing 
ovarian/fallopian tube cancer and primary peritoneal cancer (PPC), showed 
that the combinational sue of transvaginal ultrasound and CA-125 
measurement was able to diagnose 60% of patients who carry BRC1/2 
mutations or have a strong family history of OC. Following a 61-month follow 
up, the overall survival rate was 75% after diagnosis (Cortesi et al. 2017). 
However, for patients at intermediate (based on familial history of breast and 
EOC) to slightly increased risk (based on suspected familial history of breast 
and EOC), this screening method was found to be inconclusive as only 0.3% 





Current treatment strategies for newly diagnosed or reoccurring ovarian 
cancer tumours differ. 
 
1.9.1 Cytoreductive treatment for newly discovered cancer. 
 
Upon initial diagnosis of EOC, surgical removal of ovarian tumours is 
performed by a gynaecological oncologist. This is done by observing how much 
the cancer has spread followed by removal of all tissues and/or organs that 
are diseased. Depending on the spread of the cancer, a bilateral Salpingo-
oophorectomy (a surgery to remove both ovaries and both fallopian tubes), a 
unliteral Salpingo-oophorectomy (a surgery to remove only one ovary and the 
attached fallopian tube) or a hysterectomy - where the uterus is removed is 
done (Nccn.org, 2018). The overall aim of surgery is ‘debulking’ as much of 
the cancer as possible – whether contained within the ovaries and nearby 
pelvic region or distal regions. Furthermore, during surgery tissues samples 
are taken in order to precisely categorize the staging of the cancer for any 
eventual complementary cytoreductive treatment of using adjuvant 
chemotherapy. Surgery without chemotherapy is mostly used for cancers 
contained within the initial stage I. However, for stages II, II and IV, surgery 
is followed by biopsy to confirm the type of EOC and, followed by adjuvant 
chemotherapy to shrink the cancer. Adjuvant chemotherapy following 
surgery involves mostly intravenous infusion (IV) of platinum-based agents 
(which damage cell DNA, leading to cell death) and taxol-based agents (which 
stop cellular mitosis) (Vasey et al. 2004, Bookman et al. 2009, du Bois et al. 
2003). In a current phase 3 trial, the dose-dense combinational use of 
paclitaxel carboplatin has shown significant improvement in survival 
(Katsumata et al. 2013). In addition to IV, intraperitoneal (IP), where chemo 
at higher doses are directly at the site of tumor growth around the pelvic and 
abdominal area has shown to be more effective than IV. Patients 
administered IP Cisplatin and Paclitaxel showed improved overall survival of 
 41 
66 months compared to IV administered patients who had a lower overall 
survival of 50 months (Armstrong et al. 2006). Tumours that are too 
dangerous to remove (due to the scope of the spread) or too large for surgery 
are initially shrinked by neoadjuvant chemotherapy to reduce their size, 
before surgery is performed to remove any remaining tumours  (Vergote et al. 
2010).  
 
1.9.2 Managing recurrent EOC 
 
Recurrence of EOC shifts the focus of directly curing the cancer to treating it 
in order to manage its scope and spread to ensure the longest overall survival 
of the patient. Patients diagnosed in Stage I have a 10% change of recurrent 
while those diagnosed with stage III-IV have 70-95% chance of recurrence 
(Matulonis et al. 2016). If this recurrence is < 6 months since the last response 
to platinum-based chemotherapy, then the patient is platinum-resistant; if 
>6 months then the patient is acknowledged as platinum-sensitive 
(Matulonis et al. 2016). For platinum-resistance patients, a single 
chemotherapy drug is used in combination with novel drug inhibitors such as 
Bevacizumab (a vascular endothelial growth factor, VEGF, inhibitor) that 
target the hallmarks of cancer (Poveda et al. 2015). For platinum-sensitive 
patients however, further combinational use of platinum-based drugs and 
another chemotherapy agent is administered (Pujade-Lauraine et al. 2010). 
Ultimately, any treatment strategy has to be gauged with increase in survival 
rates and patient well-being. Combination of early detection and effective 
treatment strategies are key for improving patient survival. 
 
1.10 EOC biomarkers 
 
EOC is the leading cause of all gynaecological cancer deaths due to a general 
lack of effective diagnostic biomarkers. Since EOC is heterogenous in nature, 
multiple biomarkers are currently being tested in order to increase the 
sensitivity and specificity of detecting EOC. The goal has been to identify the 
next best individual or combination of biomarkers for both diagnostic and 
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prognosis purposes (Muinao, Deka Boruah, and Pal 2018). For example, 
amongst a panel of serum and urine biomarkers that included serum soluble 
mesothelin-related peptides (SMRP), human epididymis protein (HE)4, 
ostopontin, epidermal growth factor receptor (EGFR) and urinary activin and 
inhibin, HE4 on its own had the highest sensitivity (73%) and specificity 
(95%) for detecting malignancy, compared to CA-125 which has a specificity 
of 90%, but a sensitivity of 50-60% (Muinao, Deka Boruah, and Pal 2018). 
These findings were particularly important because HE4 was used in 
detecting borderline tumours and those with early FIGO stage epithelial and 
tubal cancers (Moore et al. 2008). More recently, combinational use of HE4 
and CA-125 was found to have minimal cumulative benefits in diagnosing 
patients, in clinical settings (Jacob et al. 2011). A recent review has outlined 
the current state of OC-associated biomarkers and their combination use in 
OC diagnosis and prognosis (Muinao, Deka Boruah, and Pal 2018). Overall 
an ideal biomarker should have the potential to diagnose borderline and 
FIGO stage I tumours – before the carcinoma cells acquire metastatic 
potentials.  
 
In this thesis, we study the potential use of exchange factor for Arf6 (EFA6) 
R, as a novel biomarker for EOC. EFA6R was originally discovered as 
Hepatocellular Carcinoma (HC)-associated antigen 67 (HCA67) in serum 
obtained from HC patients (Wang et al. 2002). Since EFA6R has been shown 
to be significantly downregulated in EOC (Pils et al. 2005a), we have studied 
its expression and functional relevance in EOC. Since EFA6R is an Guanine 
Exchange Factors (GEFs) for Arf6 – itself a small GTPase protein – the 
following sections aims to provide background information on the molecular 
roles of Arf6, its GEFs and GTPase activating proteins (GAPs).  
 
1.11 Small GTPases 
 
The Ras superfamily of small GTPases comprise of over 150 human members; 
with several of them having  evolutionarily conserved orthologs (Wennerberg, 
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Rossman, and Der 2005). Based on sequence and functional similarities, they 
are sub-divided into six families (Ras [Rat Sarcoma], Rho [Ras homologue], 
Rab [Ras-like protein from rat brain], Rad [Ras associated with diabetes], and 
Arf [ADP-ribosylation factor]) – where their distinct cellular localisation 
(determined by their ‘active’ and ‘inactive’ state) and tissue distribution infers 
their diverse functional roles. Briefly, the Ras family mainly controls cell-
cycle differentiation and cell proliferation whereas the Rho family modulates 
cytoskeletal dynamics associated with cell shape, movement and adhesion. 
The Rab family members are involved in membrane and protein trafficking 
in endocytic and secretory pathways, the Arfs are involved in membrane 
trafficking, endocytosis and exocytosis.  The Ran family is involved in 
nucleocytoplasmic trafficking and mitotic spindle assembly whereas the Rad 
family plays an important role in angiogenesis (Goitre et al. 2014). Since they 
are involved in virtually all key cellular functions, their normal functional 
roles are found to be perturbed in many diseases, including cancer. This 
makes them attractive targets for cancer therapeutics. For example, the use 
of NSC23766– which is an inhibitor of Rac1 (a member of the Rho family) 
activation, have been shown to reduce cell migration/invasion as well as 
target angiogenetic events in a number of cancer models (Bid et al. 2013). In 
addition, the use of small molecule inhibitors that target Arf6 signalling in 
cancer progression has been well documented: SecinH3 (an inhibitor of the 
cytohesin and GEP100 GEF family) has been used to inhibit melanoma 
invasion and metastasis in mice (Grossmann et al. 2013). Similarly, NAV-
2729 – a direct inhibitor of Arf6 activation has been shown to inhibit 
tumorigenesis and tumor growth in mouse uveal melanoma (Yoo et al. 2016). 
 
All small GTPases function as molecular ‘switches’: they generally exist in an 
‘active’ state, when they bound to guanine tri-phosphate (GTP), and an 
‘inactive’ state, when they bound to guanine di-phosphate (GDP) (Figure 1.4). 
The release of GDP bound to small GTPases, which is catalysed by GEFs, 
results in GTP binding and a subsequent effector response. Their subsequent 
inactivation, meaning the hydrolysis of the bound GTP to GDP by their own 
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GTPase activity, which is activated by GAPs (Cherfils and Zeghouf 2013). 
Therefore, the GAPs regulate their physiological responses. The 
activation/inactivation cycle is critical for small GTPases to maintain a 
















Figure 1.4. Schematic of the small GTPase cycle. The exchange of small 
GTPase bound GDP to GTP is catalysed by GEFs, leading to an ‘active’ GTP-
bound state of small GTPase, which leads to numerous effector responses. 
Thereafter, the small GTPase bound GTP is hydrolysed to GDP, which is 
stimulated by GAPs, resulting in an ‘inactive’ GDP-bound state and an 
attenuated effector response. 
 
Since (Pai et al. 1989) provided the first crystal structure of the GTP-H-Ras 
conformation, more than 500 complexes (including small GTPase complexes 
with GEFs and GAPs) have been deposited in the Protein Data Bank (PTB) 
(https://Arf.rcsb.org/). Observations of the GTP-bound forms of many of the 
Ras family members show that most of the folding of the β-pleated sheet and 
the α-helix – which make up the majority of the structure - are fairly 
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homologous. However, the switch I and switch II motifs vary depending on 
whether the small GTPase is either GTP- or GDP-bound. It has been 
suggested that one of the main functional differences between these 
conformations arise as a result of the amino acid compositions of their 
interacting surfaces – which lead to dynamic charge densities (Kosami et al. 
2014, Schaefer, Reinhard, and Hordijk 2014).  
 
1.12 The Arf Family 
 
The first member of the Arf family (Arf1) was originally discovered in 1984 
as a co-factor for cholera toxin-mediated ADP-ribosylation of the 
heterotrimeric G-protein Gs (Kahn and Gilman 1984). Since then it has been 
found to be a Ras related small GTPase with a molecular weight of ~21kDa 
(Sewell and Kahn 1988). Use of Saccharomyces cerevisiae as a model system 
allowed the determination of a role for Arf1 in the secretory pathway, along 
with its intracellular localisation at the Golgi (Stearns et al. 1990). Arfs are 
ubiquitously expressed in eukaryotic cells and are major regulators of 
intercellular vesicle trafficking. They have been found to be conserved across 
many species, including yeast, fish, insects and animals, indicating an 
important role for them in cellular functions. Subsequent characterisation of 
the Arf family in mammals has identified six members, which have been 
separated into three classes on the basis of sequence homology. Class I 
comprises Arfs 1-3, class II consists of Arfs 4 and 5, and class III contains Arf6 
(Tsuchiya et al. 1991). The classes of Arfs also differ in their intracellular 
localisation, which is dependent on their nucleotide bound states. Class I and 
II Arfs are found to be cytosolic in their GDP-bound inactive form, and 
exchange of the bound GDP for GTP (activation) stimulates their 
translocation to the Golgi membrane (Randazzo et al. 1993, Hosaka et al. 
1996). Here, localisation is a result of the N-terminal myristoylation (a lipid 
anchor modification of eukaryotes and viral proteins that targets them to 
membrane locations), which is common to all members of the Arf family 
(Haun et al. 1993, Randazzo et al. 1993, D'Souza-Schorey and Stahl 1995). 
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Arfs contain an amino-terminal amphiatic helix which is co-translationally 
modified by myrostolytaion of glycine 2, which is important for interactions 
between helix and acidic head groups of membrane lipids. Arf6 lacks 4 amino 
acid residues in the helix (Kahn, Goddard, and Newkirk 1988). Arfs are 
ubiquitously expressed and its sequence at the amino acid level is conserved 
in all eukaryotes (D'Souza-Schorey and Chavrier 2006). Arf proteins have 
been identified in Giardia lamblia, a protozoan intestinal parasite (Murtagh 
et al. 1992). Since this thesis was focused on a GEF specific for Arf6, I have 




In mouse, Arf6 expression is especially high in the brain, stomach, liver, 
kidney, large intestine, testes, ovaries and uterus, while its expression is very 
low in the heart and skeletal muscle (Akiyama et al. 2010). The human Arf6 
gene is located at chromosome location 7q22.1. It is an 175 amino acids 
protein produced with a molecular weight of 21kDa (Kim 1999). Arf6 shares 
66% sequence homology at the amino acid level with Arf1, making it the most 
divergent out of all Arfs. Arf6 appears to be localised differently to the other 
Arfs inside the cells, with its GTP-bound form being found exclusively at the 
plasma membrane, and its GDP-bound form being found predominantly on 
the membrane of a tubulovesicular structure believed to be an endocytic 
compartment (Peters et al. 1995). The presence of Arf6-GDP in the cytosol of 
cells has also been noted under certain conditions (Gaschet and Hsu 1999). 
In one study, Arf6 has also been shown, in its GDP-bound inactive form, at 
the plasma membrane (Macia et al. 2004). 
 
One of the earliest documented functions of Arf6 is its role in the secretory 
pathway of the yeast S. cerevisiae (Lee, Moss, and Vaughan 1992). Since then, 
Arf6 has been noted to be involved in cellular processes ranging from 
endocytosis (D'Souza-Schorey and Stahl 1995) and exocytosis (Galas et al. 
1997) to the activation of Rho family small GTPases (Radhakrishna et al. 
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1999) and the reorganisation of the actin cytoskeleton (D'Souza-Schorey et al. 
1997). More recently, Arf6 has been found to play roles in cytokinesis (Ueda 
et al. 2013), neutrite outgrowth (Jang et al. 2016) and stability of the platelet 
cytoskeleton (Urban et al. 2016). All of these functions are dependent on the 
GDP/GTP (‘inactivation’/’activation’) cycle of Arf6, which, as already 
mentioned previously, is mediated by GEFs and GAPs (Figure 1.5).  
 
 
Figure 1.5 Arf6 cycles between the inactive GDP-bound and active GTP-
bound forms, which is regulated by GEFs and GAPs. Upon agonist 
stimulation, GDP on Arf6 is exchanged for GTP by the action of Arf6-specific 
GEFs, resulting in the activation of Arf6 (Arf6-GTP). The activated Arf6 then 
transduces the signal downstream to regulate actin cytoskeleton remodelling 
and membrane trafficking at the plasma membrane and endosomes. 
Thereafter, Arf6 is inactivated (Arf6-GDP) by the support of GAPs. To date, 
8 members of Arf6 GEFs, which belong to BRAG, cytohesin, and EFA6 
families (highlighted in green), and 9 members of Arf6 GAPs, which belong to 
GIT, ARAP, ACAP, ADAP and SMAP families (highlighted in red), have been 
identified. Redrawn from (Yamauchi, Miura et al. 2016).  
 
The crystal structure of Arf6 bound to the GTP analogue GTPgS revealed that 
similar to the GTP-bound H-Ras conformation, the switch I and switch II 
undergo major conformational changes (Figure 1.6). During the transition 
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between the GDP to GTP conformation, Thr44 at the C-terminus of the switch 
I motif forms a hydrogen bond with the g-phosphate of GTP and Mg2+ 
(Pasqualato, Ménétrey, et al. 2001). In addition, the amino end Gly66 and 
Gln67 of switch II motif also binds the g-phosphate of GTP. This ‘active’ 
conformation state is highly stable in the absence of a GAP, the bound GTP 
hydrolysis does not occur (Pasqualato, Ménétrey, et al. 2001). Interestingly, 
in their GTP-bound states, both Arf1 and Arf6 undergo identical 
conformational changes and hence they are not recognized as different Arf 
isoforms by effectors. This suggests that the GEFs recognize other than the 
switch regions, or that cellular localisation of the GDP-bound Arf determines 
whether GEFs differentiate between these Arf isoforms (Al-Awar et al. 2000). 
In addition, (Pasqualato, Ménétrey, et al. 2001) also showed that the major 
conformational changes take place only when Arf1 and Arf6 are in their 




Figure 1.6 The crystal structures of active and inactive forms of Arf6. The 
full-length, non-myristoylated human Arf6 bound to either the GTP analogue 
GTPγS (the active form) or GDP (the inactive form). From (Menetrey et al. 
2000, Pasqualato, Menetrey, et al. 2001, Macia et al. 2004) (Menetrey, et al. 
2000;Pasqualato, et al. 2001;Macia, et al. 2004).  
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1.13.1 Subcellular localisation of Arf6  
 
Arf6 has been shown to be localised to the plasma membrane in human 
embryonic kidney (HEK) 293 cells (Peters et al. 1995) and chinese hamster 
ovary (CHO) cells (Cavenagh et al. 1996). As mentioned previously, Arf6 has 
a different amino acid sequence to other Arfs and the presence of basic 
residues around the amphiatic helix allows its interactions with acidic head 
groups of lipids at the plasma membrane. The use of Arf6 mutants locked 
either in an active or inactive state in the localisation studies confirmed that 
the subcellular localisation of Arf6 is based on its nucleotide bound status. 
The Arf6Q67L (constitutively active) is shown to localise to the plasma 
membrane whereas Arf6T27N (constitutively inactive) mutant shows the 
perinuclear endosomal localisation (D'Souza-Schorey et al. 1998, 
Venkateswarlu and Cullen 2000). In some cells, Arf6 appears to have 
different subcellular localisations. For example, in chromaffin 
neuroendocrine cells, Arf6 is localised to secretory chromaffin granules and 
upon activation, it translocates from the secretory granules to the plasma 
membrane (Caumont et al. 1998). Arf6 distribution, therefore, alters within 
the cell in response to the cellular activity. For example, it can concentrate at 
cleavage furrows during cytokinesis (Schweitzer and D'Souza-Schorey 2002).  
 
1.13.2 Functional roles of Arf6 
 
1.13.2.1 Arf6 role in activating Phosphoinositides and Lipid metabolism  
 
Upon activation by GEFs, Arf6 translocates to the plasma membrane where 
it recruits and activates various effectors to regulate membrane trafficking 
and actin cytoskeleton re-organization. The Phosphoinositides (PI) are 
inositol lipids, which – by acting as Arf6 effectors - play an important role in 
mediating the Arf6 activity. At the plasma membrane, 
phosphatidylinositol(PI)-4-phosphate 5-kinase (PI4P5K, also known as 
PIP5K) is bound and activated by Arf6-GTP to generate the PI 4,5-
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bisphosphate (PI 4,5-P2), which plays an important role in signal transduction 
pathways, actin cytoskeleton reorganization, clathrin-dependent endocytosis 
and regulation of membrane morphology (Di Paolo and De Camilli 2006). Arf6 
has been shown to activate all three isoforms (a, b and g) of PIP5K (Funakoshi 
et al. 2010). Functional significance of this has been shown in endosomal 
recycling in HeLa, COS-7 and MIN6 cells; exocytosis of neurotransmitters, 
dense core vesicles, lytic granules and insulin; recruitment of the AP-2 
adaptor required for clathrin mediated endocytosis; membrane ruffle 
formation; neurite outgrowth in rat hippocampal neurons, connecting it to 
neuronal development; and invasion into host cells by microbes such as 
Yersinia pseudotuberculosis or Chlamydia trachomatis (Funakoshi et al. 
2010).  Overexpression of PIP5Kα has been shown to cause the formation of 
large vacuoles identical to those induced by expression of the constitutively 
active mutant of Arf6 (Arf6Q67L) (Brown et al. 2001), suggesting that it has 
a role in Arf6 mediated membrane trafficking. In addition, Arf6 can activate 
other effectors such as phospholipase D (PLD), which has been shown to occur 
in a GEF-dependent manner (Santy and Casanova 2001). The product of 
activated PLD is the intracellular messenger, phosphatidic acid (PA) -  which 
itself can be converted to other lipid mediators, diacylglycerol (DAG) and  
lysophosphatidic acid (LPA) (McDermott, Wakelam, and Morris 2004).  
 
A recent study has implicated Arf6 in the trafficking of intracellular 
cholesterol distribution and metabolism. As demonstrated by (Marquer et al. 
2016), cholesterol particles in the form of cholesteryl esters are internalized 
by the Low-density Lipoprotein (LDL) receptor, trafficked to the lumen of late 
endosomes/lysosomes (LE/LYS), where they are hydrolysed to free 
cholesterol. The cholesterol is then transferred via Niemann–Pick type C 
protein (NPC2), a cargo of the Cation-Independent Mannose-6-Phosphate 
Receptor (CI-M6PR), to NPC1 which redistributes the cholesterol to other 
cellular compartments. Marquer and colleagues have shown that Arf6 
conditional knockout in mouse leads to cholesterol accumulation and 
redistributions in the LE/LYS due to the mistrafficking of NPC2 away from 
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lysosomes (Marquer et al. 2016). Hence, they proposed a mechanism for Arf6 
regulation of cholesterol homeostasis where Arf6 controls an endosomal pool 
of PI 4,5-P2 and regulates retromer tubules dynamics in the endosome-to-
TGN pathway, consequently impacting CI-M6PR and NPC2 localization.  
 
1.13.2.2. Arf6 role in actin rearrangement 
 
Arf6 and the cytohesin family of Arf GEFs play pivotal roles in the activation 
of the Rho family of small GTPases such as Rac1 (Santy, Ravichandran, and 
Casanova 2005). Previous studies have shown co-localisation of Rac1 specific 
GEFs with members of the cytohesin family, and that the formation of 
lamellipodia and subsequent cell migration is dependent on the coupling 
between Arf6 and Rac1 activities (Santy, Ravichandran, and Casanova 2005). 
This is exemplified by Arf6 recruitment of Rac1 GEF, Kalirin, to the plasma 
membrane to facilitate Rac activation and lamellipodia formation  (Koo, 
Eipper, and Donaldson 2007). Arf6 also indirectly activates the WAVE 
regulatory complex (WRC) at the plasma membrane. It recruits 
cytohesin2/ARNO to the plasma membrane, which activates Arf1 that 
subsequently activates the WRC (Humphreys et al. 2013a). The WRC 
complex is able to control actin cytoskeletal by stimulating the actin-
nucleating activity of the Arp2/3 complex at the membrane (Chen et al. 2014). 
Recently, Humphreys et al. (2016) have shown that this mechanism is 
hijacked by Escherichia coli (E.coli) in order to evade macrophage-mediated 
phagocytosis. To counter phagocytosis, E coli, inject the virulence effector 
EspG into the host cells thereby inhibiting the WRC. EspG directly binds and 
inhibits Arf6 and Arf1 signalling. This results in less actin polymerisation 
and reduced phagocytosis (Humphreys, Singh, and Koronakis 2016).  
 
1.13.2.3 Arf6 role in endocytic pathway 
 
The connection between Arf6 activation and actin organization has 
implications in the endocytotic pathway as well as the endocytotic recycling 
pathway. As previously mentioned, Arf6 modulates the activation of PLD and 
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PI4P5K, resulting in the local accumulation of PI 4,5-P2. The active GTP-
bound Arf6 directly controls the assembly of clathrin/AP-2–coated pits of 
synaptic membranes via the stimulation of PI 4,5-P2 production mediated by 
PI4P5K activation (Krauss et al. 2003, Paleotti et al. 2005)  
 
In MDCK epithelial cells, it was shown that Arf6 interacts and recruits 
NM23-H1, a Nucleoside diphosphate (NDP) kinase that functions as a GTP 
source for dynamin-dependent fission of coated vesicles during E-cadherin 
endocytosis (Palacios et al. 2002). In human platelets, it was shown that Arf6 
activation of NM23-H1 also plays a critical role in P2Y12, a G protein-coupled 
receptor (GPCR), internalisation and the receptor resensistisation 
(Kanamarlapudi, Owens, et al. 2012). In adipocytes, Arf6 plays an important 
role in endothelin-induced lipid breakdown and cell migration (Davies et al. 
2014, Davies, Bain, and Kanamarlapudi 2014). Arf6 is also essential to the 
clathrin-mediated endocytosis of other GPCRs, including the luteinizing 
hormone/choriogonadotropin receptor (LHCGR) (Kanamarlapudi, Thompson, 
et al. 2012), the β2-adrenergic receptor (β2AR) (Claing et al. 2001, Lawrence 
et al. 2005b) the angiotensin type 1 receptor and the vasopressin type 2 
receptor (Houndolo, Boulay, and Claing 2005). Arf6 is also involved in 
clathrin-independent endocytosis of alpha-amino-3-hydroxy-5-methyl-14 
isoxazolepropionic acid (AMPA) receptor in hippocampal neurons (Scholz et 
al. 2010) and its endosomal recycling (Tagliatti et al. 2016). Arf6 also appears 
to be important in caveolae-dependent or caveolae independent endocytic 
pathways (D'Souza-Schorey and Chavrier 2006). The internalisation and 
degradation of ATP binding cassette transporter A1 (ABCA1), a transporter 
in cholesterol efflux pathway, is mediated by Arf6-dependent pathway 
whereas its recycling is independent of the Arf6 activity (Mukhamedova et al. 
2016). 
 
Arf6 also participates in exocytosis by modifying fusogenic lipids at the site 
of exocytosis (Begle et al. 2009). Recently, a mechanism for Arf6-specific 
regulation of acrosomal exocytosis in human sperm cells has been proposed: 
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Exocytic stimuli activate Arf6 which mediates the activation of PLD1, 
PI4P5K and phospholipase C (PLC) . This leads to PI 4,5-P2 hydrolysis and 
Inositol 1,4,5-trisphosphate (IP3) production, which induces acrosomal 
calcium release. In conjunction with calcium efflux, Arf6 stimulates a Rab 
GEF to activate Rab3A that assembles the membrane fusion machinery, 
leading to acrosomal exocytosis (Pelletan et al. 2015). 
 
1.13.2.4 Arf6 role in post-endocytic events 
 
Following internalisation, Arf6 participates in recycling of membrane 
component back to the plasma membrane including β-1 integrin (Powelka et 
al. 2004a) and major Histocompatibility Complex (MHC) Class I and the 
endogenous glycosylphosphatidylinositol inositol-anchored protein CD59 
(Naslavsky, Weigert, and Donaldson 2004). Arf6 has also been shown to 
regulate integrin transport in neuronal axons of Central Nervous System 
(CNS), which required for the regenerative ability of neurons (Eva et al. 
2012a).  
 
At the onset of cytokinesis, Arf6 becomes concentrated at a cleavage 
furrow/midbody during telophase and an abrupt, transient increase in Arf6-
GTP occurs simultaneously with cell division progression (Schweitzer and 
D'Souza-Schorey 2002). During the last stage of cytokinesis (abscission), Arf6 
stimulates the tethering between the Rab family interacting protein 
RabFIP3/RabFIP4 and the cleavage furrow – a step that is required for 
abscission (Fielding et al. 2005). Furthermore, Arf6 controls endocytic 
vesicles required for abscission through its interaction with its downstream 
effectors c-Jun-N-terminal-kinase (JNK) interacting proteins JIP3 and JIP4 
(Montagnac et al. 2009). Arf6 has also been shown to participate in the 
formation of autophagosomes (which transport lysosome-bound materials) 
through stimulating the production of PI 4,5-P2 (George et al. 2016).  
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The expression of either Arf1 or Arf3, as well Arf6, in platelets has been 
documented (Choi, Karim, and Whiteheart 2006, Kanamarlapudi, Owens, et 
al. 2012) but the function of Arfs in these cells remains largely to be 
determined.  Choi et al. (2006) and Kanamarlapudi et al (2012) have shown 
that Arf6, but not Arf1 or Arf3, has a prominent role in platelet aggregation 
following stimulation with either collagen or ADP, respectively. The Arf6-
GTP levels have been demonstrated to be altered following stimulation of the 
platelet collagen receptor GPVI with either collagen or the snake venom toxin 
convulxin or the platelet receptor P2Y12 receptor with ADP. Arf6 has also 
been shown to function upstream of the Rho family GTPases RhoA, Rac1 and 
Cdc42 (Choi, Karim, and Whiteheart 2006). Given the fact that Arf6 regulates 
integrin endocytosis, recently, platelet-specific-Arf6-knockout mice (KO) was 
used to show that Arf6 contributes to the endocytic trafficking of platelet 
αIIbß3 (Huang et al. 2016). The PDZ-LIM protein family regulates cell 
adhesion via interactions with α-actinin and integrin, as well as stabilizes the 
actin cytoskeleton (Krcmery et al. 2010). Recently, in mouse, PdLim7 (a 
member of the PDZ-LIM family) has been shown to regulate actin 
cytoskeleton organization and stabilize the platelet shape change via the 
regulation of the Arf6 activity (Urban et al. 2016). Emerging evidence implies 
that Arf6 may be integral to platelet adhesion and aggregation and overall 
platelet function. 
 
1.14 Arf6 GEFs  
 
As mentioned previously, the spontaneous release of GDP from a Arf-GDP 
complex is not generally possible at physiological concentration of Mg2+ 
without the involvement of GEFs, which promote the substitution of GDP by 
GTP on Arfs – leading to their activation. This catalytic activity depends on 
the GEF’s Sec7 domain – a region which is folded into 10 α-helices forming a 
hydrophobic groove with polar or charged residues that reside at the edge of 
the groove (Cherfils et al. 1998). The hydrophilic region contains a conserved 
‘Glutamic finger’ which when in close proximity with the Arf-GDP complex, 
displaces Mg2+ and the β-phosphate of GDP, destabilising the complex 
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(Beraud-Dufour et al. 1998). This glutamine residue is commonly mutated to 
abolish GEF activity in Arf-related functional studies – a mutation strategy 
that has also been utilized in this thesis (see chapter 5) 
 
In addition to the Sec7 domain, Arf6 GEFs also contain a PH domain, which 
is responsible for the plasma membrane localization by interacting with PI 
4,5-P2 and PI 3,4,5-trisphosphate (PIP3) (Kanamarlapudi 2014b, Cullen and 
Venkateswarlu 1999) and a C-terminal region which consists of one or more 
Coiled-Coil (CC) motif responsible for cytoskeleton rearrangements and 
interactions with downstream signalling proteins (Kanamarlapudi 2014b, 
Venkateswarlu 2003). In the following sections, both Arf6 GEFs (Figure 1.7) 




Figure 1.7 Mammalian Arf6 GEFs. The structural domains of various Arf6 
GEF shown schematically. Within the EFA6 family of Arf6-specific GEFs, 
EFA6R is predominantly expressed as two isoforms in humans.  
 
1.14.1 Cytohesin GEF family 
 
There are four member of the cytohesin family (Cytohesins 1, 2,3 and 4), 
where only Cytohesin 1, Cytohesin 2/ARNO and Cytohesin 3/Grp1 have been 
shown to interact with Arf6 (in addition to Arf1) (Kolanus 2007). Cytohesin 4 
is the most divergent amongst the Cytohesin family of Arf GEFs and is found 
exclusively in leucocytes where it functions as a GEF for class I and II of Arfs 
rather than class III, to which Arf6 belongs to (Ogasawara et al. 2000). All 
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Cytohesins contain a Sec7 domain, a PH binding domain that specifically 
binds to PIP3 and an N-terminal CC domain (Gray, Van Der Kaay, and 
Downes 1999, Cullen and Venkateswarlu 1999) (See Figure 1.7).  
 
Cytohesin 1 (through Arf6 activation) mainly regulates cell adhesion in an 
integrin-dependent manner. In lymphocytes, it was found to interact with the 
cytoplasmic N-terminal region of β2-integrin part of Lymphocyte Function-
Associated antigen 1 (LFA-1) complex and thereby mediates β2-integrin 
binding to Intercellular Adhesion Molecule 1 (ICAM-1) (Kolanus, Nagel et al. 
1996). Since then, it has been found to promote human blood neutrophils 
adhesion and mediate dendritic cell adhesion and migration via β2-integrin 
and promote the adhesion of human hematopoteic stem and progenitor cells 
to mesenchymal stroma cells via β1-integrin (Quast et al. 2009, Boehm et al. 
2003, Rak et al. 2017).  
 
In preadipocyte 3T3-L1 cells, Cytohesin 2 has been shown to be bind (through 
its PH domain) to paxillin - the main component of focal adhesion complexes. 
The use of SecinH3 - a cytohesin antagonist - inhibited Cytohesin 2/paxillin 
complex formation, leading to significant attenuation of the Arf6-mediated 
cell migration (Torii et al. 2010). Later, (Davies et al. 2014) showed that 
Cytohesin 2 utilizes the Arf6/ERK1/2 signaling pathway during preadipocyte 
migration. In addition to cell migration, Cytohesin 2/Arf6 (and to a lesser 
extend Cytohesin 3) has been shown to be involved in insulin signaling where 
SecinH3 inhibition or siRNA knockdown of Cytohesin 2 results in hepatic 
insulin resistance, suggesting a role for it in the physiological changes that 
occur in type II diabetes  (Hafner et al. 2006). Cytohesin 2 has also been 
shown to regulates the early endosomal pathway and dendritic formation in 
neurons (Ito et al. 2018). While both Cytohesins 2 and 3 have abnormally high 
expression in hepatocellular carcinoma, knockdown studies have shown that 
cytohesin 3 potentiates tumor growth and new vasculature (Xu et al. 2013, 
Fu et al. 2014). In this thesis, we have also identified Cytohesins 2 and 3 
expressions in neuronal progenitor ReN cells with possible roles in mediating 
 58 





The first BRAG (Brefeldin Resistant Arf GEF) isoform BRAG1 was discovered 
as an interacting partner of PSD95 in the Postsynaptic density (PSD) of 
excitatory synapses in adult rat forebrain (Sakagami 2008).  BRAG2/GEP100 
and BRAG3 are also found to be highly expressed in the brain, which suggests 
probable roles in mediating neuronal cell functions. The second BRAG 
isoform exists as two isoforms BRAG2a/GEP100 (150 kDa) and BRAG2b (120 
kDa); both isoforms are specific towards Arf6 (Dunphy et al. 2006b). BRAG2 
and Arf6 expression in the hippocampus is known to be low at birth, with 
BRAG2 expression increasing with age as a result of synaptogenesis (Scholz 
et al. 2010). (Sowmya, Madhavan, and Therese 2006) showed that BRAG2a 
can function independently to its role of an Arf6 GEF in phagocytic 
monocytes, where it induces apoptosis in a mechanism analogous to the 
Tumour necrosis factor-a (TNFα) induced apoptosis. The paper goes on to 
show evidence that BRAG2 and the Rac1 GEF Dock180 are important for 




In humans, the EFA6 GEF family consist of four members: EFA6A, EFA6B, 
EFA6C and EFA6R (also known as PSD3, EFA6R or HCA67), whereby 
additional isoforms by alternative splicing have been described for each 
member. EFA6R shares a common domain organization with other EFA6 
family members which consists of a Sec7 domain, which bears the catalytic 
GEF activity, a PH domain, which is responsible for the plasma membrane 
localisation by interacting with PIs, and a C-terminal region which consists 
of one or more CC motif responsible for cytoskeleton rearrangements and 
interactions with downstream signalling proteins (Kanamarlapudi 2014a). 
EFA6 family members contain a Sec7 domain that is 60-70 % similar to each 
 59 
other, but only 30-35% similar to the Sec7 domain of ARNO/Cytohesin2 
(Derrien et al. 2002). Moreover, the PH domain of EFA6A is ~ 70% identical 
to EFA6C/EFA6R, and ~ 50% identical to EFA6B. Some isoforms of the EFA6 
family also contain a less conserved N-terminal domain, upstream of the Sec7 
domain, whose functions are mostly unknown.  
 
In human tissues, mRNA levels of EFA6A and EFA6C has been detected 
primarily in brain neuronal cells and to a lesser extent in the small intestine 
and colon. EFA6B has been detected mostly in the placenta, pancreas, spleen, 
thymus and peripheral blood while EFA6R/EFA6R expression profile reveals 
its presence is ubiquitous with highest presence in the brain and also the 
liver, the kidney, testis and the ovaries (Derrien et al. 2002). Although they 
are expressed in different tissues, their similarity in terms of protein domain, 




EFA6A was shown to be the first GEF to preferentially and exclusively 
catalyse the exchange of GDP with GTP on Arf6 rather than Arf1 (Macia, 
Chabre, and Franco 2001, Franco et al. 1999). This GEF activity is dependent 
upon a key conserved Glu424 residue; mutation of which abolishes its GEF 
activity (Franco et al. 1999). EFA6A is localised to the plasma membrane, 
where through Arf6, it assembles and organizes actin cytoskeleton and 
membrane trafficking while leaving the cis-Golgi networks, Endoplasmic 
Reticulum (ER) or lysosomal markers unperturbed (Franco et al. 1999). 
Independent of its activity and association with Arf6, EFA6 localizes and 
associates with the membrane through its PH domain (Franco et al. 1999, 
Chavrier and Franco 2001) (Deletion of the PH domain leads to cytosol 
localisation, rather than the plasma membrane). An integral part of this 
localisation is the binding affinity of the PH domain with PI 4,5-P2 (Macia et 
al. 2008). Plasma membrane localisation thereafter leads to Arf6 activation. 
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Furthermore, the PH domain simultaneously binds with F-actin, 
coordinating cortical actin dynamics (Macia et al. 2008) 
 
1.14.5 Role of EFA6A in tight junction proteins 
 
Both adherent junctions and tight junctions are associated with the actin 
cytoskeleton. EFA6A/Arf6 accelerates the formation of Tight junction (TJ) 
proteins at the plasma membrane (Tritarelli et al. 2004)(Klein et al. 2008). In 
MDCK cells, the expression of EFA6A, delayed the endocytosis of the 
transmembrane proteins claudin-2 and occludin, resulting in the retention of 
these TJ proteins at the plasma membrane. Here, EFA6A stabilizes the apical 
actin ring onto which the TJ protein is anchored (Tritarelli et al. 2004)(Luton 
2006)(Klein et al. 2008).  
 
1.14.6 The role of EFA6A in the brain 
 
EFA6A expression is shown to be predominantly a brain-specific, more 
precisely a forebrain structure of the brain (Choi, Karim, and Whiteheart 
2006). Although in rat retina, EFA6A has shown relatively low expression 
(compared to brain) at presynaptic photoreceptors (Katsumata et al. 2008). 
Furthermore, in adult mice testes, EFA6A is expressed in mitotic cells 
(Suzuki et al. 2009). Accordingly, studies into its functional role have showed 
that this multi-domain protein is involved in many neurocellular events. Its 
co-localisation with Arf6 at the plasma membrane has been shown to promote 
the formation of membrane protrusions (filopodia) in the advent of dendritic 
spine development (which assist in transmitting electrical signals to neuronal 
cells) and its maintenance of mature spines (Raemaekers et al. 2012, Choi, 
Karim, and Whiteheart 2006). In support of this, in dendritic spines, 
exogenously expressed EFA6A (via its C-terminal region) and actinin-α1 (an 
F-actin linking protein) show co-localization and interaction, highlighting a 
possible mechanism of Arf6-independent interaction with the actin 
cytoskeleton (Sakagami et al. 2007). mRNA expression of EFA6A has also 
been sighted in rat hippocampus and its protein product was observed as a 
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key mediator of neuronal development (Sakagami et al. 2006). Furthermore, 
by activating Arf6, and directly interacting with a  family of K+ ion channels, 
TWIKI1, it is able to mediate TWIKI1 internalization and recycling 
(Decressac et al. 2004). EFA6A expression is elevated in glioma tissue 
samples. The role of EFA6A in glioma cell invasion has been shown to be 
dependent on its GEF activity. Through the activation of ERK1/2 of the 
MAPK pathway signals, via Arf6 activation, EFA6A regulates the migration 
and invasion of glioma cells (Li et al. 2006). In neuroblastoma cells, Sorting 
Nexin-1 (SNX-1) interaction with the C-terminal region of EFA6A, as well as 
EFA6A-mediated Arf6 activation, has been shown to promote neutrite 




Similar to EFA6A, EFA6B preferentially functions as a GEF for Arf6 and not 
for Arf1 (Derrien et al. 2002). Initial studies into the role of EFA6B 
highlighted its involvement in accelerating the formation of TJ proteins at 
the plasma membrane (Klein et al. 2008). In MDCK cells, the over-expression 
of EFA6B delayed the endocytosis of claudin-2 and occludin, resulting in the 
retention of these TJ proteins at the plasma membrane. EFA6B has been 
shown to accelerate the assembly of TJ proteins and re-arrangement of the 
actin cytoskeleton. This action is thought to be the associated with EFA6B’s 
role in stabilizing the apical actin ring onto which the TJ protein is anchored 
during polarization of the actin cytoskeleton (Klein et al. 2008, Luton 2005).  
 
Recently, the N-terminal regions of EFA6B/EFA6R have been shown to 
associate with Dynamin2 (Dyn2) during Arf6-induced clathrin mediated 
endocytosis (Okada et al. 2015a). In breast cancer cells, reduced EFA6B 
expression correlates with disease progression (Zangari et al. 2014). 
Interestingly, EFA6B over-expression in MCF7 cells promote an epithelial 
phenotype characterized by promotion of TJ proteins as well as blocking the 
transformer growth factor β (TGF-ß) pathway – shown to be an early inducer 
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of disassembly of TJ proteins and the epithelial mesenchymal transition 




EFA6C was the third family of EFA6 to be discovered, exclusively in the brain 
(in Cerebellar Purkinje cells) as a single band of 42.kb mRNA, while no 
expression was detected in the heart, lung, thymus, spleen, liver, small 
intestine, kidney, testis or skeletal muscle (Matsuya et al. 2005). (Matsuya et 
al. 2005) showed that in Hela cells, exogenous expression of EFA6C localized 
to the plasma membrane, where it activated Arf6 (via its Sec7 domain). In 
addition, EFA6C also interacted with F-actin via its C-terminal region. 
Overall, EFA6R/Arf6 was shown to stimulate actin organization and 




As a member of the EFA6 family of Arf6-specific GEFs, EFA6R has been 
shown to preferentially activate Arf6 at the cell periphery. This GEF activity 
is dependent upon its localisation at the plasma membrane which is mediated 
by its PH domain and stabilized by its CC domain (Kanamarlapudi 2014b). 
Alternative splicing of the EFA6R gene has been described in both mouse and 
humans. However, further analysis of these variants is needed to see why 
they are differentially expressed. Thus far, four physical interacting partners 
(MX1, MLH, PMS2 and ARAP1) and one highly probably partner (Dyn2), 
based on interaction of EFA6B with Dyn2 and sequence similarity between 
EFA6B and EFA6R (Okada et al. 2015a), and one genetic interaction (TP53) 
have been identified. However, no further characterisation of these 
interactions have been undertaken so far. Recently a mechanism of Arf6-
induced clathrin mediated endocytosis (CME) has shown that Dyn2 is able to 
activate Arf6 through association with EFA6B and EFA6R. Furthermore, 
multiple Arf6 GEFs, including EFA6R, have shown to mediate β-1 integrin 
recycling, suggesting that alteration of Arf6 GEFs expression as therapeutic 
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strategy to counter angiogenesis and growth (Hongu et al. 2015). In ovarian 
cancer, EFA6R has been shown to be downregulated in high-grade EOC 
compared to low-grade EOC, indicating this GEF as a potential tumour 
suppressor gene and biomarker for ovarian cancer (Pils et al. 2005a).  
 
1.14.9.1 Sites of Expression and EFA6R isoforms 
 
Splice isoforms and sites of expression, in Mouse 
 
Initially, EFA6R was shown to encode a protein of 1004-amino acids, in the 
mouse brain (Sakagami et al. 2006). Further in situ hybridization analysis 
revealed that EFA6R was highly expressed in the hippocampal region of mice 
brain whereas other EFA6 family members differed in their spatiotemporal 
localisation. Real-time quantitative Polymerase Chain Reaction (RT-qPCR) 
analysis of various adult mice tissues showed that EFA6R expression is 
highest in the brain, eye, thymus, lung, spleen and testis while a lower 
expression in the small intestine, kidney and heart (Sakagami et al. 2006).  
 
Recent studies into EFA6R splice isoforms have broadened our 
understanding of their distinct cellular/subcellular localisations and 
expression. (Fukaya et al. 2016) detected a high mRNA expression of EFA6R 
isoform 1,2,3 and 4 in the adult mouse brain (Figure 1.8) (Fukaya et al. 2016). 
The Sec7 domain is conserved in EFA6R variants 1 and 2, whereas variants 
3 and 4 lack this domain, inferring that these isoforms have Arf6-independnet 
roles. In order to detect corresponding protein expression levels, they used 
isoform-specific anti-EFA6R antibodies to detect endogenous expression of 
EFA6R isoforms. This resulted in observing immunoreactive bands at 140-
kDa, corresponding to EFA6Rs 1 and 2, and a 43-kDa band, corresponding to 
EFA6R 3 (Fukaya et al. 2016). Interestingly, the anti-EFA6R 3/4 antibody 
failed to detect EFA6R 4, indicating that this variant could be downregulated 
post-transcriptionally (possible during translation or degradation) or, as the 
authors have noted, the antibody may not have been sufficiently sensitive 
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enough to detect endogenous expression of EFA6R 4. Immunohistochemically 
analysis into the subcellular localisation of EFA6Rs 1, 2 and 3 showed 
significant overlap in the mouse brain. In the hippocampal CA3 region for 
example, EFA6Rs 1 and 2 were predominately localized at the axon fibres of 
mossy fibres whereas EFA6R 3 was mostly localized to cell bodies, dendritic 
shafts and spines of hippocampal pyramidal cells (Fukaya et al. 2016). 
Overall, these results suggest that EFA6R variants are functionally diverse 
in the mouse brain.  
 
EFA6R expression has also been detected in mice adrenal cortical tissues and 
immunoblotting analysis revealed an immunoreactive band size of ~140kd 

























Figure 1.8. EFA6R isoforms and their domains in (A) humans and (B) mice.  
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Splice isoforms and sites of expression, in Humans 
 
Alternative splicing of the EFA6R gene generates two isoforms in humans: 
EFA6R A (1048 aa, 116kDa) and B (513 aa, 56kDa). These isoforms both 
possess a Sec7, PH and CC domain (Kanamarlapudi 2014a). Based on 
sequence comparison, the long human EFA6R A is the counterpart to mouse 
EFA6Rs 1 and 2, whereas the small human EFA6R B corresponds to mouse 
EFA6R 3 isoform. In human tissues, thus far, only EFA6R B has been 
detected with high expression levels in the brain, liver spleen and testis and 
lower expression levels in small intestine, kidney, stomach and ovaries 
(Kanamarlapudi 2014a). By taking both the mouse and human EFA6R 
expression studies into account, it seems that the expression pattern of 
EFA6R isoforms may be species-specific. However, further expression 
analysis is required to clarify the recent findings.  
 
In cell lines, a 37-56kDa protein band corresponding to EFA6R B has been 
detected in MCF7, PC12, Hela, COS-7, HEK293 and A549 cell lines 
(Kanamarlapudi 2014). Recently, we have shown that EFA6R is also 
expressed in some ovarian cancer cell lines such as OVCAR3, COV644 and 
UWB 1.289, CAOV3 while absent in TOV21G, SKOV3, OVSAHO, OVCAR8, 
IGROV1, Cis-A2780, and COV318 (unpublished data). In addition, EFA6R A 
expression has also been detected in HEK293 and ReN cells (See section 
5.3.2). 
 
1.14.9.2 The functions of EFA6R structural motifs 
 
Sequence alignment of EFA6R with other members the EFA6 family show 
that EFA6R shares the core catalytic Sec7 domain, the PH domain and the 
CC domain of EFA6 family GEFs. A recent study has shown that EFA6R 
isoform B preferentially activates Arf6 (Kanamarlapudi 2014a). In vivo 
nucleotide exchange assays indicate that EFA6R B specifically catalyse the 
GTP loading of Arf6 when over expressed in mammalian cells. Furthermore, 
EFA6R B is able to regulates Arf6 localisation and induce the loss of actin 
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stress fibres through Arf6 activation. This GEF activity is dependent upon 
the functional presence of the Sec7 catalytic domain. When the catalytically 
inactive mutant EFA6R (E134K) was exogenously expressed in COS-7 cells, 
Arf6 failed to activate (Kanamarlapudi 2014). The various EFA6R motif 
constructs have shown that the PH and CC domains contribute to the 
targeting of EFA6R to the plasma membrane, independent of the presence of 
the Sec7 domain (Kanamarlapudi 2014a). Through its PH domain, EFA6R is 
able to specifically bind PI 4,5-P2 in in vitro. Interestingly, the PH domain 
alone seems to be insufficient for the PI binding, indicating that adjacent 
sequences may be necessary for proper folding and binding to the membrane 
PIs. Therefore, EFA6R functioning as an Arf6-specific GEF depends on its 
membrane localization by the interaction of its PH domain with PI 4,5-P2 in 
the membrane. This localisation seems to be further stabilized through the 
interaction of the CC domain with the actin cytoskeleton (Kanamarlapudi 
2014a). 
 
1.14.9.3 Other EFA6R interacting protein network 
 
In humans, the BioGrid interaction repository (https://thebiogrid.org/) has 
identified four physical proteins and one genetic interaction between EFA6R 
and its interacting partners. Using a yeast-two hybrid system, ARAP1 (a 
member of the ArfGAP family) and MX1 (a dynamin-like large GTPase 
involved in viral resistance) has been shown to interact with EFA6R (Yoon et 
al. 2011, Brantis-de-Carvalho et al. 2015). In addition, Affinity Capture Mass 
Spectrometry analysis has identified MLH and PMS2 (components of the 
post-replicative DNA mismatch repair system) as interacting partners of 
EFA6R (Cannavo et al. 2007). Although there is no evidence of a physical 
interactions between EFA6R and TP53, genetic interaction analysis have 
shown that mutations in both genes result in cumulative cellular defects in 
human cancer cells (Xie et al. 2012).  
 
The role of Arf6 in CME as well as reorganization of the actin cytoskeleton 
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has been well documented (D'Souza-Schorey and Chavrier 2006). The large 
GTPase Dynamin (Dyn) proteins play a role in forming endocytic vesicles as 
well as their scission during CME (Praefcke and McMahon 2004). A recent 
study into the mechanisms of CME have shown that Dyn2 activation of Arf6 
is mediated by members of the EFA6 Arf GEF family (Okada et al. 2015a). In 
Hela cells, EFA6B and EFA6R co-localize with Dyn2 at the cell periphery 
where immunoprecipitation studies have shown the physical interaction 
between Dyn2 and EFA6B. This interaction occurs through the N-terminal 
145-185 amino acid region of EFA6B. This region is >50% conserved in 
EFA6R – raising the prospect of similar Dyn2 interactions at the plasma 
membrane. Hence, both EFA6B and EFA6R mediate Dyn2 -induced Arf6 
activation in CME, possibly by activating Arf6 sequentially at different stages 
of CME (Okada et al. 2015a).  
 
1.14.9.4 Clinical Implications 
 
The roles of EFA6R in Cancer 
 
It has been shown that the Loss Of Heterozygosity (LOH) on the short arm of 
chromosome 8 is associated with sporadic epithelial ovarian cancer (Brown et 
al. 1999). One study showed that serous and mucinous carcinomas, which 
alongside clear-cell and endometroid carcinomas make up the majority of 
epithelial ovarian cancer cases, differed with respect to the frequency and 
pattern of LOH at 8p (Lassus et al. 2001). At distal regions of chromosome 
8p, allelic analysis of 8p21-p23, showed that 67% serous carcinoma samples 
display LOH whereas only 21% of mucinous carcinomas showed allelic loss 
(Lassus et al. 2001). Hence, the study of functional characterisation of genes 
that are located at the 8p chromosomal region may lead to discovery of 
tumour suppressers involved primarily in ovarian serous carcinomas. As such 
EFA6R has been implicated in epithelial ovarian cancer as well as breast 
cancer metastasis (Pils et al. 2005a, Thomassen, Tan, and Kruse 2009).  
 
In EOC, EFA6R down-regulation in high-grade carcinomas (particularly the 
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serous subtype) compared to low-grade carcinomas significantly impacts 
survival of patients (Pils et al. 2005a). Although EFA6R was down-regulated 
in high-grade primary ovarian tumour samples, its expression in ovarian 
cancer cell lines was less clear (Pils et al. 2005a). This is possibly due to the 
poor characterization of ovarian cancer cell lines at the time. To address this 
issue, recent publications have aimed to authenticate the histological 
background of ovarian cancer cell line, as well as assess whether these cell 
lines resemble their tumours of origin - using integrated genomic and 
proteomic approaches (Domcke et al. 2013, Coscia et al. 2016). Therefore, 
EFA6R downregulation correlates with progression of ovarian carcinomas 
and hence can be used as a biomarker of ovarian carcinomas.  
 
The roles of EFA6R in other diseases 
 
In mouse brain, gene expression analysis have identified EFA6R as a 
schizophrenia-associated biomarker (Mozhui et al. 2011) while genome wide 
association studies has identified EFA6R as a genetic risk factor for 
systematic sclerosis (Martin et al. 2012, Jin et al. 2014). Recently, an in vivo 
study conducted by Hongu and colleagues showed that Arf6 is required for 
Hepatocyte growth factor (HGF) dependent tumour neoangiogenesis and 
growth (Hongu et al. 2015). Using Arf6 knockout mice, it was shown that Arf6 
deletion abolishes b-1 integrin recycling. Knockdown of Arf6 GEFs (GEP100, 
EFA6B,EFA6R and Cytohesin 3/GRP1) inhibited b-1 integrin recycling, 
suggesting that Arf6-mediated b-1 integrin recycling depends on multiple 
Arf6 GEFs. However, their functional roles may differ as EFA6R, EFA6B and 
GEP100 co-localize with β-1 integrin at the plasma membrane, whereas 
Cytohesin 3/GRP1 does not (Hongu et al. 2015).  
 
1.15 Arf6 GAPs 
 
Arf6 GAPs generally function as negative regulators through which multiple 
signals converge to control Arf6-GTP levels. This way, in addition to their 
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Arf6 GAP activity, they may act as scaffolds for proteins that directly effect 
Arf6-mediated functions (Vitali et al. 2017). (Arf6-specific GAPs are displayed 




The subfamily of ARAP includes three members: ARAP1, ARAP2, and 
ARAP3, which act as GAPs for both Arf and Rho family small GTPases. 
ARAP3 was originally identified as a phosphatidylinositol (3,4,5)-
trisphosphate (PI 3,4,5-P3) second messenger binding protein in porcine 
leukocyte cytosol (Krugmann et al. 2002). It consists of a sterile alpha motif 
(SAM) domain, five PH domains, a Rho GAP domain and an Arf GAP domain, 
and a Ras Associating (RA) domain. ARAP3 activity has been shown to be 
dependent on its N-terminal PH domain binding to PI 3,4,5-P3 (Craig et al. 
2010). It is largely localized within the cytosol of unstimulated cells and in 
the F-actin dense membrane ruffles and lamellipodia of some cells. ARAP3 
binding to PI 3,4,5-P3 through the N-terminal PH1 domain leads to its 
translocation to the plasma membrane. It has been shown to play a role in 
the regulation of the actin cytoskeleton, lamellipodia formation, cell 
spreading as well as modulating embryonic development and nerve 
regeneration (Krugmann et al. 2006, I et al. 2004, Song et al. 2014, 
Kartopawiro et al. 2014, Jeon et al. 2012). ARAP3 also inactivates RhoA in 
response to NGF, bFGF and cAMP leading to neurite outgrowth from PC12 
cells (Jeon et al. 2010). It has been shown to inhibit peritoneal dissemination 
of scirrhous gastric carcinoma cells by regulating cell adhesion and invasion 
(Yagi et al. 2011). ARAP3 is tyrosine phosphorylated by Src, which negatively 
regulates its cellular functions. It forms a multimeric protein complex with 
CIN85/CMS, SH2-containing inositol phosphatase 2 (SHIP2) and Vav2, but 
the physiological significance of these interactions are not yet fully 
understood (Raaijmakers et al. 2007). ARAP3 interacts with CIN85/CMS 
through its proline–arginine motif, with SHIP2 using the SAM domain and 
with Vav2 using two phosphorylated residues, T1403 and Y1408 (Wu et al. 
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2012). It also binds to Rap1 through the RA domain. Studies have shown that 
ARAP3 expression is ubiquitous, albeit uneven with the strongest expression 
detected in leukocytes and in the spleen (Krugmann et al. 2002).  ARAP3 
knockdown with RNAi alters cell shape and reduces PDGF-induced 
lamellipodia formation in fibroblasts, increases RhoA activity in monocytes 
and decreases migration of LED cells (Kartopawiro et al. 2014). Knockout of 
ARAP3 in mouse results in embryonic death in mid-gestation due to defect in 
sprouting angiogenesis. ARAP3 inducible knockout studies revealed that it 
regulates chemotaxis and adhesion-dependent processes in neutrophils 




The GIT family of Arf GAPs consist of GIT1 and two alternatively spliced 
GIT2 isoforms, GIT2 (short) and GIT2 (long) (Hoefen and Berk, 2006). Their 
structure consists of a core of N-terminal Arf GAP domain, followed by three 
Ankyrin (ANK) ANK repeats and a SHD domain, followed by a CC motif and 
an extended C-terminal region which contains a putative leucine zipper and 
a PBS domain for paxillin binding.  Membrane localization of GITs and their 
effect on endocytosis of GPCRs implicates them in the regulation of Arf6 
function; one of their functions being in endocytosis of GPCRs through 
binding of GRKs (Premont et al. 1998). GIT2 co-localises to focal adhesions 
following phosphorylation by FAK or Src and whilst GIT1 may also be 
phosphorylated by these kinases their focal adhesions localisation is not 
dependent on this.  Finally, the GIT family of Arf GAPs have been implicated 
in the formation of lamellipodia and filopodia required for cell migration 





The Stromal Membrane Associated Protein (SMAP) subfamily of Arf GAPs 
consists of SMAP1 and SMAP2 in mammalian cells. SMAP1 preferentially 
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interacts with Arf6 over Arf1 through its Arf GAP domain and it interacts 
directly with Clathrin heavy chain (CHC) through its clathrin-binding motif. 
In addition to these domains, SMAP2 contains a Clathrin assembly lymphoid 
myeloid (CALM) binding domain, which allows it to interact with CALM and 
regulate clathrin coat formation. Although no experimental evidence yet 
exists for SMAP1-CALM interaction, the amino acid sequence alignment of 
SMAP1 and SMAP2 shows conserved regions in the CALM-interaction 
region, an indication of similar functional role in SMAP1 (Tanabe et al. 2005). 
The functional presence of these domains allows SMAP1 and SMAP2 to 
support Arf-mediated endocytosis. The SMAP2 C-terminus region has been 
shown to be necessary for its subcellular localisation (Sakakura et al. 2011). 
Since the C-terminus region of SMAP1 shows high sequence similarity with 
that of SMAP2, it can be assumed that SMAP1 C-terminus is also essential 
for its subcellular localisation (Sakakura et al. 2011). 
 
The main functions of SMAP1 discovered so far include the regulation of 
clathrin-dependent endocytosis, specifically of E-cadherin and transferrin 
receptor (TfnR) and b-catenin and sorting of cytoplasmic c-Kit (Tanabe et al. 
2005, Kobayashi et al. 2014). Both E-cadherin and TfnR are transported in 
clathrin-coated vesicles, and overexpression of SMAP1 – which results in Arf6 
inactivation – impairs endocytosis of each molecule (Tanabe et al. 2006). 
SMAP1 preferentially interacts with Arf6 over Arf1 via its Arf GAP domain, 
clathrin proteins via its CHC and CALM domains and binds to the carboxy-
terminal of SMAP2 (Tanabe et al. 2006). However, the functional relevance 
of these interactions is yet to be fully understood. It is likely that that both 
SMAPs 1 and 2 play a and compensatory role in regulating Arf-mediated 
endocytosis. Indeed, in vivo it has been shown that SMAP2 compensates for 
the absence of SMAP1 in TfnR endocytosis (Sakakura et al. 2011). In addition 
to its involvement in embryogenesis, SMAP1 also regulates epithelial 
mesenchymal transition (EMT) (Kon, et al. 2013;Sangar, et al. 2014)(Kon et 
al. 2008). SMAP1 deficient mice showed the inhibition of E-cadherin 
endocytosis and increased levels of key EMT markers such as snail, slug and 
 73 
vimentin (Kon et al. 2008). The cumulative effect of these changes is an 
uncontrolled growth as a result of uncontrolled cell cycle– which represents 
some of the underlying reasons behind cancer progression. In cutaneous 
xerograph models, the over-expression of SMAP1 wild-type shown to inhibit 
tumour growth while its loss-of-function mutation expression increases 
tumour growth (Sangar et al. 2014). SMAP1 has been implicated in 
Microsatellite Instability Colorectal Carcinoma (MSI CRC) where its 
mutation frequency inversely correlates with disease progression (Sangar et 
al. 2014). In neuroblastoma cells, SMAP1 knockdown results in abnormal 
neurite outgrowth due to increased levels of NRF-1 (Tong et al. 2013).. Its 
association with the MLL gene implicates SMAP1 in high-risk acute 
leukaemia (Meyer et al. 2005). In summary, the SMAP family of Arf GAPs 
are key regulators of Arf6-mediated clathrin dependent endocytosis in vitro 





The ACAP (Arf GAP with coiled coil, ANK repeat and PH domains) Arf GAP 
family consists of three mammalian members: ACAP 1/Centaurin-b1, ACAP 
2/Centaurin-b2 and ACAP3/Centaurin-b3. They contain structurally a CC 
domain, followed by the PH, Arf GAP and ANK-repeat domains. Initial 
functional studies of ACAPs 1 and 2 showed that these GAPs co-localise with 
Arf6 at the cell periphery where they reduce Arf6 induced cell protrusions 
(Jackson et al. 2000). However, ACAP1 was shown to be more efficient in 
blocking protrusions than ACAP2. In contrast ACAP2 inhibited cell 
spreading in NIH3T3 cells more efficiently than ACAP1, suggesting that 
these GAPs work complementarily but are involved in different Arf6-
dependent events. The activities of ACAP1 and ACAP2 are dependent on 
Arf6-induced production of PA, which, in addition to being involved in 
membrane ruffling, is also involved in endosomal membrane recycling 
(Jovanovic, Brown, and Donaldson 2006). Knockdown of ACAP1 inhibits its 
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binding to the cytoplasmic domain of TfnR, resulting in attenuated TfnR 
recycling (Dai et al. 2004) and inhibited β1-integrin recycling and cell 
migration (Li et al. 2005). ACAP1 is also part of the clathrin coat complex, 
formed under the mediation of Arf6 which has been shown to be involved in 
GLUT4 recycling (Li et al. 2007).  
 
Similar to other GAPs, ACAPs also have Arf GAP domain dependent 
functions. For example, ACAP2 binds the Rab22 and Rab35 via its N-terminal 
region, which contains the CC domains and C-terminal region which holds 
the ANKR domain. Many studies have been conducted on the dynamic 
interaction of Rab-35 with ACAP2. Through this binding, Rab-35 localises 
ACAP2 to the plasma membrane where by inactivating Arf6, it stimulates 
the Rab-35 dependent neurite outgrowth in PC12 cells (Kanno et al. 2010, 
Kobayashi and Fukuda 2012). Activated Rab-35 is also involved in the early 
stages of phagosome formation. During FcgR phagocytosis, activated Rab-35 
recruits ACAP2 to the site of phagocytosis where it is involved in the 
formation of phagocytic cups. Through Arf6 inactivation, ACAP2 controls 
actin remodelling during the formation of these phagocytic cups (Egami, 
Fukuda, and Araki 2011). Inactivation of Arf6 by the Rab-35/ACAP2 complex 
also inhibits oligodendrocyte differentiation and myelination (Miyamoto et al. 
2014).  
 
Recently, a novel role for ACAP3 has been observed in mouse hippocampal 
neurons (Miura et al. 2016). Knockdown of ACAP3 in mouse hippocampal 
neuronal cells, resulted in attenuation of neurite outgrowth. Similarly, 
reduction of ACAP3 expression in cerebral cortex of mice reduced neuronal 
migration (Miura and Kanaho 2017). Since knockdown of Arf6 yielded similar 
results, it shows that the GAP-activity of ACAP3 negatively regulates neurite 







ADAP1 (Arf AP with dual PH domains 1), also known as Centaurin-α1 was 
originally identified as a PI 3,4,5-P3, 46-kDa binding protein in rat brain 
(Hammonds-Odie et al. 1996). Through its GAP function, it negatively regulates 
Arf6 and prevents its plasma membrane localisation, and as a result, inhibits 
cytoskeleton organization (Venkateswarlu, Brandom, and Lawrence 2004). By 
inactivating Arf6 activation, ADAP1 has also been shown to inhibit β2-
adrenoreceptor internalisation  (Lawrence et al. 2005a). ADAP1 is also 
present in both neonatal and adult rat heart – suggesting a possible role in 
organ formation of a developing foetus. More complex physiological functions 
of ADAP1 have recently been discovered. It has been shown that ADAP1 
inhibits hypertrophy in cardiomyocytes (Giguere et al. 2018). In Rat 
Neonatal Ventricular Cardiomyocytes (RNVC), ADAP1 overexpression 
blocks Mek1ca-induced hypertrophy and reduces cell surface β1-integrin 
expression effecting the hypertrophic process of cardiomyocytes (Giguere et 
al. 2018). A review by (Stricker and Reiser 2014) have highlighted the 
central role of ADAP 1 in neuronal differentiation and neurodegenerative 
diseases.  
 
1.16 Arf6 and its GEF and GAP regulators in Cancer  
 
1.16.1 Arf6 role in Breast cancer 
 
Among the Arf family of small GTPases, Arf6 has been found to be uniquely 
involved in both cell invasion and migration of breast cancer cells (Hashimoto 
2004). Among a panel of breast cancer cells which include highly invasive 
MDB-MB-231 and the less invasive MCF-7, Arf6 expression was found to be 
expressed significantly more in the former, a clear indication of its utility in 
highly-invasive cancer cells. In the highly invasive/metastatic breast cancer 
cell line MDA-MB-231, Arf6 localises at invadopodia - actin-rich protrusions 
of the plasma membrane that are associated with degradation of the 
extracellular matrix in cancer invasiveness and metastasis. The localisation 
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and targeting (but not activation) of Arf6 at the site of actin ruffling in the 
leading edge is mediated by FIP3 – a Rab11-binding protein that also 
simultaneously binds Arf6 GTPases (Barr et al. 2008). In addition, siRNA-
mediated suppression of the Arf6 cycle blocked invadopodia formation, 
localized matrix degradation and matrigel chemo invasion (Hashimoto 2004). 
However, Arf6 knockdown had no role in the secretion of MMP2/MMP9.  
 
Arf6 is further utilized during extracellular matrix remodelling of invasive 
breast cancer cells. In coordination with endosomal motor adaptor proteins 
JNK-interacting protein 3 and 4, it mediates the trafficking and exocytosis of 
membrane type 1 -matrix metalloproteinase (MT1-MMP) (Marchesin et al. 
2015). This protease is critical for breakdown of collagen in the paracellular 
matrix, during metastasis. 
 
When mutant defective in hydrolysis of the bound GTP (Arf6 Q67L, 
constitutively active) or defective in the GTP binding-(Arf6 T27N, 
constitutively inactive) or transient overexpression of Arf6, it found that 
invadopodia was blocked. This inhibition of Arf6 function by both mutants 
showed that its active/inactive cycling is necessary for invasion of cancer cells. 
However, overexpression of Arf6 did not block migration; highlighting the 
precise and unequal involvement of Arf6 in migration and invasion of breast 
cancer cells. This also highlights the importance of Arf6 regulators: GEFs and 
GAPs whose expressions and localisations likely differ during cell migration 
and invasion.  
 
Overall, a key role of Arf6 in potentially all cancer malignancies is its ability 
to influence the reorganization of the actin cytoskeleton. Cell invasion and 
metastasis is a behaviour that involved F-actin organization that in order to 
generate force and move through the physical barrier of the tumour 
microenvironment, cancer cells induce protrusions at the leading edge of 
migrating cells and invadopodia. As such, lamellipodia and invadopodia are 
key cell conformations that are regulated by Arf6. Arf6 and the cytohesin 
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family of Arf6 GEFs play pivotal roles in the activation of Rho family small 
GTPases such as Rac1 (Santy, Ravichandran, and Casanova 2005). Previous 
studies have shown co-localisation of Rac1 GEFs with members of the 
cytohesin family, and that the formation of lamellipodia and subsequent cell 
migration is dependent on this coupling between Arf6 and Rac1 activity 
(Santy, Ravichandran, and Casanova 2005). This is exemplified by Arf6 
recruitment of Rac1 GEF, Kalirin, to the plasma membrane to facilitate Rac 
activation and lamellipodia formation  (Koo, Eipper, and Donaldson 2007). In 
EGF-induced breast cancer cell invasion, Arf6-mediated recruitment and 
activation of Rac1 to the plasma membrane directly activates the WRC 
(Marchesin, Montagnac, and Chavrier 2015) Incidentally, Arf6 also indirectly 
activates the WRC at the plasma membrane by recruiting cytohesin 2/ARNO 
to the plasma membrane, which activates Arf1 that subsequently activates 
the WRC (Humphreys et al. 2013a). The WRC complex is able to control actin 
cytoskeletal by stimulating the actin-nucleating activity of the Arp2/3 
complex at the membrane, leading to formation of lamellipodia actin 
polymerization and subsequently, cell invasion (Marchesin, Montagnac, and 
Chavrier 2015) (Chen et al. 2014).  
 
1.16.1.1 GEP100/BRAG2 (Arf6 GEF) and AMAP1 (Arf6 GAP) coordinate their 
action in breast cancer cell invasion and angiogenesis.  
 
It is commonly known that EGFR is overexpressed in breast cancer (Masuda 
et al. 2012). Arf6 is involved in the protein kinase C-dependent endocytic 
recycling of the oncogenic ERbB2 (Her2/neu) – a member of the EGFR 
tyrosine kinases -  at the juxtanuclear compartment, from where the receptor 
is trafficked back to the cell surface for additional rounds of ligand binding 
(Bailey et al. 2014).  
 
GEP100/BRAG2 – an Arf6-specific GEF, plays a significant role in EGF-
induced breast cancer cell invasion (Morishige et al. 2008). Following EGF 
stimulation, GEP100 binds to and associates with phosphorylated and un-
phosphorylated-EGFR (Tyr1068) through its PH domain. This stabilizes the 
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presence of GEP100 at the plasma membrane, where it activates Arf6. 
Meanwhile, EGF-induction recruits Arf6 to the activated receptor via the 
adaptor protein complex p66Shc/Grb2 (interestingly, while p66Shc 
potentiates Arf6 recruitment and activation, it attenuates Arf1 activity) 
(Haines, Saucier, and Claing 2014). Amongst all Arf6 GEFs expressed in the 
breast cancer cell line MDB-MB-231, only the presence of GEP100 was shown 
to be indispensable to Arf6-mediated invasion in MDB-MB-231 cells (a Sec7 
mutant construct of GEP100, reduced Arf6 activation and subsequently cell 
invasion). Incidentally, the knockdown of GEP100 did not affect the secretion 
of MMP2 and MMP9 - which complemented previous findings that Arf6 
knockdown does not induce their secretion during cell invasion (Marchesin et 
al. 2015). Overexpression of GEP100/Arf6 in less invasive breast cancer cell 
line MCF-7 increased cell invasion ability of these cells. Following this study, 
one signalling pathway was elucidated to show that EGF-induction leads to 
the activation of the GEP100/Arf6/ERK/uPAR cascade, which ultimately 
result in an increase in cell invasion ability (Hu et al. 2013)  
 
Amongst all Arf6 GAPs, AMAP1 has been the most extensively studied and 
has shown to interact with several different proteins; it therefore exhibits 
different functions throughout the development of tumours. AMAP1, also 
known as ASAP1 in mouse, is a downstream effector of Arf6 that plays an 
Arf6-dependent and independent in mediating breast cancer cell invasion. It 
is found to be expressed at abnormally high levels at invadopodia of breast 
cancer cells. (Onodera et al. 2005). Downstream of Arf6, AMAP1 binds to 
mesenchymal specific protein EPB51L5 to promote EMT and focal adhesion 
dynamics. EPB41L5 itself has been found to be induced by ZEB1 -  an EMT-
related transcriptional factor (Handa et al. 2016). In addition to its GAP 
activity, it co-localizes and binds the actin-nucleation-promoting factor 
cortactin - a key player in aggressive cancers due to its ability to modulate 
actin dynamics in lamellipodial protrusions of motile cells (MacGrath and 
Koleske 2012). It also binds paxillin - a focal adhesion adaptor protein that 
serves as an important scaffolding role at focal adhesion by recruiting 
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signalling molecules involved in the regulation of cell movement (López-
Colomé et al. 2017). This ability to form a trimeric protein complex 
(interestingly the close association of cortactin and paxillin is dependent upon 
the presence of AMAP1 which acts as a bridge between these two proteins, in 
the complex) with cortactin and paxillin promotes the invasiveness of breast 
cancer cells - while also serves as a potential therapeutic target: an AMAP1 
specific peptide was shown to block the formation of AMAP1-cortactin 
complex and effectively block invasion in breast cancer cell lines (Hashimoto 
et al. 2006). In the invadopodia of breast cancer cell line MDB-MB-231, the 
proline rich regions of AMAP1 binds the SH3 domain of the multi-adaptor 
protein CNI85, itself a binding partner of an E3 ligase, Cb1 (Nam et al. 2007). 
Through this interaction, Cb1 monoubiquitinates AMAP1 – a process found 
to be crucial (for yet unclear reasons) for the ability of AMAP1 to mediate 
breast cancer cell invasion.  
 
The presence of GEP100-Arf6-AMAP1-cortactin pathway has also been 
demonstrated in Human Umbilical Vein Endothelial Cells (HUVECs) during 
angiogenesis. The constitutive activation of the VEGFR as a result of ligand 
stimulation drives the growth of vascular network, increases cell 
permeability as a result of disorganization of VE-cadherin at the cell-cell 
junctions and increased cell migration. All of these events have been shown 
to occur in a VEGF-independent manner as a result of the GEP100-Arf6-
ACAP1 pathway (Hashimoto et al. 2011). Both GFP100 and AMAP1 are 
simultaneously overexpressed in HUVECs cells. Upon VEGF stimulation, the 
PH domain of GEP100 associates with the phosphorylated but not the 
unphosphorylayed Tyr951 of VEGFR2 in order to activate Arf6 (This 
activation however has no effect on the activation or ERK and Akt which 
occurred post VEGF stimulation independent of GEP100 presence). Activated 
Arf6 induces vascular network formation and cell migration – events that are 
dependent on the presence of both GEP100, AMAP1. Overall, Arf6 induction 
increase permeability of HUVEC cells as a result VE-cadherin endocytosis. 
Silencing of both GEP100 and AMAP1 abolishes the VEGF-independent 
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vascular network formation, cell migration and VE-cadherin endocytosis. 
Recently, Arf6 has also been shown to positively control endothelial leakage 
and tight junction protein zonula occludin protein 1(ZO-1), downstream of the 
Robo4 cell surface receptor. The secinH3 (a cytohesin Arf6 GEF inhibitor) 
inhibition of Arf6 activation has shown to increase ZO-1 levels leading to 
reduction in migration, branching and angiogenesis (Zhao et al. 2016).  
 
In breast cancer cell lines that exhibited high invasive phonotypes, AMAP1 
has also been shown to co-localise and directly bind to protein kinase D2 
(PRKD2) at the plasma membrane and mediate ß-1 integrin recycling 
through the EGFR pathway (Onodera et al. 2012). In serum starved 
(unstimulated) cells, AMAP1 normally resides on intracellular vesicles of 
tubovescicular structures and PRKD2 is found localised at endosomal 
compartments and at the Golgi apparatus. Upon stimulation by EGF, a sub-
fraction of AMAP1, PRKD2 and Rab5c (from the Rab family GTPases) are 
recruited to the plasma membrane where activated-Rab5c facilitates the 
interaction between AMAP1 and PRKD2 – which in turn allows for the 
interaction between the AMAP1-PRKD2 complex with ß-1 integrin. PRKD2 
has been implicated in sorting ß-1 integrin and E-cadherin in polarized 
MDCK epithelial cells (Yeaman et al. 2004). AMAP1 is able to form a complex 
with the cytoplasmic tail of ß-1 subunit of the integrin through its binding 
with PRKD2 and therefore facilitates the recycling of ß-1 integrin from the 
intracellular endosomes to the plasma membrane. Collectively, the EGFR 
pathway is used by AMAP1 and its interacting proteins for the recycling of ß-
1 integrin and promote invasion of cells.  
 
1.16.1.2 The regulatory role of ARAP3/Arf6 in breast cancer 
 
The inhibition of Arf6 activity by ARAP3 has also been depicted in the 
endocytosis and trafficking of the membrane bound MMP14 to late 
endosomes in breast cancer cells (Loskutov et al. 2015). This is facilitated by 
NEDD9 - a focal adhesion protein that acts as a scaffold to regulate signalling 
 81 
complexes important in cell attachment, migration and invasion as well as 
apoptosis and the cell cycle. NEDD9 acts as a negative feedback loop for Arf6: 
its expression/overexpression has been shown to lead to the depletion of Arf6 
activity. This is due to its ability to bind and bring ARAP3 (an Arf6 GAP) in 
close proximity to Arf6 at the early sorting endosome. At the same time, 
NEDD9 also binds GGA3 - an early endosome Golgi-localised Arf effector and 
promotes the GTP hydrolysis of Arf6/GGA3. Therefore, Arf6 inactivation 
allows for vesicle recycling and sorting to the late endosome for MMP14.  
 
1.16.2 Arf6 role in Prostate cancer 
 
In prostate cancer tissues, Arf6 has been shown to be overexpressed (Morgan 
et al. 2015). In the prostate cancer cell line PCa, Arf6 has been shown to be 
involved in the internalization of ErbB3/Her-3 receptor through 
micropinocytosis (the actin dependent endocytic pathway) and not the 
clathrin dependent or independent pathways (Koumakpayi et al. 2011). The 
exact mechanisms of which are yet to be known. ErbB3 nuclear translocation 
has been shown to be a predominant occurrence in prostate and breast cancer 
tissues and cell lines compared with healthy and it is associated with disease 
progression (Koumakpayi et al. 2006). Normally, internalized receptors are 
mainly recycled back to the plasma membrane or degraded in the lysosomes, 
however in prostate cancer tissues, ErbB3 escapes recycling and degradation. 
Recent studies have also implicated Arf6 as a modulate of androgen-induced 
prostate cancer cell migration (Munkley et al. 2017).  
 
1.16.3 Arf6 role in Pancreatic cancer 
 
In pancreatic tissues, high Arf6 expression correlates with poor prognosis. 
Recently, in PANC-1 and MiaPaCa-2 cells, Arf6 knockdown reduced the 
expression of key glycolytic proteins GLUT1, HK2 and LDHA and hence cell 
proliferation, suggesting that Arf6 also contributes to the Warburg effect 
(Liang et al. 2017). In pancreatic cancer cell lines S2-013 (moderately 
differentiated) and PNAC-1 (poorly differentiated), Arf6 has been also shown 
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to mediate the protrusion of the peripheral cell front and subsequently 
regulate cell migration and invasion of these cells (Taniuchi et al. 2014). Here, 
Arf6 mRNA is post-transcriptionally regulated by the RNA binding protein 
Insulin-like growth factor-2 mRNA binding proteins 3 (IGF2BP3). IGF2BP3 
converges on the 3’UTRs of Arf6 mRNA. This juxtaposition of their binding 
site contributes to their co-localisation and eventual local translation of Arf6 
at the cell periphery. IGF2BP3 is contained in stress granules – cytoplasmic 
RNA granules that are involved in transport of RNA binding proteins (which 
play roles in RNA maturation, turnover, translation and movement of 
transcripts throughout the cell). These stress granules are transported along 
microtubules by KIF20A (a member of the kinesin family of motor proteins) 
transports stress granules containing IGF2BP3-bound mRNA Arf6 to cell 
protrusions (Taniuchi, Furihata, and Saibara 2014). Interestingly, IGF2BP3 
is predominantly detected in malignant tissues whereas in benign tissues it 
remains elusively undetected, highlighting its key role in driving tumour 
progression (Schaeffer et al. 2010, Kobel et al. 2009). Hence, IGFBP3 plays a 
role in cell proliferation and migration via post transcriptional regulation due 
to its binding with mRNA and assembles into protein-mRNA complexes.  
 
Furthermore, tumour cells derived from IGF2BP3 knockdown mice was 
shown to display cytoplasmic and not plasma membrane localisation as well 
as reduced peripheral actin structures (Taniuchi et al. 2014). This was 
restored through Arf6 overexpression. Overall, it was shown that IGFBP3 
drives the rearrangement of peripheral actin to induce formation of additional 
membrane protrusions. It does this through binding to Arf6 and most likely 
other mRNA transcripts such as ARHGEF4 that play key roles in ruffle 
organization, filopodia and lamellipodia assembly. This binding allows for 
local translation of Arf6 to contribute to actin remodelling and subsequently, 




1.16.4 Arf6 role in Gastric cancer 
 
Similarly, to other malignancies, in gastric cancer, Arf6 has been shown to 
play a role in the induction of an EMT phenotype, characterized by induction 
of mesenchymal markers vimentin and N-cadherin and a reduction of the 
epithelial marker, E-cadherin (Zhang et al. 2015). In EGF-induced gastric 
cancer cell line SGC-7901, the EGF/Arf6/pERK pathway has been implicated 
in the downregulation of Wnt5a – a tumor suppressor gene. Following 
EGF/Arf6 activation of ERK, pERK is transported from the cytoplasm to the 
nucleus, where it is able to bind (through its putative 12 binding motifs) to 
the Wnt5a promoter region, thereby repressing its transcription. Overall, it 
was shown that expression of Wnt6a correlative negatively with pERK, and 
its downregulation was significant in cancer tissues compared to healthy. 
Therefore, EGF/Arf6/pERK/Wnt5a pathway is a signalling pathway utilized 
by gastric cancer cells for metastasis.  
 
1.16.5 Arf6 role in Renal Cancer 
 
In clear cell Renal Cell Carcinomas (ccRCCs), the overexpression of LPA-
induced Arf6 activation promotes invasion, metastasis and drug resistance 
(Hashimoto, Mikami et al. 2016). In contrast to breast cancer cells, where 
RTK signalling is prevalent, ccRCC cells show no invasive activities when 
treated with various ligands such as the EGF, HGF, insulin, VEGF and 
PDGF AA/BB.. This abrogates their possible role in metastasis in renal 
cancer. However, in response to LPA, invasive activity of ccRCC cell line 786-
O was significantly enhanced. Following activation by LPA, Arf6 
accumulation was observed in the invadopodia of 786-O cells. The 
involvement of Arf6 mesenchymal pathway was further confirmed through 
knockdown of Arf6 leading to reduction of invadopodia. Although GEP100 is 
essential for Arf6 activation under RTKs in breast cancer cell lines, neither 
GEP100 nor the cytohesin family of Arf GEFs (confirmed through SecinH3 
inhibition) required for Arf6 activation in ccRCCs. In contrast the EFA6 
family of Arf6-sepecific GEFs (EFA6 A-C but not EFA6R/EFA6D) shown to 
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play a role in LPA stimulation promoted cell invasion activities through Arf6 
activation. In vitro studies showed that following LPA stimulation of GPCRs, 
the down-stream GTP-bound Gα12 (and not Gα13, Gαq, Gαi2 or Gß1,), a sub 
unit of heterotrimeric G-protein, binds to EFA6 A-C GEFs but not EFA6R. 
This binding is due to conserved G-protein signalling domains-like in the N-
terminal region of EFA6 A-C. These conserved amino acids are notably absent 
in EFA6R. Overall, in highly invasive renal cancer cells, LPA induction was 
shown to activate the Arf6 mesenchymal pathway (through recruitment of 
the EFA6 A-C family) to promote cancer metastasis.  
 
1.16.6 Arf6 Role in Colon Cancer 
 
In colon cancer, the serologically defined colon cancer antigen-3 is shown to 
specifically interact with Arf6 via its 101-C-terminal amino acids (Sakagami, 
Hara et al. 2016). SDCCAG3 is also predominately expressed in the testis, 
suggesting that its interaction (not yet established) with Arf6 may be an 
essential component of malignancy. Furthermore, its localisation is 
dependent on its Arf6 interaction.  
 
1.17 A brief introduction to epigenetic regulation in cancer 
 
A single cell contains close to 2 meters of DNA, wrapped around a histone 
octamer protein (H2A, H2B, H3 and H4), to make the nucleosome (often 
likened to ‘beads-on-a-string’), which are then further condensed to chromatin 
structures. Epigenetics refers to heritable changes in gene expression that 
occur without changes to the DNA sequence. DNA methylation and histone 
modifications (such as methylation, acetylation, ubiquitination and 
phosphorylation) are the two primary mechanisms through which gene 
expression is regulated. DNA methylation is linked to long-term gene 
expression changes whereas histone modifications are more specific and local 
(Sarkar & Rosenthal 2013). 
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The methylation of DNA occurs at the 5'-cytosine-phosphodiester bond-
guanine-3' position by a transfer of a methyl group from S-Adenylyl-L-
methionine. This is catalysed by a number of DNA methyltransferases 
(DNMTs) and generally leads to repression of gene expression (Baylin and 
Ohm 2006). Post-translational modification of histones mainly includes 
acetylation, methylation and phosphorylation. These modifications are 
catalysed by enzymes that ‘lay down’ or remove the mark for each type of 
modification. Histone modifications can either activate or inactivate gene 
expression (Zhang and Dent 2005, Santos-Rosa and Caldas 2005). 
 
In addition to those genetic mutations that lead to tumour transformation, 
epigenetic changes are also involved in tumour initiation and progression 
(Flavahan, Gaskell, and Bernstein 2017). For example, following cellular 
transformation as a result of DNA mutation, epigenetic transformation may 
aggravate tumour progression; in other words, epigenetic changes enhance 
the probability of tumour progression (Feinberg 2004). In other cases, 
epigenetic changes may initiate cellular transformation as well as be involved 
in their progression. It is also possible that epigenetic changes may ‘prime’ 




















1.18 Aims and Objectives 
 
The detection of EOC in early stages will dramatically improve survival. 
There are no reliable biomarkers that have both the sensitivity and specificity 
to detect EOC tumorigenesis. Although it is extremely valuable for 
monitoring treatment responses, the currently available biomarker’s (CA-
125) sensitivity and specificity is not sufficiently high enough for early 
detection. Therefore, there is an urgent need for identifying new biomarker(s) 
that could diagnose EOC at an early stage. Based on our preliminary data 
and a prior publication (Pils et al., 2005), we hypothesised that decrease in 
EFA6R expression correlates with progression of ovarian adenocarcinomas 
and therefore it could be potentially used as a biomarker to diagnose early 
stage EOC. To test this hypothesis, we: 
 
1.  evaluated EFA6R as a biomarker for EOC by analysing its expression in 
ovarian tissue and ovarian cell lines,  
 
2. studied how EFA6R expression is regulated in EOC cell lines and ovarian 
tissues isolated from different stages of the cancer,  
 
3. analysed the effect of EFA6R expression on cell migration and invasion while 
studying the signalling pathways involved in these phenotypes.  
 
4.  assessed EFA6R isoforms expression and function roles and contribution of 
distinct regions within the large isoform functions as an Arf6 GEF.  
 
In summary, the proposed study will aid in the development of biomarker for 
early detection and targeted therapy for EOC. Since detection of EOC in early 
stage would drastically improve survival, the proposed study addresses the 
priority areas of prevention and early intervention. A note to the reader: in 
this thesis we studied EFA6R isoform B (in result chapters 3 and 4) and 
EFA6R isoform A (in result chapter 5).  
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2.1.1 Double distilled water (ddH2O) 
 
The  Milli-Q® integral water purification system (Millipore, UK) was used to 
produce type 1 ultrapure water with a specific resistance of 18.2 MW × cm 
(million ohms) at 25oC – considered to be absolute pure water, free of any 
detectable chemicals, bacteria, particulates, pyrogens (endotoxins), RNases 
and DNases.  
 
2.1.2 Standard laboratory chemicals, reagents and consumables 
 
All reagents and chemicals were purchased from Sigma Aldrich (UK) – a 
subsidiary of Merck KGaA (Germany), unless otherwise stated. Glass 
coverslips (13mm for use in 24-well plates) were purchased from VWR 
international (UK). Prior to use, they were washed in nitric acid for 5 times, 
rinsed 10 times with ddH2O, twice washed with methanol and transferred to 
a 50 ml falcon tube before baking for 4 hours (hrs) at 80oC. General 
plasticware were from either VWR or Fisher Thermo-Scientific. 
 
2.1.3 EFA6R Plasmid DNA constructs and the primers used for their 
generation 
  
All human EFA6R plasmid DNA constructs were made in the laboratory, with 
the help of Professor Venkateswarlu Kanamarlapudi (Table 1). The following 
plasmids were already available in the lab: Arf6-HA/pXS, Arf1-HA/pXS, Arf6-
pmCherry, Arf1-pmCherry, Cytohesin1-pEGFPC2, Cytohesin2-pEGFPC2, 
Cytohesin3-pEGFPC2, Cytohesin3-pEGFPC2, Cytohesin4-pEGFPC2, 
EFA6A-pEGFPC2, EFA6C-pEGFPC2, Arf1-T31N-pEGFPC2, Arf1-Q711-
pEGFPC2, Arf6-T27N-pEGFPC2, Arf6-Q67L-pEGFPC2 and described some 
of these constructs elsewhere (Kanamarlapudi 2014a) 
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Table 1. Primer information for EFA6R wild-type, mutation and deletion 
constructs 
*Where applicable, restriction endonuclease sequence shown in italics and 
the gene coding or mutated sequence with underline. 
QFC = Quick-Fusion Cloning; Q5SDM = Q5 site-directed mutagenesis; QCII 
= QuikChange II  
Construct Information 

























































2.2.1 Bacterial cell culture 
 
2.2.1.1 Preparation of ultracompetent Escherichia coli strain XL1-blue cells 
for routine cloning applications 
 
The E.coli strain XL1-Blue ultracompetent (New England Biolabs, NEB, US) 
was used as the host for plasmid DNA transformation, amplification and 
generation. Using septic techniques, 5 ml of Lysogeny Broth (LB media 
containing 12.5µg/ml tetracycline was inoculated with a single colony of XL1-
Blue cells and grown at 37oC/250 rpm for 8-10 hrs. To 100ml of LB containing 
12.5µg/ml tetracycline in 250ml flask, 1 ml of the culture was added and 
grown overnight at 37oC/250 rpm. A 5% inoculum was made by adding 25 ml 
of the overnight culture to 2 x 500 ml of Super Optimal Broth [SOB, 2% (w/v) 
bacto tryptone, 0.5% (w/v) yeast extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2 and 10mM MgSO4, pH 6.7-7.0] in a 2L flask and grown at 18oC/250 
rpm (multitron standard incubation shaker, Info HT, UK) until the culture 
reached an absorbance (A) at 600nm (A600) of 0.5-0.6 (~18 hrs). The culture 
was then incubated in ice for 10 minutes (min) and thereafter transferred into 
a washed, ethanol sterilized 1000 ml centrifuge bottle for centrifugation at 
6000 xg (using a Beckman Coulter Avanti J-26 XP centrifuge and a Beckman 
JLA-8.1 rotor) for 10 min at 4oC. The cell pellet was washed once with 380 ml 
of a sterilized (using a 0.2µm filter) ice-cold Transformation Buffer (TB) 
[10mM PIPES, 55mM MnCl2, 15mM CaCl2, 250mM KCl pH 6.7], the mixture 
was centrifuged at 6000 xg (using a Beckman Coulter Avanti J-26 XP 
centrifuge and a Beckman JLA-8.1 rotor) for 10 min at 4oC. The pelleted cells 
were resuspended in 10 ml of ice-cold TB, added 750 µl DMSO (7.5% [v/v]) 
and placed on ice for 10 min. In sterile microcentrifuge tubes, 1 ml aliquots of 
cells were allocated and immediately snap frozen in liquid nitrogen; they were 
then placed at -80oC for long term storage. The competency (number of 
colonies formed for µg of plasmid DNA) of XL1-Blue cells was established by 
chemical transformation using 1ng/ml PUC18 plasmid per 25µl of competent 
 90 
cells and plating in a 10-fold serial dilution on LB-agar containing ampicillin 
(100µg/ml). 
 
2.2.2 Generation of GFP-EFA6R wild-type plasmid DNA 
 
PCR amplification of cDNA insert 
 
To generate the full-length human EFA6R, the cDNA clone (obtained from 
NITE Biological Resource Canter with Clone ID FCBBF1000023) was 
amplified by Polymerase Chain Reaction (PCR) using the Universe High-
Fidelity Hot Start DNA polymerase (Biotool, US) and sequence-specific 
primers containing EcoRI (sense) and SalI (antisense) restriction enzyme 
sites (See table 1 for primer information). Here, a 50 µl reaction mixture was 
made containing the following: 1 µl Universe High-Fidelity Hot Start DNA 
polymerase [1 U/µl], 1 µl of dNTP [500 µM final conc.], 0.2µl of sense and 
antisense primer [0.4µM final conc.], 0.3 µl of template cDNA [~ 0.6 nM final 
conc.], 25µl of 2x Universe buffer [1x] and 22.3 µl of ddH2O. PCR was 
conducted using the following cycling conditions: Initial denaturation at 95oC 
for 3 min, 4x cycles of PCR at 95oC for 15 secs, 60oC for 15 secs and 72oC for 
2 min followed by x29 further cycles of 95oC for 15 secs and 72oC for 2 min. 
Final extension of 72oC for 5 min was followed by hold at 4oC.  
 
Analysis of PCR product using agarose gel electrophoresis 
 
The PCR product was analysed on 1% (w/v) agarose gel using electrophoresis. 
Here, 1 g of agarose was dissolved (by microwave heating) in 100 ml of 1x 
Tris-Base, acetic acid and EDTA (TEA) buffer (0.4M Tris acetate, 0.01M 
EDTA, pH 8.3) (Bio-Rad, US) and 10 µl of 10 mg/ml of DNA-binding Ethidium 
Bromide was added. When the agarose gel was set (at room temperature) into 
the casting tray (Whatman, Maidstone, UK), the previously inserted comb 
was removed and TAE buffer was added to the tank to cover the gel. The PCR 
product was mixed with a 6x loading dye (0.25% [v/v] bromophenol blue, 30% 
[v/v] glycerol) and then loaded into the wells with a HyperLadder™ 1kb 
 91 
molecular weight marker. Using a PowerPac 200 (Bio-Rad, US), the gel was 
run at 100 volts for 15 min and subsequently viewed on a GelDoc machine 
(Bio-Rad, US) using Trans UV light.  
 
DNA extraction and purification   
 
The purification of the DNA fragment from the agarose gel was carried out 
using the QIAquick Gel Extraction Kit (QIAGEN, US), according to the 
manufacturers protocols. Here, while under Trans UV light, the DNA 
fragment from the agarose gel was excised with a clean, sharp scalpel and 
weighed in a 2 ml microcentrifuge tube. Based on the weight of the excised 
fragment, 3 volumes of Buffer QG to 1 volume of gel was added and incubated 
in a water bath set at 50oC for 30 min. When the gel slice was completely 
dissolved, 1 volume of isopropanol was added. To bind DNA to a QIAquick 
spin column, the sample was applied to the column and centrifuged in a table 
top Eppendorf 5415D centrifuge for 1 min at 17900 x g. The column was then 
washed with 750 µl of Buffer PE and centrifuged for 1 min at 17900 x g and 
any residual wash buffer was removed by a further centrifugation. The DNA 
was eluted into a 1.5 ml microcentrifuge microfuge tube by adding 50 µl of 
Buffer EB (10mM Tris-HCl pH 8.5) 
 
Fusion of insert to vector to make the GFP-tagged EFA6R construct 
 
The Quick-Fusion Cloning Kit (Biotool, US) was then used for directional 
cloning of the DNA fragment into a pEGFPC1 vector (Clonetech) for 
expression as green fluorescence protein (GFP)-tagged fusion protein in 
mammalian cells. Here, a 10 µl reaction mixture was made containing the 
following: 2 µl of the DNA fragment [66ng final conc.], 1 µl of the linearized 
vector [50ng final conc.], 1 µl Fusion enzyme, 2 µl of 5x Fusion buffer and 4 µl 
of ddH2O. For the fusion reaction, the mixture was incubated at 37oC for 1 hr 
and then placed on ice prior to transformation into bacteria. Here, 100 µl of 
XL1-Blue cells were added to the fusion reaction mixture (10 µl) and gently 
mixed and incubated on ice for 30 min, heat shocked at 42oC for 60 seconds 
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(sec) and transferred on ice for 2 min. The reaction mixture was added to 500 
µl of antibiotic-free LB media and incubated at 37oC/250 rpm in an orbital 
incubator for 1 hr. 100µl of culture was spread on LB-agar containing 50 
mg/ml Kanamycin (Kan) and incubated for at 37oC. About 16 hrs later, 
individual colonies from the LB plate were picked and incubated with 5 ml of 
Kan-containing liquid LB medium and incubated at 37oC/250 rpm overnight. 
The following day, a small amount of the culture was streaked on antibiotic 
containing LB agar and the rest of the culture was purified using the QIAprep 
spin Miniprep Kit (Qiagen, US) according to the manufacturers protocols. 
Here, the culture was initially centrifuged at 3320 x g (4000 rpm) for 5 min 
and the pellet was resuspended in 250 µl of buffer P1 and transferred to a 2 
ml epp. 250 µl of buffer P2 was added and mixed by inverting 4-6 times, 
followed by the addition of 350 µl of buffer N3 and again, mixed by inverting 
4-6 times. The mixture was centrifuged at 13000 rpm for 10 min. The 
supernatant was added to a QIAprep spin column and centrifuged for 30-60 
secs. The spin column was washed by addition 750 µl of buffer PE and 
centrifuged for 30-60 secs. Any residual was buffer was removed by a further 
centrifugation for 1 min and then the QIAprep column was placed in a clean 
1.5 ml microcentrifuge tube. To elute DNA, 100 µl of buffer EB (10mM Tris-
Cl, pH8.5) was added, left to stand for 1 min and subsequently centrifuged 
for 1 min (13000 rpm), resulting in a minipreparation of the desired plasmid 
DNA. 
 
Confirmation of cDNA insert by restriction enzyme digest and DNA 
sequencing 
 
To confirm the presence of the EFA6R insert within the GFP-vector, a 
restriction enzyme digest was done using 0.5 µl of EcoRI and 0.5 µl of SalI 
and 1 µg of the template plasmid DNA in 1µl of 1x H SuRE/Cut buffer (Roche, 
US) for optimal digestion. The mixture was incubated at 37oC for a minimum 
2 hrs in a Grant GD100 water bath. The resulting digested fragments was 
analysed on 1% [w/v] agarose gel. To make the gel, 1 g of agarose was added 
to 100 ml of TEA buffer and dissolved by heating in a microwave. A final 
 93 
confirmation of the generated plasmid was done by DNA sequencing (DNA 
sequencing Services, University of Dundee, UK) where 600 ng of plasmid and 
3.2 µM of sequencing primer was made up to 30 µl with ddH2O. The mixture 
was vortexed and spun down and sent for sequencing.  
 
Midiprep preparation to increase plasmid DNA yield and preparing glycerol 
stocks for long term storage of E.coli cell-containing GFP-EFA6R  
 
The GenElute HP Plasmid Midiprep Kit was used to isolate plasmid DNA 
from recombinant XL1 blue E.coli cultures according to the manufacturer’s 
protocols in order to generate a high yield of plasmid DNA, appropriate for 
experimentation. Here, a single colony was picked from the steaked plate (see 
above) and inoculated with a started culture of 1.5 ml of Kanamycin (Kan)-
containing LB medium and incubated at 37oC/250rmp overnight. For long 
term storage of XL-1 blue containing plasmid DNA, 1 ml of the culture was 
added to 0.5 ml of 50% glycerol and stored at -80oC. Meanwhile, 100 µl from 
the original culture added to 100 ml of LB-containing Kan and inoculated at 
37oC/250rmp overnight. The overnight culture was harvested by 
centrifugation at 5000 x g for 10 min and the supernatant discarded. The 
pellet was resuspended in 4 ml of resuspension/RNAse A solution and the 
cells were lysed by adding 4 ml of the lysis solution, followed by immediate 
inversion 6-8 times and allowing the mixture to sit for 3-5 min. The lysed cells 
were neutralized by adding 4 ml of chilled neutralization solution and gently 
inverted 4-6 times. 3 ml of binding solution was added to the neutralized 
lysate and inverted 1-2 times and immediately poured into the barrel of a pre-
set up filter syringe. The lysates were allowed to sit for 5 min. In the 
meantime, 4 ml of the column preparation solution was added to the binding 
column and allowed to pass by vacuum using a vacuum manifold. After using 
a plunger to expel the cleared lysates into the column, 4ml each of Wash 
solutions 1 and wash solution 2 was added and allowed to pass through the 
filter syringe. The vacuum was left on for 10 min to dry the column. The 
binding column was transferred to a collection tube and 1 ml of elution 
solution was added and centrifuged in a swinging bucket rotor at 3000 x g for 
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5 min. Recovery and purity of the plasmid DNA was determined by using a 
NanoDrop TM 2000/c Spectrophotometer (Thermo Fisher Scientific, US). The 
ratio of absorbance at A260-A320/A A280-A320 was between 1.8 and 2.0, 
conforming the purity of the plasmid DNA. 
 
2.2.3 Generation of GFP-tagged point mutants E682K, R827E, K828E, and 
double point mutant R827E/K828E 
 
The EFA6R E682K and R827R mutants was generated using QuikChange II 
site-directed mutagenesis kit (Stratagene, US) by setting up a reaction 
mixture using 0.2 µl of template DNA [50ng final conc], 0.2µl of sense and 
anti-sense primers (see table 1 for primer information) [125 ng final conc], 
0.2µl of dNTP, 2 µl of 10x Reaction buffer, 1.2 µl of Quick Solution Reagent 
and 15 µl of ddH2O. To this, 1 µl of PfuUltra HF DNA polymerase (2.5U/µl) 
was added. PCR was conducted using the following cycling conditions: Initial 
denaturation at 95oC for 1 min, 18 x cycles of denaturation and annealing at 
95oC for 50 secs, 60oC for 50 secs and elongation of 68oC for 7 min (1 min/kb). 
Final extension of 68oC for 7 min was followed by hold at 4oC. The PCR 
product was then digested by adding 1 µl of DpnI restriction enzyme (10U/µl) 
and incubated at 37oC for 2 hrs to digest the parental dsDNA. 10 µl of the 
product was then transformed into 100 µl of XL1-Blue cells for amplification 
and eventual purification of plasmid DNA using the QIAprep spin Miniprep 
Kit followed by sequencing confirmation of the mutation. Finally, the 
GenElute HP Plasmid Midiprep Kit for production of a high quantity of 
plasmid DNA for experimental purposes.  
 
The EFA6R K828E, and double point mutant R827E/K828E were generated 
using the Q5 Site-Direct-Mutagenesis kit (NEB, US) by setting up a 30 µl 
reaction mixture using 0.2 µl of template DNA [~12 ng final conc], 0.3 µl of 
sense and anti-sense primers (see table 1 for primer information) [0.5 µM 
final conc], 0.3 µl of 25 mM dNTP mix [20 µM final conc], 6µl of 5x QSR 
reaction mixture, 6 µl of 5x Q5 High GC Enhancer and 17µl of ddH2O. PCR 
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was conducted using the following cycling conditions: Initial denaturation at 
98oC for 30 secs, 25x cycles of denaturation and annealing at 98oC for 10 secs, 
55oC for 30 secs, elongation at 72oC for 2 min. Final extension of 72oC for 2 
min was followed by hold at 4oC. The PCR product was then treated with KLD 
(oligonucleotide kinase, T4DNA ligase and DpnI) where a reaction mixture of 
0.5 µl of PCR product, 2.5 µl of 2x KLD reaction buffer, 0.5µl of 10X KLD 
enzyme mix and 1.5 µl of ddH2O and incubated for at room temperature for 1 
hr. Thereafter, 5 µl of the product was then transformed into 50µl of XL1-
Blue ultracompetent cells for amplification, purification and sequencing 
confirmation of plasmid DNA.  
 
2.2.4 Generation of GFP-tagged deletion constructs ∆N548, ∆Sec7, ∆PH, ∆CC 
and N548 
 
The generation of the EFA6R construct ∆N548 along with the Arf6-HA/pXS, 
Arf1-HA/pXS plasmids have been previously described by (Kanamarlapudi 
2014b). All other deletion constructs were generated using the Q5 Site-Direct-
Mutagenesis kit (NEB, US) with a minor difference in the reaction mixture 
as compared to generation of the point mutants mentioned above. A 20 µl 
reaction mixture contained 10 µl of Q5 Hot Start High-Fidelity 2X Master 
Mix, 0.2 µl of template DNA [~8 ng final conc], 1µl of sense and anti-sense 
primers [1µM] (see table 1 for primer information) and 10µl of ddH2O. The 
PCR product then underwent KLD reaction, followed by transformation, 
purification of plasmid DNA and sequencing to confirm the generation of the 
desired constructs (see above). 
 
2.2.5 Mammalian cell culture 
 
2.2.5.1 Maintenance, cell counting, resuscitation and freezing cells  
 
All cell lines were maintained at 37oC/5%CO2 in a humidified incubator. Cell 
counting and viability determination was carried out following trypsinisation 
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of adherent cells and the cells in suspension were counted using the 
Countess® automated cell counter (Invitrogen, UK) to determine cell number. 
Here, 10 µl of 0.4% [v/v] trypan blue stain was mixed with 10 µl of the cells in 
suspension in a 0.5 ml microfuge tube. They were mixed by pipetting and 
added to the countess chamber slide. The slide was inserted into the Countess 
® reader and the total number of cells, number of live and dead cells and 
percentage viability of the cells were noted. Based on the live cell number, 
appropriate number of cells were seeded in cell culture plates.  
 
Thawing of cryopreserved cells 
 
Cells taken from liquid nitrogen were quickly thawed at 37oC in a water bath. 
The cells were then added to 10 ml of appropriate Full Serum Medium (FSM), 
spun down at 300 x g for 5 min and resuspended in 10 ml of fresh FSM. The 
cell pellet was then gently dissociated and then transferred into a 10 cm2 cell 
culture plate and incubated under healthy maintenance conditions. All cell 
lines were used for experimentation only after two passages.  
 
Making cell stocks for storage 
 
Prior to freezing down cells in liquid nitrogen, cells were grown in five 10 cm 
plates to 90% confluency, trypsinized and neutralised by resuspending each 
plate of cells in 10 ml of FSM. Following centrifugation (Heraeus Biofuge 
Primo R centrifuge (DjB LAbcare Ltd, UK) fooled cells at 350 x g for 5 min, 
the cell pellets were dissociated in 5 ml of cryopreservation medium (65% [v/v] 
Serum Free Medium [SFM], 25% [v/v] Foetal Bovine Serum [FBS], 10% [v/v] 
DMSO) and transferred 1ml of cells into each of 5 cryovial. These cryovial 
were then transferred in a Nalgene TM Cryo 1oC freezing container (Thermo 
Fisher Scientific, UK), previously filled with isopropanol and placed at -80oC 
overnight (this reduces the temperature gradually by 1oC/min) before being 
transferred and stored in liquid nitrogen. ReN cells were cryopreserved using 
the neural stem cell freezing medium from Millipore (US).  
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2.2.5.2 Ovarian Healthy and Cancer cell lines used in results chapter 3 and 
4. 
 
The immortalized healthy Human Ovarian Epithelial Cell (IOC) was 
provided by Dr. Deyarina Gonzalez (Swansea University Medical School 
[SUMS], UK); the human ovarian cancer cell lines SKOV-3 was purchased 
from ATCC (USA); OVSAHO and CAOV3 cells were obtained from Dr. 
Marion Curtis (University of Chicago Biomedical Sciences, USA). All cell lines 
were cultured aseptically in RPMI 1640 (RPMI) supplemented with 10% [v/v] 
FBS, 2 mM [v/v] glutamine, 100 U/ml [v/v] penicillin and 0.1 mg/ml [v/v] 
streptomycin (PSG), termed Full Serum Medium (FSM). The OVCAR3 cell 
line was cultured in RPMI supplemented with 20% [v/v] FBS, 1% PSG [v/v] 
and 0.01% [v/v] human recombinant insulin.  
 
2.2.5.3 Cell lines used in results Chapter 5.  
 
HeLa, COS-7, HEK293, A549, SHSY-5Y, HT22 cells were maintained in 
DMEM; MCF-7, IOC, COV644, Jurkat and CAOV3 cells were maintained in 
RPMI 1640. These cell lines culturing media were all supplemented with 10% 
fetal bovine serum, Penicillin (100 U/ml), Streptomycin (0.1 mg/ml) and 
Glutamine (2mM) (=1% PSG). PC12 cells were maintained in DMEM, 
supplemented with 10% FBS and 5% Horse serum and 1% PSG. The ReN cell 
VM Immortalized cells (derived from the ventral mesencephalon region of 
human fetal brain tissue) have the ability (under certain conditions) to 
differentiate into a high level human dopaminergic neurons, in vitro (Kindly 
provided by Dr Jeffrey Davies [SUMS], who obtained the cells from Sigma-
Aldrich) (Cell line information can be found at  
http://www.merckmillipore.com/GB/en using the product code: SCC008). 
These cells were maintained in Advanced DMEM/F-12 media (Gibco, US), 
supplemented with Penicillin (100 U/ml), Streptomycin (0.1 mg/ml), 4mM 
glutamine, 50µg/ml gentamycin, 1xB-27 supplement (Gibco, US), 50µg/ml 
Heparin, 20ng/ml bFGF and 20ng/ml EGF. The cells were cultured on coated 
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plates using the following protocol: ECM Gel from Engelbreth-Holm-Swarm 
murine sarcoma (Matrigel; Sigma) (prepared to a protein concentration of 8-
12mg/ml) was diluted 1/100 in Advanced DMEM/F-12 medium and coated on 
plates and allowed to solidify for 4-24 hours at 37°C/5%CO2. The following 
day, the coating was washed twice with PBS and immediately after, ReNcell 
maintenance medium was added. The ReNcell differentiation media is 
similar to the maintenance media, but without bFGF and EGF. All cells were 
maintained at 37°C/5%CO2 in a humid incubator. Cell counting was 
performed using Countess ® cell counter (Invitrogen, UK). 
 
To subculture cell lines in 2.2.5.2. and 2.2.5.3 in 10cm culture plates, the FSM 
was aspirated (Integra Bioscience, USA) and cells were washed with 1.5 µl of 
PBS (without Ca2+ or Mg2+). Following aspiration, 1 ml of trypsin-EDTA 
(0.05% [w/v] trypsin, 0.04% [w/v] EDTA, made in PBS) was added to the cells 
in the culture plate and the plate was placed in the incubator for ~2 min for 
cell detachment from the culture plate, the cells were then resuspended in 10 
ml of FSM and transferred to a 50 ml tube. To prevent clumping, the cells 
were vortexed and then diluted in new cell culture plates (for ReN cells, these 
plates were pre-coated with Matrigel). Cells were subcultured for 
maintenance and experimentation when they reached ~80-90% confluence.  
 
2.2.6 Transient Transfection of plasmid DNA and siRNA 
 
The siRNA oligonucleotides used in this study specifically targeted human 
EFA6R. They were: siEFA6R 1 target sequence: 5’-
GCUACUGAGUAACGAUGAA-3’, siEFA6R 2 target sequence: 5’-
GGAGAAAGCUAACGGAACA-3’, siEFA6R 3 target sequence: 5’-  
GGAUAGCGGAACGGAACA -3’ siEFA6R A target sequence: 5’-
GCCAUCAUUAUCAAUGACCG-3’ and siEFA6RB target sequence: 5’- 
GGAGAAAGCUAACGGAACA -3’. In addition, Arf6 target sequence 5’-
GCACCGCAUUAUCAAUGACCG-3’ and Arf1 target sequence: 5’- 
UAACGGAACAAUUAUCAA-3’ and universal negative control siRNA were 
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also utilized. All siRNA was synthesized by Eurogentec (Kanamarlapudi 
2014a, Kanamarlapudi, Thompson, et al. 2012). The final concentration of all 
siRNAs used in the transfection was 200nM. 
 
2.2.6.1 Transfection of HEK293, PC12 and HeLa cells 
 
 
JetPRIME ® (Polypus, US) transfection reagent was used to transfect 
HEK293, PC12 and HeLa cells, according to the manufacturer’s protocols. 
The cells were plated 24 hrs prior to transfection so that at the time of 
transfection they were 60-80% confluent for plasmid DNA transfection and 
40-50 % confluent for siRNA transfection. The transfection reagent conditions 
are displayed in the table 2. 
 
Table 2. DNA transfection guidelines according to the cell culture vessel  
Culture vessel Jetprime 
Buffer (µl) 
Amount of 







24-well plate 50 0.25-0.75 0.5 1 
6-well/3cm 
plate 
200 1-3  2.0 4 
10 cm plate 500 5-15 10.0 10 
 
The mixture of JetPrime buffer, JetPrime Reagent and nucleic acid were 
vortexed for 10 secs and incubated for 10 min at room temperature (RT). The 
transfection mixture was added dropwise to the cells followed by gently 
shaking the plate to ensure equal distribution. When necessary, the medium 
was changed 24 hrs post-transfection. 
 
2.2.6.2 Transfection of SKOV-3, CAOV3 and ReNcells  
 
SKOV-3, CAOV3 and ReNcells were transfected using the Neon Transfection 
System (Thermo Fisher Scientific, US) where nucleic acid is introduced in 
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cells using electroporation. To set up the Neon pipette station, the Neon Tube 
was filled with 3 ml of Electrolytic Buffer (Buffer E for 10 µl Neon tips and 
Buffer E2 for 100 µl Neon tip) – enough to cover the side electrode. The neon 
tube was then inserted into the Neon pipette station until a click sound is 
heard to indicate proper fitting. Cells were grown to ~90% confluency on the 
day of transfection. Following trypsinization and subsequent neutralization 
in FSM, the cells were centrifuged at 350 x g for 5 min. The media was 
aspirated and the cells were resuspended in 1-5 ml of PBS (without Ca2+ and 
Mg2+) and an aliquot was taken to count cells to determine cell density. The 
following calculation was made to determine how many cells to use for 
electroporation, using SKOV-3 and a theoretically cell count as an example: 
  
1. SKOV-3 cells desired in 10cm plate: 300,000/100µl (Neon Tip Size) = 3 
x 106 cells /ml.  
2. SKOV-3 cell count: 3.2 x 106 cells /ml resuspended in 2 ml PBS 
3. Desired cells ÷	Cell count = 3 x 106 cells /ml / 3.2 x 106 cells /ml = 0.94 
(y) 
4. y* volume of cells resuspended in PBS: 0.94 * 2ml = 1.88 ml  
 
1.88 ml of cell suspension was centrifuged at 350 x g for 5 min and the cell 
pellet was resuspended in 100 µl of Buffer R. A single cell suspension was 
achieved by gentle pipetting. At this point siRNA/plasmid DNA was added to 
the cells-Buffer R mixture. The top head of the Neon pipette was inserted into 
the Neon tip until the clamp fully picks up the mounting stem of the piston. 
While applying downward pressure on the pipette, the push-button was 
released to seal the tip onto the pipette without any gaps. The Neon pipette 
was immersed into the cell-DNA/siRNA mixture and slowly, the push bottom 
was released in such way to avoid any air bubbles. The neon pipette with the 
sample were vertically inserted into the Neon Tube until a clicking sound is 
heard. The appropriate electroporation protocol was selected (For SKOV-
3/CAOV3 1170 volts (v), 30 millisecond (ms), 2 pulses and for ReNcells 1600v, 
10ms, 3 pulse were used) and “Start” was pressed on the touchscreen. 
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Following delivery of the electric pulse, a ‘Complete’ sign is displayed on the 
touchscreen to indicate that the electroporation has finished successfully. The 
neon pipette was slowly removed and the content was immediately 
transferred into a culture plate containing prewarmed FSM. The Neon Tips 
and Neon Tube were regenerated using a protocol established by (Brees and 
Fransen 2014). After electroporation, residual plasmid DNA was removed by 
pipetting three times 100 µl of DNase I solution (1 mg/ml DNase I in PBS 
containing 5 mM MgCl2, pH 7.4) for digestion of plasmid DNA, or 100 µl of 
RNase I (1 mg/ml RNase I in PBS) for digestion of siRNA and subsequently 
incubated for 15 min at RT. The tips were then rinsed by pipetting sterile 
ddH2O three times followed by pipetting three times with 70% [v/v] ethanol. 
The tips were then air dried in a sterile laminar flow hood. The tubes were 
regenerated by washing with distilled water and 70% [v/v] ethanol and 
similarly air dried in a flow hood.  
 
For combinational treatment of 5-Aza-Cdr and siRNA, SKOV-3 cells were 
electroporated with 200nM of EFA6R siRNA1 (siEFA6R1), siRNA2 
(siEFA6R2), Arf6 siRNA (siArf6) or Control siRNA (siControl) using the 
following parameters: 1170v, 30ms, 2 pulse number. Following cell 
attachment (4-6 hours), the cells were then treated with 10µM 5-Aza-CdR for 
4 days. The cells treated with siRNA/5-Aza-CdR were used in migration and 





HeLa, COS-7 and ReN cells were plated on 13mm coverslips (For ReN cells, 
these coverslips were coated with matrigel) in a 24-well plate with FSM and 
incubated at 37°C/5%CO2 overnight. At the time of transfection, cells were at 
a confluence of ~40-50%. Two days post-transfection (see section 2.2.6), the 
cells were serum starved for 2 hrs with SFM and then fixed with 250 µl of 4% 
PFA for 15 min at RT, on a rocker. The PFA was fully removed by washing 
the wells three times with PBS. Where required the cells were permeabilised 
 102 
with 250 µl of 0.2% [v/v] Triton X-100/PBS for 10 min and then incubated 
with 250 µl of blocking buffer (1% (w/v) BSA/PBS-T [PBS-0.1% (v/v) Triton-X 
100]) for 30 min. Cells were then incubated (in the dark or covered in kitchen 
foil and on a rocker) with blocking buffer containing 1:5000 TRITC-phalloidin 
(a F-actin probe conjugated to the red-orange fluoresce dye, 
tetramethylarhodomine [TRITC])  for 1 hr. Cells were then washed three 
times with PBS-T and incubated with the nuclei stain - DAPI (1mg/ml final 
conc.) at 1:10000 dilution made in PBS-T, in the dark (or covered in kitchen 
foil) for 5 min while rocking. Finally, the coverslips were mounted onto glass 
slides using 10 µl of mounting solution (0.1 M Tris-HCl, pH 8.5, 10% Mowiol, 
and 50% [v/v] glycerol) containing 2.5% [v/v] 1,4-diazabicyclo[2.2.2.]octane 
and kept in the dark for 24 hrs for the mounting solution to dry. The following 
day, any residual mounting solution was gently removed from the top of the 
cover slips using 100% [v/v] ethanol. Immunofluorescent analysis was carried 
out using a confocal microscope (Carl Zeiss, LSM710) with a 63x oil-
immersion objective lens and a 488nm Kr/Ar laser. Emission wavelengths 
used were 405 nm for DAPI, 488 n for GFP and 543 nm for pmCherry and 
TRICE-Phalloidin. Scale bar in confocal images represent 10µm. The confocal 
images shown are representative of  >50 cells from ³2 independent cell 
preparations.  
 
2.2.8 Cell Counting Kit-8 (CCK-8) 
 
The cell viability of ovarian cell lines as a result of treatment 5-Aza, SAHA 
and NAV-2729 were determined by using the Kit-8 cell viability assay. Here, 
ovarian cell lines were pre-determined for a seeding density of 2500 cells/well 
(for SKOV-3 and IOC cell lines) and 5000 cells/well (for OVSAHO cell line) in 
a 96-well plate (Griner, USA). Following cell attachment, the cells were 
treated with 0.1µM, 1µM and 10µM of 5-Aza-CdR and SAHA or 0.1% DMSO 
(as the solvent control) for a period of four days by replacing drugs and 
medium on the third day of treatment. Where indicated, SKOV-3 cells were 
also treated with 10µM, 50µM250µM of NAV-2729 (the Arf6 inhibitor; Tocris, 
UK) or 0.1% DMSO for 2 and 5 hours. Kit-8 colorimetric cell viability assays 
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were performed by adding 10µl of reagent to each well and incubated for 1 
hour at 37oC/5%CO2. During the incubation, the cellular dehydrogenases 
reduce the highly water-soluble tetrazolium salt WST-8 [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)- 2H-tetrazolium, into a 
water-soluble formazan orange dye which is then recorded using a microplate 
reader (BMG Labteck, USA) to measure the absorption at 450 nm. The data 
was then exported in Microsoft Excel (Microsoft, US) format and analysed 




Frozen or paraffin-embedded ovarian healthy samples were obtained from 
the Department of Pathology (Singleton Hospital, Swansea, UK), under the 
authority of the Human Tissue Act (licence # 12651) . Commercial tissue 
array slides were purchased from Biomax (USA). By collaborating with 
Department of Pathology in Singleton Hospital, immunostaining of tissues 
(Immunohistochemistry [IHC]) was performed in a benchmark Ultra IHC 
staining module which is an automated immunostainer from USA-based 
Ventana Medical Systems.  The following protocol was assigned to the 
automated system and applied: following heat-induced antigen retrieval for 
32 min in CC1 retrieval buffer (pH8-8.5), a rabbit polyclonal antibody to 
EFA6R generated with the help of Eurogentec (Belgium) (Kanamarlapudi 
2014a) was used at a dilution of 1:150 and incubated at 36 degrees for 36 min. 
OptiView HQ universal linker and HRP multimer was added for 8 min to 
enhance stain quality. Diaminobenzidine (DAB) was used as the chromogen, 
and samples were counterstained with hematoxylin for 12 min. Prior to 
addition of primary antibody, to stop non-specific staining of endogenous 
peroxidase, peroxidase inhibitor was used. Table 3 displays the scoring 
method that considered two essential factors: proportion of epithelial cells 
that showed staining and the intensity of that stain. Ovarian healthy 
samples that failed to stain for EFA6R due to the absence of epithelial 
architecture on the TMA, were considered antigenically non-viable and 
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were excluded from the analysis. This was compensated by using in-house 
healthy ovarian epithelial tissues that were mounted on the same slide as 
the commercial TMA.  
 









2.2.10 Drug treatments 
 
For epigenetic studies: Ovarian cancer cell lines were electroporated with 200 
nM siEFA6R or sicontrol and plated in 6 cm or 10 cm plates at a cell density 
of 600,000/ml (see section 2.2.3.2). Following 4-6 hrs cell attachment, the 
medium was removed and replaced with 10 µM 5-Aza-Cdr, 1 µM SAHA or 
0.1% [v/v] DMSO (solvent control) for four days. Due to the relatively short 
half-life of 5-Aza-Cdr and SAHA, the drugs were replaced on day 3. After four 
days, the cells were subjected to cell migration/invasion assays (see section 
2.2.11) and various biochemical analysis (see section 2.2.14.2).  
 
For Arf6-GTP inhibition studies: SKOV-3 cells were treated with 10 µM 5-
Aza-CdR or 0.1% [v/v] DMSO for four-days, as described previously. The cells 
Guidelines for interpretation 
Distribution 




0 None 0 None 
+1 <10% +1 Weak  
+2 10-25% +2 Moderate  
+3 25-50% +3 Strong 
+4 50-75%   
+5 75-100%   
E.g.: DS = +3, IS = +1 and therefore total score = +4 
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were then treated with 50 µM NAV-2729 in SFM and proceeded to conducting 
migration/invasion assays followed by biochemical analysis.  
 
2.2.11 Cell migration and Cell invasion 
 
Prior to cell migration and invasion assays, SKOV-3 cells were electroporated 
with or without siEFA6R and siControl, followed by incubation with 10 µM 
5-Aza-CdR-Cdr for four days. The migratory and invasive phenotypes, 
following these treatments, were then assessed.  
 
Cell migration using the 2-well silicone insert: 70µl of cells (at an optimal 
seeding density of 700,000 cells/ml) were placed in each well of a 2-well 
silicone insert that has a defined cell-free gap (Ibidi, US). The aim in using 
this cell density was to obtain a fully confluent monolayer where cell-cell 
attachment and contact inhibition was visible. After cell attachment (4-24 
hrs), the culture-insert 2 Well was gently removed using a sterile tweezer by 
grabbing a corner of the insert. 250 µl of PBS was initially added to wash non-
adherent cells or cell debris and a final 500 µl of fresh culture medium was 
added to the well (the inserts were placed in a 24-well plate). Then, cell 
migration was photographed at 4-hour intervals using a Olympus IX71 
microscope and XM10 camera (Olympus, Center Valley, USA). The area 
between two edges of the migratory cells’ were measured using ImageJ 
software where cell migration presented as percentage gap closure using the 
following equation: ([pre-migration] area-[post-migration] area/[pre-
migration] area) x 100% (Davies et al. 2014). 
 
Cell migration and invasion using transwell chambers:  Prior to cell 
migration and invasion assays using 0.8µm pore sized polycarbonate 
membrane transwell chambers (Greiner, US), Matrigel (stored at -80oC) was 
thawed at 4oC for 4-24 hrs. During coating of the transwell inserts, the 
matrigel, sterile pipettes, tips, eppendorfs and the transwell inserts were pre-
cooled and maintained at 4oC. For the SKOV-3 invasion studies, the matrigel 
was diluted to 1.2mg/ml (stock concentration of 8-12 mg/ml) in cold SFM and 
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100µl of the coating media was placed inside the transwell chamber and 
allowed to polymerize for 24 hrs at 37oC/5%CO2. At the same time, control 
inserts without matrigel and only 100µl of SFM were also prepared for cell 
migration studies. Following polymerization, the unpolymerised media was 
removed, and the chamber washed with 250 µl of SFM and rehydrated with 
100µl of warm SFM for 0.5-1 hr at 37oC/5%CO2. SKOV-3 cells were 
resuspended in SFM at a concentration of 50,000 cells/ml. 250µl of the cells 
were placed onto the matrigel-coated (invasion assay) and non-matrigel-
coated (migration assay) transwell inserts. 750 µl of FSM (containing 10% 
FBS as the chemoattractant) was placed in the bottom chamber. Following 
cell invasion (16 hours) and migration (4 hours) of cells, the inserts were 
washed submerged in PBS (2x) to wash the medium and fixed by 
formaldehyde (4% in PBS) for 5 min at room temperature, on a rocker. The 
PFA was removed and the inserts were again submerged in PBS (2x) to 
remove the PFA. The cells were permeabilized by using 100% methanol for 
20 min at room temperature followed by washing with PBS (2x). The non-
invaded and non-migrated and the invaded and migrated cells were stained 
with 0.4% crystal violet (made in 10% Ethanol) and incubated at RT for 15 
min in the dark. The excess crystal violet was removed by twice washing with 
PBS and the non-invaded cells in the transwell insert were removed using a 
cotton swab. The inserts were allowed to dry for 2-24 hrs at room 
temperature, or for 1 hr at 37oC. The number of invading and migratory cells 
were assessed using two methods: (1) the membrane was cut using a scalpel, 
placed in a 24-well plate and 150µl of 5% SDS was added to extract the dye. 
This was left on a shaker for 5 min. 50µl of the extract was transferred in 
triplicates to a 96-well plate and the absorption was read at 5470nm using a 
microplate reader. (2) invading and migrating cells were counted under an 
inverted light microscope in five randomly selected positions. The criteria for 
choosing a whether a cell had migrated or invaded was counting both the cells 
on the other side of the membrane and also cells that are moving through the 
membrane pores. The number of cells were averaged.  
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2.2.12 Flow Cytometry  
 
Flow cytometry was used to analyse b-1 integrin expression in HEK293 cells, 




HEK293 cells were transiently transfected with siRNAs siControl, siEFA6R 
1 or siEFA6R IAS. Following 4 days of incubation, adherent cells were 
harvested by pipetting the HEK293 cells off the culture plate or by using 0.5 
ml of non-enzymatic cell dissociation solution.  
 
Plasmid DNA transfection (to be used for future studies): 
 
HEK293 cells will be transiently transfected with EFA6R wild-type (WT) and 
its deletion and point mutant constructs for two days, at 37oC/5%CO2.  
 
The cells were counted and 50,000-200,000 cells/ml were seeded into a 96-well 
U-bottom clear plate. For each treatment, two separate wells were seeded 
with cells: one for the antibody test, and the other for the isotype control. The 
cells were centrifuged at 300 x g for 5 min at 4oC using an Eppendorf 5810R 
centrifuge and the FSM was aspirated off, to be replaced with 100 µl of cold 
flow buffer: PBS (pH 7.4) containing 0.5% FBS, 0.1 % Sodium Azide (NaN3). 
The cells were again centrifuged at 300 x g for 5 min at 4oC and blocked in 
blocking buffer (0.2% [w/v] BSA/PBS) for 45 min at 4oC. The blocking buffer 
was removed by centrifugation and the cells were then re-suspended in 25 µl 
of cold staining flow buffer containing either 1/100 Isotype control-APC 
conjugate mouse IgG1K, clone MOPC-21, 200 µg/ml (Biolegend) or b-1 
Integrin (Phycoerythrin, PE, fluorescence emission peak of 578 nm) 578 nm 
emission for 1 hr at 4oC. The cells were washed three times by adding 100 µl 
of staining buffer followed by centrifugation. Following the final 
centrifugation, the cells were incubated with 7-aminoactinomycin D (7-AAD) 
(PE-Texas red, fluorescence emission peak of 616, Invitrogen) diluted 1:100 
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in 0.2% (w/v) BSA/PBS for 10 min at 4oC in the dark. The cells were washed 
three times with the staining buffer, centrifuged and re-suspended in 100 µl 
of staining flow buffer and the plate kept at 4oC. Quantification of β-1 Integrin 
expression was carried out using flow cytometer  
 
2.2.12.1 Fluorescence Spillover and Compensation  
 
The ultimate aim of a flow cytometry experiment is basically matching a 
colour to each antibody used in a reagent.  Spillover occurs when the emission 
spectra of certain common fluorochrome physically overlap.  Therefore, there 
is a danger of the emission fluorescence of one fluorochrome being detected 
while measuring signal from another fluorochrome. Fluorescence 
compensation is therefore setup to remove the signal from a given 
fluorochrome from all neighbouring channels. Here, a negative and positive 
population of cells (for each colour) were stained with either PE-Texas red, 
Phycoerythrin or Fluorescein (FITC) fluorochromes). These single-stained 
cellular controls contain cells that are unstained and cells stained with single 
colour. Even though compensation depends on the fluorochrome and not the 
cell type, we both positive and negative cell lines to ensure similar 
autofluorescence. Using the FlowJo 1.3 software is then used to automatically 
calculate compensation values for each fluorochrome combination. These 
values were then used to correct for all spectra Spillover in all experiments 
prior to data analysis.  
 
2.2.13 RNA extraction, cDNA synthesis and RT-qPCR 
 
RNA was extracted from cell lines using TRI-reagent following protocols 
supplied by the manufacturer (see section 2.2.14.2 for details). A NanoDrop 
(Thermo Fisher Scientific, USA) was used to measure RNA concentration and 
ensure that high quality RNA is used. For all RNA samples the RNA purity 






Single-stranded cDNA from total RNA was synthesized using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA). The 
2x reverse transcription master mix was prepared by adding 2 µl of 10XRT 
buffer, 0.8 µl of 25X dNTP mix [100 mM], 2 µl of 10X RT Random Primers, 1 
µl of MultiScribeTM Reverse Transcriptase, 1 µl of RNase inhibitor and 3.2 µl 
of ddH2O to make a 10 µl reaction mixture. 10 µl of the 2X RT master mix 
was transferred into a tube. In order to synthesis 2µg of cDNA the 
C1V1=C2V2 calculation was done (where C1 is the stock concentration, C2 is 
the desired concentration, V2 is the final reaction volume and V1 is the 
amount to be added to get the desired concertation) and the amount starting 
RNA transferred into the tube, and made to a final volume of 10 µl using 
ddH2O. The 2x RT master mix was combined with the RNA to create a 1x mix 
and mixed by briefly vortexing Reverse transcription was performed in a 
thermo cycler (Biorad T100TM Thermal Cycler) using the following 
parameters: 25oC for 10 min, 37 oC for 120 min, 85 oC for 5 min. The cDNA 




The reverse transcription reactions (cDNA) were quantified using 2 x RT2 
SYBR Green qPCR mastermix (Qiagen, USA). For each 10µl RT-qPCR, the 
following components were mixed in 5 µl of RT2 SYBR Green Mastermix, 4.5 
µl of RNase free H2O, 200 µM of both forward and reverse primers (see table 
4 below for primer details) and 0.5 µl of undiluted cDNA template.  
 
Table 4. RT-qPCR primers used in this study. 
Gene 
ID 











151 No (Y. Liu et al. 2010) 
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To control for DNA contamination, a negative control reaction was prepared 
by simply replacing template with water, so-called no template control (NTC). 
To control for genomic DNA contamination, a no reverse transcription 
reaction (NRT) was prepared for each RNA sample, during the cDNA 
synthesis stage. Initially, a standard curve was generated for each gene of 
interest and the housekeeping gene by preparing a series of 8-fold dilutions 
in triplicates using template known to represent the gene of interest. The 
plate was sealed with an adhesive optical sealing film (Bio-Rad, US) and the 
plate was run on the following program: 1 cycle of enzyme activation at 95°C 
for 30sec, followed by 40 cycles of denaturation at 95°C for 5 sec and 
annealing/extension at 60°C for 30 sec. The mRNA levels were normalized 
with housekeeping gene β-actin. All samples were used in duplicates unless 
otherwise stated and the obtained Cq values using CFX Manager Software 
version 1.6 (Bio-Rad, USA). The relative fold change in gene expression was 
analysed using the double delta Cq analysis (2-ΔΔCq) method (Livak and 
Schmittgen 2001). Here, the average of samples and reference gene is 
conducted (ΔCq), followed by normalization of sample against endogenous 
housekeeping gene (∆ΔCq). Finally, the expression fold change is obtained 
through 2-ΔΔCq. 
 
2.2.14 Protein Estimation and Immunoblotting 
 
2.2.14.1 Protein Estimation 
 




EFA6R 1  F: 5’-CGCAGCGGCAGAGACATTT-3’ 
R: 5’-TTTGGCCTTGGCAACACTCT-3’ 
70 Yes Designed and verified 
for this study 




141 No Designed and verified 
for this study  
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Scientific, UK) a set of diluted standards were prepared with the 
concentrations of 0.2, 0.4, 0.6, 0.8 and 1.0mg/ml. 10µl of BSA standards were 
added in duplicates into a 96-well flat bottom plate (Greiner, US). The 
proteins samples were diluted in ddH2O (1/5 or 1/10) and 10µl of the samples 
were added to the plate (See schematic below for reference). 
 
      BSA Standards      Diluted samples  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.0 0.0  Sam1 Sam1        
B 0.2 0.2  Sam2 Sam2        
C 0.4 0.4  Sam3 Sam3        
D 0.6 0.6  Sam4 Sam4        
E 0.8 0.8  Sam5 Sam5        
F 1 1           
G             
H             
 
The BCA working reagent (Thermo Scientific TM, US) was made by adding 50-
parts of reagent A (bicinchoninic acid solution – BCA) and 1-part reagent B 
(Copper (II) sulfate pentahydrate 4 % solution). 80µl of the BCA and copper 
sulfate solution was added to each well and the plate was incubated at 37oC 
for 30 min in an Incucell incubator. The absorption readings at 490 nm 
wavelength were taken using the Biotek plate reader and its Gen5 imaging 
software. A standard curve was prepared by plotting the average blank-
corrected 490 nm measurement for each BSA standard vs. its concentrations 
in µg/ml. This standard curve was used to determine the protein 








Preparation of whole cell lysates using TRI-Reagent (Sigma, US) 
 
Samples preparation: Monolayer cells were washed twice in PBS (Greiner, 
US) and directly lysed on the culture dish, using 1 ml of TRI reagent per 10 
cm2 of culture plate (Greiner, US), 0.4ml per 6 cm2 (Greiner, US), 0.2µl per 3 
cm2 (Greiner, US) (or a 6-well plate (Greiner, US) and 0.05ml per 24-well 
plate (Greiner, US) of the volume of the TRI reagent. Suspension cells were 
isolated by centrifugation following twice washing in PBS, and then lysed in 
TRI-reagent by repeated pipetting. To ensure complete dissociation, the cell 
lysates were sheared using a 21-gauge needle and syringe and then incubated 
for 5 min at room temperature.  At this point the samples can be stored at -
70oC for up to a month, at -20oC for up to a week and at 4oC for 24 hrs. Phase 
separation: 0.2ml of chloroform per 1ml of TRI Reagent was added to the 
samples and shaken vigorously for 1 seconds and allowed to stand for an 
addition 15 min at room temperature. Centrifugation of the resulting mixture 
at 12,000 x g for 15 min at 4oC, yields 3 layers: a red organic layer (containing 
protein), an interphase (containing DNA), and a colourless upper aqueous 
layer (Containing RNA).  
 
RNA isolation: The aqueous phase was added to a fresh 1.5 ml microfuge tube 
and 0.5 ml of 2-propanol per 1 ml of TRI Reagent used in sample preparation 
and mixed by inverting 12 times, left to stand for 10 min at RT and 
centrifuged at 12,000 x g for 10 min at 4oC, resulting in an RNA precipitate 
in the form of a pellet. The supernatant was removed and the RNA pellet was 
washed in 1ml of 75% ethanol per 1 ml TRI-Reagent using in sample 
preparation. The samples were vortexed and then centrifuged at 7500 x g for 
5 min at 4oC. At this stage, the samples can be stored in ethanol at 4oC for 1 
week and at -20oC for up to 1 year. The RNA pellet was air dried – while not 
allowing the RNA pellet to dry completely – and an appropriate volume of 
RNase free H2O was added to facilitate dissociation. The sample was briefly 
vortexed, spun down and the RNA concentration was read using a NanoDrop. 
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RNA samples were prepared free of DNA and protein as they had an A260/A280 
ratio of ≥1.7. The samples were then stored at -80oC or prepared for cDNA 
synthesis and RT-qPCR experiments.  
 
Protein isolation: The interphase containing DNA was removed and the 
protein was precipitated using 1.5 ml of 2-propanol per 1 ml of TRI Regent 
used in sample preparation and the samples were allowed to stand for 10 min 
at room temperature. They were then centrifuged at 12,000 x g for 10 min at 
4oC, resulting in a protein precipitate in form of a pellet. The supernatant was 
discarded and the pellet was washed 3 times (10 min/wash at room 
temperature) in 0.3 M guanidine hydrochloride/95% ethanol solution, using 2 
per 1 ml TRI Reagent used in sample preparation. Following each wash, the 
pellet was centrifuged at 7500 x g for 5 min at 4oC and after three washes, 2 
ml of 100% ethanol was added, vortexed and centrifuged at 7500 x g for 5 min 
at 4oC. At this stage the protein pellet can be stored at 4oC for 1 month and 
at -20oC for up to a year. The protein pellet was air dried and subsequently 
dissolved in 5% SDS aided by vortexing. Insoluble materials were removed by 
centrifugation at 10,000 x g for 10 min at 4oC. The supernatant was 
transferred to a new 1.5 ml microfuge tube where 10µl of the sample was 
taken for protein estimation (see above) and to the rest 1/5th volume of 5x 
sample loading buffer (5% [w/v] SDS, 125mM Tris HCl pH 6.8, 50% [v/v] 
glycerol, 0.005% [w/v] bromophenol blue and 20% [v/v] 2-Mercaptoethanol) 
was added boiled at 100oC for 5 min using a Grant heating block. The samples 
were stored at -20oC prior and after immunoblotting.  
 
Preparation of whole cell lysates in GST-GGA3-VHS-GAT (GST-Arf effector) 
pulldown assay  
 
Monolayer of cells in a 6 cm2 plate were serum starved by replacing the media 
with 2 ml of Serum Free Media and incubated at 3oC /5% CO2 for 2 hrs. The 
cells were then washed 3 times with cold PBS and lysed using 0.5 ml of 
pulldown lysis buffer (25mM Tris pH 7.2, 150mM NaCl, 5mM MgCl2, 1% NP-
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40/ IGEPAL®CA-630, 5% glycerol) containing 1% mammalian protease 
inhibitor cocktail (Sigma). The cell lysates were sheared using a 21-gauge 
needle and syringe (10x), transferred to a 1.5 ml microfuge tube and then 
incubated on ice for 15 min. The lysates were centrifuged at 22,000 (14000 
rpm) x g for 10 min at 4oC and the supernatant was collected into a new 1.5 
ml microfuge tube. 10µl of the sample was taken for protein estimation (see 
above); 0.35 ml of the lysate was incubated with 10µl of 25% of GST-effector 
coupled to magnetic agarose beads for 2 hrs at 4oC on microtube rotator. 
Using a magnetic stand, the beads were then washed three times with lysis 
buffer and the bound proteins were eluted by adding 50µl of 1x sample buffer 
and then boiling for 5 min at 100°C. The remaining lysates (~0.14 ml) not 
incubated with the beads were boiled after adding 35 µl of 5x sample buffer 
for 5 min at 100oC. The pulldown samples and the input samples were stored 
at -20oC prior and after immunoblotting.  
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SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Following sample preparation, the required percentage of running gel was 
made according to the following table 5. 
 
Table 5. Running Gel Protocol 
 
 *N, N, N, N’-tetramethylethylenediamine 
  
The solution was mixed by inversion and the solution was poured between a 
spacer (1.5mm) plate and a short plate (both previously washed in ddH2O and 
70% ethanol and dried) (Bio-Rad, UK). Water-saturated butanol was added 
to ensure a uniform gel edge is formed. Following polymerization (~10-15 
min), the water-saturated butanol was washed off with ddH2O and the 













ddH2O 5 ml 4.2 ml 3.5 ml 2.5 ml 




2.5 ml 2.5 ml 2.5 ml 2.5 ml 
30 % [v/v] 
Acrylamide 
















TEMED* 10 µl (0.01% 
[w/v]) 









Stacking Gel (3ml) 
 
Table 6. Stacking Gel Protocol 
*125mM Tris-HCl pH 6.8, 0.1% [w/v] SDS 
 
The stacking gel was poured onto the running gel and a comb was inserted to 
form loading wells upon polymerization (~10-15 min). The comb was removed 
and the wells were washed 3 times with ddH2O to remove unpolymerised 
acrylamide. The gel(s) were assembled into a clamping frame and placed in a 
mini tank (Bio-Rad, UK). The central reservoir was fully filled (until the top 
edge) with running buffer (25mM Tris HCl, 192 mM glycine, 0.1% [w/v] SDS, 
pH 8.3) while the tank itself was filled half-way in order to cover the bottom 
tank electrode. According to protein estimation results, up to 35 µl of protein 
samples and 3µl of protein standard (Bio-Rad) was loaded onto the wells and 
electrophoresis was carried out at 200 volts for ~ 40 min using a PowerPac 
Basic (Bio-Rad, UK).  
 
Semi-Dry Membrane transfer  
 
Prior to transfer or proteins from the acrylamide gel onto a polyvinylidene 
fluoride (PVDF) membrane (pore size 0.45µM), the PVDF membrane was 
soaked  
in methanol for ~30 seconds, rinsed in ddH2O for 2 min and then washed in 
transfer buffer (25mM Tris HCl, 192mM glycine, 20% [v/v] methanol, pH 8.3, 
 
Reagent Amount 
ddH2O 1.75 ml 
Stacking Gel* 0.75 ml 
30 % Acrylamide 0.5 ml 
APS ½ small spatula, (0.01% [w/v] 
TEMED 3 µl (0.01% [w/v]) 
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chilled at 4oC) for minimum 5 min (If the membranes were not needed 
straight away, they were placed in fridge). Inside a Trans-Blot Turbo Transfer  
system (Bio-Rad, UK), 3mm filter papers (soaked in transfer buffer), the 




The transfer was then performed at 25 V for 30 min using the Trans-Blot 
Turbo System (Bio-Rad, UK).  
 
Visualization, blocking and antibody incubation of PVDF membrane 
 
Following transfer, the membrane was washed in ddH2O for 5 min and then 
the proteins were visualized with ponceau red stain (1x prepared by diluting 
1:10 of 1% [w/v] ponceau S made in 40% [w/v] acetic acid with water) to ensure 
a high efficiency or protein transfer and in the case of GST-Arf effector 
pulldown samples, to distinguish inputs from pulldowns. The membrane was 
then appropriately labelled with a pencil and blocked in blocking buffer (5% 
[w/v] non-fat milk powder (Marvel, UK) prepared in TBS Tween-20 (10mM 
Tris HCl pH 7.4, 150mM NaCl, 0.05% [v/v] Tween 20) on a SSL4 see-saw 
rocker for 1 hr at room temperature or overnight at 4oC. The primary antibody 
(see results chapters’ figure legends for antibody details) was made in 
blocking buffer and sealed in a plastic bag with the membrane and incubated 
for 1 hr at room temperature or at 4oC, overnight on a rocker. The membrane 
was then washed 5 times for 5 min in TBS-Tween 20. The membrane was 
Top (-) cassette electrode (cathode) 
 






3x filer papers 
 
 
(Bottom (+) cassette electrode (anode) 
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then sealed in a fresh plastic bag with the secondary antibody (HPR-linked 
anti-rabbit [1:2500 dilution, from GE healthcare Cat. No. NA934] or HPR-
linked anti-mouse [1:2500 dilution, from GE healthcare Cat.  NA933], made 
in blocking buffer, for 1 hr at room temperature, on a rocker. The membrane 
was again washed 5 times for 5 min in TBS- Tween 20. 
 
Development and visualization using enhanced chemiluminescence (ECL)  
 
Using the Amersham ECL Prime Western Blotting Detection Reagent ECL 
(GE healthcare, US), the detection reagent was made from the two reagents 
(Reagent 1 and Reagent 2) in equal parts (1:1). ECL was then added in two 
ways: (1) the membrane was placed faced down in the detection reagent for 
30 seconds to 1 min (depending on the protein of interest) and then placed 
face up in the ChemiDoc TM CRS imaging machine (Bio-Rad, UK) or (2) ECL 
was added directly on top of the membrane for 30 seconds to 1 minute. The 
membrane underwent automatic exposures at anywhere between 0.5 seconds 
to 5 min – depending on the relative abundance of the protein by using 
Quantity One software (Bio-Rad, UK). Following visualization, the 
membranes were stored at 4oC. ImageJ (Fiji processing package) software 
(Schindelin et al. 2012) 
 
Stripping and re-probing 
 
The previously probed membranes were sealed in a plastic bag with an 
appropriate amount of immunoblotting stripping buffer (Thermo Scientific, 
UK) and incubated for 15 min at room temperature, on a rocker. The 
membranes were then washed twice in ddH2O for 1 min and then once in 
TBS-Tween 20 for 5 min before being blocked again and reprobed with 
another primary and secondary antibody. The newly reprobed blots were then 




2.2.15 Data Analysis 
 
Data was analysed using the graph prism program (Mac version 7). In some 
selected immunoblotting images, the average of three independent 
experiments are displayed as fold change or % change of expression. The 
D’Agostino-Pearson test was done to assess data normality and subsequently 
the non-parametric Mann-Whitney statistical test was used to compare two 
groups of data and the Kruskal-Wallis test was used to compare three or more 
groups of data. A value of P > 0.05 was considered not significant (ns) whereas 
P < 0.05, P < 0.01, P < 0.001 and P < 0.0001 (denoted as *, **, ***, ****) were 
used as the general limit of significance. For confocal images, scale bars 
represent 10 µm. The confocal images shown in figures are representatives of 
up to 100 transfected cells from three different experiments.  
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Chapter 3: EFA6R expression is 
downregulated in Epithelial 





Epithelial Ovarian Cancer (EOC) remains the most lethal gynaecological 
malignancy in the western world (Jacobs et al. 2016). Less than 40% of 
patients survive 5 years after initial diagnosis because there are no effective 
screening strategies for early detection of this disease. As a result, individuals 
that have germline mutations in BRCA1 and BRCA2 or other high-risk 
associated ovarian cancer genes or biomarkers, often undergo bilateral 
salpingo-oophorectomy (removal of ovaries and fallopian tube) surgery to 
reduce the risk of developing ovarian cancer (Matulonis et al. 2016). Current 
attempts at early detection of ovarian cancer through serum detection of CA-
125 and the use of transvaginal ultrasonography have improved initial 
detection of EOC, but have not significantly reduced mortality rates, 
highlighting the eminent need for inclusion of novel biomarkers that identify 
abnormalities (Jacobs et al. 2016, Menon et al. 2015) 
 
EOC is a highly heterogeneous disease, which is traditionally divided into 
four major histological subtypes: serous, endometroid, clear cell and 
mucinous carcinoma (Bast, Hennessy, and Mills 2009). Serous ovarian 
carcinoma is responsible for ~ 70% of EOC (Seidman et al. 2004). The most 
aggressive sub-type is high-grade serous ovarian carcinoma (HGSC), which 
accounts for 90% of these serous carcinomas and two-thirds of all ovarian 
cancer deaths, making it the most extensively studied ovarian carcinoma 
(Bowtell 2010, Gershenson et al. 2006). The features that set HGSC apart 
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from LGSC are: TP53 mutation (in over 95%), homologous recombination 
DNA repair defects, BRCA1/2 and CCNE1 aberrations and overall genomic 
instability (Bast, Hennessy, and Mills 2009, The Cancer Genome Atlas 
Research 2011, Berns and Bowtell 2012, Ahmed et al. 2010). In contrast, 
LGSC are TP53 wildtype and also have frequent activating of KRAS/BRAF 
pathways (Kurman and Shih Ie 2008). Similar to LGSC, mucinous 
carcinomas also have mutations in KRAS, whereas endometroid and clear cell 
carcinomas harbour PTEN and PIK3CA mutations respectively (Bast, 
Hennessy, and Mills 2009).  
 
The Small GTPase ADP-ribosylation factor 6 (Arf6) functions as a molecular 
switch in cellular signalling pathways by cycling between GDP-bound 
inactive and GTP-bound active form, which is precisely regulated by two 
regulators: guanine nucleotide exchange factors (GEFs) and GTPase-
activating proteins (GAPs) (Donaldson and Honda 2005). Numerous studies 
have shown that these regulators play critical roles in tumour 
angiogenesis/growth and cancer cell invasion/metastasis through regulating 
the cycling of Arf6 (Matsumoto et al. 2017, Zangari et al. 2014, Koumakpayi 
et al. 2011, Hashimoto et al. 2011, Zhang et al. 2015). However, few studies 
have investigated the expression and functional roles of Arf6 GEFs and GAPs 
in EOC. Among these Arf6 GEFs are the Cytohesins (1-3), the EFA6 (EFA6A, 
EFA6B, EFA6C and EFA6D/EFA6R/PSD3) and BRAG (GEP100/BRAG2) 
family which have been shown to be involved in many cancer types (Hongu & 
Kanaho 2014). 
 
EFA6R/PSD3/HCA67 is an Arf6-speficic GEF, initially proposed to function 
as an oncogene due to its upregulating in liver and colon cancer tissues but 
not in the healthy tissues (Wang et al. 2002). However other reports have 
shown that down-regulation of EFA6R in ovarian and glioblastoma 
carcinomas result in worse prognosis with increasing grade, implying that 
EFA6R is a tumour suppressor gene (TSG)  (Pils et al. 2005a, van den Boom 
et al. 2006). Certainly, the gene locus 8p22 at which the EFA6R exists is 
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common point for loss of heterozygosity (LOH) in EOC. Loss of heterogeneity 
(LOH) or allelic deletion is a common occurrence in cancer and high rate of 
LOH in a particular chromosome region provides strong indication that the 
region TSG (Wijnhoven et al. 2001). LOH on the short arm of chromosome 8 
is associated with sporadic EOC (Brown et al. 1999). One study showed that 
serous and mucinous carcinomas, differed with respect to the frequency and 
pattern of LOH at 8p (Lassus et al. 2001). At distal regions of chromosome 
8p, allelic analysis of 8p21-p23, showed that 67% serous carcinoma samples 
display LOH whereas only 21% of mucinous carcinomas showed allelic loss 
(Lassus et al. 2001).  
 
Therefore, a more widespread analysis of EFA6R mRNA expression in tissues 
and cancers was sought using a Real Time – quantitative Polymerase Chain 
Reaction (RT-qPCR)-based cancer array (Origene’s TissueScan Cancer 
Survey). EFA6R expression was found to be significantly increased in breast 
tissues and significantly reduced in liver and ovarian tissues. The 
downregulation of EFA6R in EOC was further validated using a larger set of 
samples and the impact of carcinoma subtype was investigated from this 
data. Out of all EOC subtypes, only mucinous carcinoma did not show 
significant reduction in EFA6R expression. Using ovarian cancer Tissue 
Microarrays (TMAs), we also undertook immunohistochemical analysis of 
EFA6R and found its downregulation to correlate with cancer progression. 
Finally, we identified EOC cell lines that are EFA6R-positive and EFA6R-
negative; which were used for functional analysis of EFA6R role in EOC 
progression in chapter 4.  
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3.2 Materials and Methods  
 
All chemicals and consumables used were obtained from Sigma (Dorset, UK) 
unless otherwise stated. Cell culture plates were obtained from Greiner-Bio 
One (Gloucestershire, UK).  GFP-tagged Cytohesins 1-4, EFA6A, EFA6R and 
EFA6C expression plasmids were available in the lab (Kanamarlapudi 
2014a). 
 
3.2.1 Ovarian healthy and cancer cell lines 
 
The immortalized healthy Human Ovarian epithelial cell (IOC) and the 
human cancer cell line TOV21G were provided by Dr. Deyarina Gonzalez 
(Swansea University Medical School, UK); the human ovarian cancer cell 
lines SKOV-3 and OVCAR3 were purchased from ATCC (USA); OVSAHO 
and CAOV3 were obtained from Dr. Marion Curtis (University of Chicago 
Biomedical Sciences, USA). OVCAR8, IGROV-1, COV504, COV318 were 
obtained from Dr. Alan Richardson (Keele University School of Pharmacy, 
UK). All cell lines were cultured aseptically in RPMI supplemented with 10% 
FBS, penicillin (100 U/ml), streptomycin (0.1 mg/ml) and glutamine (2mM) at 
37oC/5%CO2 in a humid incubator. Cell counting was performed using 
Countess® cell counter (Invitrogen, UK). Figure 3.6A shows which histology 
group these ovarian cancer cells belong to.  
 
3.2.2 RNA extraction, cDNA syntheses and RT-qPCR 
 
RNA extraction, cDNA syntheses and RT-qPCR were carried out according to 
protocol in section 2.2.13.  
 
3.2.3 Western blotting 
 
Western blotting was carried out according to protocol in section 2.2.14.2 
using primary antibody (anti-EFA6R rabbit polyclonal 1/500 dilution) diluted 
in blocking buffer or anti- β-actin mouse monoclonal at 1/10,000 dilution, 
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followed by incubation with horseradish peroxidase (HPR) -conjugated 
secondary antibody (GE Healthcare, USA) diluted in blocking buffer (anti-
rabbit or anti-mouse 1/2500 dilution). The OncoPair INSTA-Blot cat: No: 
NBP2-30124 (Novus Biological, UK) which is a ready to use PVDF membrane 
containing denatured protein lysates from serous carcinoma and matched 
healthy adjacent tissues obtained from seven patient donors was probed with 
anti-EFA6R under same conditions as immunoblotting of cell lines described 
above. 
 
3.3.4 Gene expression analysis using cDNA tissue array 
 
Gene expression analysis of healthy and cancer tissues by RT-qPCR was 
carried out using a commercial cDNA tissue array from Origene 
technologies Inc (USA). The Origene TisssuScan cancer survey I contain 
three healthy samples and nine cancer samples per tissue. The ovarian cancer 
cDNA array contains 192 healthy and cancer samples (plate I.D: HORT101, 
HORT102, HORT103 and plate HORT104). The histological and clinical 
information of the samples can be found at the OriGene website: 
https://www.origene.com/search?q=ovarian+cancer. Both cDNA arrays were 




Immunohistochemistry was carried out according to protocol in section 
2.2.9. 
 
3.3.6 Statistical Analysis  
 
Data was analysed using the Graph prism program (Mac version 7). Box blots 
are used to show three or more independent experiments, unless stated 
otherwise. The non-parametric Mann-Whitney and Kruskal-Wallis statistical 
tests was used to calculate statistical significance for the data. A value of P > 
0.05 was considered not significant (ns) whereas P < 0.05, P < 0.01, P < 0.001 
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3.3.1 Validation of EFA6R primer and characterisation of in house 
generated EFA6R antibody for immunoblotting and IHC 
 
Regardless of whether conventional PCR or RT-qPCR is used for gene 
expression analysis, there are several assay conditions that need to be 
optimized. Although factors such as instrument and reagents (such as buffer 
conditions and magnesium concentration) are important in ensuring 
successful quantification, most optimization procedures are focused on 
modification of primer binding kinetics, using primer concentration or 
annealing temperature/melting temperature. Therefore, in order to validate 
the EFA6R primers for use in amplification of EFA6R from Origene cDNA 
cancer arrays and ovarian cell lines, RT-qPCR was used to test the efficiency 
and relative stability. The EFA6R primers were designed based on the C-
terminus of the EFA6R human gene (Figure 3.1A). To maximize RT-qPCR 
efficiency, the amplicon length was designed to be <150 base pairs (b.p) 
(Figure 3.1B). The performance of the primers was assessed using GFP-
hEFA6R plasmid (Figure 3.1C left panel). We then demonstrated the 
sensitivity of the EFA6R primers using a range of the plasmid concentrations 
from which we generated a standard curve by plotting the Cq values against 
the log of amount of plasmid DNA. From this, it was calculated the R2 value 
as 0.99 with a primer efficiency of 116%. Similarly, a cDNA sample from the 
healthy ovarian cell line IOC was used to test the detection threshold of the 
assay. The use of a cell line cDNA template was particularly important as in 
the experiments that followed, we used cDNA from tissues and cell lines to 
assess EFA6R expression levels. The R2 and efficiency for EFA6R in IOC-
derived cDNA was 0.99 and 105%. An acceptable range for primer efficiency 
is 90-110%, therefore the primers were deemed suitable for usage in future 
RT-qPCR experiments.  
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Similar to the principles of RT-qPCR optimization, in order to monitor protein 
expression in cells or tissues, the suitability of the primary antibody in 
different assay conditions (immunoblotting and IHC) must be assessed. We 
used an in-house generated rabbit-anti EFA6R (raised against a peptide 
representing the last 15 amino acids at the C-terminus of EFA6R and affinity 
purified by using the immunizing peptide coupled resin through a commercial 
vendor [Eurogentec]) (Kanamarlapudi 2014a). Since EFA6R shares sequence 
homology with other members of EFA6 and Cytohesin families of Arf6 GEFs, 
we sought to determine whether the EFA6R antibody cross-reacts with any 
GEFs belong to these families. For this purpose, lysates from COS-7 
expressing GFP-tagged Arf6 GEFs (Cytohesins 1-4, EFA6A, EFA6C and 
EFA6R) immunoprobed using the anti-EFA6R and anti-GFP antibodies 
(Figure 3.1D). This analysis confirmed previous findings (Kanamarlapudi 
2014a) that the EFA6R antibody only recognizes EFA6R whereas the 
expression of all of the GFP-tagged ARF GEFs confirmed by using an anti-
GFP antibody. Finally, we optimized the dilution of the EFA6R antibody 
required for IHC using ovarian tissue samples obtained from Singleton 
Hospital pathology department (data not shown). We then used a control 
TMA (Figure 3.1E) and showed that a dilution of 1:150 is optimal for staining 
the epithelial region of the ovarian sample core (indicated by the A arrow) 
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Figure 3.1 Validation of EFA6R primer by RT-qPCR and the characterisation 
of the EFA6R antibody for immunoblotting and immunohistochemistry. The 
EFA6R primers were validated for sensitivity and detection threshold by RT-
qPCR. (A) A schematic representation of the EFA6R and (B) the primer 
design sequences. (C) Using a starting concentration of 1ng/ml of plasmids 
GFP-hEFA6R with subsequent 8-fold serial dilutions and using a cDNA from 
an EFA6R-positive cell line, IOC, an 8-fold dilution was done and a graph was 
plotted with Log10 of the DNA concentration on one axis and threshold cycle 
(Cq) on the y-axis. The reaction efficiencies (E) calculated by 10-1/gradient and 
percentage efficiency derived through the equation %E = E-1 x 100. (D) COS7 
cells were transfected for 2 days with plasmids for expressing GFP-tagged 
Cytohesins 1-4, EFA6A, EFA6R and EFA6C the lysates of transfected COS7 
cells were separated by SDS-PAGE, transferred onto a PVDF membrane and 
probed with an anti-GFP or an anti-EFA6R antibody. (E) Following antigen 
retrieval with CC1 buffer, a small sample size TMA containing ovarian 
tissues was incubated with the EFA6R antibody (1:150 dilution) at 36°C for 
36 minutes. Epithelial staining (arrow A) of EFA6R and not the stromal 
(arrow B) was observed.  
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3.3.2. EFA6R mRNA expression is significantly reduced in Ovarian tumours. 
 
EFA6R  has already been identified as a putative TSG in ovarian cancer (Pils 
et al. 2005a) and glioblastoma (van den Boom et al. 2006). Hence, we initially 
investigated the expression of EFA6R (using RT-qPCR) in breast, prostate, 
kidney, colon, lung, thyroid, ovary and liver using the Origene TissueScan 
cancer survey I containing three healthy samples and nine tumour samples 
per tissue (Figure 3.2). Healthy expression of the tissues was then displayed 
in Figure 3.2A. Relative to healthy breast (shows lowest EFA6R mRNA 
expression), EFA6R mRNA expression is higher in prostate, kidney, colon 
thyroid and lung by less than 10-fold – which was statistically not significant. 
The highest expression was observed in Ovary (40-fold increase, *P <0.01) 
and liver (65-fold increase, **P <0.03). We then compared EFA6R mRNA 
expression in healthy versus cancer tissues (Figure 3.2B) and showed that 
EFA6R expression is 40-fold higher (**P <0.0091) in breast cancer tissues, 2-
fold higher in prostate and colon, 4-fold higher in kidney and thyroid, and 3-
fold higher in lung cancer tissues compared to their healthy tissue 
counterparts. Significant down regulation in EFA6R observed in ovary (7-
fold, *P <0.0242) and liver (8-fold, **P <0.0091). Overall these data warrant 
further analysis in breast cancer due to a significant increase in EFA6R 
expression and in ovarian and liver cancers, due to a significant 
downregulation.  
 
In order to further assess the significance in ERA6R mRNA differential 
expression in healthy and tumor tissues, we further separated the data into 
low stage (tumor stages I and II) and high stage tumours (III and IV) followed 
by further separation into individual stages (I-IV) of tumor progression. 
Generally, the higher the staging or grading that is often assigned to a solid 
tumor, the more advanced the disease is. In other words, the genetic and 
proteomic make-up of the tumor is vastly abnormal. We aimed to explore how 
varied EFA6R expression is in between cancer stages. In Breast cancer 
tissues (Figure 3.2C and 3.2D), we observed significant increase in EFA6R 
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expression between healthy and high-stage cancer (*P <0357) whereas no 
statistical significance was observed, when we further expanded the data to 
individual stages. These findings suggest that EFA6R is significantly 
upregulated in breast cancer tissues.  
 
Expression of EFA6R in prostate cancer appears to be slightly influenced by 
stage, with an increase in expression as the cancer develops to higher stages 
of malignancy (Figure 3.2E and 3.2F). However, this increase was not 
significant. Given the limited sample size, no general conclusions can be 
drawn about a relationship between EFA6R expression and prostate cancer 
stage.  
  
Similarly, we found no significant difference between EFA6R expression in 
kidney healthy and cancer tissues (Figure 3.2G and 3.2H). However, the 
presence of two outliers at 8 and 20-fold, at low stage cancer could suggest 
that that high expression of EFA6R may hold a selective advantage to low 
stage cancers but the low P-value (0.999) casts doubt on this.  
 
In colon cancer tissues there was no statistical significance when the samples 
were separated as LS and HS (figure 3.2I). The only stage IV cancer sample, 
happened to express EFA6R at very low, healthy levels. This contributed to 
the skewness of the data when stages III and IV were grouped together and 
contributed to the lack of statistical significance between healthy and ‘high 
stage’ groups.  The samples were broadened again into individual stages 
(Figure 3.2J). When we compared the expression in healthy tissues versus 
stage III cancer, we saw near significant P value of 0.0571, indicating that 
further validation with a larger data set may yield significant differences 
between healthy and high stage colon cancer.  
 
Thyroid cancer tissues expressed significantly higher levels of EFA6R 
compared to healthy tissue (Figure 3.2K). When comparing EFA6R mRNA at 
low stage versus high stage of thyroid cancer, a significance increase in 
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EFA6R expression was observed (*P <0.0159) and between healthy and high 
stage samples, a P value of near significance of 0.0571 was seen. When the 
data were split into individual stages (Figure 3.2L), there was no statistical 
significance. Although the P value of 0.2 between healthy and stage III or IV 
may suggest that a more statistical significance may be observed if a larger 
dataset used. Overall, this suggests that an increase in EFA6R expression 
may correlates with an increase in cancer stage, which needs to be further 
validated using a larger cohort of samples.  
 
In lung cancer tissues (Figure 3.2N and 3.2O), when the samples were divided 
into LS and HS cohorts, near significance was observed between healthy and 
low stage cancer (P <0.095). Although these changes were not significant 
these results require further validation in a larger dataset in order to assess 
whether EFA6R expression increase correlates with lung cancer progression.  
 
When ovarian cancer tissues were divided into LS and HS (Figure 3.2P), a 
significant decrease in EFA6R expression was observed between healthy and 
HS and between LS and HS (*P <0.0357). Accordingly, when these data were 
split into individual stage (Figure 3.2Q), EFA6R expression was observed to 
decrease with cancer stage progression. Overall, these data demonstrate the 
significant loss of EFA6R expression in high stage ovarian cancer. Based on 
these preliminary results, we have shown that this expression loss may be 
attributed to increase in cancer stage, providing a rational for analysing 
EFA6R expression in ovarian cancer using a larger sample size (see Figure 
3.3).  
 
EFA6R expression was down regulated in low stage of liver cancer (*P 
<0.0238), but did not appear to distinctly alter between low and high stage – 
even when the data was further expanded into cancer stages (Figure 3.2R and 
3.2S). Based on these results, it suggests that loss of EFA6R expression in 
liver cancer cannot be attributed to cancer stage. Overall, a larger sample size 
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Figure 3.2. Analysis of EFA6R mRNA expression in Cancer tissue cDNA 
array using RT-qPCR. (A) EFA6R expression in healthy tissues was 
calculated relative to the healthy breast tissues using the double delta Cq 
analysis method. (B) The expression of EFA6R in tumor tissues was then 
calculated, relative to their healthy tissue counterparts. These data were then 
separated according to low stage, LS, (I/II) and high stage, HS, (III/IV) groups 
(C, E, G, J, K, N, P and R). These data were then further separated into 
individual tumor stages (D, F, H, J, L, O, Q and S). Box plots show the median 
for healthy tissues (n=3) and tumor tissues (n=9). *P <0.05 denotes 
significance. Statistical analysis was performed using non-parametric 







3.3.3. EFA6R expression loss in Ovarian Cancer correlates with EOC 
progression 
 
Following the preliminary data which suggested that EFA6R mRNA 
expression was specifically decreased in higher stages of ovarian cancer, we 
set out to replicate these findings using a large cohort of ovarian cancer tissue 
cDNA array. Furthermore, the large cohort allowed for further detailed 
analysis of EFA6R expression in different carcinoma subtypes. When 
compared, the expression of EFA6R in healthy ovarian tissue with that in 
ovarian cancer, there is an overall dramatic decrease in expression of 
approximately 10-fold (Figure 3.3A), and this was statistically highly 
significant (****P <0.0001). When we separated the tumor samples into their 
respective stages in Figure 3.3B, we observed a significant decrease of EFA6R 
expression (****P <0.0001). Given the highly heterogeneous nature of ovarian 
cancer and the general controversy associated with the origins, genetic and 
biochemical diversity of these subtypes (Bast, Hennessy, and Mills 2009), the 
results were compared by subtype of carcinoma: serous, clear cell, 
endometroid and mucinous to healthy (Figure 3.3C). Of these, only mucinous 
carcinoma of the ovary appeared to have no significant EFA6R expression 
decrease compared to healthy. However, when we further separated these 
subtypes into their respective stages (low stage, I/II, and high stage, III, IV), 
we noticed that EFA6R expression was significantly reduced in high stage 
mucinous carcinoma (**P > 0.0034) (Figure 3.3 D). In endometroid (Figure 
3.3 E) and clear cell (Figure 3.3 F) and Serous (Figure 3.3 G) subtypes, in both 
low and high stage samples, EFA6R expression was significantly decreased 
(****P <0.0001). In clear cell samples, further significance was noticed 
between low and high stage (**P <0.0095).  
 
The majority of EOC arise from the serous histology group and it is also the 
most lethal, accounting for 2/3 of all ovarian cancer deaths (Bowtell 2010). 
Given this fact and the availability of verifiable ovarian serous cell lines we 
turned our attention to a detailed analysis of the serous histology group. We 
separated the serous tumor samples into staging (Figure 3.3H) and saw a 
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significant decrease in EFA6R across all stages (****P <0.0001). We also 
observed significance (albeit to a lesser extent) between stage I versus stage 
II/III (***P <0.0016) and between stage I and IV (*P <0.011). These results 
matched our initial tentative assessment of EFA6R mRNA expression 
decrease in our cancer panel (see Figure 3.2P and 3.2Q).  
 
For the purpose of a more reliable comparison between our ovarian cancer 
tissue cDNA array data and the following TMA data (see Figure 3.2), we also 
separated the serous carcinomas into grades I-III (Figure 3.3F) and saw 
similar significant reduction of EFA6R expression at the protein level in 
grades II/III (****P <0.0001) compared to healthy. To a lesser but still highly 
significant extent, we also saw EFA6R protein expression decrease between 
healthy and grade I (**P <0.0038) and between grade I and II (**P <0.0004). 
Overall, the data suggest that EFA6R expression loss is observed in all EOC 
subtypes (to various significant degrees), and that EFA6R expression loss in 
serous subtype occurs at the early stage and grades of disease progression. 
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Figure 3.3. The significant reduction in EFA6R mRNA expression in Ovarian 
Cancer is confirmed by using a large cohort of samples. (A) Expression of 
EFA6R in Ovarian Cancer cDNA array was assessed by using RT-qPCR. (B) 
Data in figure 2A is separated into tumor stages and then (C) histology 
grouping (mucinous, endometroid, clear cell and serous). EFA6R expression 
in (D) Mucinous (E) Endometroid, (F) Clear cell and (G) serous subtypes were 
further separated into low stage (I/II) and high stage (III/IV). The serous 
samples were further separation into (H) individual staging and also (I) 
tumour grades I-III. Box blots show the median. P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001 denotes significance. Statistical analysis was performed 
using non-parametric Mann-Whitney test for figure 3.3A and Kruskal-Wallis 








3.3.4 EFA6R expression loss in Tissue Microarray (TMA) of serous carcinoma 
subtype increases with increase in cancer grade 
 
TMAs allow for simultaneous analysis of EFA6R protein expression in a very 
large number of tissue specimens. In addition, they also provide experimental 
uniformity, where each tissue core is treated in the same manner. Therefore, 
we used a commercially available TMA containing tissue sample of ovarian 
serous carcinoma and healthy TMA containing 8 healthy and 54 single core 
cases of serous carcinoma for analysing EFA6R protein expression by using 
immunohistochemistry (Figure 3.4). 
 
Healthy ovarian epithelial tissues have an architecture that is composed of 
simple columnar epithelium that have not broken through the basement 
membrane and invaded the underlying stroma. The epithelial cells of healthy 
ovarian tissues showed positive staining of EFA6R. (Figure 3.4A). Based on 
our immunohistochemically scoring system of distribution and intensity 
(outlined in section 3.2 of methods and materials), we have shown that 
EFA6R expression is significantly reduced in ovarian cancer tissues (****P 
<0.0001) (Figure 3.4 B). EFA6R protein expression is visibly reduced as the 
epithelium loses its healthy architecture in Grade I and as the cells progress 
towards a more undifferentiated state (Grade II-III) (Figure 3.4A) where 
EFA6R expression is fully absent, indicating that EFA6R is downregulated 
during the course of tumor progression from healthy to potentially metastatic 
cancer. We sought to understand the correlation between EFA6R expression 
loss with increased tumor grade. We therefore separated the cancer specimens 
of the serous histology subtype based on their tumor grading and found 
significance in EFA6R expression decrease between healthy and Grade I (* P 
<0.458) and healthy versus Grade II-III (****P <0.0006). Here, we showed that 
EFA6R is downregulated during ovarian cancer progression and is 

















































Figure 3.4. EFA6R protein expression is downregulated in TMAs containing 
serous ovarian cancer cores (A) Immunostaining was performed in a 
benchmark Ultra IHC staining module with anti-EFA6R antibody (see 
methods). The cores are displayed with x10 magnification and the insets were 
enlarged to x40 magnification. (B) Pooled EFA6R expression score between 
healthy and cancer specimens. (C) The cancer specimens were then separated 
into grades. Each core was scored based on the total sum of distribution of 
epithelial cells stained (score of 0 to +5) and the intensity of the staining 
(0=none, +1 = weak, +2 = moderate and 3+ = strong). Box blots show the 
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significance. Statistical analysis was performed using non-parametric Mann-
Whitney test for figure 3.4A and Kruskal-Wallis test for figures 3.4B. 
 
3.3.5. EFA6R protein expression is significantly reduced cancer serous 
carcinoma tissue lysates.  
 
In order to asses EFA6R protein expression in tissue lysates, we obtained an 
INSTA-Blot Ovary Tissue OncoPair (Novus Biologicals, Cat. No.: NBP2-
30124) in which samples are laid out in pairs of Serous (S) and healthy (H) 
tissue lysates from the same patients (Figure 3.5A). There are seven pairs of 
samples, representing seven different patients. By using immunoblotting, we 
showed that EFA6R protein expression is significantly downregulated in 6 
out of 7 OncoPair lysates. The anomaly with sample 2 skewed the data when 
the densitometry values of all OncoPairs were combined. However, we still 
saw overall reduction of EFA6R in pooled tissue lysates (*P <0.0169) (Figure 
3.5B). These findings complement our previous findings that EFA6R 






































Figure 3.5. EFA6R protein expression is reduced in 6/7 ovarian cancer tissue 
lysates, compared to healthy. (A) The OncoPair INSTA-Blot is a ready to use 
PVDF membrane containing denatured protein (~14µg/lane) lysates from 
serous carcinoma and matched non-tumor adjacent tissues obtained from 
seven patient donors, which was probed with the anti-EFA6R antibody. (B) 
Densitometry analysis of the blot in ‘A’. Box blot shows the median. P <0.05 





































H S H S 
1 
7 OncoPair of Healthy (H) and Serous carcinoma (S) 
2 3 4 5 6 7 
H S H S H S H S  H S 
    1    0.24    1    1.5      1    0.21    1   0.37    1    0.41   1     0.09    1     0.19 
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3.3.6. EFA6R is downregulated at mRNA and protein levels in a panel of 
ovarian cancer cell lines 
 
In order to study the functional relevance of EFA6R, the best representative 
model that resembles its tumor of origin are primary tissues. However, one 
key limitation in using primary tissues is the difficulty in conducting 
molecular studies. As a substitute, we have used cell lines that resemble the 
genomic and phenotypic markers of the original tumor. In addition, we also 
took into consideration the functional utility in conducting in vitro studies. 
Over the past few decades numerous ovarian cancer cell lines have been 
utilized in research, however only recently have researchers thoroughly 
characterized and identified ovarian cancer cell lines that reflect the tumor 
of origin (Domcke et al. 2013, Coscia et al. 2016). As such we gathered 10 
ovarian cell lines that not only have the highest genetic and phenotypic 
similarity to the tumor of origin but also match in their EFA6R expression 
levels (Figure 3.6). 7/10 cell lines OVSAHO (HGSC), COV318 (HGSC) 
OVCAR8 (LGSC), IGROV-1 (Mixed), SKOV-3 (LGSC) and TOV21G (HG 
Clear cell carcinoma) exhibited dramatic and varied reduction of EFA6R 
expression at both mRNA (figure 3.6A) and protein levels (Figure 3.6C and 
3.6D). Three cell lines CAOV3 (HGSC), OVCAR3 (HGSC) and COV504 
(LHSOC) were identified as EFA6R-positive cell lines, respectively. Overall, 
when EFA6R mRNA (***P <0.0003) and protein (****P <0.0001) samples were 
pooled together (Figure 3.6B and 3.6E), we observed reduction of EFA6R 
expression similar to the ovarian cancer tissue we observed previously. In 
chapter 4, we used a series of EFA6R-positive and EFA6R-negative cell lines 
to study epigenetic mechanism involved in EFA6R gene silencing and its 
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Figure 3.6. EFA6R mRNA and protein analysis in various ovarian cancer cell 
lines. RNA and protein were isolated at the same time from each cell line 
using TRI-reagent. RNA was reverse transcribed into cDNA. A) RT-qPCR was 
performed using EFA6R primer with ß-actin as housekeeping gene to which 
Cq values were normalized and (B) the overall pooled healthy and cancer 
samples are displayed. (C) The protein lysates were separated by SDS-PAGE, 
transferred onto a PVDF membrane and probed with an anti-EFA6R and an 
anti-ß actin (loading control) antibodies (D) A densitometry analysis was 
conducted and (E) the overall pooled healthy and cancer samples displayed. 
Box blot shows the median. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001 
denotes significance. Statistical analysis was performed using non-































3.7. EFA6R is upregulated in breast cancer tissue and cell lines  
 
Preliminary analysis of EFA6R protein expression in breast cancer tissue 
(Figure 3.7A) and mRNA (Figure 3.7B) and protein expression (Figure 3.7C) 
in cell lines correlate with previous findings that EFA6R is significantly 


















Figure 3.7. Analysis of EFA6R expression in breast cancer tissues and cell 
lines (A) Preliminary analysis of EFA6R staining in breast cancer tissues 
(n=1) (B) RNA and protein were isolated at the same time from each cell line 
using TRI-reagent. RNA was reverse transcribed into cDNA. (A) RT-qPCR 
was performed using EFA6R primer with ß-actin as housekeeping gene to 
which Cq values were normalized and (C) the protein lysates were separated 
by SDS-PAGE, transferred onto a PVDF membrane and probed with an anti-


























































In humans, EFA6R was original identified as HCA67 (that encodes a protein 
of 534 amino acid residues) where it was shown to be expressed in healthy 
tissues of brain, heart, kidney, liver, lung, pancreases, placenta, prostate, 
spleen and testis (Wang et al. 2002). In addition to liver cancer, it was shown 
to be expressed in the colon cancer cell line Caco2 (Wang et al., 2002). 
Similarly, we have shown that EFA6R expression is elevated in colon cancer 
tissues however due to a limited sample size and the variability that 
inherently exist in cancer tissues, we could not find statistical significance in 
these values. Breast and Thyroid tissues showed significant increases in 
EFA6R expression compared to healthy tissues. From our preliminary 
analysis, we have indeed observed EFA6R mRNA and protein expression 
increase in breast cancer cell lines MCF-7 and an approximately 10-fold 
increase in the highly invasive MDA-MB-231 as well as indications of positive 
staining in breast cancer tissues. These results warrant further analysis of 
EFA6R expression in breast cancer tissues and cells as preliminary data 
suggests a potential oncogenic role. 
 
We also showed that EFA6R expression is reduced significantly in ovarian 
and in liver cancer tissues. However, our results showed that there was no 
significant difference in EFA6R expression in kidney cancer tissues when 
compared to that in corresponding healthy tissues. Finally, in prostate cancer 
tissues, although the increase in EFA6R expression in tumor samples was 
found to be statistically insignificant, we have observed a significant increase 
in EFA6R expression in prostate cancer cell line DU145, compared to the 
healthy prostate PNT2 cell line (data not shown). Overall, utilization of the 
cancer tissue array, allowed us to look at potential significant changes in 
EFA6R expression in various cancers. However, a more conclusive 
observation can be drawn by using a cancer-specific tissue array that contains 
a significant larger sample size. Due to the inherent molecular variability of 
tissues, only a larger sample size can reduce the power of anomalies in both 
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biological and statistical observations. 
 
Therefore, we analysed EFA6R expression levels in ovarian cancer tissue 
array and showed that its expression is significantly reduced in ovarian 
tumor samples as tumor progresses from stage I to IV. Further analysis into 
ovarian carcinoma subtypes revealed that the significant reduction of EFA6R 
expression in our tissue array was due to all EOC histotype. Furthermore, 
these data suggest that this downregulation occurs prior to the advancement 
of EOC, suggesting that EFA6R expression decrease can  be a used as an 
universal early indicator and biomarker for all EOCs. It is worth noting that 
in our analysis of borderline tumours and also mixed types, we observed 
similar pattern of downregulation (data not shown). However,  it in the case 
of mucinous carcinoma samples we did not observed significant early 
downregulation of EFA6R. This is most likely due to a small sample size, but 
we do not rule out a biological reason for this observation. Interestingly, we 
have observed (data not shown) that EFA6R is highly expressed in COV644 
cell line (which is of mucinous histology), Previous studies have shown that 
serous and mucinous carcinomas differed with respect to the frequency and 
pattern of LOH at 8p. Indeed, allelic analysis of 8p21-p23 have shown that 
67% serous carcinoma samples display LOH whereas only 21% of mucinous 
carcinomas showed allelic loss (Lassus et al. 2001).  
 
Mucinous cancers are rare and at high grade more deadly than others, with 
a lower median survival time than serous carcinoma and more chance of 
cancer progression (Frumovitz et al. 2010), often because what appears to be 
a primary lesion is a metastatic lesion derived from the gut or pancreas 
(Frumovitz et al. 2010). This may be because they often express mutant 
KRAS (Ryland, Hunter, Doyle, Caramia, Li, Rowley, Christie, Allan, 
Stephens, Bowtell, Australian Ovarian Cancer Study, et al. 2015) and have 
high Src (Matsuo et al. 2011) and nuclear pERK1/2 activity (Amsterdam et 
al., 2010).  Another trait of this carcinoma subtype is its resistance to 
platinum chemotherapy such as carboplatin and oxaloplatin (Matsuo et al. 
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2011, Frumovitz et al. 2010). In the case of oxaloplatin it has been revealed 
to activate Src (Matsuo et al. 2011) and the effect of this could therefore 
promote cancer progression (Kim, Song, and Haura 2009).  
 
As the most aggressive sub-type, HGSC, accounts for 90% of serous 
carcinomas and two-thirds of all ovarian cancer deaths, making it by far the 
most extensively studied ovarian carcinoma (Bowtell 2010). Owing to this 
fact, we sought to understand the pattern of EFA6R downregulation in serous 
histology by tumor stage and grade. We saw a significant reduction of EFA6R 
from healthy to low stage (I/II) and grade I and a dramatic reduction at high 
stage (III/IV) and grade (II/III). This potentially indicates that during the 
multi-step complex process of tumor initiation and progression, EFA6R 
downregulation plays a major role in at the advent of tumor progression. 
 
We further aimed to substantiate these findings by analysing EFA6R protein 
expression in TMAs that contained serous carcinomas of grades I-III. During 
tumor progressing, we observed cytological such as variability in nuclear size 
and shape, increased nuclear staining of cells by dyes, increased ratio of 
nuclear versus cytoplasmic size and increased mitotic activity (indicating 
extensive cell proliferation). We showed that EFA6R expression loss 
correlates with increase in cancer grade. Here, EFA6R staining was prevalent 
in healthy tissues, but significantly reduced in grade I tissues. EFA6R 
staining was no longer visible in tumours of grade II/III, adding further 
evidence that EFA6R expression is reduced in early stages of serous ovarian 
cancer. Furthermore, we analysed EFA6R expression in tissue lysates; 6/7 
serous carcinoma showed reduced expression at the protein level. Similarly, 
the majority of our ovarian cancer cell lines were identified as EFA6R-
negative cell lines (COV381, OVSAHO, SKOV-3, TOV21G, IGROV-1 and 
OVCAR8) whereas CaOV3, OVCAR3 and COV504 were shown to be EFA6R 
positive. Interestingly, we observe different levels of residual EFA6R 
expression at mRNA and protein level in SKOV-3 and OVSAHO. This may 
suggest haploinsufficiency in ovarian cancer, whereby EFA6R is produced but 
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at insufficient levels to maintain a wild type phenotype. However, further 
analysis into the mechanisms that maintain EFA6R downregulation (such 
DNA methylation) may shed light on the extent to which EFA6R is 
downregulated in different cell lines. Overall, although it is important to 
choose cell lines that resemble the tumor phenotype, it is also worth 
considering their functionality during in vitro studies. Based on this, future 
studies should utilize both EFA6R negative cell lines to observe any positive 
effects as a result of EFA6R upregulation. At the same time, siRNA 
knockdown of EFA6R in EFA6R-positive cell lines may shed light on the 
consequences of EFA6R downregulation.  
 
Collectively, our results indicate that the dramatic reduction of EFA6R 
expression during the initial phases of ovarian cancer may contributes to 
ovarian cancer progression. As high stage and grade is a measure of 
invasiveness and progression of cancer, it can be loosely considered as 
prognostic indicator for ovarian cancer, which makes our data consistent with 
the (Pils et al. 2005a) study, which showed that patients with ovarian cancers 
with decreased expression of EFA6R had a worse prognosis.  
 
The functional relevance of EFA6R downregulation (with particular focus on 
serous carcinomas) is explored in the following chapter. Although a functional 
role for Arf6 activation by EFA6R has yet to be elucidated, the homology 
between EFA6R and other Arf6 GEF suggests that EFA6R may have an Arf6-
dependent and independent role in ovarian cancer. In breast cancer cells, 
GEP100/BRAG2 – a Arf6-specific GEF, is overexpressed and plays a 
significant role in EGF-induced breast cancer cell invasion (Morishige et al. 
2008). In contrast, EFA6B has been shown to play a possible role as a tumor 
suppressor in breast cancer cells (Zangari et al. 2014). Therefore, EFA6R 
expression and functional role in different cancer types and sub-types is likely 
to be varied. In summary, EFA6R appears as a potential tumor antagonist in 
a subset of ovarian cancers, whose downregulation may trigger progression 
towards EMT transition and metastasis.   
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Chapter 4: Functional analysis of 
EFA6R downregulation in 




Metastasis (migration and invasion) of cancer cells, as well as their acquired 
resistance to drug treatment are the major causes of cancer-associated deaths 
(Lambert, Pattabiraman, and Weinberg 2017). Out of all Epithelial Ovarian 
Cancer (EOC) sub-types, HGSC, accounts for two-thirds of all ovarian cancer 
deaths, making it the most extensively studied EOC (Bowtell 2010, 
Gershenson et al. 2006). The majority of HGSC are now considered to 
originate from the fallopian epithelial (rather than originating from the 
ovarian epithelial) and subsequently metastasize onto the ovaries. Our 
understanding of the impact of metastatic suppressors in ovarian cancer is 
currently limited, therefore identification of novel metastatic suppressors can 
potentially serve as a prognostic, marker, therapeutic target and predictor for 
treatment response. EFA6R expression loss in Epithelial Ovarian Cancer 
(EOC) linked to a decrease in patient survival (Pils et al. 2005a). 
 
EFA6R is a member of the EFA6 family of Arf6-specific guanine exchange 
factors (GEF). Arf6 small GTPase, which mainly mediates membrane 
trafficking and cytoskeleton reorganization at the plasma membrane, by 
cycling between an active GTP-bound and an inactive GDP-bound forms 
(Donaldson 2003).  Arf6 is activated by GEFs whereas inactivated by GTPase 
activating proteins (GAPs). When it is activated, Arf6 regulates cellular 
functions by binding to down-stream effectors such as GGA3 (Dell'Angelica et 
al. 2000c). Arf6 and its down-stream effectors are not only over-expressed in 
many cancers but also promote cancer invasion, metastasis and drug 
resistance (Yamauchi, Miura, and Kanaho 2017). In addition to its role in 
ovarian cancer, EFA6R expression shown to be altered in several other 
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cancers (see results chapter 3). Another member of the EFA6 family, EFA6B 
(through Arf6 activation), has also recently been shown to be antagonize 
breast cancer cells by promoting tight junction proteins claudin-2 and 
occludin as well as blocking the transformer growth factor-beta (TGF-ß) 
pathway – shown to be an early inducer of disassembly of tight junction 
proteins and the epithelial mesenchymal transition (EMT) (Zangari et al. 
2014). Other GEFs, such as GEP100/BRAG2 has been shown to be 
indispensable to Arf6-mediated invadopodia in breast cancer cell lines 
(Morishige et al. 2008). These studies highlight the involvement of Arf6 GEFs 
in the Arf6 activation and subsequent regulation of cancer phenotypes.   
 
In EOC, a role for EFA6R has yet to be identified. EFA6R levels are either 
low or lost in ovarian cancer tissues and cells (unpublished data; see chapter 
3) and its downregulation has been previously been shown to have an drastic 
impact on patient survival (Pils et al. 2005a).  Another mechanism of aberrant 
gene loss in EOC is interconnected with epigenetic alterations where DNA 
hypermethylation by DNA methyltransferases (DNMTs) and histone 
deacetylation by histone deacetylases (HDACs)  - within or upstream of 
promoter regions of Tumor Suppressor Genes (TSGs) have been shown to lead 
to undesirable gene silencing (Baylin and Ohm 2006). Early gene-silencing 
events (pre-invasive stages of cancer progression) might be crucial in 
predisposing cells to accumulate certain oncogenic pathways that drive 
tumor progression. As such epigenetic inhibitors have been utilized to 
revive the expression of many TSGs and subsequently reverse adverse 
phenotypes (Bohl, Bullinger, and Rucker 2018). One such inhibitor is 5-Aza-
2′-deoxycytidine (5-Aza-CdR, Decitabine): a cytidine nucleoside analogue, in 
which the carbon in the 5-position of the cytodine is replaced by nitrogen. 5-
Aza-CdR has FDA approval for the treatment of myelodysplastic syndromes 
(Saba 2007).  
 
Numerous in vitro studies have demonstrated the potent anti-cancer use of 
5-Aza-CdR as a unique demethylating agent to reactivate tumor suppressor 
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genes in many different cancer types (Merlo et al. 1995, Gonzalez-Zulueta et 
al. 1995, Schnekenburger et al. 2011, Mirza et al. 2010, Gailhouste et al. 
2018). The methylation of DNA occurs at the 5-position of the cytosine ring 
within cytosine-phosphate guanine (CpG) dinucleotide by a transfer of a 
methyl group from S-Adenylyl-L-methionine. DNMTs catalyse this reaction. 
To inactivate transcription, methylation usually occurs in the CpG islands in 
the promoter-exon regions of target genes. Following uptake of 5-Aza-CdR, it 
is phosphorylated and incorporated into DNA by DNA polymerase. The 
formation of a covalent complex between 5-Aza-CdR-DNA and DNMT1 at 
CpG methylation sites, results in the inactivation of this enzyme 
(Juttermann, Li, and Jaenisch 1994). DNMT1 inhibition results in global 
DNA hypomethylation, gene activation and induction of cellular 
differentiation, senescence and/or apoptosis (Schnekenburger et al. 2011).  
 
It has been  estimated that the transcription of 10% of genes are regulated 
globally by HDAC (Baylin and Ohm 2006). In humans, there are 18 known 
HDACs that are categorized into four classes, I-IV. HDAC inhibitors (HDACi) 
are well known as potential anti-cancer agents since they prevent gene 
silencing by inhibiting the HDACs ability to remove acetyl groups from the 
lysine residues of histones in the nucleosome (Seto and Yoshida 2014, Bolden, 
Peart, and Johnstone 2006). The HDACi are categorized into four groups 
based on their chemical structures: group A are hydroxamic acids, group B 
are short-chain fatty acids, group C are benzamides and group D are cyclic 
peptides. The pharmaceutical HDACi Trichostatin A (TSA) and 
suberanilohydroxamic acid (SAHA, also known as Vorinostat) are from group 
A of HDACi. They block HDAC enzyme activities of classes I, II and IV 
thereby upregulate the expression of a significant majority of genes that are 
regulated by HDACs (Seto and Yoshida 2014). SAHA has FDA approval for 
the treatment of advanced primary cutaneous T cell lymphoma (Mann et al. 
2007) while its sole use and in combination with other drugs are under clinical 
investigations for the treatment of other cancer types; phase 3 trials have 
been completed for the treatment of advanced malignant pleural 
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mesothelioma, acute myeloid leukemia and brain stem glioma 
(https://clinicaltrials.gov).  
 
In this study, we performed a gain of function study by using 5-Aza-CdR and 
SAHA, to revive EFA6R expression in OVSAHO andSKOV-3 cell lines, 
confirming that EFA6R is epigenetically suppressed in SOC. We also 
demonstrated that the presence of EFA6R antagonizes cell migration and 
invasion. To prove that these phenotypes are solely associated with EFA6R 
upregulation and not any other re-expressed protein, we used siRNA to 
knockdown EFA6R and demonstrated that in the absence of EFA6R, SKOV-
3 cells regain their aggressive metastatic capacity. Finally, in an attempt to 
delineate the signalling pathways of EFA6R-mediated attenuation of 
metastasis, we showed that EFA6R may utilize an Arf6-independent pathway 
to control cellular phenotype.  
 
4.2 Materials and Methods 
 
All chemicals and consumables used were obtained from Sigma (Dorset, UK) 
unless otherwise stated. Cell culture plates were obtained from Greiner-Bio 
One (Gloucestershire, UK).   
 
4.2.1 Ovarian healthy and cancer cell lines 
 
Information on the cell lines used in this chapter can be found in section 3.2.1.  
 
4.2.2 Cell viability assay (Kit-8) 
 
The cell viability of ovarian cell lines as a result of treatment 5-Aza, SAHA 
and NAV-2729 were determined by using the Kit-8 cell viability assay, 
according to protocol in section 2.2.8.  
 
4.2.3 Methods of drug treatments with 5-Aza-CdR, SAHA, and NAV-2729 
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Drug treatments in epigenetic studies and Arf6-inhibition studies were done 
according to protocol in section 2.2.10.   
 
4.2.4 Small interfering RNA (siRNA) transfection 
 
siRNA transfection was carried out according to protocol in section 2.2.6. 
 
 
4.2.5 Cell migration and invasion assays 
 





Immunoblotting was carried out according to protocol in section 2.2.14.2, 
primary antibody (anti-EFA6R rabbit polyclonal 1/500 dilution, anti-Arf6 
mouse monoclonal 1/200, anti-ARF1 rabbit monoclonal 1/3000 or anti- β-actin 
mouse monoclonal at 1/10,000 dilution) diluted in blocking buffer. Followed 
by this, the blot was incubated with horseradish peroxidase (HPR)-
conjugated secondary antibody (GE Healthcare, USA) diluted in blocking 
buffer (anti-rabbit or anti-mouse 1/2500 dilution). 
 
4.2.7 GST-tagged protein expression, purification and immobilisation  
 
 
This was carried out as described with few modifications (Venkateswarlu 
2005). GST-tagged protein expression: A single colony or a loop-full of glycerol 
stock of E.coli strain BL21(DE3) cells harbouring hGGA3 VHS-GAT/pGEX 
plasmid (was inoculated into 5ml of LB containing 100 µg/ml ampicillin and 
cultured over-night (~15 hours) by incubating at 37°C/200 rpm. The overnight 
grown culture was diluted by 1:100 into fresh LB (100 µg/ml ampicillin) and 
grew at 37°C/200 rpm until the A600 had reached to 0.5-1.0 (~3hours). 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) induction was carried out 
using 0.5mM IPTG for an additional 3 hours of incubation at 37°C/200 rpm. 
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The culture was centrifuged at 7,700 x g for 10 min at 4OC to sediment the 
cells. The cell pellet from 1L culture was re-suspended in 25 ml of PBS (ice 
cold) and lysed by sonication using the following parameters: 80% of max 
power of the sonicator for 4x 30 sec. Following the addition of 1% Triton-X-
100, the cell lysate was mixed gently for 30 min to aid in solubilisation of the 
membrane proteins and then the lysate was centrifuged at 12,000 x g for 15 
min to remove insoluble cell debris as the pellet.  
 
Purification and immobilization of the GST-fused protein to glutathione 
magnetic agarose beads: The magnetic Glutathione beads (Promega; 25% 
slurry) were vortexed to resuspend the matrix. The beads were sedimented 
by placing the matrix in a magnetic stand for 1 min. They were then washed 
by adding 50 ml of PBS (ice cold), inverted to mix and the matrix sedimented 
again. For each 2 ml of the original slurry of magnetic glutathione beads 
dispended, 1 ml of PBS was added and inverted to mix – resulting in 50% 
slurry. To 25 ml of the overnight culture, 1 ml of 50% slurry of magnetic 
glutathione beads was added and incubated (with gentle agitation) overnight 
at 4OC. The matrix was sedimented by placing the tube in a magnetic stand 
for 1 min at 4OC. The matrix was washed 4x 10 ml with PBS. 25% slurry in 
50% glycerol was made by adding 0.75 ml of PBS and 0.75 ml of cold glycerol 
and the beads stored at -20oC. The purity and the amount of the fusion protein 
immobilised to glutathione beads were analysed using coomassie blue stained 
SDS-PAGE gel and BSA as the protein standard.  
 
4.2.8 GST-GGA3 VHS-GAT pull down assay 
 
Arf6 activation was analysed using the GST-GGA3 VHS-GAT (GST-effector) 
pulldown assay (Kanamarlapudi 2014a). Following the combinational 
treatment of siRNA and 5-Aza-Cdr (see above), the cells were serum starved 
for 2 hours and lysed in ice-cold modified pulldown-lysis buffer (25mM Tris 
pH 7.2, 150mM NaCl, 5mM MgCl2, 1% NP-40/ IGEPAL®CA-630, 5% glycerol) 
containing 1% mammalian protease inhibitor cocktail (Sigma). 90% of the 
lysates were incubated with 10µl of 25% of GST-effector coupled to magnetic 
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agarose beads, which were prepared as described above, for 2 hrs at 4˚C. The 
beads were then washed 3 times with 1 ml of lysis buffer and resuspended in 
lysis buffer (1/10th of buffer used for lysing cells). The remaining lysates not 
incubated with the beads were used as analyse to total Arf6. The lysates along 
with pulldown beads were boiled by mixing with 25% of 5x sample buffer for 
5 min at 100°C. Arf6 expression and activation was assessed by 
immunoblotting (using an anti-Arf6). Arf6-GTP expression levels were 
normalized to total Arf6.  
 
4.2.9 Statistical Analysis  
 
Data was analysed using the Graph prism program (version 7). Error bars 
show the median with 95% confidence interval of three or more independent 
experiments, unless stated otherwise. The non-parametric Kruskal-Wallis 
statistical test was used to calculate statistical significance for the data. A 
value of P >0.05 was considered not significant (ns) whereas * P <0.05, **P 




4.3.1 Ovarian cell lines have different sensitivity to 5-Aza-CdR and SAHA 
 
In vitro and in vivo antitumor activities of both 5-Aza-CdR and SAHA have 
been documented previously (Karahoca and Momparler 2013, Richon 2006). 
Although the administration of both drugs generally tends to lead to 
reactivation of tumor suppressor genes involved in malignancies, their form 
of action significantly differs. 5-Aza-CdR is incorporated into DNA where it 
inhibits the activity of DNMT1, hence preventing the methylation of DNA, 
whereas SAHA inhibits HDAC (of which there are four classes) activity by 
binding to the active site of the class I, II and IV HDACs.  
 
Ovarian cell lines were initially assessed for their sensitivity to epigenetic 
drugs 5-Aza-CdR and SAHA. Following four days of incubation with various 
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concentrations of the epigenetic drugs – during which fresh drugs were added 
on the third day, given the half-life of the drugs. All cell lines showed 
differential sensitivity to both drugs (Figure 4.1), but significant reduction of 
cell viability (to various degrees) was observed only with the administration 
of 10µM SAHA for all cell lines (Figures 4.1 A-C). No significant reduction of 
viability was observed with the administration of the maximal concentration 
of 10µM 5-Aza-CdR. These data demonstrate that the optimal concentration 
of epigenetic drugs –(10µM 5-Aza-CdR and 1µM SAHA) used in the analysis 
were not toxic to the cell lines tested. Therefore, for all subsequent studies, 















































































** P < 0.0023
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Figure 4.1. Dose-dependent effect of epigenetic drugs on cell viability of (A) 
OVSAHO, (B) SKOV-3 and (C) IOC cells. Cells were seeded at a density 2500 
cells/well (for SKOV-3 and IOC cell lines) or 5000 cells/well (for OVSAHO cell 
lines) in a 96-well plate and next day treated with different concentrations of 
5-Aza-CdR and SAHA and DMSO (control) for four days. Errors bars 
represent the mean +/- s.e.m, n=3 (***P <0.01, **P <0.05). Statistical analysis 
was performed using the non-parametric Kruskal-Wallis statistical test.  
 
4.3.2 EFA6R expression is epigenetically suppressed in serous cell lines and 
other EOC histologies 
 
To determine whether EFA6R expression is epigenetically suppressed in 
ovarian cancer, OVSAHO and SKOV-3 and healthy ovarian cell line, IOC, 
treated with either 10µM 5-Aza-CdR or 1µM SAHA for 4 days were analysed 
for the EFA6R protein expression by immunoblotting (Figure 4.2). We 
demonstrated that inhibition of class I and II HDACs (by using SAHA) 
restored EFA6R expression only in the OVSAHO cells (***P <0.006) but not 
in SKOV-3 cells (Figures 4.2 A and B). This expression increases in OVSAHO 
cells reached near normal levels, like in IOC cells (Figure 4.2E). The use of 5-
Aza-CdR, however, resulted in significant increase in EFA6R expression in 
both OVSAHO and SKOV-3 cells (****P <0.0001), which showed EFA6R 
expression levels similar to that seen in IOC cells (Figure 4.2D). Neither of 
these inhibitors affected EFA6R expression in non-tumour IOC cells where 
basal EFA6R expression is already normally high. As EFA6R expression 
levels were restored in OVSAHO and SKOV-3 cells to the levels seen in 
healthy ovarian cells by using the optical concentration of SAHA and 5-Aza-
CdR, we didn’t try SAHA and 5-Aza-CdR combinatorial treatment. Overall, 
these data suggest that EFA6R expression is suppressed through 
hypermethylation and histone deacetylation of EFA6R promoter region in 
SOC. Furthermore, these epigenetic modifications can be reversed to bring 
EFA6R expression to normal basal levels by 5-Aza-CdR (in OVSAHO and 
SKOV-3 cells) or SAHA (in OVSAHO cells only) treatment. Henceforth, we 
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have used SKOV-3 cells to functionally assess the role of EFA6R in SOC due 
to its mesenchymal nature.  
 
Data from the other showed EOC histology cell lines, have shown that the use 
of 5-Aza-Cdr also revived EFA6R expression in TOV21G (clear cell) and 
IGROV-1 (unknown/mixed histology) suggesting that epigenetic mechanism 
also govern EFA6R expression in other EOC histologies (Figure 4.2.1). 
Interestingly, we did not see revival of EFA6R expression in OVCAR8 (an 
unknown grade of serous histology) through either DNA methylation or 
histone deacetylation. Although, we have not yet established the reasons 
behind this due to time constrains, it would be interesting to explore the use 
of other epigenetic modifying drugs as well as looking at other mechanisms 
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Figure 4.2. EFA6R expression is epigenetically suppressed in serous ovarian 
cell lines. (A) OVSAHO, (B) SKOV-3 and (C) healthy IOC cells were treated 
with DMSO (0.1%) and either DNA methylation inhibitor (10µM 5-Aza-CdR) 
or HDAC inhibitor (1µM SAHA) for 4 days. Fresh medium and drugs were 
added on the day 3. The cells were then lysed and the lysates were separated 
by SDS-PAGE, transferred onto a PVDF membrane and probed with an anti-
EFA6R and anti- ß actin (loading control). A densitometry analysis was 
conducted (adjacent to the western blot figures). Epigenetic-mediated revival 
of EFA6R expression in ovarian cancer cell lines was compared to endogenous 
EFA6R levels in the healthy ovarian cell line IOC cell line (5-Aza-CdR [D] 





































































**P <0.05. Statistical analysis was performed using the non-parametric 
Mann-Whitney statistical test. 
Figure 4.2.1 EFA6R expression is epigenetically suppressed in TOV21G 
(clear cell carcinoma) and IGROVA (mixed – unknown carcinoma), but not 
OVCAR8 (Borderline HGSC). (A) TOV21G, (B) IGROV-1 and (C) OVCAR 
were treated with DMSO (0.1%) and either DNA methylation inhibitor (10µM 
5-Aza-CdR) or HDAC inhibitor (1µM SAHA) for 4 days. Fresh medium and 
drugs were added on the day 3. The cells were then lysed and the lysates were 
separated by SDS-PAGE, transferred onto a PVDF membrane and probed 
with an anti-EFA6R and anti- ß actin (loading control). A densitometry 
analysis was conducted (adjacent to the western blot figures). Epigenetic-
mediated revival of EFA6R expression in ovarian cancer cell lines was 
compared to endogenous EFA6R levels in the healthy ovarian cell line IOC 
cell line (5-Aza-CdR [D] and SAHA [E]). Error bars show the median with 
95% confidence interval, n=3, ***P <0.01, **P <0.05. Statistical analysis was 

















































































































































4.3.3 Optimization of siRNA-mediated knockdown of EFA6R expression in 
HEK293 cells and 5-Aza-CdR treated SKOV-3 cells  
 
In order to address the phenotypic role of EFA6R in tumor cell behaviour, 
functional consequences of inhibition and activation of EFA6R is useful. The 
advantage of loss of function studies - through the use of small interfering 
RNA (siRNA) - is the direct translation of the results into phenotype. In other 
words, any change in cellular behaviour can be attributed to the siRNA-
mediated knockdown of the target gene. As such, to achieve maximum 
effectiveness of exogenously introduced siRNA, transfection optimization 
experiments are essential. In addition to the health of cultured cells and 
quality/quantity of siRNA, transfection methods and conditions are critical 
factors. Therefore, we used various lipid-based formulations to introduce 
EFA6R siRNA in SKOV-3 cells using the forward transfection method -where 
cells are pre-plated, allowed to attach, recover and potentially grow for 24 
hours prior to transfection. Initially, we validated siEFA6R1 and siEFA6R2 
for their ability to knockdown EFA6R expression by co-transfecting GFP-
EFA6R and either of the siRNA in HEK293 cells and analysing EFA6R 
expression by immunoblotting (Figure 4.3A). Both siEFA6R1 and siEFA6R 2 
effectively knocked down exogenously introduced GFP-EFA6R, confirming 
previous findings into the effectiveness of these siRNAs (Kanamarlapudi 
2014a). Next we introduced siEFA6R1, siEFA6R2 or siControl into 5-Aza-
CdR treated SKOV-3 cells using JetPrime, INTERFERIn or Lipofectamin 
RNAiMAX and assessed their ability to knockdown of EFA6R expression 
(Figure 4.3B). None of the chemical transfection reagents were effective in 
significantly knockdown of EFA6R expression in SKOV-3 cells. We then used 
a mechanical transfection (using the Neon system) protocol that is based on 
the reverse transfection method - where it involves the simultaneously 
transfection of suspension cells and plating of the cells – for knockdown of 
EFA6R expression in 5-Aza-CdR treated SKOV-3 cells.  The effective 
knockdown (10-20 fold) of EFA6R expression can be achieved by this method 
using either siEFA6R1 or siEFA6R2 (Figure 4.3B). The Neon system employs 
specialized consumable pipette tips (10µl and 100µl) containing gold-plated 
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electrodes as electroporation chamber. We hence attempted to optimize the 
usage of the different sized tips for transfection studies. We observed that 
using a single tip multiple times (without cleaning) reduced transfection 
efficiency in SKOV-3 cells whereas the single use of the tips achieved the 
desirable knockdown levels of EFA6R (Figure 4.3 C). Based on these data, we 
employed the use of the neon transfection system in introducing siRNA in 

































Figure 4.3. Electroporation using the Neon Transfection System is the 
optimal method for EFA6R siRNA delivery into SKOV-3 cells. (A) HEK293 
cells were co-transfected with GFP-EFA6R and 200nM of siControl, 
siEFA6R1 and siEFA6R 2 for two days. The protein lysates were separated 
by 10% SDS-PAGE, transferred onto a PVDF membrane and probed with an 
anti-EFA6R and anti- 𝛂-tubulin (loading control). (B) Following transfection 
of siControl, siEFA6R1 and siEFA6R 2 in SKOV-3 cells using three lipid-
based transfection reagents (JetPrime, INTERFERIn and RNAiMAX) and 
electroporation using Neon transfection system using the following 
parameters: 1170v, 30ms, 2 pulse number, and a cell density of 600Kcells/ml, 
10µM 5-Aza-CdR was added to the cells for four days (on day three, fresh 
medium and drugs were added). The protein lysates were processed as in (A) 
and probed with anti-EFA6R and anti-β-actin (loading control). (C) Further 
optimisation of the electroporation using 10µl and 100µl Neon ® Tips to 
introduce siEFA6R1 into SKOV-3 cells at different cell density.  
 
4.3.4 Optimisation of cell migration and cell invasion assays as phenotypic 
screening methods 
 
The cell culture wound healing assay, and the transwell cell migration and 
invasion assays are used to visually observe and subsequently quantify cell 
migratory and invasive behaviours. They can also be used to study molecular 
mechanisms of cell metastasis (Hall 2009, Haley et al. 2016, Sheets et al. 
2016). We used these cell motility assays to determine the role of EAF6R in 
migration and invasive capabilities of SKOV-3 cells. Naturally, we initially 
optimized the parameters of these assays. The cell wound closure assay 
examines the ability of a particular cell line to migrate and subsequently close 
a wound gap made in a confluent plate of cells. We first analysed a time-
dependent migration of SKOV-3 cells and showed that they are able to 
significantly migrate into the wound gap within 12 hours (~70%) and close 
the gap fully by 24 hours after making the scratch (100%). (Figure 4.4A and 
B). Therefore, we chose the sub-optimal 12-hour time point in the scratch 
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assay for subsequent SKOV-3 migration studies. Next, we assessed the ability 
of SKOV-3 cells to sense a particular chemo-attractant and migration/invade 
through a physical barrier towards it – using the transwell cell migration and 
invasion (pre-coated with 1.2mg/ml of matrigel) assays. Similar to the wound 
healing assays, we set out to find a suitable time-point where the cell 
population migrate and invade through the physical barrier at sub-optimal 
level (Figure 4.4C and D). From these assays, we found out that 4 and 8 hours, 
respectively, required for sub-optimal migration and invasion of SKOV-3 
cells. Overall, the optimisation of the combinational use of 5-Aza-CdR and 
siEFA6R1/2 in the last section, and migration and invasion assays in this 
section allowed us to next examine the migratory and invasive capacity of 
SKOV-3 cells in response to EFA6R upregulation (through 5-Aza-CdR) and 


























Figure 4.4. Optimization of migration and invasion assays using Ibidi® 
migration assay and ThinCert™ transwell inserts. (A) Migration assay using 
ibidi inserts was done by adding 70µl of SKOV-3 cells [700,000/ml] into each 
well of a 2 well insert. After 4-6 hours of incubation for cell attachment, the 
culture-insert was removed and fresh medium was added. Images at 3-5 
random positions were taken at the indicated times as the cells migrated into 
the cell-free gap using a camera-attached microscope at 4x objective lens (B) 
The percentage gap closure was calculated by taking 0 hour migration as the 
baseline. (C) Using the transwell 24-well cultural inserts, the migration and 
invasion (through 1.2 mg/ml of ECM) of SKOV-3 was assessed. Here, cells re-
suspended in serum free medium at a density of 50,000/250µl were 
transferred onto a 8µm pore transwell inserts. Full serum media was placed 
on the other side of the membrane to create a chemotaxis microenvironment. 
Following migration and invasion at the indicated times, cells were fixed 
using 4% PFA and stained with 0.2% crystal violet. The cells that had not 
migrated or invaded through the pores were removed by a cotton swap and 
images of the cells were taken at 3-5 random positions. (D) The concentration 
of crystal violet extracted from the migrated cells using 5% SDS and was 
assessed by reading its absorbance at 570 nm using a microplate reader.  
 
4.3.5 EFA6R re-expression results in inhibition of cell migration and invasion 
in SKOV-3 cells 
 
We have demonstrated in section 4.3.2 that EFA6R is epigenetically silenced 
in SKOV-3 cells and that the use of the demethylating agent, 5-Aza-CdR, 
revives EFA6R expression to similar levels that are observed in the healthy 
ovarian cell line, IOC (Figure 4.2B and D). However, in addition to regulate 
the EFA6R expression, 5-Aza-CdR treatment also alters several other 
proteins expression. Therefore, to analyse the role of EFA6R in cell 
invasion/migration, we knockdown specifically EFA6R expression (by using 
siEFA6R1) in SKOV-3 cells treated  with 5-Aza-CdR and studied the effect of 
EFA6R knockdown on SKOV-3 cell migration and invasion. For this, we 
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electroporated SKOV-3 cells with siEFA6R1, plated, treated with 5-Aza-CdR 
and then assessed the cells migration and invasion capabilities, using wound 
healing and transwell assays. It should be noted that we did not use siControl 
in this or subsequent studies as we previously established that siEFA6R1 or 
the transfection method do not have off-target effects. By using 12 hours of 
migration in the wound healing assay, we saw significant reduction of cell 
migration in 5-Aza-CdR treated SKOV-3 cells, ~ 20% of wound gap closure in 
5-Aza-CdR incubated cells compared to ~80% gap closure in untreated cells 
(**P <0.0099) (Figure 4.5A and D). Interestingly, in the siEFA6R1/5-Aza-CdR 
treated cells, we observed migratory capacity (~75% gap closure) similar to 
that of the untreated cells (~80% gap closure). To assess the role of EFA6R on 
metastasis, we used transwell migration and invasion assays.  These studies 
showed that treatment with 5-Aza-CdR reduced migration and invasion of 
SKOV-3 cells by ~5 folds (Figure 4.5B and C) whereas, siEFA6R1/5-Aza-CdR 
treated cells exhibited a resurgence of cell motility to near pre-treated levels 
(Figure 4.5E). Biochemical analysis of the effect of 5-Aza-CdR treatment on 
EFA6R expression showed a significant ~ 10-fold increase (**P <0.0026) 
(Figure 4.5F). Simultaneous treatment of SKOV-3 cells with siEFA6R1/5-
Aza-CdR inhibited the revival of EFA6R expression and hence a knockdown 
of expression levels – similar to control levels was observed. These results, 
taken together, highlight that the difference in migration and invasion 
between 5-Aza-CdR and siEFA6R1/5-Aza-CdR treated cells can be attributed 
to EFA6R alone. It can hence be stated that re-expression of EFA6R 
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 ** P < 0.0026
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Figure 4.5 EFA6R inhibits cell migration and invasion of SKOV-3 cells. 
SKOV-3 cells were electroporated with siControl or siEFA6R1. Following cell 
attachment, 10µM 5-Aza-CdR was added for four days (fresh medium and 
drug was added on third day). (A) 70µl of cells/well at a density of 700,000/ml 
were also plated into an ibidi cultural 2-well insert, followed by 6-hour cell 
attachment and start of migration assay - where the inserts were removed 
and fresh media was added. Images were taken at the indicated times using 
a camera-attached microscope at 4x objective lens. (D) Relative gap closure 
(%) compared to control was measured post-12-hour cell migration. For the 
transwell migration and invasion assays, cells at a density of 50,000 
cells/250µl for (B) cell migration and (C) cell invasion. Following 4 hours of 
cell migration and 8 hours of cell invasion, the cells were fixed with 4% PFA 
and stained with 0.2% crystal violet. Cells that had not migrated/invaded 
though the 8µm pores of the inserts were removed by a cotton swab before 
images were taken and the crystal violet extracted from the migrated/invaded 
cells using 5% SDS and read it’s OD at 570nm using a microplate reader. (F) 
From the same batch of cells, the protein lysates were separated by 10% SDS-
PAGE, transferred onto a PVDF membrane and probed with an anti-EFA6R 
and anti- β-actin (loading control). Errors bars represent the mean +/- s.e.m 
n=3, ***P <0.01, **P < 0.05. Statistical analysis was performed using the non-
parametric Kruskal-Wallis statistical test. 
 
4.3.6 Preparation of GST-GGA3 VHS-GAT for pulldown of GTP-Arf6 
 
The GGAs (Golgi-associated, γ-adaptin homologous, ARF-interacting 
proteins) constitute a family of proteins that associate with the cytoplasmic 
face of the trans-Golgi network (TGN) and interact with ADP-ribosylation 
factors (ARFs) (Dell'Angelica et al. 2000b). GGAs (of which there are three 
members GGA1, GGA2, and GGA3 in humans consist of a VHS domain and 
a region of homology termed GAT (which is directly responsible for 
interacting with GTP-bound form of ARFs). This interaction has allowed for 
determination of GTP-bound ARFs by using GGAs as effectors in the GST-
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pulldown assays and the ARFs specific antibodies in immunoblotting (Davies 
et al. 2014). Therefore prior to detection of GTP-bound Arf6 in GST-GGA3 
pulldown assay, we initially purified the GST-GGA3 fusion protein from 
E.coli strain BL21(DE3) and subsequently coupled it to glutathione agarose 
magnetic beads. The resulting resin was subjected to SDS-PAGE, followed by 
coomassie blue stain to determine the purity and amount of the GST-effector 
bound to the resin using BSA as protein standard (Figure 4.6A). This analysis 
revealed that >5 mg GST-effector bound to 1ml of the beads, which is >90% 
pure. Coomassie blue staining of SDS-PAGE gel was used to analyse the 
expression and purification of GST-effector (Figure 4.6A). Given the 
specificity of GGA proteins affinity to GTP-bound ARFs, the GST-GGA3 VHS-
GAT resin was incubated with lysates of HEK293 cells expressing ARF1 and 
Arf6 mutants that mimic either the GDP-bound (ARF1 T31N and Arf6 T27N) 
or the GTP bound forms (ARF1 Q71L and Arf6 Q67L) (Figure 4.6B). As seen 
in this figure, the GST-GGA3 VHS-GAT (GST-effector) only precipitated the 
active ARF mutants and therefore we deemed this assay suitable in assessing 






































































































Figure 4.6. GST-GGA3 VHS-GAT (GST-effector) expression, purification, 
immobilization to glutathione magnetic beads and use in GST-pulldown 
assay. (A) Analysis of GST-effector expression induction with IPTG in E. coli 
BL21(DE3) strain, purification and immobilization to glutathione agarose 
magnetic beads by SDS-PAGE and coomassie blue staining. The amount of 
GST-effector bound to glutathione beads was assessed by using BSA 
standard. (B) HEK293 cells were transfected with either the GFP-tagged 
ARF1 or Arf6. After 2 days, the cells were lysed and the resulting lysates were 
incubated with 10µl of 25% of GST-effector (~15 mg of protein/ml of beads) 
coupled to magnetic agarose beads. Following elution with SDS-PAGE 
sample buffer, the bound proteins were separated by SDS-PAGE, and 
detected by immunoblotting using anti-GFP primary antibody.  
 
4.3.7 EFA6R attenuates metastasis via an Arf6 independent pathway 
 
A recent study has shown that EFA6R functions as an Arf6 specific GEF 
(Kanamarlapudi 2014). Arf6 signalling pathways have been shown to 
regulate tumor cell migration and metastasis (Premont and Schmalzigaug 
2009;(Tamaddon-Jahromi and Kanamarlapudi 2017) ). Therefore, we wanted 
to determine whether EFA6R mediates cell migration and invasion through 
Arf6 dependent or independent pathway. To investigate this, we used two 
approaches: (1) knockdown of Arf6 using siArf6 and (2) inhibition of the Arf6 
activation using NAV-2729 - a chemical inhibitor that associates with the 
GEF-binding area of Arf6, hence prohibiting the GEF-mediated activation of 
Arf6 (Yoo et al. 2016, Zhu et al. 2017).  
 
We began this part of the study by optimizing the use of siArf6 and NAV-
2729. Endogenous Arf6 protein expression, but not ARF1, in SKOV-3 cells 
was knockdown by siArf6 and using the neon transfection system, (Figure 4.6 
A). We then assessed the dose and time-dependent inhibition of Arf6 
activation in SKOV-3 cells by NAV-2729, which showed that incubation with 
50µM NAV-2729 for 2 hours sufficiently reduces Arf6-GTP levels but it is not 
 184 
toxic to cells at that concentration. We also confirmed that NAV-2729 
uniquely inhibits Arf6-GTP and not one of its close homologs, ARF1-GTP 
(Figure 4.7D). 
 
Next, we investigated the phenotypic effects of NAV-2729 and siArf6 on 
SKOV-3 cell migration using the transwell assay (Figure 4.7 E). SKOV-3 cells 
were treated with 50µM NAV-2729 with or without the addition of 5-Aza-
CdR. We observed that cells treated with NAV-2729 alone did not 
significantly reduce cell migration whereas the combinational treatment of 
cells with NAV-2729 and 5-Aza-CdR attenuated cell migration near to that 
seen in 5-Aza-CdR alone treated cells (**P <0.0066) (Figure 4.7F). Similarly, 
knockdown of Arf6 by using its siRNA had no effect on 5-Aza-CdR inhibited 
cell motility (**P < 0.0066) (Figure 4.6F). The Arf6 activation in cells treated 
with NAV-2729 and 5-Aza-CdR was assessed by using GST-effector pulldown 
assay (the VHS-GAT domain of the ARF effector GGA3 only binds to the GTP-
bound form of ARFs (Dell'Angelica et al. 2000a). We observed that Arf6 
activation was reduced (to various degrees) by the addition of the 
demethylating agent, 5-Aza-CdR, the Arf6-GTP inhibitor, NAV-2729, and 
their combinational usage (Figure 4.7 G). Knockdown of Arf6 by siArf6 – in 
presence and absence of 5-Aza-CdR also reduced endogenous Arf6 levels 
(Figure 4.7 G). These data suggest that although Arf6-GTP and overall 
expression levels were reduced, no significant effect on metastasis was 
observed, suggesting that Arf6 may not be involved in EFA6R-mediated 

















































































































































Figure 4.7. Pharmological inhibition of Arf6 activation and siArf6-mediated 
knockdown of Arf6. (A) Immunoblotting analysis of SKOV-3 lysates 
(electroporated with 200mM siControl, siArf6 and siARF1) using anti-Arf6, 
anti-ARF1 and anti-β-actin (loading control) antibodies. (B) Cells were seeded 
at a density of 2500 cells/well and treated with using 10µM, 50µM and 250µM 
of NAV-2729 for 2 and 5 days. Cell viability was assessed using the CCK-8 
kit (C) Arf6 and (D) ARF1 activation using GST-effector pulldown assay. 
SKOV-3 cells treated with NAV2729 at the indicated concentrations and 
times were lysed and incubated the lysates with GST-effector coupled 
magnetic agarose beads. The protein bound (GTP-bound ARFs) to the beads 
and whole-cell lysates (total ARFs) were separated by 15% SDS-PAGE, 
transferred onto a PVDF membrane and probed with an anti-Arf6 and an 
anti-ARF1 antibodies. (E) For the treatment of SKOV-3 cells with NAV-2729, 
the cells were treated with or without 10µM 5’-Aza-CdR for four days (fresh 
medium with drug was added on third day). The cells were trypsinized, 
counted and plated in a transwell insert at a density of 50,000 cells/250µl and 
treated for an initial 30 minutes with or without NAV-2729 and in the 
absence of chemoattractant and then 4-hours in the presence of 
chemoattractant. For the siRNA mediated knockdown of Arf6, the cells were 
electroporated with 200mM siArf6 prior to 5-Aza-CdR treatment for 4 days. 
Then the cells were fixed with 4% PFA and stained with 0.2% crystal violet. 
Cells that had not migrated though the 8µm pores of the inserts were removed 
by a cotton swab before images were taken and the crystal violet extracted 
the stained cells using 5% SDS. (F) The absorbance of the extracted crystal 
violet was measured at 570nm using a microplate reader. (G) Lysates 
prepared as described in (C) and (D), were separated by 15% SDS-PAGE and 
transferred onto a PVDF membrane and probed with an anti-Arf6 antibody. 
Errors bars represent the mean +/- s.e.m, n=3, ***P < 0.01, **P < 0.05. 




4.4 Discussion  
 
EFA6R is amongst a cluster of genes on chromosomal region 8p22, whose 
expression have been shown to be significantly downregulated in ovarian 
cancer and hence identified as a potential TSGs (Pils et al. 2005a). In the 
previous chapter, we established the concurrent downregulation EFA6R 
mRNA and protein expression with an increase in EOC cancer stage and 
grade. As EFA6R expression loss is implicit in reduced rates of patient 
survival (Pils et al. 2005a), it is vital that the mechanisms of downregulation 
and the phenotypic roles of EFA6R are delineated. In this study, we have 
shown for the first time that: (1) EFA6R is significantly downregulated in 
Serous ovarian cancer (SOC) through epigenetic changes (2) Re-expression of 
EFA6R via 5-Aza-CdR treatment reduces migration in SKOV-3 cells and that 
(3) EFA6R-mediated migration may utilize an Arf6-independent pathway. 
 
We initially assessed the viability of SKOV-3 and OVSAHO cell following 
treatment with increasing concentrations of the demethylating agent 5-Aza-
CdR and the HDAC I and II inhibitor SAHA. Using the optimal concentration 
of these drugs, we showed that EFA6R expression is suppressed by 
hypermethylation (in SKOV-3 and OVSAHO cells) and histone deacetylation 
(in OVSAHO). The use of these drugs restored EFA6R expression levels to 
similar to that detected in IOC cells. As a result, we did not see the benefit in 
using the two drugs together as our primary aim was to utilize these drugs to 
reverse the EFA6R expression to normal levels to assess the functional role 
of this protein in SOC. Interestingly, in OVSAHO cells we observed a greater 
fold decrease of EFA6R expression at mRNA and protein levels (previous 
chapter), compared to SKOV-3 cells. This is likely to be due to the nature of 
the cells,  OVSAHO is considered as a high-grade serous ovarian cancer cell 
line whereas, based on molecular and genetic traits,  SKOV-3 is considered to 
be low-grade serous ovarian cancer cell line (Coscia et al. 2016). We have 
already seen that EFA6R expression levels are significantly reduced as SOC 
progresses to higher stages and grades in ovarian cancer patients. This 
expression decrease could be due to a more aggressive suppression of EFA6R 
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expression, epigenetically. Therefore, in OVSAHO cells, both DNA 
methylation and histone deacetylation may work together independently, to 
suppress EFA6R expression while in SKOV-3 cells, DNA methylation of 
EFA6R seems to be the sole mechanism of downregulation of the protein 
product of EFA6R.  
 
Epigenetic modifications are amongst the major mechanisms involved in 
suppressing tumor-promoting gees. Our results herein indicate that 
alteration in the expression of EFA6R in ovarian cancer is dependent on and 
caused by DNA methylation and loss of unknown modifications to histone 
proteins. Since EFA6R is considered as a TSG in EOC, its loss may contribute 
to the pathogenesis/progression of this disease. Therefore, strategies that aim 
to upregulate EFA6R expression may be of value in prevention and/or 
treatment of ovarian cancer.  
 
To study the functional relevance of EFA6R expressional changes in SKOV-3 
cells, we restored the EFA6R gene expression in SKOV-3 cells by using of the 
demethylating agent, 5-Aza-CdR in SKOV-3. 5-Aza-CdR treatment increased 
EFA6R expression by ~10 folds in SKOV-3 cells, which is similar to the levels 
observed in non-tumour the IOC cell line. We showed that restoration of 
EFA6R expression has a drastic anti-metastatic effect (a significant reduction 
in both migration and invasion). A major issue with epigenetic drugs such as 
5-Aza-CdR is their specificity: often, they target multiple sites leading to 
many side effects. Therefore, it is important to establish that the reduction in 
metastatic potential of SKOV-3 cells with 5-Aza-CdR treatment is due to 
restoration of EFA6R expression. Therefore, we showed that by siRNA-
mediated knockdown of EFA6R expression significantly reduces the response 
of SKOV-3 cells to 5-Aza-CdR treatment and as a result of this, the cells 
regained their enhanced metastatic potential. Overall, we showed that 5-Aza-
CdR treatment not only restored EFA6R expression but also reduced SKOV-
3 cell migration and invasion . SKOV-3 cell migration and invasion reduced 
by 5-Aza-CdR-treatment are revered by knockdown of EFA6R expression 
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through EFA6R siRNA treatment, highlighting the role of EFA6R in 
attenuating the metastatic potential of these cells.  
 
As EFA6R is a member of the EFA6 GEF family that specifically activate Arf6 
small GTPase, which has been shown to be an important regulator of the actin 
cytoskeleton and cell motility associated with metastasis, we sought to see if 
EFA6R regulates metastasis through its effector, Arf6. Previous studies have 
shown that in breast cancer cell lines, the migration and invasion of cells are 
Arf6-dependent and that siRNA-mediated knockdown of Arf6 reduced cell 
migration and invasiveness (Morishige et al. 2008). In contrast, here we 
report that pharmological inhibition of Arf6-GTP activity or siRNA-mediated 
knockdown of Arf6 does not have a significant effect on the migration of cells 
treated with or without 5-Aza-CdR– suggesting that EFA6R attenuation of 
metastasis occurs not through its effector, Arf6 – but through an Arf6-
independent pathway.  
 
These results were particularly surprising since the role of Arf6 in cancer cell 
migration and invasion have been extensively documented in other cancer 
types such as breast and lung carcinomas (Morishige et al. 2008, Marchesin, 
Montagnac, and Chavrier 2015, Zhang et al. 2015, Hashimoto et al. 2016, Yoo 
et al. 2016, Yamauchi, Miura, and Kanaho 2017)(Li et al. 2017). Therefore, 
further assessment of the role of Arf6 in ovarian cancer cell line SKOV-3 
should be undertaken to further substantiate the findings of this study. The 
presence of endogenous Arf6-GTP clearly indicates that it could be mediating 
other phenotypes associated with tumor progression. Due to the broad action 
of 5-Aza-CdR on suppressed genes which would naturally include some Arf6 
GEFs and GAPs –it would be a point of interest to see what happens to the 
expression of these auxiliary proteins following 5-Aza-CdR treatment. 
However, when we reduced endogenous Arf6 levels (both through siArf6 and 
the use of NAV-2729), we did not observe any phenotypic changes associated 
with cell migration and therefore no further studies were conducted on the 
regulation of the Arf6 cycle.  
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In conclusion, we have identified a novel role for EFA6R in SKOV-3 cell lines 
(Figure 4.8). We had previously shown that EFA6R is downregulated in a 
large proportion of ovarian cancer tissues and cells both at mRNA and protein 
levels. We identified that the suppression of EFA6R expression is 
epigenetically regulated in SOC cell lines and that re-expression of EFA6R - 
by using demethylating agent 5-Aza-CdR – dramatically reduced the 
metastatic potential of SKOV-3 cells. To identify the role of EFA6R amongst 
a cluster of hypomethylated proteins, we knocked out EFA6R expression by 
its siRNA to show that the significant metastatic potential of SKOV-3 cells is 
due to the absence of EFA6R. We also shown that EFA6R attenuation of 
SKOV-3 cell lines utilizes an Arf6-independent pathway– an observation that 






Figure 4.8. Schematic model representing EFA6R-mediated attenuation of 
cell migration and invasion, as deduced from the current study. (A) SKOV-3 
cell migration and invasion are reduced upon-upregulation of EFA6R and 
other unknown proteins’ expressions via the demethylating agent 5-Aza-CdR 
treatment. Based on the results of this study, amongst all potential 
demethylated proteins, EFA6R pathway plays a major role in attenuating 
metastasis. (B) The attenuation of metastasis is reversed by knockdown of 5-
































4.5 Future studies 
 
Future studies should expand the scope of epigenetic analysis to include cell 
lines of other EOC subtypes to see if the mechanism of EFA6R 
downregulation occurs through epigenetic means in all subtypes. In addition 
to SAHA, TSA is a class I, II and IV HDCA inhibitor and Nicotinamide is a 
class III HDCA inhibitor. Further analysis of histone deacetylation role in 
EFA6R expression should utilize these drugs as both a confirmation (in the 
case of TSA) and complementary forms of analysing a closed chromatin 
structure (Seto and Yoshida 2014). In addition, chromatin 
immunoprecipitation (ChIP) assay can be used to dissect the associations of 
EFA6R promoter region with any histone modifications and non-histone 
DNA-binding proteins (Milne, Zhao, and Hess 2009). To identify differentially 
methylated regions in our panel of EOC cell lines, the bisulphite sequencing 
assay can be used (O'Sullivan and Goggins 2013). Here, treatment of 
bisulphite with DNA converts cytosine residues into uracil – which will be 
read as thymine as determined by PCR-amplification and subsequent sanger 
sequencing analysis. However, 5mC residues are resistant to this conversion 
and so will remain as cytosine enabling the detection and measure of the 
methylated cytosine.  
 
Future studies should assess the involvement of EFA6R in the metastatic 
potential of EFA6R-positive ovarian cancer cell lines (such as CAOV3 and 
OVCAR3) using siRNA mediated knockdown followed by cell migration and 
invasion assays (both 2D and 3D). Our preliminary biochemical analysis has 
shown that siEFA6R knockdown of EFA6R in CAOV3 cell lines results in 
reduction of the Arf6-GTP activity (Figure 4.9). We are currently 
investigating the phenotypic consequences of reduction of EFA6R and Arf6-
GTP levels.  
 
Additionally, SKOV-3 cells stably expressing EFA6R may be used to assesses 
the effect of alteration in EFA6R expression on cell invasion/migration of 
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SKOV-3 cells. Currently, we are performing G418 titration to determine the 
optimal antibiotic concentration for selecting stable cell colonies. Biochemical 
analysis of SKOV-3 cells showed that these cells express high basal Arf6-GTP 
activity - indicative of the likely expression of other Arf6 GEFs such as the 
EFA6 GEF family (EFA6A-C), the Cytohesins 1-3 and BRAG2/GEP100. This 
confers numerous roles for Arf6 in SKOV-3 cell phenotype as a result of the 
expression and functional activity of Arf6 GEFs. Indeed, out of all members 
of the cytohesin ARF GEF family, we have observed the expression of 
cytohesin 3 at protein level (data not shown) in SKOV-3 cells. So, it is 
important to study the expression and functional relevance of all Arf6 GEFs 
to better understand the global role of Arf6 in SKOV-3 cells. Therefore, future 
studies should use SecinH3 (an Arf6 inhibitor of Cytohesins and GEP100 
and/or PIT-1 (which antagonizes PIP3 binding to PH domains of ARNO 
[cytohesin 2] and GRP1 [cytohesin 3]) to see whether preventing the 
activation of Arf6 by these particular GEFs has any effects on cancer 
progression. Interestingly, the direct inhibition of Arf6 activation by NAV-
2729 – which binds to the Arf6 in the Arf6-GEF binding region, thus 
preventing the GEF association with Arf6 – nor siRNA mediated knockdown 
of Arf6 have any significant inhibitory effects on cell migration. This was the 
case even when EFA6R was re-expressed in SKOV-3 cells – which potentially 
indicates that Arf6 is not involved in the regulation of metastasis of SKOV-3 
cells by EFA6R.   
 
During our biochemical analysis of the effects of 5-Aza-CdR in SKOV-3 cells, 
we noticed a reduction of Arf6-activity by ~ 40-50%. This shows that 5-Aza-
Cdr is potentially reversing the suppression of Arf6 GAPs, which inactivates 
Arf6, by hypomethylation. In order to mitigate the off-target effects of this 
demethylating agent, future studies should study the effects of QS11 (an 
ARF-GAP inhibitor (Zhang et al. 2007) in preventing inactivation of Arf6 to 
see if Arf6 positively regulates cancer cell invasion and metastasis since 
cycling of Arf6 between the active and inactive conformation might be crucial 





















Figure 4.9. siRNA mediated knockdown of EFA6R in CAOV3 cell lines results 
in reduction of Arf6 activity. Preliminary analysis of the expression and 
knockdown in CAOV3 cell line: CAOV3 cells were electroporated with 
siControl or siEFA6R1. Following 4-days incubation, the cells were lysed and 
the protein lysates were separated by 10% SDS-PAGE, transferred onto a 






















Chapter 5: Study of EFA6R 
isoforms expression and functions 
5.1 Introduction 
 
The ADP-Ribosylation Factor (Arf) family of small GTP-binding proteins are 
ubiquitously expressed and involved in many cellular events such as cell 
adhesion, cell migration, neurite outgrowth, cell secretion, endocytosis and 
exocytosis and maintenance of the platelet cytoskeleton (D'Souza-Schorey 
and Chavrier 2006, Urban et al. 2016, Ueda et al. 2013, Jang et al. 2016). In 
mammals, the Arf family consist of 6 members (Arfs 1-6) where they differ in 
their localisation and function. Arfs 1-5 function at the Golgi whereas Arf6 
regulates cellular events at the plasma membrane (Donaldson and Jackson 
2011). Arfs belong to the Ras superfamily of GTPases and therefore they act 
as molecular switches by cycling between the inactive GDP-bound and active 
GTP-bound forms. They depend on Guanine Exchange Factors (GEFs) for the 
activation and GTPase-Activating Proteins (GAPs) for the inactivation 
(Donaldson and Honda 2005). Mammalian cells express 14 Arf GEFs, which 
are classified into the following 5 families: EFA6s (A-D), Cytohesins (1-4), 
BRAGs (1-3), GBF1 and BIGs (1-2).  
 
In humans, the Exchange Factor for Arf6 (EFA6) GEF family consist of four 
members: EFA6A, EFA6B, EFA6C and EFA6R (also known as PSD3, EFA6D 
or HCA67). The existence of several isoforms, by alternative splicing, have 
been described for each member. EFA6R shares a common domain 
organization with other members of the EFA6 family Arf GEFs, which 
commonly contain a Sec7 catalytic domain without an invariant glutamic 
residue – referred to as a ‘glutamic finger’ –essential in displacing Mg2+ ion 
and β-phosphate of GDP to destabilize the GDP: Arf interaction. The GEF 
activity is abolished upon mutation of the glutamic residue to lysine  
(Renault, Guibert, and Cherfils 2003, Matsuya et al. 2005, Kanamarlapudi 
2014b, Luton et al. 2004). In addition to the Sec7 domain, the EFA6 GEF 
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family members also contain a pleckstrin homology (PH) domain which is 
responsible for the plasma membrane localisation by interacting with 
phosphatidylinositols (PIs) and a C-terminal region which consists of one or 
more coiled-coil (CC) domains responsible for cytoskeleton rearrangements 
and interactions with downstream signalling proteins (Kanamarlapudi 
2014a) Some isoforms of the EFA6 family also contain a less conserved 
extended N-terminal region, upstream of the Sec7 domain, whose function is 
mostly unknown. However, recently, the N-terminal region of EFA6B has 
been shown to associate with Dynamin2 (Dyn2) during Arf6-induced clathrin 
mediated endocytosis and its N-terminal region interaction with the adaptor 
protein NUMB has been shown to regulate membrane protrusions associated 
with cell migration (Okada et al. 2015a, Zobel et al. 2018).  
 
Recent studies by (Fukaya et al. 2016) and (Chomphoo et al. 2016) have 
identified a ~140kDa protein immunoreactive to EFA6R antibody  - wildly 
believed to correspond to the human EFA6R large isoform (A), in the 
hippocampal CA3 region of mouse brain as well as in mice adrenal cortical 
tissues. However, no expression and functional analysis of EFA6R isoform A 
has thus far been conducted in human cells and tissues. Our lab 
((Kanamarlapudi 2014b) has also shown that EFA6R small isoform (B) is 
indeed detected in human brain, heart, liver skeletal muscle, spleen, and 
testis tissues and in a panel of cell lines which include MCF7, HeLa  and COS-
7 cells lines. 
 
Here we expanded on our previous studies on EFA6R isoform B by analysing 
the expression and localisation of EFA6R isoform A in tissues and cell lines. 
This resulted in identifying the EFA6R isoform A expression in cell lines such 
as HEK293 and ReN cells but not in any human tissues analysed. By using 
various EFA6R deletion and site-directed mutant constructs, we showed that 
first of all EFA6R is an Arf6-specific GEF. EFA6R GEF activity depends on 
its catalytic Sec7 domain and its ability to localise to the plasma membrane 
through the association of PH domain with inositol lipid PI 4,5-bisphosphate 
 197 
(PI 4,5-P2) in the membrane. Furthermore, we showed that EFA6R is able to 
regulate Arf6 localisation and induce the loss of actin stress fibres through 
regulation of Arf6 activation. Analysis of EFA6R in HEK293 cells revealed 
that depletion of EFA6R reduces Arf6-GTP levels. Furthermore, this 
tentatively corresponded to loss of surface β1 integrin expression. Finally, the 
expression analysis of EFA6R was also conducted in ReN cells where we 
showed that EFA6R isoform A expression decreases in differentiated cells 
when compared to that in undifferentiated cells. The knockdown of EFA6R 
isoform A by using siEFA6R had no effect on Arf6 GTP levels, suggesting an 
alternative, unknown, Arf6-independent role for EFA6R in differentiating 
ReN cells. 
 
5.2 Methods and Materials 
 
5.2.1 Preparation of EFA6R mutation and deletion constructs 
 
For full details, see bacterial cell culture, section 2.2.1. 
 
5.2.2 Cell Culture 
 
Cell line information can be found in the protocol in section 2.2.5.3.  
5.2.3 Small interfering RNA (siRNA) and Plasmid DNA transfection 
 
The siRNA and plasmid DNA used in this study have been outlined in the 
protocol in section 2.2.2 to 2.2.6.  
 
To transiently transfect COS-7, HEK293 and HeLa cells with siRNA and 
plasmid DNA, jetPRIME® (Polypus, US) was used according to the 
manufacturer’s protocols. To introduce siRNA and plasmid DNA in 
undifferentiated ReN cells, the mechanical Neon transfection system 
(Thermofisher Scientific, US) was used according to manufacturer’s protocol. 
The final concentration of all siRNAs used were 200nM. The final 
concentration of plasmid DNA used were: 0.5µg for 24-well plates, 2 µg for 6-









Immunoblotting was carried out according to protocol in section 2.2.14.2 with 
minor modifications; the lysates were separated by SDS-PAGE using 10% or 
15% (for detection of Arf proteins). Primary antibody (anti-EFA6R rabbit 
polyclonal 1/500 dilution, anti-Arf6 mouse monoclonal 1/200, anti-ARF1 
rabbit monoclonal 1/3000, anti- β-actin mouse monoclonal at 1/10,000 dilution 
and anti-GAPDH goat monoclonal at 1/2000 dilution) diluted in blocking 
buffer. Followed by this, the blot was incubated with horseradish peroxidase 
(HPR)-conjugated secondary antibody (GE Healthcare, USA) diluted in 
blocking buffer (anti-rabbit, anti-mouse or anti-goat using 1/2500 dilution). 
 
5.2.6 In Vitro Phosphatidylinositol 4,5-bisphosphate (PI 4,5-P2) Binding 
Assay 
 
The in vitro PI 4,5-P2 binding assay was performed as described previously 
(Kanamarlapudi 2014b). Here, COS-7 cells transfected for 2 days with GFP-
tagged EFA6R or its point mutant constructs were treated with lysis buffer 
(10 mM HEPES, pH-7.4, 150mM NaCl, 0.5% NP40, 5mM DTT) containing 1% 
mammalian protease inhibitor mixture. Cell lysates were then incubated 
with streptavidin magnetic beads (Genscript, US) coupled to biotinylated PI-
4,5-P2 (Cell Signaling Technology, US) and incubated with gentle agitation 
(rotary mixer) for 2h at 4°C. Coupling of streptavidin magnetic beads to PI 
was done according to (Kanamarlapudi 2014a). Using a magnetic stand, the 
beads were then washed three times with lysis buffer and the bound proteins 
were eluted by 50µl of 1x sample buffer and then boiling for 5 min at 100°C. 
Proteins were then separated by SDS-PAGE and transferred to PVDF 
membrane. The blots were probed with an anti-GFP antibody.  
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5.2.7 Membrane fractionation by ultracentrifugation 
 
HEK293 cells were plated in 10x 10cm plates and grown to 90% confluency. 
The cells were then dissociated from the culture plate using Hank’s Balances 
Salt Solution (HBSS). Upon harvesting by centrifugation as a pellet, the cells 
were dispersed in 5 ml of ice-cold resuspension buffer (10 mM Tris-HCl, pH 
7.5, and 0.1 M sucrose with 1% mammalian protease inhibitor mixture) and 
lysed by passing 10-20 times through a 26-gauge needle attached to a 5 ml 
syringe. 0.5 ml of the whole cell lysate was taken and the remaining 4.5 ml 
cell lysate was centrifuged at 1000 x g for 5 min at 4oC to obtain the 
postnuclear supernatant. The supernatant was further centrifuged at 
100,000 x g for 30 minutes at 4oC to obtain the cytosolic (supernatant) and 
membrane fractions (pellet). The membrane fraction was resuspended in 0.5 
ml of resuspension buffer. The protein concentration of the whole cell lysate, 
cytosolic and membrane fractions was assessed by BCA assay and the lysates 
subjected to immunoblotting using anti-α-tubulin (a cytosolic protein) and 
epidermal growth factor receptor (EGFR, a membrane protein) and EFA6R 
in each fraction.  
 
5.2.8 GST-GGA3 VHS-GAT pull down assay 
 
Arf activation was analysed using the GST-GGA3 VHS-GAT (GST-Arf 
effector) pulldown assay (see previous results chapter for further detail; 
section 4.2.8). Following the co-transfection of GFP, EFA6R isoform A and B 
and EFA6A with HA-tagged Arf1 or Arf6, the cells were serum starved for 2 
hours and lysed in ice-cold modified pulldown-lysis buffer. 90% of the lysates 
were used for GST-effector pull downs while the remaining 10% lysates not 
incubated with the beads were used to analyse total Arf. Arf expression and 
activation was assessed by immunoblotting (using an anti-Arf6 at 1:200 
dilution and an anti-Arf1 at 1:3000 dilution). Arf-GTP expression levels were 
normalized to total Arf. 
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5.2.8 Statistical Analysis  
 
Data was analysed using the Graph prism program (version 7). Error bars 
show the median with 95% confidence interval of three or more independent 
experiments, unless stated otherwise. The non-parametric Kruskal-Wallis 
statistical test was used to calculate statistical significance for the data. A 
value of P >0.05 was considered not significant (ns) whereas * P <0.05, **P 






5.3.1 Validation of EFA6R (isoform A-specific) primer by RT-qPCR and 
finding a suitable antibody for immunoblotting.  
 
In humans, alternative splicing of the EFA6R gene generates primarily two-
well characterized variants in humans: EFA6R A (1048 aa, 116-150kDa) and 
EFA6R B (513 aa,45-53 kDa). They differ from each other in the length of the 
N-terminal region (Figure 5.1A), meaning that our western blot antibody 
(raised against a peptide corresponding to the C-terminus) and EFA6R 2 
primer (the target sequence is in the 3’ end) is able to recognize both isoforms. 
In this chapter, EFA6R primer set 1 is used to address the presence of the 
larger isoform as it targets the 5’ end of EFA6R isoform A mRNA that absent 
in the isoform B. Figure 5.1B shows that the EFA6R1 Forward 5’ and the 
reverse 3’ primer sequences matches the EFA6R human gene of the larger 
isoform. Unlike EFA6R1 primer, the EFA6R2 primer recognises both of the 
EFA6R variants (isoforms A and B). To maximize RT-qPCR efficiency, the 
amplicon length was designed to be <150 base pairs (bp). The performance of 
the primer was then assessed (Figure 5.1C). Using GFP-EFA6R 
(corresponding to the larger variant A) plasmid DNAs as template, we 
demonstrated the specificity of EFA6R1 primer using a range of 
concentrations of the plasmid from which we generated a standard curve and 
plotted Cq value against log of the amount of plasmid. From this, it was 
calculated that the R2 value for the fit of the data points to the trend line was 
0.98 with a primer efficiency of 114%. Similarly, a cDNA sample from ReNcell 
was used to test the efficiency and stability of the primers in RT-qPCR 
conditions. The R2 and efficiency for EFA6R1 in ReN cell-derived cDNA was 
0.98 and 100%. An acceptable range for primer efficiency is 90-110%, 
therefore the isoform A-unique primer was deemed suitable for usage in 
future RT-qPCR experiments.  
 
Similar to the principles of RT-qPCR optimization, in order to monitor protein 
expression in cells or tissues, the quality of the primary antibody must be 
 202 
assessed. We used our in-house generated rabbit-anti EFA6R (raised against 
a peptide representing the last 15-C-terminal amino acids of EFA6R and 
affinity purified by using the immunizing peptide coupled resin through a 
commercial vendor [Eurogentec]) and compared it to the EFA6R expression 
levels with other readily available commercial anti-EFA6R antibodies. 
Western blot analysis of extracts from COS-7 cells transfected with GFP-
EFA6R (isoforms A and B) confirmed the specificity of the antibodies (Figure 
5.1D and E). However, the antibody obtained from Avivo biosystems did not 
recognize the intended target and showed non-specific binding for unknown 
reasons. Notably, the Everest anti-EFA6R antibody only recognized over-
expressed EFA6R isoform A, but not EFA6R isoform B, as it was raised 
against the N-terminal region of EFA6R. However, we were not able to detect 
EFA6R A (endogenous) in HEK293 or RenCells using this antibody. This 
could be due to the lack of sensitivity of the antibody towards endogenous 
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NM_015310.3 Homo sapiens pleckstrin 
and Sec7 domain containing 3 (PSD3), 
mRNA/EFA6R. Primer set 1
Antibodies
A GFP = Roche: 1 814460001
(1:500 dil.) mouse monoclonal
B EFA6R = Everest biotech: 
EB06133
(1:500 dil.) Goat polyclonal)
expected to recognize only the 
reported splice variant A
C EFA6R = Avivo system: 
ARP42443_T100 
(1:500 dil.) Rabbit polyclonal; 
expected to recognize both the 
splice variants.
D EFA6R = Eurogentec 
(1:500 dil.) Rabbit polyclonal; 
expected to target the C-
terminus and therefore recognize 
both the splice variants
E EFA6R = Abcam: ab36165
(1:500 dil.) Goat polyclonal; 
expected to target the C-
terminus and therefore recognize 
both the splice variants
F EFA6R = Genetex: GTX22930
(1:500 dil.) Rabbit polyclonal; 
expected to target the C-
terminus and therefore recognize 
both the splice variants
(D) (E)













1  2 1  2 1  2 1  2 1  2
Lane 1: COS-7/GFP-EFA6R A







Figure 5.1. Validation of EFA6R ( Isoform A-specific) primers by RT-qPCR 
and characterisation of various EFA6R antibodies for immunoblotting. The 
isoform specific EFA6R primer was validated for specificity and profile range 
by RT-qPCR. (A) A schematic representation of EFA6R isoforms, showing a 
conserved SEC7, PH and CC domains and the regions where primers and 
antibody recognize (B) the primer design sequence for EFA6R 1 primer. (C) 
Using a starting concentration of 1ng/ml of plasmids GFP-hEFA6R A with 
subsequent 8-fold serial dilutions and using a cDNA from an EFA6R-positive 
cell line, ReN, an 8-fold dilution was done and a graph was plotted with Log10 
of the DNA concentration on one axis and threshold cycle (Cq) on the y-axis. 
The reaction efficiencies, E, calculated by 10-1/gradient and percentage efficiency 
derived through the equation %E = E-1 x 100. (D) COS-7 cells were 
transfected with either GFP-EFA6R A or GFP-EFA6R B for two days. The 
cells were lysed and the cell lysates were separated by 10% SDS-PAGE, 
transferred onto a PVDF membrane and probed with various anti-EFA6R 
antibodies, displayed in figure 1E. The list of antibodies are displayed along 
with the antibody dilutions used, the catalogue number (and company where 
applicable) and the host used for raising the antibody.  
 
5.3.2 EFA6R isoform A expression is limited to few cell lines 
 
EFA6R expression has been previously observed in mouse brain tissues 
demonstrating the presence of both isoforms (Sakagami et al. 2006, Fukaya 
et al. 2016). A recent study from our lab has not only functionally 
characterized the smaller EFA6R isoform but also showed its ubiquitous 
expression  (Kanamarlapudi 2014) . We set out to see the presence of both 
isoforms in tissues and cell lines and hence we probed an INSTA-blot Human 
Tissues [NBP2-31378] (containing ~ 50µg per lane of human tissue lysates) 
with anti-EFA6R. We showed the expression of the smaller isoform (~45kDa) 
was abundant in Liver, Lung, Spleen and Testis; moderate in the Brain, 
 205 
heart, Kidney, Skeletal muscle, Stomach and Ovaries; and low expression in 
small intestine (Figure 5.2A). However, we did not detect the larger isoform 
in any of the tissues analysed. When we assed EFA6R expression in cell lines, 
we observed the presence of the larger isoform as a ~ 150kDa protein in ReN 
cells (human), HEK293 (human) and HT22 (mouse) cells (Figure 5.2B). In 
order to assess that the 150kDa protein is the EFA6R isoform A, we have 
used siRNA-mediated knockdown of human form of both isoforms in HEK293 
and ReN cells (see figure 5.6). However, to validate these siRNA, we initially 
co-transfected HEK293 cells with EFA6R isoforms A and B with a panel of 
siRNA oligonucleotides. siEFA6R 1 and 2 are generic siRNAs that target both 
slice variants whereas siEFA6RA and B target only the larger one (Figure 5.2 
C). Hence we showed that EFA6R siRNAs, siEFA6R A and siEFA6R B, are 
unique to the larger isoform. Overall, we observed the presence of the larger 
isoform in ReN cells and HEK293 cells and characterized our siRNA for 




















































































































































































Figure 5.2. Analysis of EFA6R protein expression in tissues and cell lines by 
immunoblotting (IB) and various EFA6R siRNAs isoform specificity. (A) The 
INSTA-blot Human Tissues [NBP2-31378] (containing ~ 50µg per lane of 
human tissue lysates) was probed with anti-EFA6R and anti-GAPDH 
(loading control). (B) The protein lysates from various cell lines were 
separated by 10% SDS-PAGE, transferred onto a PVDF membrane and 
probed with an anti-EFA6R and anti-𝛂-tubulin (loading control). EFA6R 
expression in both tissues and cell lines is detected predominantly as a 37-
50KDa protein (resembling isoform B). In ReN cells, HEK293 and possibly 
HT22 (highlighted red) cells, a ~150kDa protein is detected (indication of 
isoform A expression). (C). EFA6R isoform A or B was co-transfected with a 
panel of EFA6R siRNAs in HEK293 cells. Following 3 days of transfection, 
the lysates obtained from the cells were subjected to immunoblotting using 
an anti-EFA6R and an anti-β-Actin (loading control) antibodies.  
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5.3.2 EFA6R isoform A localises to the plasma membrane in PC12 and HeLa 
cells  
Studies into the localisation of EFA6A have shown that this Arf6 GEF 
localises to the plasma membrane through its PH domain – where deletion of 
the PH domain resulted in localisation of EFA6R at the cytosol (Luton et al. 
2004). Furthermore, the PH domain of EFA6A is ~ 70% identical to 
EFA6C/EFA6R (EFA6D) and ~ 50% identical to EFA6B, indicating the 
likelihood of localisation of EFA6R to the plasma membrane. Previously it 
has been demonstrated that EFA6R (the small isoform) plasma membrane 
localisation is dependent on both the PH and CC domains (Kanamarlapudi 
2014b). (Kanamarlapudi 2014b) also showed that in HeLa cell fractions 
EFA6R isoform B expression was more abundant in membrane fractions 
rather than the cytosol. Therefore, we set out to investigate which protein 
domains are sufficient for the localisation of EFA6R isoform A. We generated 
various point and deletion mutants of EFA6R isoform A, expressed them  with 
an N-terminal GFP fusion and analysed their subcellular localisation in Hela 
and COS-7 cells by cell imaging using confocal microscopy (Figure 5.3A). In 
both cell lines, the deletion or point mutation (for catalytically inactivation) 
of the SEC7 domain did not prevent the localisation of EFA6R to the plasma 
membrane. Similarly, EFA6R ∆N548 (isoform B) also showed plasma 
membrane localisation suggesting that the N-terminal region of EFA6R 
isoform A may not be essential for its plasma membrane localisation (Figure 
5.3B). EFA6R lacking the SEC7 domain (EFA6R ∆SEC7) or its point mutant 
(EFA6R E682K) also localised to the plasma membrane. However, EFA6R 
lacking the PH domain (EFA6R ∆PH) failed to localise to the plasma 
membrane (Figure 5.3B). Moreover, we showed that, within the PH domain, 
point mutation of either R827E, K828E or the double mutant R827E/K282R 
were sufficient to incapacitate PH domain-mediated plasma membrane 
localisation. EFA6R lacking the CC domain (EFA6R showed weak membrane 
localisation. Overall, these results indicate that the PH and to a lesser extent, 
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Figure 5.3. EFA6R constructs used in this study and their subcellular 
localisation in PC12 and HeLa cells. (A) Schematic view of EFA6R isoform A 
and the various deletion and point mutation constructs used in this study. (B) 
The intracellular localisation of various EFA6R constructs shown in (A) in 
PC12 or HeLa cells: The cells were transfected with GFP-tagged EFA6R 
constructs, fixed with 4% PFA and stained DNA using DAPI (0.1µg/ml). The 
cells were then visualized by confocal microscopy. The images are 
representatives of 50-70 transfected cells from three different cell 
preparations. A cross-section scanning profile for each construct’s localisation 
and quantification by showing % of localization at the PM (P) and in the 
cytosol (C) are displayed on the right side.  
 
5.3.4 EFA6R binds to PI 4,5-P2 (PIP2) through the PH domain in vitro 
 
It is commonly known that the PH domain in most proteins binds to the  PIs  
embedded in lipid bilayer (Yamamoto et al. 2016). (Kanamarlapudi 2014b) 
has shown that EFA6R isoform B specifically binds to PI 4,5-P2 and not PI 
3,4,5-trisphosphate (PI 3,4,5-P3), PI 3,4-P2 or PI 3-phosphate (PI 3-P). 
Therefore, we aimed to assess whether EFA6R isoform A also binds to PI 4,5-
P2. For this purpose, we incubated the lysate of cells expressing either EFA6R 
isoform A or its SEC7 and PH mutants with streptavidin beads coupled to 
biotinylated PI 4,5-P2 and showed that EFA6R PH mutants failed to bind to 
PI 4,5-P2 beads whereas the SEC7 mutant did bind to PI 4,5-P2 beads. This 
suggests that the ability of EFA6R isoform A to bind to PI 4,5-P2 is 
independent of its GEF activity (through the SEC7 domain) but dependent 




Figure 5.4. Analysis of EFA6R binding to PI 4,5-P2 (PIP2) in vitro. (A) 
HEK293 cells transfected with GFP-tagged EFA6R and its Sec7 mutant 
(EFA6R [E682K]), and PH mutants (EFA6R [R827E], EFA6R [K828E] and 
EFA6R [R827E/K828E]). Following 2 days, the cells were lysed and the 
lysates were then incubated with biotinylated PIP2 coupled to streptavidin 
magnetic beads for 2-hours at 4oC. Proteins that remained bound to PIP2 
beads after washing with binding buffer were analysed by immunoblotting 
(IB) using an anti-GFP antibody. (B) The percentage of GFP-EFA6R and its 
mutants bound to PI 4,5-P2 beads was calculated. Errors bars represent the 
mean +/- s.e.m, n=3 (****P <0.0001). Statistical analysis was performed using 
the non-parametric Kruskal-Wallis statistical test. 
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**** P < 0.0001
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5.3.5. EFA6R isoform A specifically activates Arf6 in the SEC7 domain 
dependent manner 
 
In order to determine whether EFA6R functions as an Arf6-specific GEF, we 
co-transfected GFP-EFA6R isoform A and B, GFP-EFA6A or GFP plasmids 
with either HA-Arf1 or HA-Arf6 in HEK293 cells. Arf activation was then 
analysed using the GST-GGA3 VHS-GAT (GST-Arf effector) pulldown assay 
which solely binds active GTP-bound conformation of Arfs (Dell'Angelica et 
al. 2000a). Immunoblotting with Anti-HA antibody revealed the total 
expression of Arf1 and Arf6 in the cells whereas the active GTP-bound Arfs 
could only be detected in cells co-transfected with HA-Arf6 and EFA6R (both 
isoforms A and B) or EFA6A whereas no active Arf1 could be detected (Figure 
5.5A). This confirms that the EFA6 family are Arf6 (and not Arf1) specific 
GEFs. Next, we co-transfected HEK293 cells with Arf6 and various EFA6R 
spice variant A deletion or point mutant constructs (Figure 5.5B) in order to 
see which domain is essential for the EFA6R GEF activity. A significant 
reduction in the GEF activity was observed with expression of EFA6R ∆SEC7 
(***P < 0.0004), the catalytically inactive SEC7 mutant E682K and ∆PH 
(****P <0.0001) and the construct with only the N-terminal region of EFA6R 
isoform A (***P <0.0007). With the EFA6R ∆CC expression, we detected 
active Arf6-GTP but at reduced levels, however this was not statistically 
significant. These data imply that EFA6R isoform A GEF activity is 
dependent on plasma membrane localisation (via PH domain) and a 
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Figure 5.5. In vitro analysis of EFA6R activation of Arf6. (A) HEK293 cells 
were transfected with either HA-tagged Arf1 or Arf6 and either GFP-EFA6R, 
GFP-EFA6A or GFP empty vector. Following 2 days incubation, the cells were 
serum starved for 2 hours and lysed and the GTP-bound Arf proteins were 
precipitated from the lysates using the GST-Arf effector magnetic beads. The 
active GTP-bound Arf proteins and lysates (total Arf) were analysed by 
immunoblotting (IB) using an anti-HA antibody. The lower panel shows the 
corresponding quantitative data for figure above. (B) The EFA6R isoform 
Aand its deletion and mutation constructs were expressed in HEK293 cells 
and the GEF activity of these constructs were analysed by pulldown of 
endogenous Arf6-GTP. The GST-Arf effector pulldown (active Arf6) and 
lysates (total Arf6) were analysed by immunoblotting using an anti-Arf6 and 
the corresponding quantitative data displayed. Errors bars represent the 
mean +/- s.e.m, n=3 (****P <0.0001). Statistical analysis was performed using 
the non-parametric Kruskal-Wallis statistical test.  
 
5.3 6. EFA6R isoform A induces re-organization of actin cytoskeleton through 
Arf6 activation.  
 
Upon activation by its GEFs, Arf6 translocates from the endosomes to the 
plasma membrane where it controls membrane trafficking and  
reorganization of the actin cytoskeleton (Myers and Casanova 2008, Cotton 
et al. 2007, Humphreys et al. 2013b). (Kanamarlapudi 2014b) has previously 
shown that the EFA6R isoform B activates Arf6 and causes reorganization of 
the actin cytoskeleton, which is an indicative for the activation of endogenous 
Arf6 by EFA6R isoform B. Here, we aimed to confirm that EFA6R isoform A 
is also able to modulate actin re-organisation through Arf6 activation. In 
addition, by using an actin binding probe conjugated to the red-orange 
fluorescent dye, tetramethylarhodomine (TRITC), we aimed to see whether 
exogenously expressed EFA6R is able to modulate actin re-organization 
through activation of endogenous Arf6. For these purposes, we initially co-
transfected pmCherry tagged Arf6 with GFP tagged EFA6R and its various 
deletion constructs in HeLa cells and assessed their subcellular localisations 
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using immunofluorescence (Figure 5.6). The exogenously expressed Arf6 
showed strong the plasma membrane localisation in the cells co-expressing 
GFP-EFA6R, GFP-EFA6R ∆N548 and the weak localisation in EFA6R ∆CC 
expressing cells. In contrast, EFA6R ∆Sec7, GFP-EFA6R ∆PH and ∆N548 
failed to translocate Arf6 to the plasma membrane. These findings are similar 
to previous studies that shown the Sec7 domain (which is required for Arf6 
GEF activity) and the PH domain (which is responsible for PIP2 binding at 
the plasma membrane) of EFA6R isoform B are critical components for 
modulating the Arf6 activation and thereby its localisation to the plasma 
membrane. To assess the effect of EFA6R activation of the endogenous Arf6 
on actin re-organization, we simply transfected HeLa cells with EFA6R and 
its various deletion or point mutants encoding constructs and observed that 
actin filaments clearly assembled at the plasm membrane (cortical actin) only 
in HeLa cells expressing GFP-EFA6R isoform A, GFP-EFA6R ∆N548 (isoform 
B) and EFA6R ∆CC. However, the loss of actin stress fibres were not observed 
in cells expressing GFP-tagged EFA6R ∆Sec7, EFA6R ∆PH and EFA6R N548. 
Overall these data suggest that the Sec7, PH and to a lesser extent, the CC 
domain mediate Arf6-dependent loss of actin stress fibres and actin re-
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Figure 5.6. Analysis of the role of EFA6R in Arf6 localisation and actin re-
organization by immunofluorescence. GFP-tagged EFA6R and its various 
deletion constructs were co-transfected with pmCherry-Arf6 in HeLa cells. 
Following 2 days of transfection, the cells were serum starved, fixed with 4% 
paraformaldehyde, permeabilized with 0.2% Triton X-100 and where 
required, the cells were incubated with TRITC-phalloidin (1:3000 dilution) to 
stain actin. Prior to imaging using a confocal microscope, the cells were 
stained with the DNA stain DAPI. The images are representatives of 40-60 
transfected cells from two different cell preparations. 
 
5.3 7. The EFA6R isoform A function in HEK293 cells  
 
Following the observation of endogenous EFA6R isoform A in HEK293 cell 
lines, we looked more closely at the functional relevance of EFA6R in these 
cells. In order to determine whether endogenously expressed EFA6R isoform 
A in HEK293 cells is membrane bound, we performed membrane 
fractionation using differential centrifugation to separate the membrane and 
cytoplasmic cell fractions (Figure 5.7A). Upon analysis of the isolated cell 
fractions, we observed that > 90% of EFA6R expression was distributed in the 
membrane fraction in comparison to the cytosolic fraction. Here, we used anti-
a-tubulin and anti-EGFR as loading controls for the cytosolic and membrane 
fractions, respectively. To further verify that EFA6R isoform A expression is 
present in HEK293 cells, we showed that the approximately 150kDa band 
(corresponding to EFA6R) was significantly reduced upon transfection with a 
panel of EFA6R siRNAs (Figure 5.7B). However, the universal scrambled 
siRNA control (siRNA) failed to knockdown the expression of EFA6R, hence 
confirming the expression of the larger EFA6R isoform in HEK293 cells. 
Following observations of EFA6R knockdown by siEFA6R 1 and siEFA6R B 
(an EFA6R isoform A specific siRNA), we looked to see whether EFA6R 
downregulation reduce the endogenous Arf6 activation, which was assessed 
by GST- GST-Arf effector pulldown assay (Figure 5.7C). Endogenous Arf6 
(and not Arf1) activity was reduced in HEK293 transfected with siEFA6R 1 
and siEFA6R B, hence further confirming previous findings that both EFA6R 
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isoforms function as Arf6-specific GEFs. Having shown the presence of 
EFA6R isoform A and its ability to function as an Arf6-specific GEF, we 
finally set out to see whether theArf6 activated through EFA6R is able to 
mediate β-1 integrin surface expression in HEK293 cells (Figure 5.6E and F). 
Previous studies have shown that Arf6 deletion abolishes b1 integrin 
recycling. Knockdown of Arf6 GEFs (GEP100, EFA6B and EFA6D and GRP1 
inhibited b-1 integrin recycling, suggesting that Arf6-mediated b-1 integrin 
recycling depends upon multiple Arf6 GEFs (Hongu et al. 2015). Here, we 
initially characterized siArf6 and siArf1 by observing a significant reduction 
in endogenous Arf6 and Arf1 expression in HEK293 transfected with siArf6 
and siArf1, respectively (Figure 5.6D). Next, we transfected with either the 
EFA6R or Arf siRNAs in HEK293 cells and analysed the percentage loss of 
surface b-1 integrin expression using flow cytometry (Figure 5.6 E). Following 
EFA6R depletion with siEFA6R 1 and siEFA6R B, the surface expression of 
b-1 integrin was reduced by 17% (± 1.4, n = 3) (*P < 0.02) and 1.6% (± 2.3, n = 
3) respectively. We also directly knocked down endogenous Arf6 and Arf1 
through siRNA and showed a modest reduction of b-1 integrin surface 
expression by 11.3 % (± 4.05, n = 3) and 10.3% (± 1.56, n = 3). (Figure 5.6F). 
But the siArfs failed to reduce b-1 integrin cell surface expression. This result 
tentatively demonstrates that in HEK293 cells, b-1 integrin expression is 


























































Figure 5.7. Membrane bound endogenous EFA6R, functions as an Arf6 
specific GEF in HEK293 cells. (A) HEK293 cells were mechanically disrupted 
to get whole cell lysate and then the cell lysate separated using 
ultracentrifugation into cytosolic and membrane fractions, which along with 
whole cell lysate were subjected to immunoblotting using an anti-EFA6R, an 
anti-a-tubulin (as marker for cytosolic fraction) and an anti-EGFR (as the 
marker for the plasma membrane fraction) antibodies. (B) HEK293 cells were 
transfected with siControl, siEFA6R 1, siEFA6R 2, siEFA6R 3 or siEFA6R B 
for 4 days. The cell lysates were immunoblotted with an anti-EFA6R and an 
anti-b-Actin (loading control) antibodies. (C) Following knockdown of EFA6R 
by siEFA6R 1 and siEFA6R B, HEK293 cell lysates were analysed by 
pulldown of GTP-bound Arf1/6. The GST-Arf effector pulldown (active Arf) 
and lysates (total Arf) were analysed by immunoblotting using an anti-Arf6 
and an anti Arf1 antibodies. (D) siRNA mediated knockdown of Arf1 and Arf6 
in HEK293 cells. (E) Flow cytometry analysis of b-1 integrin expression. Data 
in figure A was conducted once; in figure B, C and D are n=3 and in E and F, 
n=2 where errors bars represent the mean +/- s.e.m. Statistical analysis using 
the non-parametric Kruskal-Wallis statistical test. 
 
5.3.8. Analysis of EFA6R expression in ReN cells  
 
ReNcell VM cells (obtained from Millipore) are immortalized human neural 
stem cells. Upon b-FGF and EGF withdrawal, these cells have the ability to 
undergo differentiation from neuron stem cells into dopaminergic neurons, 
astrocytes, and oligodendrocytes, thus creating a neuronal cell system (Pai et 
al. 2012). We have shown in section 5.3.2 that these cells express EFA6R 
isoform A. Recent studies have implicated Arf6 in regulating neurite 
outgrowth of hippocampal neurons (Miura et al. 2016) and regulating 
dendritic spine formation in developing neurons (Kim et al. 2015). Hence we 
aimed to see what role EFA6R (an Arf6-specific GEF) plays in 
undifferentiated and differentiating ReN cells. Using phase contrast 
microscopy, we observed, as expected, loss of cell proliferation and clear cell 
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morphological changes (such as contraction of the cell body and beginning of 
neurite outgrowth) when ReN cells were deprived of bFGF and EGF in the 
medium for 3 days (Figure 5.8A). These changes were linked to significant 
variation in the expression of EFA6R in differentiating cells (Figure 5.8B). 
When compared to that in undifferentiated ReN cells, EFA6R isoform A 
expression in ReN cells was reduced by ~ 50% within 6 days, and ~90% within 
12 days of differentiation. On day 30 of differentiation, EFA6R expression 
was completely abolished, a significant loss of Nestin expression – a 
molecular marker of neuronal cells – was also observed indicating that cells 
were differentiated. Next, in order to elucidate the importance of EFA6R in 
differentiating ReN cells, we assessed suitability of various methods to 
transfect siRNA into undifferentiated ReN cells (Figure 5.9). Transfection of 
siRNA into the ReN cells through chemically based transfection reagent 
JetPrime did not yield a significant loss of EFA6R expression (Figure 5.9C). 
Since electroporation worked in transfecting ovarian cancer cell lines in the 
previous results chapter, we used the same method to introduce siRNA into 
these cells. Initially, we optimised the use of the Neon transfection system by 
using more than 10 different parameters recommended by the manufacturer 
(Thermo Fisher Scientific) (Figure 5.9D) and observed that using 3 pulses of 
1600 volts for a duration of 10ms, gave the optimal transfection efficiency of 
GFP plasmid (pEGFP-N1) (67%). Therefore, we used these parameters to 
transfect siEFA6R 3 and siEFA6R B into ReN cells and observed an ~ 8-fold 
and ~14-fold decrease in EFA6R expression by siEFA6R 3 and siEFA6R B, 
respectively (Figure 5.9 E). Upon EFA6R knockdown in ReNCells, we 
observed a reduction of Arf6-GTP levels (~ 1.5-2.5-fold decrease). Since 
EFA6R expression goes down during ReN cell differentiation, we also 
analysed Arf6 activation levels simultaneously in the differentiated cell. 
During the 6-day differentiation time course, we saw a significant reduction 
in EFA6R expression and a modest < 1-fold reduction of Arf6-GTP levels 
(Figure 5.9F). This indicated that EAF6R may regulate ReNcell 
differentiation in a GEF dependent manner, but also highlights the potential 
involvement of other Arf6 GEFs during differentiation. In undifferentiated 
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ReN cells, following our preliminary expression analysis of the cytohesin GEF 
family (by immunoblotting) and EFA6 family (by qPCR) (Figure 5.8G and H), 
we found the expression of Cytohesins 2-4 and tentatively the absence of 
EFA6A-C in these cell lines. Overall, our initial assessments of EFA6R 
expression in ReN cells are that this protein is significantly reduced during 
differentiation of these cells, corresponding to clear morphological changes to 
the cells. However, EFA6R expression loss (both through siRNA-mediated 
knockdown or the natural differentiation progression) does not seem to 
significantly alter Arf6 activation, suggesting the presence of other Arf6 



















Day 3 Day 12Day 6
Day 24Day 18
IB: Nestin antibody250
Days           0         6       12       18      24       30
(A)
(B)














































1 2 3 4 5
6 7 8 9 10
11
Transfection of GFP vector in ReN cells using electroporation
# Parameters (Voltage, pulse 
width and pulse number)
Transfection efficiency (%)
1 990v, 40ms, 1 9% 
2 1400v, 10ms, 3 21%
3 1200v, 20ms, 2 32%
4 1300v, 20ms, 2 44%
5 1500v, 10ms, 3 40%
6 1600v, 10ms, 3 67%
7 1200v, 30ms, 1 22%
8 1100v, 30ms, 1 11%
9 1050v, 30ms, 2 25%
10 1300v, 10ms, 3 23%


















































































































































































































































































Figure 5.8. Membrane bound endogenous EFA6R, functions as an Arf6 
specific GEF in ReN cells. (A) ReN cells were grown to ~ 80-90% confluency 
and then deprived of growth factors bFGF and EGF. The resulting 
morphological changes associated with differentiation of these cells on days 
6, 12, 18, 24 and 30 were observed by phase contrast microscopy. (B) EFA6R 
expression was assessed in undifferentiated (UD) and 3-30 days 
differentiated (Dif) ReN cells. Here, on each specified day, ReN cells were 
lysed using TRI-reagent and the lysates separated by 10% SDS-PAGE, 
transferred onto a PVDF membrane and probed with an anti-EFA6R, anti-
Nestin and anti-b-actin (loading control) antibodies. (C) ReN cells were 
chemically transfected with a panel of EFA6R siRNA and the lysates 
subjected to immunoblotting (IB). (D) Transfection of GFP plasmid in ReN 
cells was conducted by electroporation using 11 different parameters to find 
the optimal parameter with the highest, viable transfection efficiency. Here, 
following electroporation, the cells were plated on matrigel coated 13mm 
cover slips. Following 2 days of transfection, the cells were washed with PBS, 
fixed with 4% PFA and stained with DAPI (0.1µg/ml). This was followed by 
visualization of the cells by confocal microscopy. (E) Electroporation of 
siEFA6R 3 and siEFA6R B in ReN cells using the previously optimized 
transfection parameters. Following transfection of ReN cells using 200nM 
siRNA, the cells were incubated for 4-days and ½ of the cells were lysed and 
the GTP-bound Arf6 proteins were precipitated from the lysates using the 
GST-Arf effector magnetic beads. The active GTP-bound Arf6 protein and 
lysates (total Arf6) and EFA6R expression were analysed by immunoblotting 
using an anti-Arf6 and an anti-EFA6R, and anti-b-actin (loading control) 
antibodies. (F) Ren cells were deprived of growth factors to induce 
differentiation for up to 9 days. On days 0, 3, 6 and 9, the cells were lysed 
using the same method as Figure 5.8E. (G) Expression profile of Cytohesins 
1-4 at protein level – indicated by black arrow - (using immunoblotting with 
the anti-cytohesin 1-4 and anti-b-actin [loading control] antibodies) and EFA6 




Here we expanded on our previous studies on EFA6R isoform B by analysing 
the expression and localisation of EFA6R isoform A in tissues and cell lines. 
This resulted in identification of the EFA6R isoform A expression in cell lines 
such as HEK293 and ReN cells but not in any human tissues analysed. By 
using various EFA6R deletion and site-directed mutant constructs, we 
showed that first of all EFA6R is an Arf6-specific GEF. EFA6R GEF activity 
depends on its catalytic Sec7 domain and its ability to localise to the plasma 
membrane through the association of the PH domain with inositol lipid PI-
4,5-P2 in the membrane. Furthermore, we showed that EFA6R is able to 
regulate Arf6 localisation and induce the loss of actin stress fibres through 
regulation of Arf6 activation. Analysis of EFA6R in HEK293 cells revealed 
that depletion of EFA6R reduces Arf6-GTP levels. Furthermore, this 
tentatively corresponded to loss of surface β1 integrin expression. Finally, the 
expression analysis of EFA6R was also conducted in ReN cells where we 
showed that EFA6R isoform A expression decreases in differentiated cells 
when compared to that in undifferentiated cells. The knockdown of EFA6R 
isoform A by using siEFA6R had no effect on Arf6-GTP levels, suggesting an 
alternative, unknown, Arf6-independent role for EFA6R in differentiating 
ReN cells. 
 
In mammals, the exchange factor for Arf6 (EFA6R) is present in many 
isoforms; five in mice and two in humans (Fukaya et al. 2016, Kanamarlapudi 
2014a). In this study, we attempted to characterise these two isoforms from 
human, referred to as EFA6R isoform A which corresponds to an ~150kD 
band observed in neural progenitor ReN cells and HEK293 cells and EFA6R 
isoform B – the predominant variant of EFA6R that corresponds to a 
molecular band of 37-50KDa. EFA6R shares a common domain organization 
with other EFA6 family members which consists of a SEC7 domain (named 
after the gene product of Saccharomyces cerevisiae), which bears the catalytic 
GEF activity, the PI lipid binding PH domain and the CC domain, which 
known to play a role in protein-protein interactions. In addition, some 
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members contain an extended N-terminal domain. The Sec7 domain of the 
EFA6R (both isoforms) shows identity at the amino acid level 60-70 % to other 
EFA6 family and only ~30-35% to the Sec7 domain of the cytohesin  family of 
Arf GEFs (Derrien et al. 2002). Similarly, EFA6R PH and CC share sequence 
homology to the rest of the EFA6 family. Previous studies on particularly 
EFA6A have shown that the presence and functioning of the PH domain is 
responsible for the plasma membrane localisation of EFA6A. An integral part 
of this localisation is its binding affinity with P I4,5-P2 (Macia et al. 2008). 
Similarly, the PH domain of the smaller EFA6R isoform (isoform B) has been 
shown to be responsible for the plasma membrane localisation by interacting 
with the phosphatidylinositol (PIs) P I,4-5,-P-2. In addition, (Kanamarlapudi 
2014b) also showed that CC domain within the C-terminal region contributes 
to the stabilisation of EFA6R at the plasma membrane and cytoskeleton 
rearrangements. Previously,  (Kanamarlapudi 2014b) investigated the 
functional role and cellular localisation of the EFA6R isoform  B whereas this 
study set out to investigate the expression, localisation and functional 
relevance of the large isoform both exogenously and endogenously.  
 
To investigate the functional significance of the Sec7, PH and CC domain we 
constructed various GFP-tagged EFA6R mutant and deletion constructs. 
Cellular localisation studies showed that EFA6R PH mutant constructs GFP-
EFA6R R827E, GFP-EFA6R K828E and GFP-EFA6R R827E/K828E failed to 
localise the plasma membrane. This was due to their failure in binding to PI 
4,5-P2. The deletion construct GFP-EFA6R ∆CC showed weak plasma 
membrane localisation and the catalytically inactive GFP-EFA6R Sec7 
domain was able to localise to the plasma membrane. Taken together, these 
findings demonstrate the importance of a functional PH domain for EFA6R 
localisation. The localisation of EFA6R at the plasma membrane is essential 
to its GEF-dependent and GEF-independent activities. Before analysing the 
importance of various domains within EFA6R isoform A for the activation of 
Arf6 (Arf6-GTP), we first established that EFA6R is an Arf6-specific GEF. 
For this, we co-expressed Arf6 or Arf1 with EFA6R or EFA6A and showed 
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that only Arf6-GTP levels were significantly increased, and not Arf1-GTP 
levels. We then analysed the endogenous Arf6-GTP levels in cells with 
various EFA6R deletion and mutant constructs described above. This 
analysis revealed that the catalytically inactive mutant GFP-EFA6R (E682K) 
and the Sec7, PH and N-∆548 deletion constructs were inefficient in 
activating Arf6. The ∆CC construct was to able (but not to the same extent as 
EFA6R WT) to activate Arf6. Overall, these data showed that EFA6R GEF 
activity is dependent upon its ability to localise to the plasma membrane, 
whereby it can then function as an Arf6-specific GEF. This plasma membrane 
localisation and subsequent the GEF activity is also supported by the CC 
domain.  
 
We next investigated the role of EFA6R on re-organization of the actin 
cytoskeleton through its ability activate Arf6 at the plasma membrane. 
Previous studies have demonstrated that the ability of Arf6 to effectively 
modulate the actin cytoskeleton during many cellular processes depends on 
its activation (Marchesin, Montagnac, and Chavrier 2015). By overexpressing 
the various EFA6R deletion and point mutants in HEK293 cells, we found 
that Arf6 translocation to the plasma membrane and loss of actin stress fibres 
is induced by EFA6R  mutants that contain both the Sec7 (required for the 
catalytic activity) and PH domain (essential for the membrane localisation). 
In contrast, the expression of the Sec7, PH or ∆N548 deletion mutants 
abolished Arf6 translocation to the plasma membrane and hence did not alter 
the actin cytoskeleton. 
 
Previous work has implicated Arf6 in the endocytic pathway and its ability to 
modulate actin-reorganization as essential parts of endosomal compartment 
formation during the internalisation of b1-ntegrins and cell motility (Brown 
et al. 2001, Powelka et al. 2004b). Furthermore, siRNA mediated knockdown 
of Arf6 has been shown to reduce the surface pool of b-1 integrin and inhibit 
cell attachment (Dunphy et al. 2006a). It has also been shown that Arf6 
activation alters b-1 integrin cell surface levels (Eva et al. 2012b). These 
 235 
results together suggest that internalisation of b-1 integrin is mediated by 
the activation of Arf6 at the plasma membrane. Since we have shown in intact 
cells that EFA6R is an Arf6-specific GEF, we wanted to see whether EFA6R 
depletion has any effects on Arf6-GTP levels and thereby the surface pool of 
b-1 integrin in HEK293 cells. Since the localisation of endogenous EFA6R 
isoform A has not been conducted before, we analysed its expression sub-
cellular fractions of HEK293 cells and showed that EFA6R large isoform is 
predominantly membrane bound. Further, in our initial standardisation of 
siEFA6R mediated knockdown of EFA6R, we showed that the 150kDa 
molecular band observed is in fact isoform A. Next, we depleted endogenous 
EFA6R expression using siRNA and showed that Arf6-GTP activation was 
reduced but only by 2-3 folds – implicating other potential Arf GEFs in 
HEK293 cells maintaining Arf6-GTP levels. Further, EFA6R depletion by 
using siEFA6R 1 and siEFA6R B in HEK293 cells resulted in modest 
reduction in surface expression of b-1 integrin. Also, the siRNA-mediated 
knock down of endogenous Arf6 and Arf1 showed a slight reduction in b-1 
integrin surface expression in HEK293 cells. Based on these results, we 
cannot conclusively say that Arf6 or Arf1 is involved in internalisation of b-1 
integrin. Although we saw a modest reduction in b-1 integrin cell surface 
expression following EFA6R depletion, these results could not be replicated 
with a second siRNA that targets only the isoform A. In addition, it could be 
that EFA6R mediation of b-1 integrin could also follow an Arf6-independent 
pathway. These issues need to be further investigated to get some clarity on 
the role of EFA6R in b-1 integrin internalisation (see future work section for 
further discussion in this regard). 
 
Finally, we began to establish a functional role for EFA6R in undifferentiated 
and differentiating ReN cells. We saw that upon growth factor deprivation, 
the ReN cells begin differentiating into neuronal cells within 3 and 6 days. 
This corresponded with reduction of EFA6R expression. However, the 
reduction of EFA6R had no significant effects on Arf6-GTP levels. This was 
not surprising given the number of GEFs that also control Arf6 activation and 
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are also present in undifferentiated ReN cells. Indeed, we showed that the 
cytohesin family of GEFs were present in undifferentiating ReN cells (Figure 
5.8G and H). Furthermore, upon knockdown of EFA6R in these cells, we did 
not see any changes to Arf6-GTP levels, again showing that EFA6R could 
potentially also have an Arf6-independent function in undifferentiated and 
differentiating ReN cells.   
 
5.5 Future work  
 
Thus far, two EFA6R isoforms have been discovered in humans. The EFA6R 
isoform A was the main object of this chapter. The significant difference 
between isoform A and isoform B is the additional 548 amino acid N-terminal 
region in isoform A which thus far have not been found to contain any well-
known motifs. Recent studies however have identified that dynamin 2, which 
induces membrane scission to produce free endocytic vesicles, recruits to the 
site through biding to the N-terminal region of EFA6B and thereby initiate 
Arf6 activation through EFA6B (Okada et al. 2015a). In addition (Okada et 
al. 2015a) also showed that EFA6R is able to interact with dynamin. Future 
research should look into the significance of the N-terminal region of EFA6R 
as it is potential to interact with dynamin 2 and the importance of EFA6R-
dynamin 2 interaction in Arf6 activation. To achieve this, various GFP-tagged 
deletion mutants of EFA6R with or without the N-terminus will be generated 
and co-expressed with an epitope-tagged dynamin 2 and their interactions 
can be assessed by immunoprecipitation, immunofluorescence and GST-Arf 
effector pulldown assays.  
 
Our functional analysis of EFA6R isoform A in HEK293 cells were limited in 
various ways. We observed discrepancies between the depletion of siEFA6R 
1 and siEFA6R B on b-1 integrin expression. Whereas the cells transfected 
with siEFA6R 1 potentially show a reduction of b-1 integrin, siEFA6R B-
mediated knockdown did not. This could be due to the unconfirmed presence 
of other EFA6R isoforms, as siEFA6R 1 targets the C-terminal region of all 
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EFA6R isoforms whereas siEFA6R B targets only the of isoform A through 
its N-terminal region. Therefore, further assessment of change in b-1 integrin 
cell surface expression as a result of EFA6R knockdown is essential. These 
studies should be complemented with exogenous expression of EFA6R and its 
various constructs to see their role in regulating b-1 integrin expression at 
the cell surface. In addition, although previous studies have implicated Arf6 
in the internalisation and recycling of b-1 integrin (Hongu et al. 2015), here 
we failed to see a significant reduction in b-1 integrin cell surface expression 
as a result of siArf6 treatment. To delve further into the role of Arf6 in b-1 
integrin surface expression loss, we could express the dominant negative 
(T27N) and constitutively active (Q67L) mutants of Arf6 to see whether it 
regulate b-1 integrin internalisation in based on its activation or inactivation 
status.  
 
In this study, we have ReN cells found that EFA6R expression is gradually 
reduced during the course of ReNcell differentiation from stem to neuronal 
cells. Nestin is a well-established stem cell antibody (Suzuki et al. 2010) 
whereas MAP-2 has been shown to be significantly upregulated in neutrite 
and neuronal cell bodies (Choi et al. 2014). Future studies shall utilize these 
key markers to look at whether siRNA mediated knockdown of EFA6R results 
in reduction of Nestin and/or increase in MAP2 expression in undifferentiated 
ReN cells to see whether absence of EFA6R is prerequisite for the 
acquirement of differentiation markers. Furthermore, we have yet to 
establish fully the numerous Arf6-specific GEFs that could compensate for 
the loss of EFA6R expression during differentiation.  
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Chapter 6: Final Discussion 
 
Epithelial Ovarian Cancer (EOC) is a heterogeneous disease, composed of 
different histology subtypes whereby each differs in pathogenicity and 
behaviour. As EOC becomes more aggressive in stages and gradings, the 
expression of Exchange factor for Arf6 (EFA6) R is found to be decreased – 
potentially highlighting this Arf6 activator as a candidate tumor suppressor 
gene. Initial gene expression analysis by (Pils et al. 2005b) in patient tissues 
(majority of them being of Serous histology) and several ovarian 
adenocarcinoma cell lines including MDAH-2774 (Endometroid), ES2 (Clear 
cell), SKOV-3 (Low-grade Serous) and OVCAR3 (High-grade Serous) found 
that EFA6R was particularly low in tumours of higher grade, potentially 
reflecting the loss of this gene as a relatively late event in EOC. The 
expression loss of EFA6R also had an apparent impact on survival of EOC 
patients. Before these findings, EFA6R (also referred to as Pleckstrin and 
Sec7 domain containing 3 (PSD3) and Hepatocellular Carcinoma-Associated 
Antigen 67 (HCA67) was identified as an oncogene – given its abnormal high 
expression in colon tumours (Wang, Han et al. 2002). These findings 
highlighted an unsurprising (due to the heterogenesity of cancer) key concept, 
that EFA6R is diferentially expressed in cancer types.  
 
This study builds on these previous findings and aimed to answer the 
following questions: (1) what is the expression of EFA6R in different cancer 
types (relative to the healthy) and (2) is EFA6R expression significantly 
downregulated in Ovarian cancer cell lines and tissues? 
 
To answer these questions, we utilised commercially available cDNA arrays 
to analyse the expression of EFA6R in different cancer types, with particular 
focus on its expression in ovarain cancer. We observed <10 fold increases in 
EFA6R expression in prostage, kidney, colon, thyroid and lung cancers. 
However these must be interpreted with caution  due to a small sample size. 
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By means of a larger cohort of cancer tissues we may find significant evidence 
that EFA6R functions as an aggressive tumour surpressor gene in these 
cancer types. In breast cancer tissues, however, we noticed an ~ 40-fold 
increase in EFA6R expression. Indeed in the highly metastatic breast cancer 
cell line MDB-MB-231 and to a lesser extend the non-invasive breast cancer 
cell line MCF-7, we saw increases in EFA6R at the protein level. EFA6R is 
part of a wider family of Arf6-specific Guanine Exhange Factors (GEFs) which 
include the EFA6 family (EFA6A-D), cytohesin 1, cytohesin 2/ARNO and 
cytohesin 3/Grp1 and GEP100/BRAG2. Some of these GEFs are likely due to 
be found to be indispensable to tumour growth and invasion – a scenario 
which is highly probable given that Arf6 expression has been found to be 
increased in prostate, panceatic, gastric and renal cancer  (Morgan et al. 2015, 
Liang et al. 2017, Zhang et al. 2015, Hashimoto et al. 2016). The role of  
GEP100 in breast cancer is well established. Its abnormal high levels in 
breast cancer cell lines (a consequence of epidermal growth factor (EGF) 
overstimuation), which activates Arf6 – leading to cancer invasion (Morishige 
et al. 2008). Interestingly, (Morishige et al. 2008) also found that, only 
knockdown of GEP100, significantly blocked matrigel invasion of breast 
cancer cells (MDB-MB-231). This could mean that EFA6R may play other 
functional roles in breast cancer cells. One such role could be in 
macropinocytosis – the actin-dependent process initiated fom surface 
membrane ruffles that fold back onto themselfes , engulfing exosomes and 
forming large endocytic vacuoles (Lim and Gleeson 2011). Since this process 
involves actin reorganization and membrane ruffling – two physiological 
processes that are tightly regulated by Arf6 (Kanamarlapudi 2014a, Santy, 
Ravichandran, and Casanova 2005), further research may show that elevated 
EFA6R and Arf6 expressions in breast cancer contribute to the formation of 
macropinosomes.  
 
In contrast to elevated levels of EFA6R in breast cancer tissues, we observed 
a significant decrease in its expression in Ovarian and Liver tissue samples. 
We followed these results by expanding our analysis into EFA6R expression 
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in ovarian cancer tissues – using a larger cDNA array -  and showed a 
significant decrease in overall expression in cancer tissues. By looking at 
individual ovarian cancer histologies and their stages, we saw that in all EOC 
histologies, EFA6R expression decrease correlated with increases in cancer 
stages. Further research should look look into whether EFA6R can therefore 
be used as a early universal biomarker for EOC progression. Particularly 
when current attempts at early detection of ovarian cancer through serum 
detection of CA125 and the use of transvaginal ultrasonography have not 
significantly reduced mortality rates (Jacobs et al. 2016).  
 
We continued to focus on one particular histology group (Serous ovarian 
cancer) for EFA6R expression analysis. Serous ovarian carcinoma is 
responsible for ~ 70% of EOC (Seidman et al. 2004). The most aggressive sub-
type is HGSC, which accounts for 90% of these serous carcinomas and two-
thirds of all ovarian cancer deaths, making it the most extensively studied 
ovarian carcinoma (Bowtell 2010, Gershenson et al. 2006). Our analysis of 
EFA6R expression in serous adenocarcinoma extended to TMAs where we 
saw that highly malignant and undifferentiated tissue cores displayed a lack 
of EFA6R staining – most likely due to the plasticity of the cancer in changing 
the healthy epithelial structure of the tissues and cells.  Nevertheless, we saw 
a gradual decrease in EFA6R staining from grade I to II and a complete 
absence of it in grade III – suggesting that the more aggressive and 
metastatic a serous cancer type, the more likely it is to find EFA6R expression 
absent. Finally, when we examined lysates from ovarian cancer tissues and 
saw that in all but one cases (6 out of 7 EOC tissue lysate samples), EFA6R 
downregulation was evident. In cell lines we saw EFA6R expression decrease 
in some cell lines such as OVSAHO (high-grade serous), COV318 (high-grade 
serous, TOV21G (clear cell), SKOV-3 (Low-grade serous), while in CAOV3 
(high-grade serous) and OVCAR3 (high-grade serous) we saw EFA6R 
expression akin to normal levels. It is worth noting that these cell lines have 
recently been verified to resemble their tumours of origin by means of 
genomic and proteomic analysis (Domcke et al. 2013, Beaufort et al. 2014, 
 241 
Coscia et al. 2016). Therefore, the differential EFA6R expression – 
particularly – between high-grade serous cell lines can be attributed to the 
heterogeneity of mutations even amongst the same sub-type of EOC. 
Naturally, this can lead to a fundamental problem of relevance in that may 
not resemble its tumour of origin. However even in our cDNA tissue array 
samples, we did see healthy samples with high and cancer samples with low 
EFA6R expression. Hence, for the purposes of providing a groundwork for 
future research – which should involve using tumour cells derived from ascitic 
fluids - for now, we deemed using cell lines as appropriate models to observe 
EFA6R expression and undertake studies into the reasons of its 
downregulation and phenotypic consequences of such absence in ovarian 
cancer cells.   
 
Overall in chapter 3, we analysed the expression of EFA6R in a panel of 
cancer types and found that in ovarian cancer, EFA6R is significantly 
downregulated. Next, we posed another short yet complex question: How does 
EFA6R downregulation occur in cell lines of serous adenocarcinoma origin? 
DNA methylation and histone deacetylation are two common mechanisms 
that known to play important roles in down regulation of tumor suppressor 
gene expression during tumorigenesis (Robertson 2005). Following the use of 
5-Aza-Cdr (a widely used DNA methylation inhibitor) we saw evidence of 
DNA methylation in both our high-grade serous cell line OVSAHO, and low-
grade serous cell line SKOV-3. Interestingly, when we treated both cell lines 
with the histone deacetylation inhibitor SAHA, EFA6R levels remained 
unchanged in SKOV-3 cells whereas in OVSAHO cells, we saw revival of 
expression to near normal levels. Suggesting that there may not be a cross-
talk between DNA methylation and histone deacetylation in regulating 
EFA6R expression in OVSAHO cell lines. Therefore, further analysis of the 
role of the methylation status and histone modifications in regulation of 
EFA6R expression may clarify why this is the case. In addition, we 
hypothesize that due to the more aggressive nature of OVSAHO cell lines, 
compared to SKOV-3, both of these epigenetic mechanisms are utilized to 
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suppress EFA6R expression. It would be useful to utilize other HDACi or 
same class as SAHA (such as TSA) or of entirely different class such as 
Nicotinamide to further analyse patterns of histone modifications.  
 
There are some tumor suppressor genes that are directly involved in 
suppression of tumor growth and metastasis. A perfect example for this is the 
recently discovered breast cancer tumor suppressor EFA6B, which shown to 
promote an epithelial phenotype characterized by promotion of the tight 
junction proteins (Zangari et al. 2014). While the other tumor suppressors are 
mere components of cellular control pathways that inhibit proliferation in 
response to genomic instability and metabolic imbalances. In order to 
understand the functional and phenotypic role of EFA6R in ovarian cancer, 
we revived EFA6R expression (through the use of 5-Aza-Cdr) in SKOV-3 cells 
to see what role this Arf6 GEF plays in cancer cell migration and invasion. 
This strategy of restoring gene expression – through the use of demethylating 
agents has various limitations – the foremost being the widespread off target 
effects of 5-Aza-Cdr on other tumor suppressed genes. However, following an 
example of (Petrocca et al. 2006), we used EFA6R siRNA (siEFA6R) to 
suppress the revived expression of EFA6R in 5-Aza-Cdr treated SKOV-3 cells 
so that any phenotypic difference between revived EFA6R expression and 
suppressed EFA6R expression, can be attributed to EFA6R itself and not any 
other off-target effect. We chose to study the anti-metastatic effects of EFA6R 
because that EFA6R is plasma membrane localised and shown to regulate re-
arrangement of actin cytoskeleton (Kanamarlapudi 2014a). We report that 
suppression of EFA6R (following upregulation through 5-Aza-Cdr in SKOV-
3 cells) significantly attenuated cell migration (by ~60% decrease in our ibid 
migration assays and ~5-folds decrease in transwell migration assays) and 
cell invasion through matrigel (~5-fold decrease in transwell invasion). 
Therefore, we showed in this study that the absence of EFA6R expression 




In order to corroborate these findings, we are currently adopting other 
methods or gene restoration to study the role of EFA6R in ovarian cancer cell 
lines. Here, we are using G418 to generate stably transfected cell lines. Once 
stable cell colonies are identified and isolated, we will perform further assays 
and biochemical analysis to observe cell phenotype differences between 
EFA6R-negative SKOV-3 and SKOV-3 positive cells. In addition, we are also 
conducting studies using CAOV3 cell line, which represents high-grade 
serous histology, however, it is EFA6R-positive. We have already established 
that siEFA6R-mediated knockdown of EFA6R in CAOV-3 cell lines may 
potentiate cellular migration and invasion. However, these findings will need 
to be verified through further biochemical analysis. Interestingly, 
pharmological inhibition of Arf6 activation by using NAV-2729 and 
knockdown of Arf6 via Arf6 siRNA did not alleviate cell migration, suggesting 
that EFA6R mediated attenuation of SKOV-3 metastasis occurs via an Arf6-
independent pathway. Overall, our study suggests that epigenetic silencing 
of EFA6R provides one of the molecular signatures that makes EOC 
aggressive and that EFA6R contributes to the aggressive nature of SKOV 3 
cells.  
 
Alternative splicing of EFA6R yields two differently sized isoforms (larger 
isoform A and shorter isoform B), both containing a conserved Sec7, PH and 
CC motifs (Figure 6.2). The variant A also has an additional N-terminal 
region in which possible interaction protein sites may be found – based on 
similar findings in the N-terminal region of EFA6B (Okada et al. 2015b) 
(Figure 6.1). Incidentally, in our ovarian cancer cell lines, we only saw 
evidence of the shorter isoform. Only in HEK293 and ReNCells did we saw 
expression of an ~150kDa protein which we showed through siRNA 
knockdown to be the larger EFA6R variant A. Interestingly, (Morishige et al. 
2008) have also seen evidence of EFA6R isoform A in MDB-MB-231 cells. 
However, we did not see such evidence in these cells, a reason that can be 
attributed to the sensitivity of our antibody. It is difficult to say whether 
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(Morishige et al. 2008) also saw the smaller isoform since they didn’t mention 


















Figure 6.2. Multiple EFA6R Isoforms. (A) A diagram of the intron and exon 
boundaries within EFA6R gene, showing the contribution of each exon to the 
two EFA6R isoforms they encode. Exons are shown by as grey boxes. Coding 
regions are dark shade green while non-coding regions are light green. 
Roughly, Exon 1-4 code for the extended N-terminal region of EFA6R 
isoform13 A, Exons 7-8 code for the conserved Sec7 domain, Exons 13-16 code 
for the conserved PH domain and Exon 16-17 code for the conserved CC 
domain. (B) Protein 3D structure of EFA6R isoforms showing the 
corresponding folds of the various regions of EFA6R isoforms. This predicted 
structure was obtained using I-TASSER (Iterative Threading ASSEmbly 
Refinement) online server from (Zhanglab 2018).  
 













NCBI Reference Sequence: NM_206909.2
EFA6R Isoform A EFA6R Isoform B
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Overall, the presence of the larger isoform is not a surprise as it was initially 
discovered to encode a protein of 1004-amino acids, in the mouse brain 
(Sakagami et al. 2006). Further in situ hybridization analysis revealed that 
EFA6R was highly expressed in the hippocampal region of mice brain 
whereas other EFA6 family members differed in their spatiotemporal 
localisation. Real-time qPCR analysis of various adult mice tissues showed 
EFA6R expression is highest in the brain, eye, thymus, lung, spleen and testis 
while a lower expression in the small intestine, kidney and heart (Sakagami 
et al. 2006). However, by probing INSTA-blot human tissue blot with EFA6R 
antibody (which can recognise both the isoforms), we did not observe the 
larger isoform A in any of these tissues. Therefore, future research should 
initially verify the expression of EFA6R isoform A in mouse tissues and also 
look into using antibodies of high sensitivity to possibly detect EFA6R isoform 
A – an issue that has been reported previously in mouse tissues (Fukaya et 
al. 2016). Furthermore, analysis of cDNA arrays of mouse and human tissues 
will show whether EFA6R isoform A is present at the mRNA level. Recent 
studies into EFA6R isoforms have broadened our understanding of their 
distinct cellular/subcellular localisations and expression. In the mouse 
hippocampal CA3 region for example, isoforms with ~140 kDa molecular 
wright were predominately localized at the axon fibres of mossy fibres 
whereas a ~45 kDa band was mostly localized to cell bodies, dendritic shafts 
and spines of hippocampal pyramidal cells (Fukaya et al. 2016). Overall, 
these results suggest that EFA6R variants are functionally diverse in the 
mouse brain – a fact that may also be likely in other tissues.  
 
Previously, (Kanamarlapudi 2014a) had studied the localisation and cellular 
functions of the human EFA6R isoform B and showed that it is plasma 
membrane localised, where it regulates actin re-organization through Arf6 
activation. Here, we asked whether EFA6R isoform A is able to function in a 
similar way given the conserved Sec7, PH and CC motifs. Therefore, we 
generated various point and deletion mutants of EFA6R to further analyse 
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the functional role of the larger isoform (the details of these mutants can be 
seen in Chapter 5, Figure 5.3). 
 
The references and clues for our constructs came from previous studies into 
the functional roles of ARFGEFs. The EFA6 family members contain a Sec7 
domain, with 60-70 % similar to EFA6R each other and only ~30-35% 
identical to ARNO/cytohesin Sec7 domains (Derrien et al. 2002). (Table 7) 
 
Table 7. Sequence identity (and similarity) of Sec7, PH AND CC domains of 
EFA6R and EFA6 family.  
Sequence information was obtained from Uniprot and % identify and 
similarity analysed by pairwise sequence alignment (protein) using EMBOSS 
Needle servers of EMBL-EBI (2018). 
 
Moreover, the PH domain of EFA6R is 65-85% similar to other EFA6 
members. The CC domain. The GEF activity of the first EFA6 family, EFA6A, 
was found to be dependent on the Glu424 residue, where its substitution with 
lysine was found to inhibit nucleotide exchange activity on Arf6 (M Franco et 
al. 1999). Similarly, the GEF-defective mutant brought about as a result of 
substitution of Glu651 of EFA6B, Glu347 of EFA6C, Glu134 of EFA6R 
isoform B and also Glu156 of cytohesin 2/ARNO (ARF nucleotide-binding site 
opener), an ARF-specific GEF; all showed inhibitory effects on the activation 
of their corresponding ARFs (Michel Franco et al. 1999)(Matsuya et al. 2005). 
Consistent with this, when we mutated the conserved Glu682 of EFA6R 
isoform A to lysine (E682K), the mutant lost the ability to act as a GEF for 
Arf6. However, the localisation of EFA6R to the plasma membrane was not 
affected by E682K mutation. Similar results were observed when the whole 
 EFA6A EFA6B EFA6C ARNO Mouse EFA6R 
EFA6R Sec7 61.7 (77.6) 47.4 (63.0) 60.3 (74.5) 19.4 (34.8) 85.6 (89.5) 
EFA6 R PH 68.4 (84.2) 52.1 (66.7) 73.7 (82.5) 22.5 (38.4) 98.2 (100) 
EFA6 R CC 50.0 (71.9) 21.3 (24.6) 65.6 (81.2) 12.1 (29.3) 100 (100) 
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Sec7 was deleted from EFA6R (EFA6R ∆Sec7). Therefore, it is not the Sec7 
domain that is responsible for plasma membrane localisation. The membrane 
localisation of EFA6R is dependent on the PH domain. Previous studies with 
EFA6A and EFA6R isoform B have shown that an integral part of this 
localisation is dependent on the ability of the PH domain of these proteins 
binding to an inositol lipid PI (4,5) P2 (PIP2). Cells treatment with Ionomycin, 
which hydrolyses PIP2, leads to depletion of PIP2 levels in the plasma 
membrane and a consequence of this was EFA6A/EFA6R localisation to the 
cytosol (Kanamarlapudi 2014a, Macia et al. 2008). Here, we showed that 
mutation of the PH domain (R827E and/or K828E) affects the interaction 
between EFA6R and PIP2, and thereby make EFA6R localises to the cytosol. 
The EFA6R ∆CC deletion mutant showed a weak plasma membrane 
localisation. After demonstrating that EFA6R preferentially functions as an 
Arf6-speciifc GEF, we showed that the Sec7 domain (as evident by using the 
∆Sec7 deletion and E682K mutant constructs) is essential for the activation 
of Arf6. This activation is dependent on the membrane localisation, through 
the PH domain binding to PIP2 in the plasma membrane, which is further 
stabilised by the presence of the CC domain. When studying the functional 
role of exogenously expressed EFA6R in HEK293 cells, we found, similarly to 
the findings of (Kanamarlapudi 2014a), that EFA6R modulates the loss of 
stress actin fibres through co-localisation with and activation of Arf6. Re-
organization of the actin cytoskeleton is central to many cellular processes, 
including cell motility associated with metastasis.  
 
We finally undertook preliminary analysis of EFA6R isoform A functional 
significance in HEK293 and ReNcells. Fractioning of HEK293 cells showed 
that EFA6R is membrane bound rather than cytosolic. The presence of the 
larger isoform was further validated by siRNA-mediated knockdown of 
EFA6R. Following siRNA-knockdown of EFA6R isoform A, we showed that 
endogenous Arf6-GTP activity was also decreased, resulting in a modest 
alteration of surface b-1 integrin expression. This modest alteration could be 
explained by the presence of other GEFs that could potentially be 
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compensating for the absence of EFA6R. Recently, an in vivo study conducted 
by Hongu and colleagues showed that Arf6 is required for hepatocyte growth 
factor (HGF) dependent tumour neoangiogenesis and growth (Hongu et al. 
2015). Using Arf6 knockout mice, it was shown that Arf6 deletion abolishes 
b-1 integrin recycling. Knockdown of Arf6 GEFs (GEP100, EFA6B and 
EFA6R and cytohesin3/GRP1) inhibited b-1 integrin recycling, suggesting 
that Arf6-mediated b-1 integrin recycling depends on multiple Arf6 GEFs. 
However, their functional roles may differ as EFA6R, EFA6B and GEP100 
co-localize with b-1 integrin at the plasma membrane, whereas 
cytohesin3/GRP1 recruits transiently to the membrane by binding to inositol 
lipid PI 3,4,5-P3 (Hongu et al. 2015, Venkateswarlu et al. 1998) 
(Venkateswarlu et al. 2008). Based on these findings, and our preliminary 
data, further investigation of EFA6R/Arf6-mediated regulation of b-1 integrin 
expression is essential. Part of these studies should entail overexpression of 
the EFA6R and its point and deletion mutants to see how they regulate b-1 
integrin expression. Furthermore, in ovarian cancer cells, this may prove an 
invaluable pathway utilized prior to downregulation of EFA6R since b-1 
integrins has been shown to be involved in many ovarian cancer hallmarks, 
including tumour progression, development of angiogenesis, promote 
migration/invasion (Blandin et al. 2015). 
 
Our analysis of EFA6R isoform A in ReN cells is incomplete. Although we 
have shown that EFA6R expression is reduced during the differentiation 
process of stem into neuronal cells – with an ~50% reduction of expression 
within 6 days and a complete absence of EFA6R on day 30 of differentiation, 
we have yet to elucidate the functions of EFA6R in these cells. Admittedly, 
these findings need to be corroborated with further experimentations. In 
undifferentiated ReN cells we have shown (through siRNA-mediated 
knockdown of EFA6R) that the larger isoform is present in these cells. 
However, the reductions of endogenous EFA6R did not reduce endogenous 
Arf6-GTP levels – an indication of the presence of other Arf6-GEFs in ReN 
cells with thus far, unknown functions. Currently, we are evaluating the 
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potential of EFA6R in inducing stem-cell type characteristics. Following 
siEFA6R treatment of these cells, we are analysing Nestin and MAP2 
expression levels by qPCR. Nestin is a stem cell marker, while MAP2 has 
been shown to be only expressed in mature, differentiated neuronal cells 
(Choi et al. 2014). If we observe reduction in Nestin in conjunction with 
increases of MAP2 mRNA levels in siRNA-treated cells, we will begin to 
investigate the role of EFA6R in mediating neuronal stem cell differentiation.  
 
In conclusion, this study provides various foundations and avenues to further 
expand the knowledge of EFA6R in ovarian cancer, and its differential 
isoform expressions in HEK293 and ReN cells (A summary of the major 
findings in this study is presented in Figure 6.3). In OC research, any future 
investigations should attempt to utilize tissues derived from the ascites fluid 
of ovarian cancer patients because it represents the microenvironment in 







































Figure 6.2. Diagram summarizing all major findings. (1) EFA6R isoform B 
expression is significantly downregulated in EOC tissues and cell lines. (2) 
This downregulation is epigenetically controlled; Re-expression of EFA6R 
isoform B via a demethylating drug 5-Aza-Cdr reduced cell migration and 
invasion via an Arf6 independent pathway. (3) EFA6R isoform A expression 
was observed in ReN and HEK293 cells; in the former its expression 
decreases as ReN stem cells are differentiating into neurons. In the latter, 
exogenous and endogenous studies showed that EFA6R isoform A localises to 
the plasma membrane via its PH domain (and its presence is stabilized via 
the CC domain). There, it functions as an Arf6 GEF via its Sec7 domain – 
regulating re-organization of the actin cytoskeleton and possibly being 






Nccn.org. (2018). NCCN Clinical Practice Guidelines in Oncology. [online] 
Available at: 
https://www.nccn.org/professionals/physician_gls/default.aspx#ovarian 
[Accessed 18 Sep. 2018]. 
 
Targetovariancancer.org.uk. (2018). Pathfinder | Target EOC. [online] 
Available at: https://www.targetovariancancer.org.uk/our-
campaigns/pathfinder [Accessed 16 Sep. 2018]. 
 
Cancer Research UK. (2018). EOC statistics. [online] Available at: 
https://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/ovarian-cancer [Accessed 16 Sep. 2018]. 
 
Ebi.ac.uk. (2018). EMBOSS Needle < Pairwise Sequence Alignment < EMBL-
EBI. [online] Available at: https://www.ebi.ac.uk/Tools/psa/emboss_needle/ 
[Accessed 20 Sep. 2018]. 
 
Zhanglab.ccmb.med.umich.edu. (2018). I-TASSER server for protein 
structure and function prediction. [online] Available at: 






Abramson, D. H. 2005. "Retinoblastoma in the 20th century: past 
success and future challenges the Weisenfeld lecture."  Invest 
Ophthalmol Vis Sci 46 (8):2683-91. doi: 10.1167/iovs.04-1462. 
Ahmed, A. A., D. Etemadmoghadam, J. Temple, A. G. Lynch, M. Riad, 
R. Sharma, C. Stewart, S. Fereday, C. Caldas, A. Defazio, D. 
Bowtell, and J. D. Brenton. 2010. "Driver mutations in TP53 are 
ubiquitous in high grade serous carcinoma of the ovary."  J 
Pathol 221 (1):49-56. doi: 10.1002/path.2696. 
 252 
Akiyama, M., M. Zhou, R. Sugimoto, T. Hongu, M. Furuya, Y. 
Funakoshi, M. Kato, H. Hasegawa, and Y. Kanaho. 2010. 
"Tissue- and development-dependent expression of the small 
GTPase Arf6 in mice."  Dev Dyn 239 (12):3416-35. doi: 
10.1002/dvdy.22481. 
Al-Awar, Omayma, Harish Radhakrishna, Natasha N. Powell, and 
Julie G. Donaldson. 2000. "Separation of Membrane Trafficking 
and Actin Remodeling Functions of Arf6 with an Effector 
Domain Mutant."  Molecular and Cellular Biology 20 (16):5998-
6007. 
Alsop, Kathryn, Sian Fereday, Cliff Meldrum, Anna deFazio, 
Catherine Emmanuel, Joshy George, Alexander Dobrovic, 
Michael J. Birrer, Penelope M. Webb, Colin Stewart, Michael 
Friedlander, Stephen Fox, David Bowtell, and Gillian Mitchell. 
2012. "BRCA Mutation Frequency and Patterns of Treatment 
Response in BRCA Mutation–Positive Women With Ovarian 
Cancer: A Report From the Australian Ovarian Cancer Study 
Group."  Journal of Clinical Oncology 30 (21):2654-2663. doi: 
10.1200/JCO.2011.39.8545. 
Amampai, Rattapon, and Prapaporn Suprasert. 2018. "Cancer 
Antigen 125 during Pregnancy in Women without Ovarian 
Tumor Is Not Often Rising."  Obstetrics and Gynecology 
International 2018:4. doi: 10.1155/2018/8141583. 
Armstrong, D. K., B. Bundy, L. Wenzel, H. Q. Huang, R. Baergen, S. 
Lele, L. J. Copeland, J. L. Walker, and R. A. Burger. 2006. 
"Intraperitoneal cisplatin and paclitaxel in ovarian cancer."  N 
Engl J Med 354 (1):34-43. doi: 10.1056/NEJMoa052985. 
Bailey, T. A., H. Luan, E. Tom, T. A. Bielecki, B. Mohapatra, G. 
Ahmad, M. George, D. L. Kelly, A. Natarajan, S. M. Raja, V. 
Band, and H. Band. 2014. "A kinase inhibitor screen reveals 
protein kinase C-dependent endocytic recycling of ErbB2 in 
breast cancer cells."  J Biol Chem 289 (44):30443-58. doi: 
10.1074/jbc.M114.608992. 
Barr, D. J., A. G. Ostermeyer-Fay, R. A. Matundan, and D. A. Brown. 
2008. "Clathrin-independent endocytosis of ErbB2 in 
geldanamycin-treated human breast cancer cells."  J Cell Sci 
121 (Pt 19):3155-66. doi: 10.1242/jcs.020404. 
Bassuk, S. S., and J. E. Manson. 2015. "Oral contraceptives and 
menopausal hormone therapy: relative and attributable risks of 
cardiovascular disease, cancer, and other health outcomes."  
Ann Epidemiol 25 (3):193-200. doi: 
10.1016/j.annepidem.2014.11.004. 
 253 
Bast, R. C., Jr., B. Hennessy, and G. B. Mills. 2009. "The biology of 
ovarian cancer: new opportunities for translation."  Nat Rev 
Cancer 9 (6):415-28. doi: 10.1038/nrc2644. 
Baylin, Stephen B., and Joyce E. Ohm. 2006. "Epigenetic gene 
silencing in cancer – a mechanism for early oncogenic pathway 
addiction?"  Nature Reviews Cancer 6:107. doi: 10.1038/nrc1799. 
Beaufort, C. M., J. C. Helmijr, A. M. Piskorz, M. Hoogstraat, K. 
Ruigrok-Ritstier, N. Besselink, M. Murtaza, IJcken W. F. van, 
A. A. Heine, M. Smid, M. J. Koudijs, J. D. Brenton, E. M. Berns, 
and J. Helleman. 2014. "Ovarian cancer cell line panel (OCCP): 
clinical importance of in vitro morphological subtypes."  PLoS 
One 9 (9):e103988. doi: 10.1371/journal.pone.0103988. 
Begle, A., P. Tryoen-Toth, J. de Barry, M. F. Bader, and N. Vitale. 
2009. "Arf6 regulates the synthesis of fusogenic lipids for 
calcium-regulated exocytosis in neuroendocrine cells."  J Biol 
Chem 284 (8):4836-45. doi: 10.1074/jbc.M806894200. 
Bentink, S., B. Haibe-Kains, T. Risch, J. B. Fan, M. S. Hirsch, K. 
Holton, R. Rubio, C. April, J. Chen, E. Wickham-Garcia, J. Liu, 
A. Culhane, R. Drapkin, J. Quackenbush, and U. A. Matulonis. 
2012. "Angiogenic mRNA and microRNA gene expression 
signature predicts a novel subtype of serous ovarian cancer."  
PLoS One 7 (2):e30269. doi: 10.1371/journal.pone.0030269. 
Beral, V., K. Gaitskell, C. Hermon, K. Moser, G. Reeves, and R. Peto. 
2015. "Menopausal hormone use and ovarian cancer risk: 
individual participant meta-analysis of 52 epidemiological 
studies."  Lancet 385 (9980):1835-42. doi: 10.1016/s0140-
6736(14)61687-1. 
Beraud-Dufour, S., S. Robineau, P. Chardin, S. Paris, M. Chabre, J. 
Cherfils, and B. Antonny. 1998. "A glutamic finger in the 
guanine nucleotide exchange factor ARNO displaces Mg2+ and 
the beta-phosphate to destabilize GDP on ARF1."  Embo j 17 
(13):3651-9. doi: 10.1093/emboj/17.13.3651. 
Berns, E. M., and D. D. Bowtell. 2012. "The changing view of high-
grade serous ovarian cancer."  Cancer Res 72 (11):2701-4. doi: 
10.1158/0008-5472.can-11-3911. 
Bid, H. K., R. D. Roberts, P. K. Manchanda, and P. J. Houghton. 2013. 
"RAC1: an emerging therapeutic option for targeting cancer 
angiogenesis and metastasis."  Mol Cancer Ther 12 (10):1925-34. 
doi: 10.1158/1535-7163.MCT-13-0164. 
Blandin, Anne-Florence, Guillaume Renner, Maxime Lehmann, 
Isabelle Lelong-Rebel, Sophie Martin, and Monique Dontenwill. 
2015. "β1 Integrins as Therapeutic Targets to Disrupt 
Hallmarks of Cancer."  Frontiers in Pharmacology 6:279. doi: 
10.3389/fphar.2015.00279. 
 254 
Boehm, T., S. Hofer, P. Winklehner, B. Kellersch, C. Geiger, A. 
Trockenbacher, S. Neyer, H. Fiegl, S. Ebner, L. Ivarsson, R. 
Schneider, E. Kremmer, C. Heufler, and W. Kolanus. 2003. 
"Attenuation of cell adhesion in lymphocytes is regulated by 
CYTIP, a protein which mediates signal complex sequestration."  
Embo j 22 (5):1014-24. doi: 10.1093/emboj/cdg101. 
Bohl, S. R., L. Bullinger, and F. G. Rucker. 2018. "Epigenetic therapy: 
azacytidine and decitabine in acute myeloid leukemia."  Expert 
Rev Hematol 11 (5):361-371. doi: 
10.1080/17474086.2018.1453802. 
Bolden, J. E., M. J. Peart, and R. W. Johnstone. 2006. "Anticancer 
activities of histone deacetylase inhibitors."  Nat Rev Drug 
Discov 5 (9):769-84. doi: 10.1038/nrd2133. 
Bolton, K. L., G. Chenevix-Trench, C. Goh, S. Sadetzki, S. J. Ramus, 
B. Y. Karlan, D. Lambrechts, E. Despierre, D. Barrowdale, L. 
McGuffog, S. Healey, D. F. Easton, O. Sinilnikova, J. Benitez, 
M. J. Garcia, S. Neuhausen, M. H. Gail, P. Hartge, S. Peock, D. 
Frost, D. G. Evans, R. Eeles, A. K. Godwin, M. B. Daly, A. 
Kwong, E. S. Ma, C. Lazaro, I. Blanco, M. Montagna, E. 
D'Andrea, M. O. Nicoletto, S. E. Johnatty, S. K. Kjaer, A. 
Jensen, E. Hogdall, E. L. Goode, B. L. Fridley, J. T. Loud, M. H. 
Greene, P. L. Mai, A. Chetrit, F. Lubin, G. Hirsh-Yechezkel, G. 
Glendon, I. L. Andrulis, A. E. Toland, L. Senter, M. E. Gore, C. 
Gourley, C. O. Michie, H. Song, J. Tyrer, A. S. Whittemore, V. 
McGuire, W. Sieh, U. Kristoffersson, H. Olsson, A. Borg, D. A. 
Levine, L. Steele, M. S. Beattie, S. Chan, R. L. Nussbaum, K. B. 
Moysich, J. Gross, I. Cass, C. Walsh, A. J. Li, R. Leuchter, O. 
Gordon, M. Garcia-Closas, S. A. Gayther, S. J. Chanock, A. C. 
Antoniou, and P. D. Pharoah. 2012. "Association between 
BRCA1 and BRCA2 mutations and survival in women with 
invasive epithelial ovarian cancer."  Jama 307 (4):382-90. doi: 
10.1001/jama.2012.20. 
Bonadona, V., B. Bonaïti, S. Olschwang, and et al. 2011. "Cancer risks 
associated with germline mutations in mlh1, msh2, and msh6 
genes in lynch syndrome."  JAMA 305 (22):2304-2310. doi: 
10.1001/jama.2011.743. 
Bookman, M. A., M. F. Brady, W. P. McGuire, P. G. Harper, D. S. 
Alberts, M. Friedlander, N. Colombo, J. M. Fowler, P. A. 
Argenta, K. De Geest, D. G. Mutch, R. A. Burger, A. M. Swart, 
E. L. Trimble, C. Accario-Winslow, and L. M. Roth. 2009. 
"Evaluation of new platinum-based treatment regimens in 
advanced-stage ovarian cancer: a Phase III Trial of the 
Gynecologic Cancer Intergroup."  J Clin Oncol 27 (9):1419-25. 
doi: 10.1200/jco.2008.19.1684. 
 255 
Bowtell, D. D. 2010. "The genesis and evolution of high-grade serous 
ovarian cancer."  Nat Rev Cancer 10 (11):803-8. doi: 
10.1038/nrc2946. 
Brantis-de-Carvalho, C. E., G. Maarifi, P. E. Goncalves Boldrin, C. F. 
Zanelli, S. Nisole, M. K. Chelbi-Alix, and S. R. Valentini. 2015. 
"MxA interacts with and is modified by the SUMOylation 
machinery."  Exp Cell Res 330 (1):151-63. doi: 
10.1016/j.yexcr.2014.10.020. 
Brees, C., and M. Fransen. 2014. "A cost-effective approach to 
microporate mammalian cells with the Neon Transfection 
System."  Anal Biochem 466:49-50. doi: 
10.1016/j.ab.2014.08.017. 
Brown, F. D., A. L. Rozelle, H. L. Yin, T. Balla, and J. G. Donaldson. 
2001. "Phosphatidylinositol 4,5-bisphosphate and Arf6-regulated 
membrane traffic."  J Cell Biol 154 (5):1007-17. doi: 
10.1083/jcb.200103107. 
Brown, M. R., R. Chuaqui, C. D. Vocke, A. Berchuck, L. P. Middleton, 
M. R. Emmert-Buck, and E. C. Kohn. 1999. "Allelic loss on 
chromosome arm 8p: analysis of sporadic epithelial ovarian 
tumors."  Gynecol Oncol 74 (1):98-102. doi: 
10.1006/gyno.1999.5439. 
Cannavo, E., B. Gerrits, G. Marra, R. Schlapbach, and J. Jiricny. 
2007. "Characterization of the interactome of the human MutL 
homologues MLH1, PMS1, and PMS2."  J Biol Chem 282 
(5):2976-86. doi: 10.1074/jbc.M609989200. 
Caumont, A. S., M. C. Galas, N. Vitale, D. Aunis, and M. F. Bader. 
1998. "Regulated exocytosis in chromaffin cells. Translocation of 
Arf6 stimulates a plasma membrane-associated phospholipase 
D."  J Biol Chem 273 (3):1373-9. 
Cavenagh, M. M., J. A. Whitney, K. Carroll, Cj Zhang, A. L. Boman, A. 
G. Rosenwald, I. Mellman, and R. A. Kahn. 1996. "Intracellular 
distribution of Arf proteins in mammalian cells. Arf6 is uniquely 
localized to the plasma membrane."  J Biol Chem 271 
(36):21767-74. 
Chavrier, P., and M. Franco. 2001. "Expression, purification, and 
biochemical properties of EFA6, a Sec7 domain-containing 
guanine exchange factor for ADP-ribosylation factor 6 (Arf6)."  
Methods Enzymol 329:272-9. 
Chen, B., K. Brinkmann, Z. Chen, C. W. Pak, Y. Liao, S. Shi, L. 
Henry, N. V. Grishin, S. Bogdan, and M. K. Rosen. 2014. "The 
WAVE regulatory complex links diverse receptors to the actin 
cytoskeleton."  Cell 156 (1-2):195-207. doi: 
10.1016/j.cell.2013.11.048. 
 256 
Cherfils, J., and M. Zeghouf. 2013. "Regulation of small GTPases by 
GEFs, GAPs, and GDIs."  Physiol Rev 93 (1):269-309. doi: 
10.1152/physrev.00003.2012. 
Cherfils, Jacqueline, Julie Ménétrey, Magali Mathieu, Gérard Le 
Bras, Sylviane Robineau, Sophie Béraud-Dufour, Bruno 
Antonny, and Pierre Chardin. 1998. "Structure of the Sec7 
domain of the Arf exchange factor ARNO."  Nature 392:101. doi: 
10.1038/32210. 
Choi, Se Hoon, Young Hye Kim, Matthias Hebisch, Christopher 
Sliwinski, Seungkyu Lee, Carla D’Avanzo, Jennifer Chen, 
Basavaraj Hooli, Caroline Asselin, Julien Muffat, Justin B. 
Klee, Can Zhang, Brian J. Wainger, Michael Peitz, Dora M. 
Kovacs, Clifford J. Woolf, Steven L. Wagner, Rudolph E. Tanzi, 
and Doo Yeon Kim. 2014. "A three-dimensional human neural 
cell culture model of Alzheimer’s disease."  Nature 515 
(7526):274-278. doi: 10.1038/nature13800. 
Choi, W., Z. A. Karim, and S. W. Whiteheart. 2006. "Arf6 plays an 
early role in platelet activation by collagen and convulxin."  
Blood 107 (8):3145-52. 
Chomphoo, S., W. Mothong, T. Sawatpanich, P. Kanla, H. Sakagami, 
H. Kondo, and W. Hipkaeo. 2016. "Ultrastructural Localization 
of Endogenous Exchange Factor for Arf6 in Adrenocortical Cells 
In Situ of Mice."  Acta Histochem Cytochem 49 (3):83-7. doi: 
10.1267/ahc.16008. 
Claing, A., W. Chen, W. E. Miller, N. Vitale, J. Moss, R. T. Premont, 
and R. J. Lefkowitz. 2001. "beta-Arrestin-mediated ADP-
ribosylation factor 6 activation and beta 2-adrenergic receptor 
endocytosis."  J Biol Chem 276 (45):42509-13. doi: 
10.1074/jbc.M108399200. 
Cortesi, L., E. De Matteis, A. Toss, I. Marchi, V. Medici, G. Contu, A. 
Xholli, G. Grandi, A. Cagnacci, and M. Federico. 2017. 
"Evaluation of Transvaginal Ultrasound plus CA-125 
Measurement and Prophylactic Salpingo-Oophorectomy in 
Women at Different Risk Levels of Ovarian Cancer: The Modena 
Study Group Cohort Study."  Oncology 93 (6):377-386. doi: 
10.1159/000479155. 
Coscia, F., K. M. Watters, M. Curtis, M. A. Eckert, C. Y. Chiang, S. 
Tyanova, A. Montag, R. R. Lastra, E. Lengyel, and M. Mann. 
2016. "Integrative proteomic profiling of ovarian cancer cell 
lines reveals precursor cell associated proteins and functional 
status."  Nat Commun 7:12645. doi: 10.1038/ncomms12645. 
Cotton, Mathieu, Pierre-Luc Boulay, Tanguy Houndolo, Nicolas 
Vitale, Julie A. Pitcher, and Audrey Claing. 2007. "Endogenous 
Arf6 Interacts with Rac1 upon Angiotensin II Stimulation to 
 257 
Regulate Membrane Ruffling and Cell Migration."  Molecular 
Biology of the Cell 18 (2):501-511. doi: 10.1091/mbc.E06-06-
0567. 
Craig, H. E., J. Coadwell, H. Guillou, and S. Vermeren. 2010. "ARAP3 
binding to phosphatidylinositol-(3,4,5)-trisphosphate depends on 
N-terminal tandem PH domains and adjacent sequences."  Cell 
Signal 22 (2):257-64. doi: 10.1016/j.cellsig.2009.09.025. 
Cullen, P. J., and K. Venkateswarlu. 1999. "Potential regulation of 
ADP-ribosylation factor 6 signalling by phosphatidylinositol 
3,4,5-trisphosphate."  Biochemical Society Transactions 27 
(4):683-689. doi: 10.1042/bst0270683. 
D'Souza-Schorey, C., R. L. Boshans, M. McDonough, P. D. Stahl, and 
L. Van Aelst. 1997. "A role for POR1, a Rac1-interacting protein, 
in Arf6-mediated cytoskeletal rearrangements."  Embo j 16 
(17):5445-54. doi: 10.1093/emboj/16.17.5445. 
D'Souza-Schorey, C., and P. Chavrier. 2006. "ARF proteins: roles in 
membrane traffic and beyond."  Nat Rev Mol Cell Biol 7 (5):347-
58. doi: 10.1038/nrm1910. 
D'Souza-Schorey, C., and P. D. Stahl. 1995. "Myristoylation is 
required for the intracellular localization and endocytic function 
of Arf6."  Exp Cell Res 221 (1):153-9. 
D'Souza-Schorey, Crislyn, Elly van Donselaar, Victor W. Hsu, 
Chunzhi Yang, Philip D. Stahl, and Peter J. Peters. 1998. "Arf6 
Targets Recycling Vesicles to the Plasma Membrane: Insights 
from an Ultrastructural Investigation."  The Journal of Cell 
Biology 140 (3):603-616. doi: 10.1083/jcb.140.3.603. 
Dai, J., J. Li, E. Bos, M. Porcionatto, R. T. Premont, S. Bourgoin, P. J. 
Peters, and V. W. Hsu. 2004. "ACAP1 promotes endocytic 
recycling by recognizing recycling sorting signals."  Dev Cell 7 
(5):771-6. doi: 10.1016/j.devcel.2004.10.002. 
Davies, J. C., S. C. Bain, and V. Kanamarlapudi. 2014. "ADP-
ribosylation factor 6 regulates endothelin-1-induced lipolysis in 
adipocytes."  Biochem Pharmacol 90 (4):406-13. doi: 
10.1016/j.bcp.2014.06.012. 
Davies, J. C., S. Tamaddon-Jahromi, R. Jannoo, and V. 
Kanamarlapudi. 2014. "Cytohesin 2/Arf6 regulates preadipocyte 
migration through the activation of ERK1/2."  Biochem 
Pharmacol 92 (4):651-60. doi: 10.1016/j.bcp.2014.09.023. 
Decressac, Sonia, Michel Franco, Said Bendahhou, Richard Warth, 
Sebastian Knauer, Jacques Barhanin, Michel Lazdunski, and 
Florian Lesage. 2004. "Arf6-dependent interaction of the TWIK1 
K(+) channel with EFA6, a GDP/GTP exchange factor for Arf6."  
EMBO Reports 5 (12):1171-1175. doi: 10.1038/sj.embor.7400292. 
 258 
Dell'Angelica, E. C., R. Puertollano, C. Mullins, R. C. Aguilar, J. D. 
Vargas, L. M. Hartnell, and J. S. Bonifacino. 2000a. "GGAs: a 
family of ADP ribosylation factor-binding proteins related to 
adaptors and associated with the Golgi complex."  J Cell Biol 
149 (1):81-94. 
Dell'Angelica, Esteban C., Rosa Puertollano, Chris Mullins, Rubén C. 
Aguilar, José D. Vargas, Lisa M. Hartnell, and Juan S. 
Bonifacino. 2000b. "Ggas."  A Family of Adp Ribosylation 
Factor-Binding Proteins Related to Adaptors and Associated 
with the Golgi Complex 149 (1):81-94. doi: 10.1083/jcb.149.1.81. 
Dell'Angelica, Esteban C., Rosa Puertollano, Chris Mullins, Rubén C. 
Aguilar, José D. Vargas, Lisa M. Hartnell, and Juan S. 
Bonifacino. 2000c. "Ggas: A Family of Adp Ribosylation Factor-
Binding Proteins Related to Adaptors and Associated with the 
Golgi Complex."  The Journal of Cell Biology 149 (1):81-94. 
Derrien, V., C. Couillault, M. Franco, S. Martineau, P. Montcourrier, 
R. Houlgatte, and P. Chavrier. 2002. "A conserved C-terminal 
domain of EFA6-family Arf6-guanine nucleotide exchange 
factors induces lengthening of microvilli-like membrane 
protrusions."  J Cell Sci 115 (Pt 14):2867-79. 
Devarbhavi, H., D. Kaese, A. W. Williams, J. Rakela, G. G. Klee, and 
P. S. Kamath. 2002. "Cancer antigen 125 in patients with 
chronic liver disease."  Mayo Clin Proc 77 (6):538-41. doi: 
10.4065/77.6.538. 
Di Paolo, G., and P. De Camilli. 2006. "Phosphoinositides in cell 
regulation and membrane dynamics."  Nature 443 (7112):651-7. 
doi: 10.1038/nature05185. 
Djordjevic, Bojana, Bryan T. Hennessy, Jie Li, Bedia A. Barkoh, 
Rajyalakshmi Luthra, Gordon B. Mills, and Russell R. 
Broaddus. 2012. "Clinical Assessment of PTEN Loss in 
Endometrial Carcinoma: Immunohistochemistry Out-Performs 
Gene Sequencing."  Modern pathology : an official journal of the 
United States and Canadian Academy of Pathology, Inc 25 
(5):699-708. doi: 10.1038/modpathol.2011.208. 
Domcke, S., R. Sinha, D. A. Levine, C. Sander, and N. Schultz. 2013. 
"Evaluating cell lines as tumour models by comparison of 
genomic profiles."  Nat Commun 4:2126. doi: 
10.1038/ncomms3126. 
Donaldson, J. G. 2003. "Multiple roles for Arf6: sorting, structuring, 
and signaling at the plasma membrane."  J Biol Chem 278 
(43):41573-6. doi: 10.1074/jbc.R300026200. 
Donaldson, J. G., and A. Honda. 2005. "Localization and function of 
Arf family GTPases."  Biochem Soc Trans 33 (Pt 4):639-42. doi: 
10.1042/bst0330639. 
 259 
Donaldson, J. G., and C. L. Jackson. 2011. "ARF family G proteins and 
their regulators: roles in membrane transport, development and 
disease."  Nat Rev Mol Cell Biol 12 (6):362-75. doi: 
10.1038/nrm3117. 
du Bois, A., H. J. Luck, W. Meier, H. P. Adams, V. Mobus, S. Costa, T. 
Bauknecht, B. Richter, M. Warm, W. Schroder, S. Olbricht, U. 
Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn, and J. 
Pfisterer. 2003. "A randomized clinical trial of 
cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line 
treatment of ovarian cancer."  J Natl Cancer Inst 95 (17):1320-9. 
Dunphy, J. L., R. Moravec, K. Ly, T. K. Lasell, P. Melancon, and J. E. 
Casanova. 2006a. "The Arf6 GEF GEP100/BRAG2 regulates cell 
adhesion by controlling endocytosis of beta1 integrins."  Curr 
Biol 16 (3):315-20. doi: 10.1016/j.cub.2005.12.032. 
Dunphy, Jillian L., Radim Moravec, Kim Ly, Troy K. Lasell, Paul 
Melancon, and James E. Casanova. 2006b. "The Arf6 GEF 
GEP100/BRAG2 Regulates Cell Adhesion by Controlling 
Endocytosis of β1 Integrins."  Current biology : CB 16 (3):315-
320. doi: 10.1016/j.cub.2005.12.032. 
Eeles, Rosalind A, James P Morden, Martin Gore, Janine Mansi, John 
Glees, Miklos Wenczl, Christopher Williams, Henry Kitchener, 
Richard Osborne, and David Guthrie. 2016. "Adjuvant hormone 
therapy may improve survival in epithelial ovarian cancer: 
results of the AHT randomized trial."  Obstetrical & 
Gynecological Survey 71 (4):223-224. 
Egami, Y., M. Fukuda, and N. Araki. 2011. "Rab35 regulates 
phagosome formation through recruitment of ACAP2 in 
macrophages during FcgammaR-mediated phagocytosis."  J Cell 
Sci 124 (Pt 21):3557-67. doi: 10.1242/jcs.083881. 
Eva, R., S. Crisp, J. R. Marland, J. C. Norman, V. Kanamarlapudi, C. 
ffrench-Constant, and J. W. Fawcett. 2012a. "Arf6 directs axon 
transport and traffic of integrins and regulates axon growth in 
adult DRG neurons."  J Neurosci 32 (30):10352-64. doi: 
10.1523/jneurosci.1409-12.2012. 
Eva, Richard, Sarah Crisp, Jamie R. K. Marland, Jim C. Norman, 
Venkateswarlu Kanamarlapudi, Charles ffrench-Constant, and 
James W. Fawcett. 2012b. "Arf6 Directs Axon Transport and 
Traffic of Integrins and Regulates Axon Growth in Adult DRG 
Neurons."  The Journal of Neuroscience 32 (30):10352-10364. 
doi: 10.1523/jneurosci.1409-12.2012. 
Evans, D. Gareth. 2016. "Genetic predisposition to cancer."  Medicine 
44 (1):65-68. doi: https://doi.org/10.1016/j.mpmed.2015.10.003. 
Feinberg, A. P. 2004. "The epigenetics of cancer etiology."  Semin 
Cancer Biol 14 (6):427-32. doi: 10.1016/j.semcancer.2004.06.005. 
 260 
Fielding, Andrew B., Eric Schonteich, Johanne Matheson, Gayle 
Wilson, Xinzi Yu, Gilles R. X. Hickson, Sweta Srivastava, 
Stephen A. Baldwin, Rytis Prekeris, and Gwyn W. Gould. 2005. 
"Rab11-FIP3 and FIP4 interact with Arf6 and the Exocyst to 
control membrane traffic in cytokinesis."  The EMBO Journal 24 
(19):3389-3399. doi: 10.1038/sj.emboj.7600803. 
Flavahan, W. A., E. Gaskell, and B. E. Bernstein. 2017. "Epigenetic 
plasticity and the hallmarks of cancer."  Science 357 (6348). doi: 
10.1126/science.aal2380. 
Fortún, J., P. Martín-Dávila, R. Méndez, A. Martínez, F. Norman, J. 
Rubi, E. Pallares, E. Gómez-Mampaso, and S. Moreno. 2009. 
"Ca-125: A Useful Marker to Distinguish Pulmonary 
Tuberculosis from Other Pulmonary Infections."  The Open 
Respiratory Medicine Journal 3:123-127. doi: 
10.2174/1874306400903010123. 
Franco, M., P. J. Peters, J. Boretto, E. van Donselaar, A. Neri, C. 
D'Souza-Schorey, and P. Chavrier. 1999. "EFA6, a sec7 domain-
containing exchange factor for Arf6, coordinates membrane 
recycling and actin cytoskeleton organization."  Embo j 18 
(6):1480-91. doi: 10.1093/emboj/18.6.1480. 
Frumovitz, Michael, Kathleen M. Schmeler, Anais Malpica, Anil K. 
Sood, and David M. Gershenson. 2010. "Unmasking the 
complexities of mucinous ovarian carcinoma."  Gynecologic 
oncology 117 (3):491-496. doi: 10.1016/j.ygyno.2010.02.010. 
Fu, Y., J. Li, M. X. Feng, X. M. Yang, Y. H. Wang, Y. L. Zhang, W. 
Qin, Q. Xia, and Z. G. Zhang. 2014. "Cytohesin-3 is upregulated 
in hepatocellular carcinoma and contributes to tumor growth 
and vascular invasion."  Int J Clin Exp Pathol 7 (5):2123-32. 
Fukaya, M., D. Fukushima, Y. Hara, and H. Sakagami. 2014. 
"EFA6A, a guanine nucleotide exchange factor for Arf6, 
interacts with sorting nexin-1 and regulates neurite outgrowth."  
J Neurochem 129 (1):21-36. doi: 10.1111/jnc.12524. 
Fukaya, M., S. Ohta, Y. Hara, H. Tamaki, and H. Sakagami. 2016. 
"Distinct subcellular localization of alternative splicing variants 
of EFA6D, a guanine nucleotide exchange factor for Arf6, in the 
mouse brain."  J Comp Neurol 524 (13):2531-52. doi: 
10.1002/cne.24048. 
Gailhouste, L., L. C. Liew, I. Hatada, H. Nakagama, and T. Ochiya. 
2018. "Epigenetic reprogramming using 5-azacytidine promotes 
an anti-cancer response in pancreatic adenocarcinoma cells."  
Cell Death Dis 9 (5):468. doi: 10.1038/s41419-018-0487-z. 
Gaitskell, K., J. Green, K. Pirie, G. Reeves, and V. Beral. 2016. "Tubal 
ligation and ovarian cancer risk in a large cohort: Substantial 
 261 
variation by histological type."  Int J Cancer 138 (5):1076-84. 
doi: 10.1002/ijc.29856. 
Galas, M. C., J. B. Helms, N. Vitale, D. Thierse, D. Aunis, and M. F. 
Bader. 1997. "Regulated exocytosis in chromaffin cells. A 
potential role for a secretory granule-associated Arf6 protein."  J 
Biol Chem 272 (5):2788-93. 
Gambardella, L., K. E. Anderson, C. Nussbaum, A. Segonds-Pichon, T. 
Margarido, L. Norton, T. Ludwig, M. Sperandio, P. T. Hawkins, 
L. Stephens, and S. Vermeren. 2011. "The GTPase-activating 
protein ARAP3 regulates chemotaxis and adhesion-dependent 
processes in neutrophils."  Blood 118 (4):1087-98. doi: 
10.1182/blood-2010-10-312959. 
Gaschet, J., and V. W. Hsu. 1999. "Distribution of Arf6 between 
membrane and cytosol is regulated by its GTPase cycle."  J Biol 
Chem 274 (28):20040-5. 
George, A. A., S. Hayden, G. R. Stanton, and S. E. Brockerhoff. 2016. 
"Arf6 and the 5'phosphatase of Synaptojanin 1 regulate 
autophagy in cone photoreceptors."  Inside Cell 1 (2):117-133. 
doi: 10.1002/icl3.1044. 
Gershenson, D. M., C. C. Sun, K. H. Lu, R. L. Coleman, A. K. Sood, A. 
Malpica, M. T. Deavers, E. G. Silva, and D. C. Bodurka. 2006. 
"Clinical behavior of stage II-IV low-grade serous carcinoma of 
the ovary."  Obstet Gynecol 108 (2):361-8. doi: 
10.1097/01.AOG.0000227787.24587.d1. 
Giguere, H., A. A. Dumont, J. Berthiaume, V. Oliveira, G. Laberge, 
and M. Auger-Messier. 2018. "ADAP1 limits neonatal 
cardiomyocyte hypertrophy by reducing integrin cell surface 
expression."  Sci Rep 8 (1):13605. doi: 10.1038/s41598-018-
31784-w. 
Goitre, L., E. Trapani, L. Trabalzini, and S. F. Retta. 2014. "The Ras 
superfamily of small GTPases: the unlocked secrets."  Methods 
Mol Biol 1120:1-18. doi: 10.1007/978-1-62703-791-4_1. 
Gonzalez-Zulueta, M., C. M. Bender, A. S. Yang, T. Nguyen, R. W. 
Beart, J. M. Van Tornout, and P. A. Jones. 1995. "Methylation of 
the 5' CpG island of the p16/CDKN2 tumor suppressor gene in 
normal and transformed human tissues correlates with gene 
silencing."  Cancer Res 55 (20):4531-5. 
Gray, A., J. Van Der Kaay, and C. P. Downes. 1999. "The pleckstrin 
homology domains of protein kinase B and GRP1 (general 
receptor for phosphoinositides-1) are sensitive and selective 
probes for the cellular detection of phosphatidylinositol 3,4-
bisphosphate and/or phosphatidylinositol 3,4,5-trisphosphate in 
vivo."  Biochem J 344 Pt 3:929-36. 
 262 
Grivennikov, S. I., F. R. Greten, and M. Karin. 2010. "Immunity, 
inflammation, and cancer."  Cell 140 (6):883-99. doi: 
10.1016/j.cell.2010.01.025. 
Grossmann, A. H., J. H. Yoo, J. Clancy, L. K. Sorensen, A. Sedgwick, 
Z. Tong, K. Ostanin, A. Rogers, K. F. Grossmann, S. R. Tripp, K. 
R. Thomas, C. D'Souza-Schorey, S. J. Odelberg, and D. Y. Li. 
2013. "The small GTPase Arf6 stimulates β-catenin 
transcriptional activity during WNT5A-mediated melanoma 
invasion and metastasis."  Sci Signal 6 (265):ra14. doi: 
10.1126/scisignal.2003398. 
Hafner, M., A. Schmitz, I. Grune, S. G. Srivatsan, B. Paul, W. 
Kolanus, T. Quast, E. Kremmer, I. Bauer, and M. Famulok. 
2006. "Inhibition of cytohesins by SecinH3 leads to hepatic 
insulin resistance."  Nature 444 (7121):941-4. doi: 
10.1038/nature05415. 
Haines, E., C. Saucier, and A. Claing. 2014. "The adaptor proteins 
p66Shc and Grb2 regulate the activation of the GTPases ARF1 
and Arf6 in invasive breast cancer cells."  J Biol Chem 289 
(9):5687-703. doi: 10.1074/jbc.M113.516047. 
Haley, J., S. Tomar, N. Pulliam, S. Xiong, S. M. Perkins, A. R. Karpf, 
S. Mitra, K. P. Nephew, and A. K. Mitra. 2016. "Functional 
characterization of a panel of high-grade serous ovarian cancer 
cell lines as representative experimental models of the disease."  
Oncotarget 7 (22):32810-20. doi: 10.18632/oncotarget.9053. 
Hall, A. 2009. "The cytoskeleton and cancer."  Cancer Metastasis Rev 
28 (1-2):5-14. doi: 10.1007/s10555-008-9166-3. 
Hammonds-Odie, L. P., T. R. Jackson, A. A. Profit, I. J. Blader, C. W. 
Turck, G. D. Prestwich, and A. B. Theibert. 1996. "Identification 
and cloning of centaurin-alpha. A novel phosphatidylinositol 
3,4,5-trisphosphate-binding protein from rat brain."  J Biol 
Chem 271 (31):18859-68. 
Hanahan, D., and R. A. Weinberg. 2011. "Hallmarks of cancer: the 
next generation."  Cell 144 (5):646-74. doi: 
10.1016/j.cell.2011.02.013. 
Handa, H., A. Hashimoto, S. Hashimoto, and H. Sabe. 2016. "Arf6 and 
its ZEB1-EPB41L5 mesenchymal axis are required for both 
mesenchymal- and amoeboid-type invasion of cancer cells."  
Small GTPases:1-7. doi: 10.1080/21541248.2016.1249043. 
Hashimoto, A., S. Hashimoto, R. Ando, K. Noda, E. Ogawa, H. Kotani, 
M. Hirose, T. Menju, M. Morishige, T. Manabe, Y. Toda, S. 
Ishida, and H. Sabe. 2011. "GEP100-Arf6-AMAP1-cortactin 
pathway frequently used in cancer invasion is activated by 
VEGFR2 to promote angiogenesis."  PLoS One 6 (8):e23359. doi: 
10.1371/journal.pone.0023359. 
 263 
Hashimoto, Shigeru 2004. "Requirement for Arf6 in breast cancer 
invasive activities."  PNAS. 
Hashimoto, Shigeru, Mayumi Hirose, Ari Hashimoto, Masaki 
Morishige, Atsuko Yamada, Harumi Hosaka, Ken-ichi Akagi, 
Eiji Ogawa, Chitose Oneyama, Tsutomu Agatsuma, Masato 
Okada, Hidenori Kobayashi, Hiromi Wada, Hirofumi Nakano, 
Takahisa Ikegami, Atsushi Nakagawa, and Hisataka Sabe. 
2006. "Targeting AMAP1 and cortactin binding bearing an 
atypical src homology 3/proline interface for prevention of breast 
cancer invasion and metastasis."  Proceedings of the National 
Academy of Sciences of the United States of America 103 
(18):7036-7041. doi: 10.1073/pnas.0509166103. 
Hashimoto, Shigeru, Shuji Mikami, Hirokazu Sugino, Ayumu 
Yoshikawa, Ari Hashimoto, Yasuhito Onodera, Shotaro 
Furukawa, Haruka Handa, Tsukasa Oikawa, Yasunori Okada, 
Mototsugu Oya, and Hisataka Sabe. 2016. "Lysophosphatidic 
acid activates Arf6 to promote the mesenchymal malignancy of 
renal cancer."  Nature Communications 7:10656. doi: 
10.1038/ncomms10656. 
Haun, R. S., S. C. Tsai, R. Adamik, J. Moss, and M. Vaughan. 1993. 
"Effect of myristoylation on GTP-dependent binding of ADP-
ribosylation factor to Golgi."  J Biol Chem 268 (10):7064-8. 
Havrilesky, L. J., J. M. Gierisch, P. G. Moorman, R. R. Coeytaux, R. P. 
Urrutia, W. J. Lowery, M. Dinan, A. J. McBroom, L. Wing, M. D. 
Musty, K. R. Lallinger, V. Hasselblad, G. D. Sanders, and E. R. 
Myers. 2013. "Oral contraceptive use for the primary prevention 
of ovarian cancer."  Evid Rep Technol Assess (Full Rep) (212):1-
514. 
Havrilesky, L. J., P. G. Moorman, W. J. Lowery, J. M. Gierisch, R. R. 
Coeytaux, R. P. Urrutia, M. Dinan, A. J. McBroom, V. 
Hasselblad, G. D. Sanders, and E. R. Myers. 2013. "Oral 
contraceptive pills as primary prevention for ovarian cancer: a 
systematic review and meta-analysis."  Obstet Gynecol 122 
(1):139-47. doi: 10.1097/AOG.0b013e318291c235. 
Hildebrand, J. S., S. M. Gapstur, H. S. Feigelson, L. R. Teras, M. J. 
Thun, and A. V. Patel. 2010. "Postmenopausal hormone use and 
incident ovarian cancer: Associations differ by regimen."  Int J 
Cancer 127 (12):2928-35. doi: 10.1002/ijc.25515. 
Ho, E. S., C. R. Lai, Y. T. Hsieh, J. T. Chen, A. J. Lin, M. H. Hung, 
and F. S. Liu. 2001. "p53 mutation is infrequent in clear cell 
carcinoma of the ovary."  Gynecol Oncol 80 (2):189-93. doi: 
10.1006/gyno.2000.6025. 
 264 
Hoefen, R. J., and B. C. Berk. 2006. "The multifunctional GIT family 
of proteins."  J Cell Sci 119 (Pt 8):1469-75. doi: 
10.1242/jcs.02925. 
Hongu, T., Y. Funakoshi, S. Fukuhara, T. Suzuki, S. Sakimoto, N. 
Takakura, M. Ema, S. Takahashi, S. Itoh, M. Kato, H. 
Hasegawa, N. Mochizuki, and Y. Kanaho. 2015. "Arf6 regulates 
tumour angiogenesis and growth through HGF-induced 
endothelial beta1 integrin recycling."  Nat Commun 6:7925. doi: 
10.1038/ncomms8925. 
Hosaka, M., K. Toda, H. Takatsu, S. Torii, K. Murakami, and K. 
Nakayama. 1996. "Structure and intracellular localization of 
mouse ADP-ribosylation factors type 1 to type 6 (ARF1-Arf6)."  J 
Biochem (Tokyo) 120 (4):813-9. 
Houndolo, T., P. L. Boulay, and A. Claing. 2005. "G protein-coupled 
receptor endocytosis in ADP-ribosylation factor 6-depleted cells."  
J Biol Chem 280 (7):5598-604. doi: 10.1074/jbc.M411456200. 
Hu, Z., R. Xu, J. Liu, Y. Zhang, J. Du, W. Li, W. Zhang, Y. Li, Y. Zhu, 
and L. Gu. 2013. "GEP100 regulates epidermal growth factor-
induced MDA-MB-231 breast cancer cell invasion through the 
activation of Arf6/ERK/uPAR signaling pathway."  Exp Cell Res 
319 (13):1932-41. doi: 10.1016/j.yexcr.2013.05.028. 
Huang, Y., S. Joshi, B. Xiang, Y. Kanaho, Z. Li, B. A. Bouchard, C. L. 
Moncman, and S. W. Whiteheart. 2016. "Arf6 controls platelet 
spreading and clot retraction via integrin alphaIIbbeta3 
trafficking."  Blood 127 (11):1459-67. doi: 10.1182/blood-2015-05-
648550. 
Humphreys, D., A. C. Davidson, P. J. Hume, L. E. Makin, and V. 
Koronakis. 2013a. "Arf6 coordinates actin assembly through the 
WAVE complex, a mechanism usurped by Salmonella to invade 
host cells."  Proc Natl Acad Sci U S A 110 (42):16880-5. doi: 
10.1073/pnas.1311680110. 
Humphreys, Daniel, Anthony C. Davidson, Peter J. Hume, Laura E. 
Makin, and Vassilis Koronakis. 2013b. "Arf6 coordinates actin 
assembly through the WAVE complex, a mechanism usurped by 
Salmonella to invade host cells."  Proceedings of the National 
Academy of Sciences of the United States of America 110 
(42):16880-16885. doi: 10.1073/pnas.1311680110. 
Humphreys, Daniel, Vikash Singh, and Vassilis Koronakis. 2016. 
"Inhibition of WAVE Regulatory Complex Activation by a 
Bacterial Virulence Effector Counteracts Pathogen 
Phagocytosis."  Cell Reports 17 (3):697-707. doi: 
10.1016/j.celrep.2016.09.039. 
I, S. T., Z. Nie, A. Stewart, M. Najdovska, N. E. Hall, H. He, P. A. 
Randazzo, and P. Lock. 2004. "ARAP3 is transiently tyrosine 
 265 
phosphorylated in cells attaching to fibronectin and inhibits cell 
spreading in a RhoGAP-dependent manner."  J Cell Sci 117 (Pt 
25):6071-84. doi: 10.1242/jcs.01526. 
Ito, Akiko, Masahiro Fukaya, Shintaro Saegusa, Emi Kobayashi, 
Takeyuki Sugawara, Yoshinobu Hara, Junji Yamauchi, 
Hirotsugu Okamoto, and Hiroyuki Sakagami. 2018. "Pallidin is 
a novel interacting protein for cytohesin-2 and regulates the 
early endosomal pathway and dendritic formation in neurons."  
Journal of Neurochemistry. doi: 10.1111/jnc.14579. 
Jackson, Trevor R., Fraser D. Brown, Zhongzhen Nie, Koichi Miura, 
Letizia Foroni, Jianlan Sun, Victor W. Hsu, Julie G. Donaldson, 
and Paul A. Randazzo. 2000. "Acaps Are Arf6 Gtpase-Activating 
Proteins That Function in the Cell Periphery."  The Journal of 
Cell Biology 151 (3):627-638. doi: 10.1083/jcb.151.3.627. 
Jacob, Francis, Mara Meier, Rosmarie Caduff, Darlene Goldstein, 
Tatiana Pochechueva, Neville Hacker, Daniel Fink, and Viola 
Heinzelmann-Schwarz. 2011. "No benefit from combining HE4 
and CA125 as ovarian tumor markers in a clinical setting."  
Gynecologic Oncology 121 (3):487-491. doi: 
https://doi.org/10.1016/j.ygyno.2011.02.022. 
Jacobs, I. J., U. Menon, A. Ryan, A. Gentry-Maharaj, M. Burnell, J. K. 
Kalsi, N. N. Amso, S. Apostolidou, E. Benjamin, D. 
Cruickshank, D. N. Crump, S. K. Davies, A. Dawnay, S. Dobbs, 
G. Fletcher, J. Ford, K. Godfrey, R. Gunu, M. Habib, R. Hallett, 
J. Herod, H. Jenkins, C. Karpinskyj, S. Leeson, S. J. Lewis, W. 
R. Liston, A. Lopes, T. Mould, J. Murdoch, D. Oram, D. J. 
Rabideau, K. Reynolds, I. Scott, M. W. Seif, A. Sharma, N. 
Singh, J. Taylor, F. Warburton, M. Widschwendter, K. 
Williamson, R. Woolas, L. Fallowfield, A. J. McGuire, S. 
Campbell, M. Parmar, and S. J. Skates. 2016. "Ovarian cancer 
screening and mortality in the UK Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS): a randomised 
controlled trial."  Lancet 387 (10022):945-956. doi: 
10.1016/s0140-6736(15)01224-6. 
Jang, D. J., Y. W. Jun, J. Shim, S. E. Sim, J. A. Lee, C. S. Lim, and B. 
K. Kaang. 2016. "Activation of Aplysia Arf6 induces neurite 
outgrowth and is sequestered by the overexpression of the PH 
domain of Aplysia Sec7 proteins."  Neurobiol Learn Mem. doi: 
10.1016/j.nlm.2016.06.017. 
Jeon, C. Y., H. J. Kim, H. Morii, N. Mori, J. Settleman, J. Y. Lee, J. 
Kim, S. C. Kim, and J. B. Park. 2010. "Neurite outgrowth from 
PC12 cells by basic fibroblast growth factor (bFGF) is mediated 
by RhoA inactivation through p190RhoGAP and ARAP3."  J Cell 
Physiol 224 (3):786-94. doi: 10.1002/jcp.22184. 
 266 
Jeon, C. Y., M. Y. Moon, J. H. Kim, H. J. Kim, J. G. Kim, Y. Li, J. K. 
Jin, P. H. Kim, H. C. Kim, K. E. Meier, Y. S. Kim, and J. B. 
Park. 2012. "Control of neurite outgrowth by RhoA 
inactivation."  J Neurochem 120 (5):684-98. doi: 10.1111/j.1471-
4159.2011.07564.x. 
Jin, Jingxiao, Chou Chou, Maria Lima, Danielle Zhou, and Xiaodong 
Zhou. 2014. "Systemic Sclerosis is a Complex Disease Associated 
Mainly with Immune Regulatory and Inflammatory Genes."  
The Open Rheumatology Journal 8:29-42. doi: 
10.2174/1874312901408010029. 
Jovanovic, Olivera A., Fraser D. Brown, and Julie G. Donaldson. 2006. 
"An Effector Domain Mutant of Arf6 Implicates Phospholipase 
D in Endosomal Membrane Recycling."  Molecular Biology of the 
Cell 17 (1):327-335. doi: 10.1091/mbc.E05-06-0523. 
Juttermann, R., E. Li, and R. Jaenisch. 1994. "Toxicity of 5-aza-2'-
deoxycytidine to mammalian cells is mediated primarily by 
covalent trapping of DNA methyltransferase rather than DNA 
demethylation."  Proc Natl Acad Sci U S A 91 (25):11797-801. 
Kahn, R. A., and A. G. Gilman. 1984. "Purification of a protein 
cofactor required for ADP-ribosylation of the stimulatory 
regulatory component of adenylate cyclase by cholera toxin."  J 
Biol Chem 259 (10):6228-34. 
Kahn, R. A., C. Goddard, and M. Newkirk. 1988. "Chemical and 
immunological characterization of the 21-kDa ADP-ribosylation 
factor of adenylate cyclase."  J Biol Chem 263 (17):8282-7. 
Kanamarlapudi, V. 2014a. "Exchange factor EFA6R requires C-
terminal targeting to the plasma membrane to promote 
cytoskeletal rearrangement through the activation of ADP-
ribosylation factor 6 (Arf6)."  J Biol Chem 289 (48):33378-90. 
doi: 10.1074/jbc.M113.534156. 
Kanamarlapudi, V., A. Thompson, E. Kelly, and A. Lopez Bernal. 
2012. "Arf6 activated by the LHCG receptor through the 
cytohesin family of guanine nucleotide exchange factors 
mediates the receptor internalization and signaling."  J Biol 
Chem 287 (24):20443-55. doi: 10.1074/jbc.M112.362087. 
Kanamarlapudi, Venkateswarlu. 2014b. "Exchange Factor EFA6R 
Requires C-terminal Targeting to the Plasma Membrane to 
Promote Cytoskeletal Rearrangement through the Activation of 
ADP-ribosylation Factor 6 (Arf6)."  Journal of Biological 
Chemistry 289 (48):33378-33390. doi: 10.1074/jbc.M113.534156. 
Kanamarlapudi, Venkateswarlu, Sian E. Owens, Keya Saha, Robert J. 
Pope, and Stuart J. Mundell. 2012. "Arf6-Dependent Regulation 
of P2Y Receptor Traffic and Function in Human Platelets."  
PLoS ONE 7 (8):e43532. doi: 10.1371/journal.pone.0043532. 
 267 
Kanno, E., K. Ishibashi, H. Kobayashi, T. Matsui, N. Ohbayashi, and 
M. Fukuda. 2010. "Comprehensive screening for novel rab-
binding proteins by GST pull-down assay using 60 different 
mammalian Rabs."  Traffic 11 (4):491-507. doi: 10.1111/j.1600-
0854.2010.01038.x. 
Karahoca, Metin, and Richard L. Momparler. 2013. "Pharmacokinetic 
and pharmacodynamic analysis of 5-aza-2’-deoxycytidine 
(decitabine) in the design of its dose-schedule for cancer 
therapy."  Clinical Epigenetics 5 (1):3-3. doi: 10.1186/1868-7083-
5-3. 
Karnezis, A. N., K. R. Cho, C. B. Gilks, C. L. Pearce, and D. G. 
Huntsman. 2017. "The disparate origins of ovarian cancers: 
pathogenesis and prevention strategies."  Nat Rev Cancer 17 
(1):65-74. doi: 10.1038/nrc.2016.113. 
Kartopawiro, J., N. I. Bower, T. Karnezis, J. Kazenwadel, K. L. 
Betterman, E. Lesieur, K. Koltowska, J. Astin, P. Crosier, S. 
Vermeren, M. G. Achen, S. A. Stacker, K. A. Smith, N. L. 
Harvey, M. Francois, and B. M. Hogan. 2014. "Arap3 is 
dysregulated in a mouse model of hypotrichosis-lymphedema-
telangiectasia and regulates lymphatic vascular development."  
Hum Mol Genet 23 (5):1286-97. doi: 10.1093/hmg/ddt518. 
Katsumata, N., M. Yasuda, S. Isonishi, F. Takahashi, H. Michimae, E. 
Kimura, D. Aoki, T. Jobo, S. Kodama, F. Terauchi, T. Sugiyama, 
and K. Ochiai. 2013. "Long-term results of dose-dense paclitaxel 
and carboplatin versus conventional paclitaxel and carboplatin 
for treatment of advanced epithelial ovarian, fallopian tube, or 
primary peritoneal cancer (JGOG 3016): a randomised, 
controlled, open-label trial."  Lancet Oncol 14 (10):1020-6. doi: 
10.1016/s1470-2045(13)70363-2. 
Katsumata, O., T. Honma, M. Sanda, A. Kamata, S. Takeda, H. 
Kondo, and H. Sakagami. 2008. "Predominant localization of 
EFA6A, a guanine nucleotide exchange factor for Arf6, at the 
perisynaptic photoreceptor processes."  Brain Res 1234:44-9. doi: 
10.1016/j.brainres.2008.07.093. 
Keum, N., D. C. Greenwood, D. H. Lee, R. Kim, D. Aune, W. Ju, F. B. 
Hu, and E. L. Giovannucci. 2015. "Adult weight gain and 
adiposity-related cancers: a dose-response meta-analysis of 
prospective observational studies."  J Natl Cancer Inst 107 (2). 
doi: 10.1093/jnci/djv088. 
Kim, H. S. 1999. "Assignment of the human ADP-ribosylation factor 6 
(Arf6) gene to chromosome 7q22.1 by radiation hybrid mapping."  
Cytogenet Cell Genet 84 (1-2):94. doi: 15225. 
 268 
Kim, L. C., L. Song, and E. B. Haura. 2009. "Src kinases as 
therapeutic targets for cancer."  Nat Rev Clin Oncol 6 (10):587-
95. doi: 10.1038/nrclinonc.2009.129. 
Kim, Y., S. E. Lee, J. Park, M. Kim, B. Lee, D. Hwang, and S. Chang. 
2015. "ADP-ribosylation factor 6 (Arf6) bidirectionally regulates 
dendritic spine formation depending on neuronal maturation 
and activity."  J Biol Chem 290 (12):7323-35. doi: 
10.1074/jbc.M114.634527. 
Klein, Stéphanie, Mariagrazia Partisani, Michel Franco, and Frédéric 
Luton. 2008. "EFA6 Facilitates the Assembly of the Tight 
Junction by Coordinating an Arf6-dependent and -independent 
Pathway."  The Journal of Biological Chemistry 283 (44):30129-
30138. doi: 10.1074/jbc.M803375200. 
Kobayashi, H., and M. Fukuda. 2012. "Rab35 regulates Arf6 activity 
through centaurin-beta2 (ACAP2) during neurite outgrowth."  J 
Cell Sci 125 (Pt 9):2235-43. doi: 10.1242/jcs.098657. 
Kobayashi, H., Y. Yamada, T. Sado, M. Sakata, S. Yoshida, R. 
Kawaguchi, S. Kanayama, H. Shigetomi, S. Haruta, Y. Tsuji, S. 
Ueda, and T. Kitanaka. 2008. "A randomized study of screening 
for ovarian cancer: a multicenter study in Japan."  Int J Gynecol 
Cancer 18 (3):414-20. doi: 10.1111/j.1525-1438.2007.01035.x. 
Kobayashi, N., S. Kon, Y. Henmi, T. Funaki, M. Satake, and K. 
Tanabe. 2014. "The Arf GTPase-activating protein SMAP1 
promotes transferrin receptor endocytosis and interacts with 
SMAP2."  Biochem Biophys Res Commun 453 (3):473-9. doi: 
10.1016/j.bbrc.2014.09.108. 
Kobel, M., H. Xu, P. A. Bourne, B. O. Spaulding, M. Shih Ie, T. L. 
Mao, R. A. Soslow, C. A. Ewanowich, S. E. Kalloger, E. Mehl, C. 
H. Lee, D. Huntsman, and C. B. Gilks. 2009. "IGF2BP3 (IMP3) 
expression is a marker of unfavorable prognosis in ovarian 
carcinoma of clear cell subtype."  Mod Pathol 22 (3):469-75. doi: 
10.1038/modpathol.2008.206. 
Kolanus, W. 2007. "Guanine nucleotide exchange factors of the 
cytohesin family and their roles in signal transduction."  
Immunol Rev 218:102-13. doi: 10.1111/j.1600-
065X.2007.00542.x. 
Kon, S., K. Tanabe, T. Watanabe, H. Sabe, and M. Satake. 2008. 
"Clathrin dependent endocytosis of E-cadherin is regulated by 
the Arf6GAP isoform SMAP1."  Exp Cell Res 314 (7):1415-28. 
doi: 10.1016/j.yexcr.2007.11.006. 
Koo, Tae Hyeon, Betty A. Eipper, and Julie G. Donaldson. 2007. "Arf6 
recruits the Rac GEF Kalirin to the plasma membrane 
facilitating Rac activation."  BMC Cell Biology 8:29-29. doi: 
10.1186/1471-2121-8-29. 
 269 
Kosami, Ken-ichi, Izuru Ohki, Minoru Nagano, Kyoko Furuita, 
Toshihiko Sugiki, Yoji Kawano, Tsutomu Kawasaki, Toshimichi 
Fujiwara, Atsushi Nakagawa, Ko Shimamoto, and Chojiro 
Kojima. 2014. "The Crystal Structure of the Plant Small GTPase 
OsRac1 Reveals Its Mode of Binding to NADPH Oxidase."  
Journal of Biological Chemistry 289 (41):28569-28578. doi: 
10.1074/jbc.M114.603282. 
Koumakpayi, I. H., J. S. Diallo, C. Le Page, L. Lessard, M. Gleave, L. 
R. Begin, A. M. Mes-Masson, and F. Saad. 2006. "Expression 
and nuclear localization of ErbB3 in prostate cancer."  Clin 
Cancer Res 12 (9):2730-7. doi: 10.1158/1078-0432.ccr-05-2242. 
Koumakpayi, I. H., C. Le Page, N. Delvoye, F. Saad, and A. M. Mes-
Masson. 2011. "Macropinocytosis inhibitors and Arf6 regulate 
ErbB3 nuclear localization in prostate cancer cells."  Mol 
Carcinog 50 (11):901-12. doi: 10.1002/mc.20766. 
Koushik, A., M. Wang, K. E. Anderson, P. van den Brandt, T. V. 
Clendenen, A. H. Eliassen, J. L. Freudenheim, J. M. Genkinger, 
N. Hakansson, J. R. Marshall, M. L. McCullough, A. B. Miller, 
K. Robien, T. E. Rohan, C. Schairer, L. J. Schouten, S. S. 
Tworoger, Y. Wang, A. Wolk, A. Zeleniuch-Jacquotte, and S. A. 
Smith-Warner. 2015. "Intake of vitamins A, C, and E and folate 
and the risk of ovarian cancer in a pooled analysis of 10 cohort 
studies."  Cancer Causes Control 26 (9):1315-27. doi: 
10.1007/s10552-015-0626-0. 
Krauss, Michael, Masahiro Kinuta, Markus R. Wenk, Pietro De 
Camilli, Kohji Takei, and Volker Haucke. 2003. "Arf6 stimulates 
clathrin/AP-2 recruitment to synaptic membranes by activating 
phosphatidylinositol phosphate kinase type Iγ."  The Journal of 
Cell Biology 162 (1):113-124. doi: 10.1083/jcb.200301006. 
Krcmery, J., T. Camarata, A. Kulisz, and H. G. Simon. 2010. 
"Nucleocytoplasmic functions of the PDZ-LIM protein family: 
new insights into organ development."  Bioessays 32 (2):100-8. 
doi: 10.1002/bies.200900148. 
Krugmann, S., K. E. Anderson, S. H. Ridley, N. Risso, A. McGregor, J. 
Coadwell, K. Davidson, A. Eguinoa, C. D. Ellson, P. Lipp, M. 
Manifava, N. Ktistakis, G. Painter, J. W. Thuring, M. A. Cooper, 
Z. Y. Lim, A. B. Holmes, S. K. Dove, R. H. Michell, A. Grewal, A. 
Nazarian, H. Erdjument-Bromage, P. Tempst, L. R. Stephens, 
and P. T. Hawkins. 2002. "Identification of ARAP3, a novel PI3K 
effector regulating both Arf and Rho GTPases, by selective 
capture on phosphoinositide affinity matrices."  Mol Cell 9 
(1):95-108. 
Krugmann, S., S. Andrews, L. Stephens, and P. T. Hawkins. 2006. 
"ARAP3 is essential for formation of lamellipodia after growth 
 270 
factor stimulation."  J Cell Sci 119 (Pt 3):425-32. doi: 
10.1242/jcs.02755. 
Kuo, Kuan-Ting, Tsui-Lien Mao, Siân Jones, Emanuela Veras, Ayse 
Ayhan, Tian-Li Wang, Ruth Glas, Dennis Slamon, Victor E. 
Velculescu, Robert J. Kuman, and Ie-Ming Shih. 2009. 
"Frequent Activating Mutations of PIK3CA in Ovarian Clear 
Cell Carcinoma."  The American Journal of Pathology 174 
(5):1597-1601. doi: 10.2353/ajpath.2009.081000. 
Kurman, R. J., and M. Shih Ie. 2008. "Pathogenesis of ovarian cancer: 
lessons from morphology and molecular biology and their 
clinical implications."  Int J Gynecol Pathol 27 (2):151-60. doi: 
10.1097/PGP.0b013e318161e4f5. 
Kurman, R. J., R. Vang, J. Junge, C. G. Hannibal, S. K. Kjaer, and M. 
Shih Ie. 2011. "Papillary tubal hyperplasia: the putative 
precursor of ovarian atypical proliferative (borderline) serous 
tumors, noninvasive implants, and endosalpingiosis."  Am J 
Surg Pathol 35 (11):1605-14. doi: 
10.1097/PAS.0b013e318229449f. 
Lambert, Arthur W., Diwakar R. Pattabiraman, and Robert A. 
Weinberg. 2017. "EMERGING BIOLOGICAL PRINCIPLES OF 
METASTASIS."  Cell 168 (4):670-691. doi: 
10.1016/j.cell.2016.11.037. 
Lassus, H., M. P. Laitinen, M. Anttonen, M. Heikinheimo, L. A. 
Aaltonen, O. Ritvos, and R. Butzow. 2001. "Comparison of 
serous and mucinous ovarian carcinomas: distinct pattern of 
allelic loss at distal 8p and expression of transcription factor 
GATA-4."  Lab Invest 81 (4):517-26. 
Lawrence, J., S. J. Mundell, H. Yun, E. Kelly, and K. Venkateswarlu. 
2005a. "Centaurin-alpha 1, an ADP-ribosylation factor 6 
GTPase activating protein, inhibits beta 2-adrenoceptor 
internalization."  Mol Pharmacol 67 (6):1822-8. doi: 
10.1124/mol.105.011338. 
Lawrence, Joanna, Stuart J. Mundell, Hongruo Yun, Eamonn Kelly, 
and Kanamarlapudi Venkateswarlu. 2005b. "Centaurin-
α<sub>1</sub>, an ADP-Ribosylation Factor 6 GTPase 
Activating Protein, Inhibits β<sub>2</sub>-Adrenoceptor 
Internalization."  Molecular Pharmacology 67 (6):1822-1828. doi: 
10.1124/mol.105.011338. 
Lee, F. J., J. Moss, and M. Vaughan. 1992. "Human and Giardia ADP-
ribosylation factors (ARFs) complement ARF function in 
Saccharomyces cerevisiae."  J Biol Chem 267 (34):24441-5. 
Li, J., B. A. Ballif, A. M. Powelka, J. Dai, S. P. Gygi, and V. W. Hsu. 
2005. "Phosphorylation of ACAP1 by Akt regulates the 
stimulation-dependent recycling of integrin beta1 to control cell 
 271 
migration."  Dev Cell 9 (5):663-73. doi: 
10.1016/j.devcel.2005.09.012. 
Li, J., P. J. Peters, M. Bai, J. Dai, E. Bos, T. Kirchhausen, K. V. 
Kandror, and V. W. Hsu. 2007. "An ACAP1-containing clathrin 
coat complex for endocytic recycling."  J Cell Biol 178 (3):453-64. 
doi: 10.1083/jcb.200608033. 
Li, R., C. Peng, X. Zhang, Y. Wu, S. Pan, and Y. Xiao. 2017. "Roles of 
Arf6 in cancer cell invasion, metastasis and proliferation."  Life 
Sci 182:80-84. doi: 10.1016/j.lfs.2017.06.008. 
Liang, C., Y. Qin, B. Zhang, S. Ji, S. Shi, W. Xu, J. Liu, J. Xiang, D. 
Liang, Q. Hu, Q. Ni, X. Yu, and J. Xu. 2017. "Arf6, induced by 
mutant Kras, promotes proliferation and Warburg effect in 
pancreatic cancer."  Cancer Lett 388:303-311. doi: 
10.1016/j.canlet.2016.12.014. 
Lim, Jet Phey, and Paul A. Gleeson. 2011. "Macropinocytosis: an 
endocytic pathway for internalising large gulps."  Immunology 
And Cell Biology 89:836. doi: 10.1038/icb.2011.20. 
Liu, G., D. Yang, Y. Sun, I. Shmulevich, F. Xue, A. K. Sood, and W. 
Zhang. 2012. "Differing clinical impact of BRCA1 and BRCA2 
mutations in serous ovarian cancer."  Pharmacogenomics 13 
(13):1523-35. doi: 10.2217/pgs.12.137. 
Livak, K. J., and T. D. Schmittgen. 2001. "Analysis of relative gene 
expression data using real-time quantitative PCR and the 2(-
Delta Delta C(T)) Method."  Methods 25 (4):402-8. doi: 
10.1006/meth.2001.1262. 
Loskutov, Y. V., P. Y. Kozyulina, V. K. Kozyreva, R. J. Ice, B. C. Jones, 
T. J. Roston, M. B. Smolkin, A. V. Ivanov, R. B. Wysolmerski, 
and E. N. Pugacheva. 2015. "NEDD9/Arf6-dependent endocytic 
trafficking of matrix metalloproteinase 14: a novel mechanism 
for blocking mesenchymal cell invasion and metastasis of breast 
cancer."  Oncogene 34 (28):3662-75. doi: 10.1038/onc.2014.297. 
Loveday, C., C. Turnbull, E. Ramsay, D. Hughes, E. Ruark, J. R. 
Frankum, G. Bowden, B. Kalmyrzaev, M. Warren-Perry, K. 
Snape, J. W. Adlard, J. Barwell, J. Berg, A. F. Brady, C. Brewer, 
G. Brice, C. Chapman, J. Cook, R. Davidson, A. Donaldson, F. 
Douglas, L. Greenhalgh, A. Henderson, L. Izatt, A. Kumar, F. 
Lalloo, Z. Miedzybrodzka, P. J. Morrison, J. Paterson, M. 
Porteous, M. T. Rogers, S. Shanley, L. Walker, D. Eccles, D. G. 
Evans, A. Renwick, S. Seal, C. J. Lord, A. Ashworth, J. S. Reis-
Filho, A. C. Antoniou, and N. Rahman. 2011. "Germline 
mutations in RAD51D confer susceptibility to ovarian cancer."  
Nat Genet 43 (9):879-882. doi: 10.1038/ng.893. 
Lowe, K. A., V. M. Chia, A. Taylor, C. O'Malley, M. Kelsh, M. 
Mohamed, F. S. Mowat, and B. Goff. 2013. "An international 
 272 
assessment of ovarian cancer incidence and mortality."  Gynecol 
Oncol 130 (1):107-14. doi: 10.1016/j.ygyno.2013.03.026. 
Luton, F. 2005. "The role of EFA6, exchange factor for Arf6, for tight 
junction assembly, functions, and interaction with the actin 
cytoskeleton."  Methods Enzymol 404:332-45. doi: 
10.1016/s0076-6879(05)04029-2. 
Luton, Frédéric, Stéphanie Klein, Jean-Paul Chauvin, André Le Bivic, 
Sylvain Bourgoin, Michel Franco, and Pierre Chardin. 2004. 
"EFA6, Exchange Factor for Arf6, Regulates the Actin 
Cytoskeleton and Associated Tight Junction in Response to E-
Cadherin Engagement."  Molecular Biology of the Cell 15 
(3):1134-1145. doi: 10.1091/mbc.E03-10-0751. 
López-Colomé, Ana María, Irene Lee-Rivera, Regina Benavides-
Hidalgo, and Edith López. 2017. "Paxillin: a crossroad in 
pathological cell migration."  Journal of Hematology & Oncology 
10:50. doi: 10.1186/s13045-017-0418-y. 
MacGrath, Stacey M., and Anthony J. Koleske. 2012. "Cortactin in cell 
migration and cancer at a glance."  Journal of Cell Science 125 
(7):1621-1626. doi: 10.1242/jcs.093781. 
Macia, E., M. Chabre, and M. Franco. 2001. "Specificities for the small 
G proteins ARF1 and Arf6 of the guanine nucleotide exchange 
factors ARNO and EFA6."  J Biol Chem 276 (27):24925-30. doi: 
10.1074/jbc.M103284200. 
Macia, E., F. Luton, M. Partisani, J. Cherfils, P. Chardin, and M. 
Franco. 2004. "The GDP-bound form of Arf6 is located at the 
plasma membrane."  J Cell Sci 117 (Pt 11):2389-98. doi: 
10.1242/jcs.01090. 
Macia, E., M. Partisani, C. Favard, E. Mortier, P. Zimmermann, M. F. 
Carlier, P. Gounon, F. Luton, and M. Franco. 2008. "The 
pleckstrin homology domain of the Arf6-specific exchange factor 
EFA6 localizes to the plasma membrane by interacting with 
phosphatidylinositol 4,5-bisphosphate and F-actin."  J Biol 
Chem 283 (28):19836-44. doi: 10.1074/jbc.M800781200. 
Mann, B. S., J. R. Johnson, M. H. Cohen, R. Justice, and R. Pazdur. 
2007. "FDA approval summary: vorinostat for treatment of 
advanced primary cutaneous T-cell lymphoma."  Oncologist 12 
(10):1247-52. doi: 10.1634/theoncologist.12-10-1247. 
Marchesin, V., A. Castro-Castro, C. Lodillinsky, A. Castagnino, J. 
Cyrta, H. Bonsang-Kitzis, L. Fuhrmann, M. Irondelle, E. 
Infante, G. Montagnac, F. Reyal, A. Vincent-Salomon, and P. 
Chavrier. 2015. "Arf6-JIP3/4 regulate endosomal tubules for 
MT1-MMP exocytosis in cancer invasion."  J Cell Biol 211 
(2):339-58. doi: 10.1083/jcb.201506002. 
 273 
Marchesin, V., G. Montagnac, and P. Chavrier. 2015. "Arf6 promotes 
the formation of Rac1 and WAVE-dependent ventral F-actin 
rosettes in breast cancer cells in response to epidermal growth 
factor."  PLoS One 10 (3):e0121747. doi: 
10.1371/journal.pone.0121747. 
Marquer, C., H. Tian, J. Yi, J. Bastien, C. Dall'Armi, Y. Yang-Klingler, 
B. Zhou, R. B. Chan, and G. Di Paolo. 2016. "Arf6 controls 
retromer traffic and intracellular cholesterol distribution via a 
phosphoinositide-based mechanism."  Nat Commun 7:11919. 
doi: 10.1038/ncomms11919. 
Martin, J. E., J. C. Broen, F. D. Carmona, M. Teruel, C. P. Simeon, M. 
C. Vonk, R. van 't Slot, L. Rodriguez-Rodriguez, E. Vicente, V. 
Fonollosa, N. Ortego-Centeno, M. A. Gonzalez-Gay, F. J. Garcia-
Hernandez, P. G. de la Pena, P. Carreira, Group Spanish 
Scleroderma, A. E. Voskuyl, A. J. Schuerwegh, P. L. van Riel, A. 
Kreuter, T. Witte, G. Riemekasten, P. Airo, R. Scorza, C. 
Lunardi, N. Hunzelmann, J. H. Distler, L. Beretta, J. van Laar, 
M. M. Chee, J. Worthington, A. Herrick, C. Denton, F. K. Tan, 
F. C. Arnett, S. Assassi, C. Fonseca, M. D. Mayes, T. R. 
Radstake, B. P. Koeleman, and J. Martin. 2012. "Identification 
of CSK as a systemic sclerosis genetic risk factor through 
Genome Wide Association Study follow-up."  Hum Mol Genet 21 
(12):2825-35. doi: 10.1093/hmg/dds099. 
Masuda, Hiroko, Dongwei Zhang, Chandra Bartholomeusz, Hiroyoshi 
Doihara, Gabriel N. Hortobagyi, and Naoto T. Ueno. 2012. "Role 
of epidermal growth factor receptor in breast cancer."  Breast 
Cancer Research and Treatment 136 (2):331-345. doi: 
10.1007/s10549-012-2289-9. 
Matsumoto, Y., H. Sakurai, Y. Kogashiwa, T. Kimura, Y. Matsumoto, 
T. Shionome, M. Asano, K. Saito, and N. Kohno. 2017. 
"Inhibition of epithelial-mesenchymal transition by cetuximab 
via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck 
cancer."  Head Neck 39 (3):476-485. doi: 10.1002/hed.24626. 
Matsuo, K., M. Nishimura, J. N. Bottsford-Miller, J. Huang, K. 
Komurov, G. N. Armaiz-Pena, M. M. Shahzad, R. L. Stone, J. W. 
Roh, A. M. Sanguino, C. Lu, D. D. Im, N. B. Rosenshien, A. 
Sakakibara, T. Nagano, M. Yamasaki, T. Enomoto, T. Kimura, 
P. T. Ram, K. M. Schmeler, G. E. Gallick, K. K. Wong, M. 
Frumovitz, and A. K. Sood. 2011. "Targeting SRC in mucinous 
ovarian carcinoma."  Clin Cancer Res 17 (16):5367-78. doi: 
10.1158/1078-0432.ccr-10-3176. 
Matsuya, S., H. Sakagami, A. Tohgo, Y. Owada, H. W. Shin, H. 
Takeshima, K. Nakayama, S. Kokubun, and H. Kondo. 2005. 
"Cellular and subcellular localization of EFA6C, a third member 
 274 
of the EFA6 family, in adult mouse Purkinje cells."  J 
Neurochem 93 (3):674-85. doi: 10.1111/j.1471-
4159.2005.03072.x. 
Matulonis, Ursula A., Anil K. Sood, Lesley Fallowfield, Brooke E. 
Howitt, Jalid Sehouli, and Beth Y. Karlan. 2016. "Ovarian 
cancer."  Nature Reviews Disease Primers 2:16061. doi: 
10.1038/nrdp.2016.61. 
McDermott, M., M. J. Wakelam, and A. J. Morris. 2004. 
"Phospholipase D."  Biochem Cell Biol 82 (1):225-53. doi: 
10.1139/o03-079. 
Meindl, A., H. Hellebrand, C. Wiek, V. Erven, B. Wappenschmidt, D. 
Niederacher, M. Freund, P. Lichtner, L. Hartmann, H. Schaal, 
J. Ramser, E. Honisch, C. Kubisch, H. E. Wichmann, K. Kast, H. 
Deissler, C. Engel, B. Muller-Myhsok, K. Neveling, M. Kiechle, 
C. G. Mathew, D. Schindler, R. K. Schmutzler, and H. 
Hanenberg. 2010. "Germline mutations in breast and ovarian 
cancer pedigrees establish RAD51C as a human cancer 
susceptibility gene."  Nat Genet 42 (5):410-4. doi: 
10.1038/ng.569. 
Menetrey, Julie, Eric Macia, Sebastiano Pasqualato, Michel Franco, 
and Jacqueline Cherfils. 2000. "Structure of Arf6-GDP suggests 
a basis for guanine nucleotide exchange factors specificity."  Nat 
Struct Mol Biol 7 (6):466-469. 
Menon, U., A. Ryan, J. Kalsi, A. Gentry-Maharaj, A. Dawnay, M. 
Habib, S. Apostolidou, N. Singh, E. Benjamin, M. Burnell, S. 
Davies, A. Sharma, R. Gunu, K. Godfrey, A. Lopes, D. Oram, J. 
Herod, K. Williamson, M. W. Seif, H. Jenkins, T. Mould, R. 
Woolas, J. B. Murdoch, S. Dobbs, N. N. Amso, S. Leeson, D. 
Cruickshank, I. Scott, L. Fallowfield, M. Widschwendter, K. 
Reynolds, A. McGuire, S. Campbell, M. Parmar, S. J. Skates, 
and I. Jacobs. 2015. "Risk Algorithm Using Serial Biomarker 
Measurements Doubles the Number of Screen-Detected Cancers 
Compared With a Single-Threshold Rule in the United Kingdom 
Collaborative Trial of Ovarian Cancer Screening."  J Clin Oncol 
33 (18):2062-71. doi: 10.1200/jco.2014.59.4945. 
Merlo, A., J. G. Herman, L. Mao, D. J. Lee, E. Gabrielson, P. C. 
Burger, S. B. Baylin, and D. Sidransky. 1995. "5' CpG island 
methylation is associated with transcriptional silencing of the 
tumour suppressor p16/CDKN2/MTS1 in human cancers."  Nat 
Med 1 (7):686-92. 
Merritt, M. A., E. M. Poole, S. E. Hankinson, W. C. Willett, and S. S. 
Tworoger. 2014. "Dairy food and nutrient intake in different life 
periods in relation to risk of ovarian cancer."  Cancer Causes 
Control 25 (7):795-808. doi: 10.1007/s10552-014-0381-7. 
 275 
Meyer, C., B. Schneider, M. Reichel, S. Angermueller, S. Strehl, S. 
Schnittger, C. Schoch, M. W. Jansen, J. J. van Dongen, R. 
Pieters, O. A. Haas, T. Dingermann, T. Klingebiel, and R. 
Marschalek. 2005. "Diagnostic tool for the identification of MLL 
rearrangements including unknown partner genes."  Proc Natl 
Acad Sci U S A 102 (2):449-54. doi: 10.1073/pnas.0406994102. 
Milne, T. A., K. Zhao, and J. L. Hess. 2009. "Chromatin 
immunoprecipitation (ChIP) for analysis of histone 
modifications and chromatin-associated proteins."  Methods Mol 
Biol 538:409-23. doi: 10.1007/978-1-59745-418-6_21. 
Mirza, S., G. Sharma, P. Pandya, and R. Ralhan. 2010. 
"Demethylating agent 5-aza-2-deoxycytidine enhances 
susceptibility of breast cancer cells to anticancer agents."  Mol 
Cell Biochem 342 (1-2):101-9. doi: 10.1007/s11010-010-0473-y. 
Miura, Y., T. Hongu, Y. Yamauchi, Y. Funakoshi, N. Katagiri, N. 
Ohbayashi, and Y. Kanaho. 2016. "ACAP3 regulates neurite 
outgrowth through its GAP activity specific to Arf6 in mouse 
hippocampal neurons."  Biochem J 473 (17):2591-602. doi: 
10.1042/bcj20160183. 
Miura, Y., and Y. Kanaho. 2017. "ACAP3, the GTPase-activating 
protein specific to the small GTPase Arf6, regulates neuronal 
migration in the developing cerebral cortex."  Biochem Biophys 
Res Commun 493 (2):1089-1094. doi: 10.1016/j.bbrc.2017.09.076. 
Miyamoto, Y., N. Yamamori, T. Torii, A. Tanoue, and J. Yamauchi. 
2014. "Rab35, acting through ACAP2 switching off Arf6, 
negatively regulates oligodendrocyte differentiation and 
myelination."  Mol Biol Cell 25 (9):1532-42. doi: 
10.1091/mbc.E13-10-0600. 
Montagnac, G., J. B. Sibarita, S. Loubery, L. Daviet, M. Romao, G. 
Raposo, and P. Chavrier. 2009. "Arf6 Interacts with JIP4 to 
control a motor switch mechanism regulating endosome traffic 
in cytokinesis."  Curr Biol 19 (3):184-95. doi: 
10.1016/j.cub.2008.12.043. 
Moore, R. G., A. K. Brown, M. C. Miller, S. Skates, W. J. Allard, T. 
Verch, M. Steinhoff, G. Messerlian, P. DiSilvestro, C. O. Granai, 
and R. C. Bast, Jr. 2008. "The use of multiple novel tumor 
biomarkers for the detection of ovarian carcinoma in patients 
with a pelvic mass."  Gynecol Oncol 108 (2):402-8. doi: 
10.1016/j.ygyno.2007.10.017. 
Morgan, C., P. D. Lewis, L. Hopkins, S. Burnell, H. Kynaston, and S. 
H. Doak. 2015. "Increased expression of ARF GTPases in 
prostate cancer tissue."  Springerplus 4:342. doi: 
10.1186/s40064-015-1136-y. 
 276 
Morishige, M., S. Hashimoto, E. Ogawa, Y. Toda, H. Kotani, M. 
Hirose, S. Wei, A. Hashimoto, A. Yamada, H. Yano, Y. Mazaki, 
H. Kodama, Y. Nio, T. Manabe, H. Wada, H. Kobayashi, and H. 
Sabe. 2008. "GEP100 links epidermal growth factor receptor 
signalling to Arf6 activation to induce breast cancer invasion."  
Nat Cell Biol 10 (1):85-92. doi: 10.1038/ncb1672. 
Mozhui, K., X. Wang, J. Chen, M. K. Mulligan, Z. Li, J. Ingles, X. 
Chen, L. Lu, and R. W. Williams. 2011. "Genetic regulation of 
Nrxn1 [corrected] expression: an integrative cross-species 
analysis of schizophrenia candidate genes."  Transl Psychiatry 
1:e25. doi: 10.1038/tp.2011.24. 
Muinao, Thingreila, Hari Prasanna Deka Boruah, and Mintu Pal. 
2018. "Diagnostic and Prognostic Biomarkers in ovarian cancer 
and the potential roles of cancer stem cells – An updated 
review."  Experimental Cell Research 362 (1):1-10. doi: 
https://doi.org/10.1016/j.yexcr.2017.10.018. 
Mukhamedova, N., A. Hoang, H. L. Cui, I. Carmichael, Y. Fu, M. 
Bukrinsky, and D. Sviridov. 2016. "Small GTPase Arf6 
Regulates Endocytic Pathway Leading to Degradation of ATP-
Binding Cassette Transporter A1."  Arterioscler Thromb Vasc 
Biol 36 (12):2292-2303. doi: 10.1161/atvbaha.116.308418. 
Munkley, J., U. L. McClurg, K. E. Livermore, I. Ehrmann, B. Knight, 
P. McCullagh, J. McGrath, M. Crundwell, L. W. Harries, H. Y. 
Leung, I. G. Mills, C. N. Robson, P. Rajan, and D. J. Elliott. 
2017. "The cancer-associated cell migration protein TSPAN1 is 
under control of androgens and its upregulation increases 
prostate cancer cell migration."  Sci Rep 7 (1):5249. doi: 
10.1038/s41598-017-05489-5. 
Murtagh, J. J., Jr., M. R. Mowatt, C. M. Lee, F. J. Lee, K. Mishima, T. 
E. Nash, J. Moss, and M. Vaughan. 1992. "Guanine nucleotide-
binding proteins in the intestinal parasite Giardia lamblia. 
Isolation of a gene encoding an approximately 20-kDa ADP-
ribosylation factor."  J Biol Chem 267 (14):9654-62. 
Mutch, D. G., and J. Prat. 2014. "2014 FIGO staging for ovarian, 
fallopian tube and peritoneal cancer."  Gynecol Oncol 133 
(3):401-4. doi: 10.1016/j.ygyno.2014.04.013. 
Myers, Kenneth R., and James E. Casanova. 2008. "Regulation of 
actin cytoskeleton dynamics by Arf-family GTPases."  Trends in 
cell biology 18 (4):184-192. doi: 10.1016/j.tcb.2008.02.002. 
Nagle, C. M., S. C. Dixon, A. Jensen, S. K. Kjaer, F. Modugno, A. 
deFazio, S. Fereday, J. Hung, S. E. Johnatty, P. A. Fasching, M. 
W. Beckmann, D. Lambrechts, I. Vergote, E. Van 
Nieuwenhuysen, S. Lambrechts, H. A. Risch, M. A. Rossing, J. 
A. Doherty, K. G. Wicklund, J. Chang-Claude, M. T. Goodman, 
 277 
R. B. Ness, K. Moysich, F. Heitz, A. du Bois, P. Harter, I. 
Schwaab, K. Matsuo, S. Hosono, E. L. Goode, R. A. Vierkant, M. 
C. Larson, B. L. Fridley, C. Hogdall, J. M. Schildkraut, R. P. 
Weber, D. W. Cramer, K. L. Terry, E. V. Bandera, L. Paddock, 
L. Rodriguez-Rodriguez, N. Wentzensen, H. P. Yang, L. A. 
Brinton, J. Lissowska, E. Hogdall, L. Lundvall, A. Whittemore, 
V. McGuire, W. Sieh, J. Rothstein, R. Sutphen, H. Anton-Culver, 
A. Ziogas, C. L. Pearce, A. H. Wu, and P. M. Webb. 2015. 
"Obesity and survival among women with ovarian cancer: 
results from the Ovarian Cancer Association Consortium."  Br J 
Cancer 113 (5):817-26. doi: 10.1038/bjc.2015.245. 
Nam, Jin-Min, Yasuhito Onodera, Yuichi Mazaki, Hiroyuki Miyoshi, 
Shigeru Hashimoto, and Hisataka Sabe. 2007. "CIN85, a Cbl-
interacting protein, is a component of AMAP1-mediated breast 
cancer invasion machinery."  The EMBO Journal 26 (3):647-656. 
doi: 10.1038/sj.emboj.7601534. 
Narayanan, D. L., R. N. Saladi, and J. L. Fox. 2010. "Ultraviolet 
radiation and skin cancer."  Int J Dermatol 49 (9):978-86. doi: 
10.1111/j.1365-4632.2010.04474.x. 
Naslavsky, Naava, Roberto Weigert, and Julie G. Donaldson. 2004. 
"Characterization of a Nonclathrin Endocytic Pathway: 
Membrane Cargo and Lipid Requirements."  Molecular Biology 
of the Cell 15 (8):3542-3552. doi: 10.1091/mbc.E04-02-0151. 
Nath, Sritama, and Pinku Mukherjee. 2014. "Muc1: a multifaceted 
oncoprotein with a key role in cancer progression."  Trends in 
molecular medicine 20 (6):332-342. doi: 
10.1016/j.molmed.2014.02.007. 
Norquist, B. M., M. I. Harrell, M. F. Brady, T. Walsh, M. K. Lee, S. 
Gulsuner, S. S. Bernards, S. Casadei, Q. Yi, R. A. Burger, J. K. 
Chan, S. A. Davidson, R. S. Mannel, P. A. DiSilvestro, H. A. 
Lankes, N. C. Ramirez, M. C. King, E. M. Swisher, and M. J. 
Birrer. 2016. "Inherited Mutations in Women With Ovarian 
Carcinoma."  JAMA Oncol 2 (4):482-90. doi: 
10.1001/jamaoncol.2015.5495. 
O'Donovan, Peter J., and David M. Livingston. 2010. "BRCA1 and 
BRCA2: breast/ovarian cancer susceptibility gene products and 
participants in DNA double-strand break repair."  
Carcinogenesis 31 (6):961-967. doi: 10.1093/carcin/bgq069. 
O'Sullivan, E., and M. Goggins. 2013. "DNA methylation analysis in 
human cancer."  Methods Mol Biol 980:131-56. doi: 10.1007/978-
1-62703-287-2_7. 
Ogasawara, Masahito, Sei-Chang Kim, Ronald Adamik, Akira 
Togawa, Victor J. Ferrans, Kazuyo Takeda, Martha Kirby, Joel 
Moss, and Martha Vaughan. 2000. "Similarities in Function and 
 278 
Gene Structure of Cytohesin-4 and Cytohesin-1, Guanine 
Nucleotide-exchange Proteins for ADP-ribosylation Factors."  
Journal of Biological Chemistry 275 (5):3221-3230. doi: 
10.1074/jbc.275.5.3221. 
Okada, R., Y. Yamauchi, T. Hongu, Y. Funakoshi, N. Ohbayashi, H. 
Hasegawa, and Y. Kanaho. 2015a. "Activation of the Small G 
Protein Arf6 by Dynamin2 through Guanine Nucleotide 
Exchange Factors in Endocytosis."  Sci Rep 5:14919. doi: 
10.1038/srep14919. 
Okada, Risa, Yohei Yamauchi, Tsunaki Hongu, Yuji Funakoshi, 
Norihiko Ohbayashi, Hiroshi Hasegawa, and Yasunori Kanaho. 
2015b. "Activation of the Small G Protein Arf6 by Dynamin2 
through Guanine Nucleotide Exchange Factors in Endocytosis."  
Scientific Reports 5:14919. doi: 10.1038/srep14919 
https://www.nature.com/articles/srep14919#supplementary-
information. 
Oliveira, M. A. P., T. S. Raymundo, L. C. Soares, T. R. D. Pereira, and 
A. V. E. Demoro. 2017. "How to Use CA-125 More Effectively in 
the Diagnosis of Deep Endometriosis."  Biomed Res Int 
2017:9857196. doi: 10.1155/2017/9857196. 
Olsen, C. M., C. M. Nagle, D. C. Whiteman, R. Ness, C. L. Pearce, M. 
C. Pike, M. A. Rossing, K. L. Terry, A. H. Wu, H. A. Risch, H. 
Yu, J. A. Doherty, J. Chang-Claude, R. Hein, S. Nickels, S. 
Wang-Gohrke, M. T. Goodman, M. E. Carney, R. K. Matsuno, G. 
Lurie, K. Moysich, S. K. Kjaer, A. Jensen, E. Hogdall, E. L. 
Goode, B. L. Fridley, R. A. Vierkant, M. C. Larson, J. 
Schildkraut, C. Hoyo, P. Moorman, R. P. Weber, D. W. Cramer, 
A. F. Vitonis, E. V. Bandera, S. H. Olson, L. Rodriguez-
Rodriguez, M. King, L. A. Brinton, H. Yang, M. Garcia-Closas, J. 
Lissowska, H. Anton-Culver, A. Ziogas, S. A. Gayther, S. J. 
Ramus, U. Menon, A. Gentry-Maharaj, and P. M. Webb. 2013. 
"Obesity and risk of ovarian cancer subtypes: evidence from the 
Ovarian Cancer Association Consortium."  Endocr Relat Cancer 
20 (2):251-62. doi: 10.1530/erc-12-0395. 
Onodera, Y., J. M. Nam, A. Hashimoto, J. C. Norman, H. Shirato, S. 
Hashimoto, and H. Sabe. 2012. "Rab5c promotes AMAP1-
PRKD2 complex formation to enhance beta1 integrin recycling 
in EGF-induced cancer invasion."  J Cell Biol 197 (7):983-96. doi: 
10.1083/jcb.201201065. 
Onodera, Yasuhito, Shigeru Hashimoto, Ari Hashimoto, Masaki 
Morishige, Yuichi Mazaki, Atsuko Yamada, Eiji Ogawa, 
Masashi Adachi, Takaki Sakurai, Toshiaki Manabe, Hiromi 
Wada, Nariaki Matsuura, and Hisataka Sabe. 2005. "Expression 
of AMAP1, an ArfGAP, provides novel targets to inhibit breast 
 279 
cancer invasive activities."  The EMBO Journal 24 (5):963-973. 
doi: 10.1038/sj.emboj.7600588. 
Pai, Emil F., Wolfgang Kabsch, Ute Krengel, Kenneth C. Holmes, 
Jacob John, and Alfred Wittinghofer. 1989. "Structure of the 
guanine-nucleotide-binding domain of the Ha-ras oncogene 
product p21 in the triphosphate conformation."  Nature 341:209. 
doi: 10.1038/341209a0. 
Pai, S., F. Verrier, H. Sun, H. Hu, A. M. Ferrie, A. Eshraghi, and Y. 
Fang. 2012. "Dynamic mass redistribution assay decodes 
differentiation of a neural progenitor stem cell."  J Biomol 
Screen 17 (9):1180-91. doi: 10.1177/1087057112455059. 
Pajcini, Kostandin V., Jason H. Pomerantz, Ozan Alkan, Regis 
Doyonnas, and Helen M. Blau. 2008. "Myoblasts and 
macrophages share molecular components that contribute to 
cell–cell fusion."  The Journal of Cell Biology 180 (5):1005-1019. 
doi: 10.1083/jcb.200707191. 
Palacios, F., J. K. Schweitzer, R. L. Boshans, and C. D'Souza-Schorey. 
2002. "Arf6-GTP recruits Nm23-H1 to facilitate dynamin-
mediated endocytosis during adherens junctions disassembly."  
Nat Cell Biol 4 (12):929-36. doi: 10.1038/ncb881. 
Paleotti, O., E. Macia, F. Luton, S. Klein, M. Partisani, P. Chardin, T. 
Kirchhausen, and M. Franco. 2005. "The small G-protein 
Arf6GTP recruits the AP-2 adaptor complex to membranes."  J 
Biol Chem 280 (22):21661-6. doi: 10.1074/jbc.M503099200. 
Pasqualato, S., J. Menetrey, M. Franco, and J. Cherfils. 2001. "The 
structural GDP/GTP cycle of human Arf6."  EMBO Rep 2 
(3):234-8. doi: 10.1093/embo-reports/kve043. 
Pasqualato, Sebastiano, Julie Ménétrey, Michel Franco, and 
Jacqueline Cherfils. 2001. "The structural GDP/GTP cycle of 
human Arf6."  EMBO Reports 2 (3):234-238. doi: 10.1093/embo-
reports/kve043. 
Pearce, Celeste Leigh, Karine Chung, Malcolm C. Pike, and Anna H. 
Wu. 2009. "Increased Ovarian Cancer Risk Associated with 
Menopausal Estrogen Therapy is Reduced by Adding a 
Progestin."  Cancer 115 (3):531-539. doi: 10.1002/cncr.23956. 
Pelletan, L. E., L. Suhaiman, C. C. Vaquer, M. A. Bustos, G. A. De 
Blas, N. Vitale, L. S. Mayorga, and S. A. Belmonte. 2015. "ADP 
ribosylation factor 6 (Arf6) promotes acrosomal exocytosis by 
modulating lipid turnover and Rab3A activation."  J Biol Chem 
290 (15):9823-41. doi: 10.1074/jbc.M114.629006. 
Pennington, K. P., and E. M. Swisher. 2012. "Hereditary ovarian 
cancer: beyond the usual suspects."  Gynecol Oncol 124 (2):347-
53. doi: 10.1016/j.ygyno.2011.12.415. 
 280 
Peters, P. J., V. W. Hsu, C. E. Ooi, D. Finazzi, S. B. Teal, V. Oorschot, 
J. G. Donaldson, and R. D. Klausner. 1995. "Overexpression of 
wild-type and mutant ARF1 and Arf6: distinct perturbations of 
nonoverlapping membrane compartments."  J Cell Biol 128 
(6):1003-17. 
Petrocca, F., D. Iliopoulos, H. R. Qin, M. S. Nicoloso, S. Yendamuri, S. 
E. Wojcik, M. Shimizu, G. Di Leva, A. Vecchione, F. Trapasso, A. 
K. Godwin, M. Negrini, G. A. Calin, and C. M. Croce. 2006. 
"Alterations of the tumor suppressor gene ARLTS1 in ovarian 
cancer."  Cancer Res 66 (21):10287-91. doi: 10.1158/0008-
5472.CAN-06-2289. 
Pils, D., P. Horak, A. Gleiss, C. Sax, G. Fabjani, V. J. Moebus, C. 
Zielinski, A. Reinthaller, R. Zeillinger, and M. Krainer. 2005a. 
"Five genes from chromosomal band 8p22 are significantly 
down-regulated in ovarian carcinoma: N33 and EFA6R have a 
potential impact on overall survival."  Cancer 104 (11):2417-29. 
doi: 10.1002/cncr.21538. 
Pils, Dietmar, Peter Horak, Andreas Gleiss, Cornelia Sax, Gerhild 
Fabjani, Volker J. Moebus, Christoph Zielinski, Alexander 
Reinthaller, Robert Zeillinger, and Michael Krainer. 2005b. 
"Five genes from chromosomal band 8p22 are significantly 
down-regulated in ovarian carcinoma."  Cancer 104 (11):2417-
2429. doi: doi:10.1002/cncr.21538. 
Poveda, A. M., F. Selle, F. Hilpert, A. Reuss, A. Savarese, I. Vergote, 
P. Witteveen, A. Bamias, N. Scotto, L. Mitchell, and E. Pujade-
Lauraine. 2015. "Bevacizumab Combined With Weekly 
Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in 
Platinum-Resistant Recurrent Ovarian Cancer: Analysis by 
Chemotherapy Cohort of the Randomized Phase III AURELIA 
Trial."  J Clin Oncol 33 (32):3836-8. doi: 
10.1200/jco.2015.63.1408. 
Powelka, A. M., J. Sun, J. Li, M. Gao, L. M. Shaw, A. Sonnenberg, and 
V. W. Hsu. 2004a. "Stimulation-dependent recycling of integrin 
beta1 regulated by Arf6 and Rab11."  Traffic 5 (1):20-36. 
Powelka, Aimee M., Jianlan Sun, Jian Li, Minggeng Gao, Leslie M. 
Shaw, Arnoud Sonnenberg, and Victor W. Hsu. 2004b. 
"Stimulation-Dependent Recycling of Integrin β1 Regulated by 
Arf6 and Rab11."  Traffic 5 (1):20-36. doi: doi:10.1111/j.1600-
0854.2004.00150.x. 
Praefcke, G. J., and H. T. McMahon. 2004. "The dynamin superfamily: 
universal membrane tubulation and fission molecules?"  Nat 
Rev Mol Cell Biol 5 (2):133-47. doi: 10.1038/nrm1313. 
Premont, R. T., A. Claing, N. Vitale, J. L. Freeman, J. A. Pitcher, W. 
A. Patton, J. Moss, M. Vaughan, and R. J. Lefkowitz. 1998. 
 281 
"beta2-Adrenergic receptor regulation by GIT1, a G protein-
coupled receptor kinase-associated ADP ribosylation factor 
GTPase-activating protein."  Proc Natl Acad Sci U S A 95 
(24):14082-7. 
Proctor, R. N. 2001. "Tobacco and the global lung cancer epidemic."  
Nat Rev Cancer 1 (1):82-6. doi: 10.1038/35094091. 
Pujade-Lauraine, E., U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. 
Heywood, P. A. Vasey, B. Volgger, I. Vergote, S. Pignata, A. 
Ferrero, J. Sehouli, A. Lortholary, G. Kristensen, C. Jackisch, F. 
Joly, C. Brown, N. Le Fur, and A. du Bois. 2010. "Pegylated 
liposomal Doxorubicin and Carboplatin compared with 
Paclitaxel and Carboplatin for patients with platinum-sensitive 
ovarian cancer in late relapse."  J Clin Oncol 28 (20):3323-9. doi: 
10.1200/jco.2009.25.7519. 
Quast, Thomas, Barbara Tappertzhofen, Cora Schild, Jessica Grell, 
Niklas Czeloth, Reinhold Förster, Ronen Alon, Line Fraemohs, 
Katrin Dreck, Christian Weber, Tim Lämmermann, Michael 
Sixt, and Waldemar Kolanus. 2009. "Cytohesin-1 controls the 
activation of RhoA and modulates integrin-dependent adhesion 
and migration of dendritic cells."  Blood 113 (23):5801-5810. doi: 
10.1182/blood-2008-08-176123. 
Raaijmakers, J. H., L. Deneubourg, H. Rehmann, J. de Koning, Z. 
Zhang, S. Krugmann, C. Erneux, and J. L. Bos. 2007. "The PI3K 
effector Arap3 interacts with the PI(3,4,5)P3 phosphatase 
SHIP2 in a SAM domain-dependent manner."  Cell Signal 19 
(6):1249-57. doi: 10.1016/j.cellsig.2006.12.015. 
Radhakrishna, H., O. Al-Awar, Z. Khachikian, and J. G. Donaldson. 
1999. "Arf6 requirement for Rac ruffling suggests a role for 
membrane trafficking in cortical actin rearrangements."  J Cell 
Sci 112 ( Pt 6):855-66. 
Raemaekers, Tim, Aleksandar Peric, Pieter Baatsen, Ragna 
Sannerud, Ilse Declerck, Veerle Baert, Christine Michiels, and 
Wim Annaert. 2012. "Arf6-mediated endosomal transport of 
Telencephalin affects dendritic filopodia-to-spine maturation."  
The EMBO Journal 31 (15):3252-3269. doi: 
10.1038/emboj.2012.182. 
Rafnar, T., D. F. Gudbjartsson, P. Sulem, A. Jonasdottir, A. 
Sigurdsson, A. Jonasdottir, S. Besenbacher, P. Lundin, S. N. 
Stacey, J. Gudmundsson, O. T. Magnusson, L. le Roux, G. 
Orlygsdottir, H. T. Helgadottir, H. Johannsdottir, A. Gylfason, 
L. Tryggvadottir, J. G. Jonasson, A. de Juan, E. Ortega, J. M. 
Ramon-Cajal, M. D. Garcia-Prats, C. Mayordomo, A. Panadero, 
F. Rivera, K. K. Aben, A. M. van Altena, L. F. Massuger, M. 
Aavikko, P. M. Kujala, S. Staff, L. A. Aaltonen, K. Olafsdottir, J. 
 282 
Bjornsson, A. Kong, A. Salvarsdottir, H. Saemundsson, K. 
Olafsson, K. R. Benediktsdottir, J. Gulcher, G. Masson, L. A. 
Kiemeney, J. I. Mayordomo, U. Thorsteinsdottir, and K. 
Stefansson. 2011. "Mutations in BRIP1 confer high risk of 
ovarian cancer."  Nat Genet 43 (11):1104-7. doi: 10.1038/ng.955. 
Rak, J., K. Foster, K. Potrzebowska, M. S. Talkhoncheh, N. Miharada, 
K. Komorowska, T. Torngren, A. Kvist, A. Borg, L. Svensson, D. 
Bonnet, and J. Larsson. 2017. "Cytohesin 1 regulates homing 
and engraftment of human hematopoietic stem and progenitor 
cells."  Blood 129 (8):950-958. doi: 10.1182/blood-2016-06-
720649. 
Randazzo, P. A., Y. C. Yang, C. Rulka, and R. A. Kahn. 1993. 
"Activation of ADP-ribosylation factor by Golgi membranes. 
Evidence for a brefeldin A- and protease-sensitive activating 
factor on Golgi membranes."  J Biol Chem 268 (13):9555-63. 
Renault, L., B. Guibert, and J. Cherfils. 2003. "Structural snapshots of 
the mechanism and inhibition of a guanine nucleotide exchange 
factor."  Nature 426 (6966):525-30. doi: 10.1038/nature02197. 
Rice, Megan S., Susan E. Hankinson, and Shelley S. Tworoger. 2014. 
"Tubal ligation, hysterectomy, unilateral oophorectomy, and risk 
of ovarian cancer in the Nurses&#x2019; Health Studies."  
Fertility and Sterility 102 (1):192-198.e3. doi: 
10.1016/j.fertnstert.2014.03.041. 
Richon, V. M. 2006. "Cancer biology: mechanism of antitumour action 
of vorinostat (suberoylanilide hydroxamic acid), a novel histone 
deacetylase inhibitor."  British Journal Of Cancer 95:S2. doi: 
10.1038/sj.bjc.6603463. 
Robertson, K. D. 2005. "DNA methylation and human disease."  Nat 
Rev Genet 6 (8):597-610. doi: 10.1038/nrg1655. 
Romero, I., C. C. Sun, K. K. Wong, R. C. Bast, Jr., and D. M. 
Gershenson. 2013. "Low-grade serous carcinoma: new concepts 
and emerging therapies."  Gynecol Oncol 130 (3):660-6. doi: 
10.1016/j.ygyno.2013.05.021. 
Ryland, Georgina L., Sally M. Hunter, Maria A. Doyle, Franco 
Caramia, Jason Li, Simone M. Rowley, Michael Christie, Prue 
E. Allan, Andrew N. Stephens, David D. L. Bowtell, Group 
Australian Ovarian Cancer Study, Ian G. Campbell, and Kylie 
L. Gorringe. 2015. "Mutational landscape of mucinous ovarian 
carcinoma and its neoplastic precursors."  Genome Medicine 7 
(1):87. doi: 10.1186/s13073-015-0210-y. 
Ryland, Georgina L., Sally M. Hunter, Maria A. Doyle, Franco 
Caramia, Jason Li, Simone M. Rowley, Michael Christie, Prue 
E. Allan, Andrew N. Stephens, David D. L. Bowtell, Ian G. 
Campbell, Kylie L. Gorringe, and Australian Ovarian Cancer 
 283 
Study Group. 2015. "Mutational landscape of mucinous ovarian 
carcinoma and its neoplastic precursors."  Genome Medicine 7 
(1):87. doi: 10.1186/s13073-015-0210-y. 
Saba, H. I. 2007. "Decitabine in the treatment of myelodysplastic 
syndromes."  Ther Clin Risk Manag 3 (5):807-17. 
Sakagami, H. 2008. "The EFA6 family: guanine nucleotide exchange 
factors for ADP ribosylation factor 6 at neuronal synapses."  
Tohoku J Exp Med 214 (3):191-8. 
Sakagami, H., T. Honma, J. Sukegawa, Y. Owada, T. Yanagisawa, and 
H. Kondo. 2007. "Somatodendritic localization of EFA6A, a 
guanine nucleotide exchange factor for ADP-ribosylation factor 
6, and its possible interaction with alpha-actinin in dendritic 
spines."  Eur J Neurosci 25 (3):618-28. doi: 10.1111/j.1460-
9568.2007.05345.x. 
Sakagami, H., H. Suzuki, A. Kamata, Y. Owada, K. Fukunaga, H. 
Mayanagi, and H. Kondo. 2006. "Distinct spatiotemporal 
expression of EFA6D, a guanine nucleotide exchange factor for 
Arf6, among the EFA6 family in mouse brain."  Brain Res 1093 
(1):1-11. doi: 10.1016/j.brainres.2006.02.058. 
Sakakura, I., K. Tanabe, N. Nouki, M. Suzuki, M. Satake, and T. 
Watanabe. 2011. "The carboxy-terminal region of SMAP2 directs 
subcellular localization as well as Arf protein specificity."  
Biochem Biophys Res Commun 404 (2):661-6. doi: 
10.1016/j.bbrc.2010.12.035. 
Sangar, F., A. S. Schreurs, C. Umana-Diaz, A. Claperon, C. Desbois-
Mouthon, C. Calmel, O. Mauger, A. Zaanan, C. Miquel, J. F. 
Flejou, and F. Praz. 2014. "Involvement of small ArfGAP1 
(SMAP1), a novel Arf6-specific GTPase-activating protein, in 
microsatellite instability oncogenesis."  Oncogene 33 (21):2758-
67. doi: 10.1038/onc.2013.211. 
Santos-Rosa, H., and C. Caldas. 2005. "Chromatin modifier enzymes, 
the histone code and cancer."  Eur J Cancer 41 (16):2381-402. 
doi: 10.1016/j.ejca.2005.08.010. 
Santy, L. C., and J. E. Casanova. 2001. "Activation of Arf6 by ARNO 
stimulates epithelial cell migration through downstream 
activation of both Rac1 and phospholipase D."  J Cell Biol 154 
(3):599-610. doi: 10.1083/jcb.200104019. 
Santy, L. C., K. S. Ravichandran, and J. E. Casanova. 2005. "The 
DOCK180/Elmo complex couples ARNO-mediated Arf6 
activation to the downstream activation of Rac1."  Curr Biol 15 
(19):1749-54. doi: 10.1016/j.cub.2005.08.052. 
Schaefer, A., N. R. Reinhard, and P. L. Hordijk. 2014. "Toward 
understanding RhoGTPase specificity: structure, function and 
 284 
local activation."  Small GTPases 5 (2):6. doi: 
10.4161/21541248.2014.968004. 
Schaeffer, David F., Daniel R. Owen, Howard J. Lim, Andrew K. 
Buczkowski, Stephen W. Chung, Charles H. Scudamore, David 
G. Huntsman, Sylvia SW Ng, and David A. Owen. 2010. 
"Insulin-like growth factor 2 mRNA binding protein 3 
(IGF2BP3) overexpression in pancreatic ductal adenocarcinoma 
correlates with poor survival."  BMC Cancer 10 (1):59. doi: 
10.1186/1471-2407-10-59. 
Schindelin, Johannes, Ignacio Arganda-Carreras, Erwin Frise, Verena 
Kaynig, Mark Longair, Tobias Pietzsch, Stephan Preibisch, 
Curtis Rueden, Stephan Saalfeld, Benjamin Schmid, Jean-Yves 
Tinevez, Daniel James White, Volker Hartenstein, Kevin 
Eliceiri, Pavel Tomancak, and Albert Cardona. 2012. "Fiji: an 
open-source platform for biological-image analysis."  Nature 
Methods 9:676. doi: 10.1038/nmeth.2019 
https://www.nature.com/articles/nmeth.2019#supplementary-
information. 
Schnekenburger, M., C. Grandjenette, J. Ghelfi, T. Karius, B. 
Foliguet, M. Dicato, and M. Diederich. 2011. "Sustained 
exposure to the DNA demethylating agent, 2'-deoxy-5-
azacytidine, leads to apoptotic cell death in chronic myeloid 
leukemia by promoting differentiation, senescence, and 
autophagy."  Biochem Pharmacol 81 (3):364-78. doi: 
10.1016/j.bcp.2010.10.013. 
Scholz, R., S. Berberich, L. Rathgeber, A. Kolleker, G. Kohr, and H. C. 
Kornau. 2010. "AMPA receptor signaling through BRAG2 and 
Arf6 critical for long-term synaptic depression."  Neuron 66 
(5):768-80. doi: 10.1016/j.neuron.2010.05.003. 
Schweitzer, J. K., and C. D'Souza-Schorey. 2002. "Localization and 
activation of the Arf6 GTPase during cleavage furrow ingression 
and cytokinesis."  J Biol Chem 277 (30):27210-6. doi: 
10.1074/jbc.M201569200. 
Seidman, J. D., I. Horkayne-Szakaly, M. Haiba, C. R. Boice, R. J. 
Kurman, and B. M. Ronnett. 2004. "The histologic type and 
stage distribution of ovarian carcinomas of surface epithelial 
origin."  Int J Gynecol Pathol 23 (1):41-4. doi: 
10.1097/01.pgp.0000101080.35393.16. 
Seto, Edward, and Minoru Yoshida. 2014. "Erasers of Histone 
Acetylation: The Histone Deacetylase Enzymes."  Cold Spring 
Harbor Perspectives in Biology 6 (4):a018713. doi: 
10.1101/cshperspect.a018713. 
 285 
Sewell, J. L., and R. A. Kahn. 1988. "Sequences of the bovine and 
yeast ADP-ribosylation factor and comparison to other GTP-
binding proteins."  Proc Natl Acad Sci U S A 85 (13):4620-4. 
Sheets, J. N., M. Iwanicki, J. F. Liu, B. E. Howitt, M. S. Hirsch, J. A. 
A. Gubbels, R. Drapkin, and K. A. Egland. 2016. "SUSD2 
expression in high-grade serous ovarian cancer correlates with 
increased patient survival and defective mesothelial clearance."  
Oncogenesis 5:e264. doi: 10.1038/oncsis.2016.64. 
Singer, G., R. Oldt, 3rd, Y. Cohen, B. G. Wang, D. Sidransky, R. J. 
Kurman, and M. Shih Ie. 2003. "Mutations in BRAF and KRAS 
characterize the development of low-grade ovarian serous 
carcinoma."  J Natl Cancer Inst 95 (6):484-6. 
Song, Y., J. Jiang, S. Vermeren, and W. Tong. 2014. "ARAP3 functions 
in hematopoietic stem cells."  PLoS One 9 (12):e116107. doi: 
10.1371/journal.pone.0116107. 
Sowmya, P., HN Madhavan, and KL Therese. 2006. "Evaluation of 
three Polymerase chain reaction tests targeting morphological 
transforming region II, UL-83 gene and glycoprotein O gene for 
the detection of Human Cytomegalovirus genome in clinical 
specimens of immunocompromised patients in Chennai, India."  
Virology Journal 3 (1):20. doi: 10.1186/1743-422x-3-20. 
Stearns, T., M. C. Willingham, D. Botstein, and R. A. Kahn. 1990. 
"ADP-ribosylation factor is functionally and physically 
associated with the Golgi complex."  Proc Natl Acad Sci U S A 
87 (3):1238-42. 
Stricker, R., and G. Reiser. 2014. "Functions of the neuron-specific 
protein ADAP1 (centaurin-alpha1) in neuronal differentiation 
and neurodegenerative diseases, with an overview of structural 
and biochemical properties of ADAP1."  Biol Chem 395 
(11):1321-40. doi: 10.1515/hsz-2014-0107. 
Suzuki, H., A. R. Forrest, E. van Nimwegen, C. O. Daub, P. J. 
Balwierz, K. M. Irvine, T. Lassmann, T. Ravasi, Y. Hasegawa, 
M. J. de Hoon, S. Katayama, K. Schroder, P. Carninci, Y. 
Tomaru, M. Kanamori-Katayama, A. Kubosaki, A. Akalin, Y. 
Ando, E. Arner, M. Asada, H. Asahara, T. Bailey, V. B. Bajic, D. 
Bauer, A. G. Beckhouse, N. Bertin, J. Bjorkegren, F. 
Brombacher, E. Bulger, A. M. Chalk, J. Chiba, N. Cloonan, A. 
Dawe, J. Dostie, P. G. Engstrom, M. Essack, G. J. Faulkner, J. 
L. Fink, D. Fredman, K. Fujimori, M. Furuno, T. Gojobori, J. 
Gough, S. M. Grimmond, M. Gustafsson, M. Hashimoto, T. 
Hashimoto, M. Hatakeyama, S. Heinzel, W. Hide, O. Hofmann, 
M. Hornquist, L. Huminiecki, K. Ikeo, N. Imamoto, S. Inoue, Y. 
Inoue, R. Ishihara, T. Iwayanagi, A. Jacobsen, M. Kaur, H. 
Kawaji, M. C. Kerr, R. Kimura, S. Kimura, Y. Kimura, H. 
 286 
Kitano, H. Koga, T. Kojima, S. Kondo, T. Konno, A. Krogh, A. 
Kruger, A. Kumar, B. Lenhard, A. Lennartsson, M. Lindow, M. 
Lizio, C. Macpherson, N. Maeda, C. A. Maher, M. Maqungo, J. 
Mar, N. A. Matigian, H. Matsuda, J. S. Mattick, S. Meier, S. 
Miyamoto, E. Miyamoto-Sato, K. Nakabayashi, Y. Nakachi, M. 
Nakano, S. Nygaard, T. Okayama, Y. Okazaki, H. Okuda-
Yabukami, V. Orlando, J. Otomo, M. Pachkov, N. Petrovsky, C. 
Plessy, J. Quackenbush, A. Radovanovic, M. Rehli, R. Saito, A. 
Sandelin, S. Schmeier, C. Schonbach, A. S. Schwartz, C. A. 
Semple, M. Sera, J. Severin, K. Shirahige, C. Simons, G. St 
Laurent, M. Suzuki, T. Suzuki, M. J. Sweet, R. J. Taft, S. 
Takeda, Y. Takenaka, K. Tan, M. S. Taylor, R. D. Teasdale, J. 
Tegner, S. Teichmann, E. Valen, C. Wahlestedt, K. Waki, A. 
Waterhouse, C. A. Wells, O. Winther, L. Wu, K. Yamaguchi, H. 
Yanagawa, J. Yasuda, M. Zavolan, D. A. Hume, T. Arakawa, S. 
Fukuda, K. Imamura, C. Kai, A. Kaiho, T. Kawashima, C. 
Kawazu, Y. Kitazume, M. Kojima, H. Miura, K. Murakami, M. 
Murata, N. Ninomiya, H. Nishiyori, S. Noma, C. Ogawa, T. 
Sano, C. Simon, M. Tagami, Y. Takahashi, J. Kawai, and Y. 
Hayashizaki. 2009. "The transcriptional network that controls 
growth arrest and differentiation in a human myeloid leukemia 
cell line."  Nat Genet 41 (5):553-62. doi: 10.1038/ng.375. 
Suzuki, Sayuri, Jun Namiki, Shinsuke Shibata, Yumi Mastuzaki, and 
Hideyuki Okano. 2010. "The Neural Stem/Progenitor Cell 
Marker Nestin Is Expressed in Proliferative Endothelial Cells, 
but Not in Mature Vasculature."  Journal of Histochemistry and 
Cytochemistry 58 (8):721-730. doi: 10.1369/jhc.2010.955609. 
Tagliatti, Erica, Manuela Fadda, Antonio Falace, Fabio Benfenati, 
and Anna Fassio. 2016. "Arf6 regulates the cycling and the 
readily releasable pool of synaptic vesicles at hippocampal 
synapse."  eLife 5:e10116. doi: 10.7554/eLife.10116. 
Tamaddon-Jahromi, Salman, and Venkateswarlu Kanamarlapudi. 
2017. ADP-Ribosylation Factor-6 (Arf6). 
Tanabe, K., S. Kon, W. Natsume, T. Torii, T. Watanabe, and M. 
Satake. 2006. "Involvement of a novel ADP-ribosylation factor 
GTPase-activating protein, SMAP, in membrane trafficking: 
implications in cancer cell biology."  Cancer Sci 97 (9):801-6. doi: 
10.1111/j.1349-7006.2006.00251.x. 
Tanabe, K., T. Torii, W. Natsume, S. Braesch-Andersen, T. Watanabe, 
and M. Satake. 2005. "A novel GTPase-activating protein for 
Arf6 directly interacts with clathrin and regulates clathrin-
dependent endocytosis."  Mol Biol Cell 16 (4):1617-28. doi: 
10.1091/mbc.E04-08-0683. 
 287 
Taniuchi, K., M. Furihata, K. Hanazaki, M. Saito, and T. Saibara. 
2014. "IGF2BP3-mediated translation in cell protrusions 
promotes cell invasiveness and metastasis of pancreatic cancer."  
Oncotarget 5 (16):6832-45. doi: 10.18632/oncotarget.2257. 
Taniuchi, K., M. Furihata, and T. Saibara. 2014. "KIF20A-mediated 
RNA granule transport system promotes the invasiveness of 
pancreatic cancer cells."  Neoplasia 16 (12):1082-93. doi: 
10.1016/j.neo.2014.10.007. 
The Cancer Genome Atlas Research, Network. 2011. "Integrated 
Genomic Analyses of Ovarian Carcinoma."  Nature 474 
(7353):609-615. doi: 10.1038/nature10166. 
Thomassen, M., Q. Tan, and T. A. Kruse. 2009. "Gene expression 
meta-analysis identifies chromosomal regions and candidate 
genes involved in breast cancer metastasis."  Breast Cancer Res 
Treat 113 (2):239-49. doi: 10.1007/s10549-008-9927-2. 
Tian, Chunqiao, Maurie Markman, Richard Zaino, Robert F. Ozols, 
William P. McGuire, Franco M. Muggia, Peter G. Rose, David 
Spriggs, and Deborah K. Armstrong. 2009. "CA-125 Change 
Following Chemotherapy in Prediction of Treatment Outcome 
among Advanced Mucinous and Clear Cell Epithelial Ovarian 
Cancers: A Gynecologic Oncology Group Study."  Cancer 115 
(7):1395-1403. doi: 10.1002/cncr.24152. 
Tong, C. W., J. L. Wang, M. S. Jiang, C. H. Hsu, W. T. Chang, and A. 
M. Huang. 2013. "Novel genes that mediate nuclear respiratory 
factor 1-regualted neurite outgrowth in neuroblastoma IMR-32 
cells."  Gene 515 (1):62-70. doi: 10.1016/j.gene.2012.11.026. 
Torii, T., Y. Miyamoto, A. Sanbe, K. Nishimura, J. Yamauchi, and A. 
Tanoue. 2010. "Cytohesin-2/ARNO, through its interaction with 
focal adhesion adaptor protein paxillin, regulates preadipocyte 
migration via the downstream activation of Arf6."  J Biol Chem 
285 (31):24270-81. doi: 10.1074/jbc.M110.125658. 
Tothill, R. W., A. V. Tinker, J. George, R. Brown, S. B. Fox, S. Lade, D. 
S. Johnson, M. K. Trivett, D. Etemadmoghadam, B. Locandro, 
N. Traficante, S. Fereday, J. A. Hung, Y. E. Chiew, I. Haviv, D. 
Gertig, A. DeFazio, and D. D. Bowtell. 2008. "Novel molecular 
subtypes of serous and endometrioid ovarian cancer linked to 
clinical outcome."  Clin Cancer Res 14 (16):5198-208. doi: 
10.1158/1078-0432.ccr-08-0196. 
Tsuchiya, M., S. R. Price, S. C. Tsai, J. Moss, and M. Vaughan. 1991. 
"Molecular identification of ADP-ribosylation factor mRNAs and 
their expression in mammalian cells."  J Biol Chem 266 
(5):2772-7. 
Ueda, T., A. Hanai, T. Takei, K. Kubo, M. Ohgi, H. Sakagami, S. 
Takahashi, H. W. Shin, and K. Nakayama. 2013. "EFA6 
 288 
activates Arf6 and participates in its targeting to the Flemming 
body during cytokinesis."  FEBS Lett 587 (11):1617-23. doi: 
10.1016/j.febslet.2013.03.042. 
Urban, Alexander E., Erin O. Quick, Kaylie P. Miller, Jennifer 
Krcmery, and Hans-Georg Simon. 2016. "Pdlim7 Regulates 
Arf6-Dependent Actin Dynamics and Is Required for Platelet-
Mediated Thrombosis in Mice."  PLoS ONE 11 (10):e0164042. 
doi: 10.1371/journal.pone.0164042. 
van den Boom, J., M. Wolter, B. Blaschke, C. B. Knobbe, and G. 
Reifenberger. 2006. "Identification of novel genes associated 
with astrocytoma progression using suppression subtractive 
hybridization and real-time reverse transcription-polymerase 
chain reaction."  Int J Cancer 119 (10):2330-8. doi: 
10.1002/ijc.22108. 
Vasey, P. A., G. C. Jayson, A. Gordon, H. Gabra, R. Coleman, R. 
Atkinson, D. Parkin, J. Paul, A. Hay, and S. B. Kaye. 2004. 
"Phase III randomized trial of docetaxel-carboplatin versus 
paclitaxel-carboplatin as first-line chemotherapy for ovarian 
carcinoma."  J Natl Cancer Inst 96 (22):1682-91. doi: 
10.1093/jnci/djh323. 
Vellekoop, Annelies, and Stacy Loeb. 2013. "More Aggressive Prostate 
Cancer in Elderly Men."  Reviews in Urology 15 (4):202-204. 
Venkateswarlu, K. 2003. "Interaction protein for cytohesin exchange 
factors 1 (IPCEF1) binds cytohesin 2 and modifies its activity."  
J Biol Chem 278 (44):43460-9. doi: 10.1074/jbc.M304078200. 
Venkateswarlu, K., K. G. Brandom, and J. L. Lawrence. 2004. 
"Centaurin-alpha1 is an in vivo phosphatidylinositol 3,4,5-
trisphosphate-dependent GTPase-activating protein for Arf6 
that is involved in actin cytoskeleton organization."  J Biol 
Chem 279 (8):6205-8. doi: 10.1074/jbc.C300482200. 
Venkateswarlu, K., and P. J. Cullen. 2000. "Signalling via ADP-
ribosylation factor 6 lies downstream of phosphatidylinositide 3-
kinase."  Biochem J 345 Pt 3:719-24. 
Venkateswarlu, K., F. Gunn-Moore, P. B. Oatey, J. M. Tavaré, and P. 
J. Cullen. 1998. "Nerve growth factor- and epidermal growth 
factor-stimulated translocation of the ADP-ribosylation factor-
exchange factor GRP1 to the plasma membrane of PC12 cells 
requires activation of phosphatidylinositol 3-kinase and the 
GRP1 pleckstrin homology domain."  Biochemical Journal 335 
(Pt 1):139-146. 
Venkateswarlu, Kanamarlapudi. 2005. "Analysis of the Interaction 
Between Cytohesin 2 and IPCEF1." In Methods in Enzymology, 
252-266. Academic Press. 
 289 
Vergote, I., C. G. Trope, F. Amant, G. B. Kristensen, T. Ehlen, N. 
Johnson, R. H. Verheijen, M. E. van der Burg, A. J. Lacave, P. 
B. Panici, G. G. Kenter, A. Casado, C. Mendiola, C. Coens, L. 
Verleye, G. C. Stuart, S. Pecorelli, and N. S. Reed. 2010. 
"Neoadjuvant chemotherapy or primary surgery in stage IIIC or 
IV ovarian cancer."  N Engl J Med 363 (10):943-53. doi: 
10.1056/NEJMoa0908806. 
Verhoeven, R. H. A., A. Gondos, M. L. G. Janssen-Heijnen, K. U. 
Saum, D. H. Brewster, B. Holleczek, E. Crocetti, S. Rosso, T. 
Hakulinen, T. Aareleid, H. Brenner, and Eunice Survival 
Working Group The. 2013. "Testicular cancer in Europe and the 
USA: survival still rising among older patients."  Annals of 
Oncology 24 (2):508-513. doi: 10.1093/annonc/mds460. 
Vijayvergia, Namrata, and Crystal S. Denlinger. 2015. "Lifestyle 
Factors in Cancer Survivorship: Where We Are and Where We 
Are Headed."  Journal of Personalized Medicine 5 (3):243-263. 
doi: 10.3390/jpm5030243. 
Vitali, T., S. Girald-Berlingeri, P. A. Randazzo, and P. W. Chen. 2017. 
"Arf GAPs: A family of proteins with disparate functions that 
converge on a common structure, the integrin adhesion 
complex."  Small GTPases:1-9. doi: 
10.1080/21541248.2017.1299271. 
Walsh, T., S. Casadei, M. K. Lee, C. C. Pennil, A. S. Nord, A. M. 
Thornton, W. Roeb, K. J. Agnew, S. M. Stray, A. 
Wickramanayake, B. Norquist, K. P. Pennington, R. L. Garcia, 
M. C. King, and E. M. Swisher. 2011. "Mutations in 12 genes for 
inherited ovarian, fallopian tube, and peritoneal carcinoma 
identified by massively parallel sequencing."  Proc Natl Acad Sci 
U S A 108 (44):18032-7. doi: 10.1073/pnas.1115052108. 
Wang, Y., K. J. Han, X. W. Pang, H. A. Vaughan, W. Qu, X. Y. Dong, 
J. R. Peng, H. T. Zhao, J. A. Rui, X. S. Leng, J. Cebon, A. W. 
Burgess, and W. F. Chen. 2002. "Large scale identification of 
human hepatocellular carcinoma-associated antigens by 
autoantibodies."  J Immunol 169 (2):1102-9. 
Wennerberg, Krister, Kent L. Rossman, and Channing J. Der. 2005. 
"The Ras superfamily at a glance."  Journal of Cell Science 118 
(5):843-846. doi: 10.1242/jcs.01660. 
White, Mary C., Dawn M. Holman, Jennifer E. Boehm, Lucy A. 
Peipins, Melissa Grossman, and S. Jane Henley. 2014. "Age and 
Cancer Risk: A Potentially Modifiable Relationship."  American 
journal of preventive medicine 46 (3 0 1):S7-15. doi: 
10.1016/j.amepre.2013.10.029. 
Wiegand, K. C., S. P. Shah, O. M. Al-Agha, Y. Zhao, K. Tse, T. Zeng, J. 
Senz, M. K. McConechy, M. S. Anglesio, S. E. Kalloger, W. Yang, 
 290 
A. Heravi-Moussavi, R. Giuliany, C. Chow, J. Fee, A. Zayed, L. 
Prentice, N. Melnyk, G. Turashvili, A. D. Delaney, J. Madore, S. 
Yip, A. W. McPherson, G. Ha, L. Bell, S. Fereday, A. Tam, L. 
Galletta, P. N. Tonin, D. Provencher, D. Miller, S. J. Jones, R. A. 
Moore, G. B. Morin, A. Oloumi, N. Boyd, S. A. Aparicio, M. Shih 
Ie, A. M. Mes-Masson, D. D. Bowtell, M. Hirst, B. Gilks, M. A. 
Marra, and D. G. Huntsman. 2010. "ARID1A mutations in 
endometriosis-associated ovarian carcinomas."  N Engl J Med 
363 (16):1532-43. doi: 10.1056/NEJMoa1008433. 
Wijnhoven, Susan W. P., Hanneke J. M. Kool, Corrie M. M. van 
Teijlingen, Albert A. van Zeeland, and Harry Vrieling. 2001. 
"Loss of heterozygosity in somatic cells of the mouse: An 
important step in cancer initiation?"  Mutation 
Research/Fundamental and Molecular Mechanisms of 
Mutagenesis 473 (1):23-36. doi: https://doi.org/10.1016/S0027-
5107(00)00163-9. 
Wong, K. K., Y. T. Tsang, M. T. Deavers, S. C. Mok, Z. Zu, C. Sun, A. 
Malpica, J. K. Wolf, K. H. Lu, and D. M. Gershenson. 2010. 
"BRAF mutation is rare in advanced-stage low-grade ovarian 
serous carcinomas."  Am J Pathol 177 (4):1611-7. doi: 
10.2353/ajpath.2010.100212. 
Wu, B., F. Wang, J. Zhang, Z. Zhang, L. Qin, J. Peng, F. Li, J. Liu, G. 
Lu, Q. Gong, X. Yao, J. Wu, and Y. Shi. 2012. "Identification and 
structural basis for a novel interaction between Vav2 and 
Arap3."  J Struct Biol 180 (1):84-95. doi: 
10.1016/j.jsb.2012.06.011. 
Xie, L., C. Gazin, S. M. Park, L. J. Zhu, M. A. Debily, E. L. Kittler, M. 
L. Zapp, D. Lapointe, S. Gobeil, C. M. Virbasius, and M. R. 
Green. 2012. "A synthetic interaction screen identifies factors 
selectively required for proliferation and TERT transcription in 
p53-deficient human cancer cells."  PLoS Genet 8 (12):e1003151. 
doi: 10.1371/journal.pgen.1003151. 
Xu, K., J. Gao, X. Yang, Y. Yao, and Q. Liu. 2013. "Cytohesin-2 as a 
novel prognostic marker for hepatocellular carcinoma."  Oncol 
Rep 29 (6):2211-8. doi: 10.3892/or.2013.2366. 
Yagi, R., M. Tanaka, K. Sasaki, R. Kamata, Y. Nakanishi, Y. Kanai, 
and R. Sakai. 2011. "ARAP3 inhibits peritoneal dissemination of 
scirrhous gastric carcinoma cells by regulating cell adhesion and 
invasion."  Oncogene 30 (12):1413-21. doi: 10.1038/onc.2010.522. 
Yamamoto, Eiji, Antreas C Kalli, Kenji Yasuoka, and Mark S P. 
Sansom. 2016. "Interactions of Pleckstrin Homology Domains 
with Membranes: Adding Back the Bilayer via High-Throughput 
Molecular Dynamics."  Structure 24 (8):1421-1431. doi: 
https://doi.org/10.1016/j.str.2016.06.002. 
 291 
Yamauchi, Y., Y. Miura, and Y. Kanaho. 2017. "Machineries 
regulating the activity of the small GTPase Arf6 in cancer cells 
are potential targets for developing innovative anti-cancer 
drugs."  Adv Biol Regul 63:115-121. doi: 
10.1016/j.jbior.2016.10.004. 
Yang, D., S. Khan, Y. Sun, and et al. 2011. "Association of brca1 and 
brca2 mutations with survival, chemotherapy sensitivity, and 
gene mutator phenotype in patients with ovarian cancer."  
JAMA 306 (14):1557-1565. doi: 10.1001/jama.2011.1456. 
Yeaman, Charles, M. Inmaculada Ayala, Jessica R. Wright, Frederic 
Bard, Carine Bossard, Agnes Ang, Yusuke Maeda, Thomas 
Seufferlein, Ira Mellman, W. James Nelson, and Vivek 
Malhotra. 2004. "Protein kinase D regulates basolateral 
membrane protein exit from trans-Golgi network."  Nature Cell 
Biology 6:106. doi: 10.1038/ncb1090. 
Yoo, J. H., D. S. Shi, A. H. Grossmann, L. K. Sorensen, Z. Tong, T. M. 
Mleynek, A. Rogers, W. Zhu, J. R. Richards, J. M. Winter, J. 
Zhu, C. Dunn, A. Bajji, M. Shenderovich, A. L. Mueller, S. E. 
Woodman, J. W. Harbour, K. R. Thomas, S. J. Odelberg, K. 
Ostanin, and D. Y. Li. 2016. "Arf6 Is an Actionable Node that 
Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma."  
Cancer Cell 29 (6):889-904. doi: 10.1016/j.ccell.2016.04.015. 
Yoon, H. Y., S. C. Kales, R. Luo, S. Lipkowitz, and P. A. Randazzo. 
2011. "ARAP1 association with CIN85 affects epidermal growth 
factor receptor endocytic trafficking."  Biol Cell 103 (4):171-84. 
doi: 10.1042/BC20100154. 
Zangari, J., M. Partisani, F. Bertucci, J. Milanini, G. Bidaut, C. 
Berruyer-Pouyet, P. Finetti, E. Long, F. Brau, O. Cabaud, B. 
Chetaille, D. Birnbaum, M. Lopez, P. Hofman, M. Franco, and F. 
Luton. 2014. "EFA6B antagonizes breast cancer."  Cancer Res 
74 (19):5493-506. doi: 10.1158/0008-5472.CAN-14-0298. 
Zhang, K., and S. Y. Dent. 2005. "Histone modifying enzymes and 
cancer: going beyond histones."  J Cell Biochem 96 (6):1137-48. 
doi: 10.1002/jcb.20615. 
Zhang, Q., M. B. Major, S. Takanashi, N. D. Camp, N. Nishiya, E. C. 
Peters, M. H. Ginsberg, X. Jian, P. A. Randazzo, P. G. Schultz, 
R. T. Moon, and S. Ding. 2007. "Small-molecule synergist of the 
Wnt/beta-catenin signaling pathway."  Proc Natl Acad Sci U S A 
104 (18):7444-8. doi: 10.1073/pnas.0702136104. 
Zhang, S., R. Royer, S. Li, J. R. McLaughlin, B. Rosen, H. A. Risch, I. 
Fan, L. Bradley, P. A. Shaw, and S. A. Narod. 2011. 
"Frequencies of BRCA1 and BRCA2 mutations among 1,342 
unselected patients with invasive ovarian cancer."  Gynecol 
Oncol 121 (2):353-7. doi: 10.1016/j.ygyno.2011.01.020. 
 292 
Zhang, Yujie, Jun Du, Jianchao Zheng, Jiaojing Liu, Rui Xu, Tian 
Shen, Yichao Zhu, Jun Chang, Hong Wang, Zhihong Zhang, 
Fanqing Meng, Yan Wang, Yongchang Chen, Yong Xu, and Luo 
Gu. 2015. "EGF-reduced Wnt5a transcription induces epithelial-
mesenchymal transition via Arf6-ERK signaling in gastric 
cancer cells."  Oncotarget 6 (9):7244-7261. 
Zhao, H., D. K. Ahirwar, S. Oghumu, T. Wilkie, C. A. Powell, M. W. 
Nasser, A. R. Satoskar, D. Y. Li, and R. K. Ganju. 2016. 
"Endothelial Robo4 suppresses breast cancer growth and 
metastasis through regulation of tumor angiogenesis."  Mol 
Oncol 10 (2):272-81. doi: 10.1016/j.molonc.2015.10.007. 
Zhu, W., D. S. Shi, J. M. Winter, B. E. Rich, Z. Tong, L. K. Sorensen, 
H. Zhao, Y. Huang, Z. Tai, T. M. Mleynek, J. H. Yoo, C. Dunn, J. 
Ling, J. A. Bergquist, J. R. Richards, A. Jiang, L. A. Lesniewski, 
M. E. Hartnett, D. M. Ward, A. L. Mueller, K. Ostanin, K. R. 
Thomas, S. J. Odelberg, and D. Y. Li. 2017. "Small GTPase Arf6 
controls VEGFR2 trafficking and signaling in diabetic 
retinopathy."  J Clin Invest 127 (12):4569-4582. doi: 
10.1172/JCI91770. 
Zobel, M., A. Disanza, F. Senic-Matuglia, M. Franco, I. N. Colaluca, S. 
Confalonieri, S. Bisi, E. Barbieri, G. Caldieri, S. Sigismund, S. 
Pece, P. Chavrier, P. P. Di Fiore, and G. Scita. 2018. "A NUMB-
EFA6B-Arf6 recycling route controls apically restricted cell 
protrusions and mesenchymal motility."  J Cell Biol. doi: 
10.1083/jcb.201802023. 
 
